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Abstract 
Abstract 
The Medicines Use Review and Prescription Intervention (MUR) service was commissioned as 
part of the 2005 community pharmacy contract for England and Wales. The aim of the MUR 
service ŝƐ ƚŽ ŝŵƉƌŽǀĞ ƉĂƚŝĞŶƚƐ ? ŬŶŽǁůĞĚŐĞand use of medicines and to reduce avoidable 
medicines waste. MURs form part of a Government strategy that aims to improve patientƐ ?
adherence to medicines in order to optimise health gain and reduce cost associated with 
unused medicines. MURs are also seen as a  ‘concordance review ? and pŚĂƌŵĂĐǇ ?ƐƉƌŽĨĞƐƐŝŽŶĂů
bodies acknowledge the service as a means to further the professional role of community 
pharmacists. However, it remains uncertain from studies investigating the outcomes of MURs, 
the extent to which the service is benefitting patients. One significant drawback to previous 
studies is the lack of in-depth investigation of the MUR consultation ĂŶĚ ƚŚĞ ƉĂƚŝĞŶƚƐ ?
perspective of the service.  
 
This thesis provides valuable insights into what occurs during an MUR consultation and 
investigates the patient ?Ɛ perspective of the service and that of the pharmacy staff. This work 
also explores whether the MUR policy aims are being realised in practice and translated into 
more effective use of medicines. Ten weeks of fieldwork observations were undertaken in two 
English community pharmacies. One-week placements were made over a 12-month period 
between November 2008 and October 2009. Observations were made of all pharmacy 
activities, including fifty-four MUR consultations. Thirty-four patients subsequently agreed to 
be interviewed about their experience of the MUR. Eight patients were observed to decline 
the offer of an MUR, of which three patients were interviewed about the reasons why they 
declined. After the pharmacy observations were completed, five pharmacists and twelve 
support staff interviews were held to discuss professional perspectives of MURs.  
 
The findings from this study suggest that the MUR service is a modern and developing service 
but one that remains unestablished. Patient awareness of MURs was poor and nearly all MURs 
were initiated by the pharmacist; no patients were referred from the GP. Pharmacy staff did 
not actively seek to recruit patients who may benefit most from an MUR and the majority 
were invited in ad hoc manner. Patients were given little time to consider whether to take part 
in an MUR and were insufficiently informed of their purpose or personal value. MURs were 
framed as a monitoring activity and most patients reported that the MUR did little to improve 
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their knowledge of their medicines and rarely affected their use. They perceived their GP to 
have the main authority over their medicines. Patients considered that significant medicine-
related problems would be best resolved by talking to the GP rather than with the pharmacist 
during an MUR. In effect, a supplier induced demand for MURs was observed. Nevertheless, all 
patients reported feeling comfortable speaking to the pharmacist during an MUR and most 
described the consultation in positive terms. Most patients viewed the pharmacist as a 
knowledgeable expert and some felt reassured about their medicines following an MUR.    
  
Observations of the MUR consultation revealed pharmacists were subordinate to the 
 ‘ƚĞĐŚŶŽůŽŐǇ ? ŽĨ ƚŚĞ DhZ ĨŽƌŵand adhered to ŝƚƐ  ‘ƚŝĐŬ-ďŽǆ ? format. Pharmacists used 
predominantly closed questions which enabled the MUR form to be completed efficiently, but 
this forestalled wider discussion ŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐŚĞĂůƚŚĂŶĚŵĞĚŝĐŝŶĞƐ ?The MUR service was at 
odds with the intention to create a patient-centred service. When complex or indeterminate 
issues were raised, these were often circumvented or the patient referred to the GP. 
Pharmacists reported in their interviews that they welcomed MURs and the resultant potential 
to raise their profile with patients. However, they were unclear about what they wanted to 
advise during an MUR and how patients might gain maximum benefit from the review. They 
also reported concerns over patient recruitment, organisational pressures to pursue a target 
number of MURs and difficulties integrating MURs within their existing activities. MURs were 
pragmatically accommodated alongside existing duties without additional resource. Support 
staff reported feeling discomfort when they were left to explain to patients and customers 
why the pharmacist was absent during an MUR and described using various strategies and 
personal judgements to deal with waiting patients.    
 
This study has important implications for patients, professionals and policy makers. Patients 
should be aware that the MUR service is funded by the NHS and is available for them to use. 
More support from GPs is needed to identify patients who may most benefit from an MUR. 
This study highlights the need for consultation and communication skills training for 
pharmacists, so they are able to effectively elicit patient beliefs, concerns and preferences 
about medicines during the MUR. Organisations also need to reconsider the way they motivate 
pharmacists to undertake MURs to avoid unintended consequences for patient care. Policy 
makers should reconsider strategies that are based on rationalised policies as a means to 
improving patient adherence to medicines. Effective services need to be responsive to the 
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ƉĂƚŝĞŶƚ ?Ɛindividual circumstance and preference. Further research is needed into MURs in a 
wider and more diverse range of pharmacy settings in order to explore these issues further.  
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1. CHAPTER ONE Introduction 
CHAPTER ONE 
Introduction 
 
This thesis contributes to a better understanding of patient and pharmacy staff perspectives of 
the UK community pharmacy Medicines Use Review (MUR) service (DH 2005a). It describes an 
in-depth investigation conducted in two English community pharmacies and explores how the 
MUR service is being integrated into  ‘real life ? practice. Using qualitative methods, this study 
explores the extent to which MURs are achieving their policy aims and intentions.  
 
There is a compelling need to understand what is happening currently in practice and what 
MURs are actually achieving for patients ? dŚĞ ƉĂƚŝĞŶƚƐ ? ƉĞƌƐƉĞĐƚŝǀĞ ŽĨ the MUR service and 
their views on the consultation is under-reported. In Chapter Two, I consider and present the 
literature about the MUR service and related research. Relevant background information 
about community pharmacy, the role of the pharmacist, and the MUR service is initially 
described. The different agendas that are being promoted about MURs are then discussed. 
This chapter concludes with defining the research aims and objectives of this study.        
 
Chapter Three, is divided into two parts. In the first part of this chapter, I discuss the 
ontological, epistemological and methodological approach that has underpinned this study. In 
the second part of this chapter, I describe the method that was adopted for this study. Two 
research methods were used in this study. Ethnographically-oriented observations were used 
to understand the context in which MURs were being performed. Interviews with patients and 
pharmacy staff confirmed and extended this understanding. A detailed rationale for using 
these methods is laid out along with the ethical considerations that shaped the research 
design.  
 
The findings of this study are presented in Chapters Four to Seven. In Chapter Four, I present 
the findings of my fieldwork observations in the two study pharmacies. I outline the activities 
of the pharmacist and pharmacy staff and the different types of interactions they had with 
patients and customers. I also present the context of how MURs were managed in the 
pharmacies and the processes that led to patients being offered an MUR. This chapter 
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provides an essential backdrop against which the MUR service is being implemented. In 
Chapter Five, I present my findings from the observed MUR consultations. A detailed 
description of what happened during the review, the nature of the patient-pharmacist 
interaction and an analysis of the consultation is presented.  
 
In Chapter Six, the patients ?ƉĞƌƐƉĞĐƚŝǀĞ is presented. I report their opinions and feelings about 
being approached in the pharmacy through to their reflections on what they perceived the 
purpose of the MUR to be. The findings from the interviews with patients who declined the 
invitation for an MUR are also presented. In Chapter Seven, I explore the perspectives of the 
pharmacists and support staff of the MUR service. I report on how they perceive the service 
and how they manage MURs alongside the other services provided. These findings confirm and 
extend the fieldwork observations made in the pharmacy. 
 
In Chapter Eight, the findings from this study and the literature are drawn together and a 
discussion of these findings and their significance is presented. A reflection of the strengths 
and limitations of this study is given as well as consideration of the practice implications of this 
study. Finally, the chapter ends by suggesting avenues for future research. In the final chapter 
of this thesis, Chapter Nine, I present my concluding remarks for this study.  
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2. CHAPTER TWO Literature review 
CHAPTER TWO 
Literature review 
2.1 Introduction  
The purpose of this chapter is to review the literature relevant to this study. The literature 
review strategy can be found in Appendix One ?dŚĞDhZƐĞƌǀŝĐĞƌĞƉƌĞƐĞŶƚƐĂŶĞǁ ‘ĞǆƚĞŶĚĞĚ
ƌŽůĞ ?ĂĐƚŝǀŝƚǇĨŽƌĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?/ŶŽƌĚĞƌƚŽƵŶĚĞƌƐƚĂŶĚƚŚĞĐŽŶƚĞxt in which this role 
developed, I briefly present the historical developments that have led to these extended roles. 
I then provide an outline to the 2005 Community Pharmacy Contractual Framework, hereafter 
ƌĞĨĞƌƌĞĚ ƚŽ ĂƐ ƚŚĞ  ‘ƉŚĂƌŵĂĐǇ ĐŽŶƚƌĂĐƚ ? ? ĂůŽŶŐ ǁŝƚŚ Ă ĚĞƐĐƌŝƉƚŝŽŶ ŽĨ ƚŚĞ DhZ ƐĞƌǀŝĐe. The 
different and sometimes conflicting policy, professional and ideological agendas are then 
discussed in order to demonstrate their influence on the MUR service. The chapter concludes 
with an outline of the aims and objectives of this study.  
 
2.2 The United Kingdom health care system    
Patients access health services in the UK largely through the National Health Service (NHS). 
This is typically free at the point of use, however, patients pay subsidies for certain services 
such as dental and optical treatments. The NHS is funded through general taxation and 
operates within a framework that overtly acknowledges limited resources but aims to provide 
equitable access to health care (Elliot and Payne 2005; Ham 2009). The purchasing of health 
services is the responsibility of Primary Care Organisations (PCOs) (Primary Care Trusts in 
England, Health Boards in Scotland, Local Health Groups in Wales and Primary Care 
Partnerships in Northern Ireland) (Ham 2009). Although this responsibility is being reviewed in 
light of recent NHS reforms to allow General Practitioner (GP) led commissioning (Mannion 
2011). Broadly, there are three levels of care provided to patients in the UK: primary, 
secondary and tertiary. Primary care includes medical services provided by GPs and dentists. 
Pharmaceutical care is provided mainly through community pharmacies which are mostly 
privately owned businesses contracted to dispense NHS prescriptions (Noyce 2007). Secondary 
care (hospital based care) is accessed via the GP.  Tertiary care, typically involves specialised 
consultative care, usually on referral from primary or secondary medical care personnel. This 
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care involves advanced medical investigation and treatment such as cancer management or 
other complex medical and surgical interventions. 
2.3 Community pharmacies in England   
In 2010, there were 10,691 registered community pharmacies in England which dispensed 
813.3 million prescription items: an increase of 41.8 million (5%) from 2008-09 (NHS 
Information centre 2010). It has been estimated that over 80% of the income of community 
pharmacies is from dispensed NHS prescriptions (Noyce 2007). Approximately 1.8 million 
people visit a pharmacy in England every day and it has been estimated that 99% of the 
population, including people living in the most deprived areas, can access a community 
pharmacy within 20 minutes by car and 96% by walking or using public transport (DH 2008). 
There has been a trend over time towards the corporatisation of community pharmacy (Bush 
et al 2009; Gidman 2010).  ‘DƵůƚŝƉůĞƐ ? ĂƌĞ ƉŚĂƌŵĂĐŝĞƐ ƚŚĂƚ ĨŽƌŵ ƉĂƌƚ ŽĨ Ă ĐŚĂŝŶ ĐŽƌƉŽƌĂƚĞ
structure and are defined in the UK as owning 6 pharmacies or more with groups of 5 or fewer 
regarded as  ‘independent ?ƉŚĂƌŵĂĐŝĞƐ ?NHS Information Centre 2010). Approximately 62% of 
pharmacies in England are multiples. This compares with 17% in 1969 and 34% in 1995 (Hassell 
and Symonds 2001). Each community pharmacy is to be operated by a pharmacist and most 
pharmacists (71%) work within this sector. Amongst other roles, pharmacists are required to 
ƉĞƌĨŽƌŵ Ă  ‘ĐůŝŶŝĐĂů ĐŚĞĐŬ ?ŽŶ ƉƌĞƐĐƌŝƉƚŝŽŶƐ ƌĞĐĞŝǀĞĚ ?dŚŝƐ ŝƐ Ă ůĞŐĂů ƌĞƋƵŝƌĞŵĞŶƚ ĂŶĚ ƌĞƋƵŝƌĞƐ
the pharmacist to assess the appropriateness of the drug, the dose and the strength 
prescribed. They can delegate other stages of preparation or counselling to pharmacy support 
staff. A final accuracy check is typically undertaken by the pharmacist but this can be 
undertaken by Accredited Checking Technicians (ACTs) trained to perform this task. However, 
the pharmacist is legally responsible for each medicine dispensed and supplied.      
 
Community pharmacists are aided by support staff who typically include dispensing assistants 
or dispensers and Medicines Counter Assistants (MCAs). Dispensers support the pharmacist in 
the assembly of prescribed medicines including the generation of labels and can be involved in 
providing advice when handing out dispensed prescriptions. Dispensers are involved in a range 
of pharmacy support activities including receiving prescriptions from patients and ordering 
pharmaceutical stock. The DƐ ?ŵĂŝŶƌŽůĞŝƐƚŽƐƵƉƉŽƌƚƚŚĞĚĞůŝǀĞƌǇŽĨƐĞƌǀŝĐĞƐĂŶĚthe retail 
functions of the pharmacy. Their activities include the sale of non-prescription medicines 
according to protocols and under the supervision of the pharmacist, as well as advising 
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patients on self-limiting illnesses and basic healthy lifestyle. They may also be involved with 
the receipt of prescriptions and handing out of dispensed prescriptions.  
 
2.4 The 2005 community pharmacy contract 
The 2005 community pharmacy contract built on policy and professional ambitions to improve 
services to patients, reward for the quality of the services provided, to harness the skills of 
pharmacists and support staff in addition to providing minimum standards for pharmacy 
(Bellingham 2004; PSNC 2004). This differs from the previous contract from 1987 which 
focused on dispensing a high volume of prescriptions (Bellingham 2004). The reforms made to 
the contract have been welcomed by pharmacy representative bodies and leaders who have 
long-held ambitions to shape community pharmacy services for the future (PSNC 2004). The 
2005 pharmacy contract received significant support from pharmacy contractors who voted in 
favour of the proposed changes (Anon 2004).  
2.4.1 Structure of the 2005 community pharmacy contract  
The 2005 pharmacy contract differed from previous contracts as it moved away from 
remunerating pharmacies almost completely based on the number of prescriptions dispensed. 
The 2005 contract is made up of three different service levels.  Essential and Advanced services 
ĨŽƌŵƉĂƌƚŽĨƚŚĞŶĂƚŝŽŶĂůƉŚĂƌŵĂĐǇĐŽŶƚƌĂĐƚŝŶŶŐůĂŶĚĂŶĚtĂůĞƐĂŶĚƌĞŵƵŶĞƌĂƚĞ ‘ŶĂƚŝŽŶĂůůǇ
ĂŐƌĞĞĚ ? ƉŚĂƌŵĂĐǇ ƐĞƌǀŝĐĞƐ ? ŶŚĂŶĐĞĚ ƐĞƌǀŝĐĞƐ ŚĂǀĞ ƚŚĞŝƌƐĞƌǀŝĐĞ ƐƉĞĐŝĨŝĐĂƚŝŽŶƐ ĂŐƌĞĞĚ
nationally but are commissioned locally by PCOs (Noyce 2007; PSNC 2009). 
 
Essential services are offered by all pharmacy contractors. These are: dispensing of medicines; 
repeat dispensing (the management of repeatable NHS prescriptions); disposal of unwanted 
drugs; promotion of healthy lifestyles; signposting (provision of information on other health 
and social care providers); support for self-care (provision of advice and support to help people 
care for themselves or their families) and clinical governance requirements (to improve the 
quality of care provided) (PSNC 2009).   
 
Advanced services are optional for community pharmacies and typically require pharmacists to 
undertake additional training before they can be offered. The first Advanced service was 
commissioned in 2005 and is ƚŚĞ ‘DĞĚŝĐŝŶĞƐhƐĞZĞǀŝĞǁĂŶĚWƌĞƐĐƌŝƉƚioŶ/ŶƚĞƌǀĞŶƚŝŽŶ ?ƐĞƌǀŝĐĞ ?
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Other Advanced services include Appliance Use Reviews (AURs), which improve the patients ? 
ŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨĂŶǇ  ‘ƐƉĞĐŝĨŝĞĚĂƉƉůŝĂŶĐĞ ?  ?ƐƵĐŚĂƐĐ ƚŚĞƚĞƌŽƌ ŝŶĐŽŶƚŝŶĞŶĐĞĂƉƉůŝĂŶĐĞƐ )
and Stoma Appliance Customisation (SAC) which aims to ensure proper use and comfortable 
fitting of stoma appliances (PSNC 2011a). The New Medicine Service (NMS) which aims to 
provide support for people with long-term conditions on a newly prescribed medicine is set to 
be the fourth Advanced service scheduled to be introduced in October 2011 (PSNC 2011b). 
  
>ĂƐƚůǇĂƌĞƚŚĞ ‘ŶŚĂŶĐĞĚ ?ƐĞƌǀŝĐĞƐ ?WŚĂƌŵĂĐŝĞƐĂƌĞĂďůĞƚŽĂƉƉůǇƚŽƚŚĞŝƌůŽĐĂůWKƚŽƉĞƌĨŽƌŵ
these according to needs of the local community. The wide range of services indicates the 
broad scope of community pharmacist activities (Figure 1).  
 
 
 
Anticoagulant monitoring service 
Care home service including care home staff training 
Clinical medication review (typically within GP practice, intermediate care facility or patient ?Ɛ
home and with access to patient notes) 
Head lice prescribing and supply service 
Minor ailments service 
Out of hours dispensing 
Prescribing (supplementary or independent prescribing) 
Substance misuse services (needle and syringe exchange, supervised consumption)  
Sexual health services (Chlamydia screening and treatment, emergency hormonal 
contraception (EHC))  
Vascular services (screening, BP measurement, diabetes screening service, weight 
management services, stop smoking service) 
 
 
Figure 1: Range of community pharmacy Enhanced services (PSNC 2011c) 
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2.4.2 The Medicines Use Review and Prescription Intervention service 
The MUR service is the first NHS funded service that remunerates community pharmacists for 
undertaking a documented face-to Wface consultation with a patient specifically to discuss their 
medication. In England, over 2 million MURs were conducted in the 2010-2011 financial year at 
a cost of £58.8m (PSNC 2011d). Patients are eligible for the service if they are taking two or 
more medicines for long term conditions and who have been using the pharmacy for the 
dispensing of prescriptions for at least the previous three months. Local PCOs also have been 
empowered to identify specific patient target groups, such as patients with asthma, based on 
the needs of the local community. Currently, each pharmacy is entitled to claim £28 
reimbursement from the NHS for each MUR performed. Since 2006, payments for MURs have 
been capped at a maximum of 400 (originally 200) MURs each year.  Similar medication 
reviews form part of community pharmacy services in Australia (Commonwealth Department 
of Health and Aged Care 2001), the United States (DaVanzo et al 2005; Thompson 2008), 
Germany (Blenkinsopp and Celino 2006) and more recently in New Zealand (Lee et al 2009). 
 
MURs are typically performed annually and can be prompted either by a request from a 
patient who meets the eligibility criteria for an MUR, pro-actively by the pharmacist or a 
referral from the GP ?   ‘WƌĞƐĐƌŝƉƚŝŽŶ /ŶƚĞƌǀĞŶƚŝŽŶ ? ĐĂn also trigger an MUR in response to a 
 ‘significant problem ? ǁŝƚŚ Ă ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐĂƚŝŽŶ ? dŚŝƐ ŝƐ ŵŽƐƚ ůŝŬĞůǇ ƚŽ ŽĐĐƵƌ ĂƐ ƉĂƌƚ ŽĨ ƚŚĞ
dispensing process. A significant problem has been described as an intervention which requires 
more than brief advice which a pharmacist would make as part of the essential level 
dispensing service (PSNC 2009). Whether the MUR is an annual review or a Prescription 
Intervention MUR, the consultation needs to be performed in a consultation room. The 
specifications for these rooms have been left deliberately flexible in order for pharmacy 
contractors to work within the physical limitations of their pharmacies (Buisson 2005). 
Performing MURs offers the pharmacist an opportunity for a private and more detailed 
discussions about the ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞƐrather than the brief counselling interaction that 
typically occurs on the shop floor. The underlying purpose of the MUR service is described in 
the following section.  
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2.4.2.1 Aims of the MUR 
The MUR involves completion of a national standard form (Appendix Two).  ‘sĞƌƐŝŽŶ ? ?ĨŽƌŵ
is currently used after the Department of Health (DH) and Pharmaceutical Services Negotiating 
Committee (PSNC) sought to streamline the original MUR form following feedback from GPs 
and pharmacists (PSNC 2007). Information that the pharmacist is expected to elicit from the 
patient in order to complete this includes whether they use the medicine as prescribed, 
ǁŚĞƚŚĞƌ ƚŚĞǇ ŬŶŽǁ ƚŚĞ ŵĞĚŝĐŝŶĞ ?Ɛ ƉƵƌƉŽƐĞ ? ŝĨ ƚŚĞ ĨŽƌŵƵůĂƚŝŽŶ ŝƐ ĂƉƉƌŽƉƌŝĂƚĞ ĂŶĚ ƌĞƉŽƌƚĞĚ
side effects. The format of the form is  ‘tick-box ? allowing a yes/no response to questions. The 
DH has set out the underlying purpose of the MUR service ǁŚŝĐŚ  ‘ĂŝŵƐ ? ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
agreement, to improve his or her knowledge and use of drugs ? (DH 2005a: 2). This purpose is to 
be achieved through: 
 
a) ƐƚĂďůŝƐŚŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐĂĐƚƵĂůƵƐĞ ?ƵŶĚĞƌƐƚĂŶĚŝŶŐĂďŽƵƚĂŶĚĞǆƉĞƌŝĞŶĐĞŽĨƚĂŬŝŶŐ
his or her medications; 
b) Identifying, discussing and resolving poor or ineffective use of medicines by the 
patient; 
c) Identifying side effects and drug interactions that may affect patient compliance and 
d) Improving the clinical and cost-effectiveness of prescribed medicines thereby 
reducing the wastage of such drugs. 
 (DH 2005a: 2) 
 
Furthermore, the MUR service specification provides guidance on what is expected from the 
pharmacist:  
  
 “The pharmacist will perform an MUR to help assess any problems patients have with 
ƚŚĞŝƌŵĞĚŝĐŝŶĞƐĂŶĚƚŽŚĞůƉĚĞǀĞůŽƉƚŚĞƉĂƚŝĞŶƚ ?ƐŬŶŽǁůĞĚŐĞĂďŽƵƚƚŚĞŝƌŵĞĚŝĐŝŶĞƐ ? ?  
(PSNC 2009) 
 
In the following section, I situate the MUR service firstly in relation to other medication review 
services that the patient may receive and secondly with other patient-pharmacist interactions 
that typically occur in the pharmacy.          
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2.4.3 Situating MUR services 
In the UK, the first recognised requirement that medication reviews should be carried out 
ĂƉƉĞĂƌĞĚǁŝƚŚŝŶƚŚĞEĂƚŝŽŶĂů^ĞƌǀŝĐĞ&ƌĂŵĞǁŽƌŬ  ?E^& )ĨŽƌKůĚĞƌWĞŽƉůĞǁŚŝĐŚǁĂƐƚŚĞ  “first 
ever comprehensive strategy to ensure fair, high quality, integrated health and social care 
services for older people ? (DH 2001: i). This strategy suggested that all people over 75 years 
should have their medicines reviewed at least annually and those taking 4 or more medicines 
every 6 months. These reviews typically occurred with the patieŶƚƐ ?GP at the surgery. Clarity 
over what constituted a medication review was provided by the medicines partnership (Figure 
2).  
 
 
 
Level 0 - Ad hoc (Unstructured, opportunistic review) 
Level 1 - WƌĞƐĐƌŝƉƚŝŽŶƌĞǀŝĞǁ ?dĞĐŚŶŝĐĂůƌĞǀŝĞǁŽĨĂůŝƐƚŽĨƉĂƚŝĞŶƚƐ ? medicines) 
Level 2 - dƌĞĂƚŵĞŶƚƌĞǀŝĞǁ ?ZĞǀŝĞǁŽĨŵĞĚŝĐŝŶĞƐǁŝƚŚƉĂƚŝĞŶƚ ?ƐĨƵůůŶŽƚĞƐ ) 
Level 3 - ůŝŶŝĐĂůŵĞĚŝĐĂƚŝŽŶƌĞǀŝĞǁ ?ZĞǀŝĞǁŽĨŵĞĚŝĐŝŶĞƐǁŝƚŚƉĂƚŝĞŶƚ ?ƐĨƵůůŶŽƚĞƐĂŶĚǁŝƚŚƚŚĞ
patient) 
 
 
Figure 2: Medication review classification: Task Force on Medicines Partnership and the National 
collaborative Medicines Management Services Programme (2002: 6)    
 
 
Reforms to the General Medical Services Contract in 2006 led to medication reviews becoming 
a formal part of the Quality and Outcomes Framework (QOF) (DH 2004). With only level 1 and 
2 reviews being specified within the early QOF framework, medication review activity could be 
undertaken without the patient being present. The lack of a patient-centred approach to 
medication reviews and the introduction of MURs led to a clarified framework (Clyne et al 
2008). Three new classifications for medication review have been proposed (Figure 3). 
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Prescription review - Intended to identify prescription anomalies such as duplicate 
prescribing and does not require the patient or their clinical notes to be present at the 
review (includes Prescription Intervention MURs).  
Concordance/compliance review - Addresses patient medicines-taking behaviours and 
designed to discover patient views of their medicines and their willingness to take 
them (includes MURs). 
Clinical review - Includes consideration of both prescribed and purchased medicines 
and must be undertaken with the patient and with their clinical notes to enable a 
holistic view of the appropriateness of the medicines in relation to their conditions.  
 
 
Figure 3: Current medication review classification (Clyne et al 2008) 
 
MURs have been recognised as a concordance / compliance review. Under these reviews the 
ƉƌĂĐƚŝƚŝŽŶĞƌƐŚŽƵůĚĞǆƉůŽƌĞƉĂƚŝĞŶƚƐ ?ĂĐƚƵĂůŵĞĚŝĐŝŶĞƚĂŬŝŶŐ ?WĂƚŝĞŶƚƐƐŚŽƵůĚĂůƐŽďĞĂďůĞƚŽĂƐŬ
ƋƵĞƐƚŝŽŶƐĂŶĚƚŚĞƌĞƐƉĞĐƚĨŽƌƚŚĞƉĂƚŝĞŶƚƐ ?ďĞůŝĞĨƐĂďŽƵƚŵĞĚŝĐŝŶĞƐŝƐĐĞŶƚƌĂůƚŽƚŚĞŵĞĚŝĐĂƚŝŽŶ
review process (Clyne et al 2008). With prescription and clinical reviews typically occurring at 
the GP ?Ɛ surgery under the QOF framework, there is little understanding of how MURs 
delivered from community pharmacies have been contextualised by patients. Likewise, there 
has been no research comparing MUR activity with other interactions that occur in the 
ƉŚĂƌŵĂĐǇ ?dŚĞƐĞ ‘ƚƌĂĚŝƚŝŽŶĂů ?ƉĂƚŝĞŶƚ-pharmacist interactions are discussed next.   
 
2.5  ‘dƌĂĚŝƚŝŽŶĂů ? patient-pharmacist interactions in 
community pharmacies  
Most patient-pharmacist interactions in ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝĞƐ ŽĐĐƵƌ ŽŶ ƚŚĞ  ‘ƐŚŽƉ-ĨůŽŽƌ ?
when the pharmacist supplies dispensed medicines to patients. This encounter, described in 
ƚŚĞh<ĂƐ ‘ĐŽƵŶƐĞůůŝŶŐ ? ?ƚǇƉŝĐĂůůǇƐĞĞŬƐƚŽĞŶƐƵƌĞƚŚĂƚƚŚĞĚŝƌĞĐƚŝŽŶƐŽŶƚŚĞůĂďĞůƐŽĨĚŝƐƉĞŶƐĞĚ
products are understood (RPSGB 2009). Variations in how pharmacists provide information on 
prescribed medicines have been reported. For example, information on directions, medicine 
name, and indications for use were given more frequently than information on side effects, 
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cautions and interactions (Laaksonen et al 2004; Puspitasari et al 2009). However, the 
ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚƐ ? ĐŽŶƐƵůƚĂƚŝǀĞ ƌŽůĞ ƌĞŵĂŝŶƐunderdeveloped and the concept of 
 ‘ƉĂƚŝĞŶƚĐŽƵŶƐĞůůŝŶŐ ?ƉŽŽƌůǇĚĞĨŝŶĞĚ ?WŝůŶŝĐŬ  ? ? ? ? ) ?^ƚƵĚŝĞƐ ĂƐƐĞƐƐŝŶŐĐŽƵŶƐĞůůŝŶŐƉĞƌĨŽƌŵance 
have revealed that pharmacist counselling is usually based on a one-way communicative and 
information deficit model, where the pharmacist provides information to the patients without 
actively engaging them in the process (Heath 2003; Pilnick 2003; Rutter et al 2004). Shah and 
Chewning (2006) found that the definition of patient counselling varied across studies with half 
conceptualising patient-ƉŚĂƌŵĂĐŝƐƚ ĐŽŵŵƵŶŝĐĂƚŝŽŶ ĂƐ ŝŶĨŽƌŵĂƚŝŽŶ ƉƌŽǀŝƐŝŽŶ ? WŚĂƌŵĂĐŝƐƚƐ ?
attitude to focus upon pharmacological knowledge without consideration of the patient as an 
ŝŶĚŝǀŝĚƵĂů ŚĂƐ ďĞĞŶ ƐƵŐŐĞƐƚĞĚ ƚŽ ĚĞǀĂůƵĞ ƉĂƚŝĞŶƚƐ ? ƉĞƌƐŽŶĂů ƵŶĚĞƌƐƚĂŶĚŝŶŐ ŽĨ ƚŚĞŝƌ ŽǁŶ
situation and negatively affect care (Ramalho de Oliveira and Shoemaker 2006). The 
predominantly information-based focus of patient-pharmacist interaction means that 
counselling in the pharmacy context carries a somewhat different meaning to that in other 
settings, such as psychotherapy, where there is a process of subjective scrutiny and greater 
engagement with, and contribution from, the client (Greenhill et al 2011; Pilnick 2003; Shah 
and Chewning 2006). 
  
Another patient-professional interaction relates to over-the-counter (OTC) sales of medicines. 
These are initiated by the patient and can involve the request to buy a medicine or to seek 
advice on treating an ailment. The pharmacist here offers of a professional opinion about a 
course of action, whilst allowing the final decision about how to manage the condition to lie 
with the patient (Owen et al 2000). This contrasts with counselling offered on dispensed 
ŵĞĚŝĐŝŶĞƐǁŚĞƌĞƉĂƚŝĞŶƚƐ ?ŝŶĨŽƌŵĂƚŝŽŶŶĞĞĚƐŵĂǇďĞĂƐƐƵŵĞĚƚŽŚĂǀĞďĞĞŶĂĚĚƌĞƐƐĞĚďǇƚŚĞ
GP and where patients lack interest in receiving further information on their subsequent refill 
prescriptions (Hassell et al 1998; Hirsch et al 2009; Puspitasari et al 2010). Although OTC 
interactions potentially offer more scope for the pharmacist to explore patientƐ ? perspectives 
and concerns, they are usually problem-specific and have attracted criticism as lost 
opportunities to discuss wider health issues (Hassell et al 1998; Smith et al 1990). Most OTC 
sales of medicines are routinely undertaken by MCAs. MCA-patient interactions have been 
shown to be complex, characterised by multiple discourses in which both parties commit to 
legitimise the MCA as a medical advisor (Banks et al 2007). MCAs play a gatekeeper role and 
pharmacist involvement typically occurs when MCAs want more specialist advice or if 
requested by a patient (Ylänne and John 2008).  
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MURs present an opportunity for pharmacists to extend their currently limited counselling role 
by engaging in wider discussions of patient beliefs and concerns about their medicines. 
However, as Latter et al (2000) suggest, the extent to which patients are able to participate 
may be influenced by previous expectations about the roles and relationships that have been 
formed during patient and health-professional interactions. This was found in their study of 
ŶƵƌƐĞƐ ?ĐŽŶƚƌŝďƵƚŝŽŶƚŽŵĞĚŝĐĂƚŝŽŶĞĚƵĐĂƚŝŽŶ ?ĚǀŝĐĞŚĞƌĞǁĂƐĨŽƵŶĚƚŽďĞ ůŝŵŝƚĞĚƚŽ simple 
information giving about medicines such as the name, purpose and number of tablets with 
little evidence of assessment of health beliefs, establishing patient learning needs, mutual goal 
setting and shared decision-making. The author concluded that nurses considered that 
patients did not wish to know more about their medicines and that they did not expect nurses 
to provide further advice. This raises questions about MUR activity and how the patient and 
pharmacist are interpreting this role in practice.    
 
In this section, I have provided an outline of the 2005 pharmacy contract and of the MUR 
service.  I have briefly discussed the aims of the MUR and the wider context in which MURs lie 
within the scope of medication review activity provided by others. I have also described some 
of the existing patient-pharmacist interactions that occur in the pharmacy. In order to better 
understand how the role of the pharmacist has developed, the next section briefly describes 
the historical context which has brought about these changes.  
 
2.6 Historical role development of pharmacists 
Hepler and Strand (1990) have described three periods that reflect the pharmacy ƉƌŽĨĞƐƐŝŽŶ ?Ɛ
distinctive function, obligations and social role. The first period is ĚĞĨŝŶĞĚ ĂƐ ƚŚĞ  ‘traditional 
stage ? of the ƉŚĂƌŵĂĐŝƐƚ ?ƐƉƌŽĨĞƐƐŝŽŶĂůĚĞǀĞůŽƉŵĞŶƚ. This occurred as pharmacists entered the 
twentieth century performing the social role of apothecary together with the knowledge and 
the skills needed to compound a drug product (Mrtek and Catizone 1989). The second period 
ŝŶǀŽůǀĞĚ Ă  ‘transitional stage ?  ? ? ? ? ?-1970) that was facilitated by the realisation that 
compounding medicines from their constituent ingredients was in decline due to the 
developments of industrialisation and large scale manufacturing by the pharmaceutical 
industry. It has been noted that over the past 60 years the pharmacy profession has lost three 
of the four functions that have traditionally been the mainstay of its work; drug procurement, 
storage and the compounding of medicines. Dispensing of medicines according to a 
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ƉƌĞƐĐƌŝďĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶ ŝƐ ƚŚĞ ŽŶůǇprominent remaining function (Harding and Taylor 1997; 
Mrtek and Catizone 1989).  
 
The creation of the NHS in 1948 was another major factor in determining the course of UK 
community pharmacy practice. Prior to 1948, dispensing accounted for less than 10% of 
community pharmacy ?s income. This situation changed following 1948 as dispensing activity 
grew quickly because most of the population obtained free or subsidised medicines following 
consultations with doctors (Anderson 2001). Previous activities such as dispensing private 
prescriptions, counter prescribing activities and sales of proprietary medicines declined and 
the increase in prescription numbers effectively meant that pharmacists moved from the front 
of the shop to the dispensary in order to prepare and label medicines. Consequently, 
pharmacists faded from public view as their purpose quickly became accuracy checking 
prescriptions that had been assembled by others (Anderson 2001).  
 
ƐĂƌĞƐƵůƚŽĨƚŚĞ ‘transitional stage ?ƉŚĂƌŵĂĐŝƐƚs were seen to have lost control over many of 
the qualities that pharmacy had relied upon for its professional existence. This gave rise to 
assertions that pharmacy was ĂŶ ‘incomplete profession ?ĚƵĞto  “its failure to gain control over 
the social object [the drug] which justified the existence of its professional qualities in the first 
place ? (Denzin and Metlin 1968: 378). Growing attention focused on  ‘ƌĞ-ƉƌŽĨĞƐƐŝŽŶĂůŝƐĂƚŝŽŶ ?
towards a more clinical role for pharmacists (Birembaum 1982; Edmund and Calnan 2001; 
Gilbert 1998). This has resulted in the final stage for the profession which has been described 
ĂƐƚŚĞ ‘patient care ? stage where pharmacists find themselves faced with new patient-oriented 
roles. MURs are one such extended role. There is a strong political desire for patients to 
adhere to their medicines and to reduce the cost associated with avoidable medicines wastage 
and the MUR service is part of a strategy to address this. The MUR service has therefore 
evolved from several political and professional motivations to re-professionalise and take 
advantage of community pharmacists potential ?WŚĂƌŵĂĐǇ ?Ɛ professional agenda to extend the 
role of the community pharmacist is discussed below.  
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2.7 Professionalising agendas and the extended role 
DĂĐĚŽŶĂůĚ  ? ? ? ? ? ) ŚĂƐ ƵƐĞĚ ƚŚĞ ƚĞƌŵ  ‘professional project ? ĨŽƌ ŽĐĐƵƉĂƚŝŽŶĂů ŐƌŽƵƉƐ ǁŚŽ ĂƌĞ
involved in a strategy of professionalisation. A professionalising project aims to convince the 
state and the public that the work of the occupational group is reliable and valuable. Work by 
the occupational group that promotes  ‘mystical ? or  ‘esoteric ? knowledge can be said to 
increase the knowledge gap between them and the clients they serve, creating dependency 
and an opportunity for autonomous work (Harding and Taylor 2001). Medicine and law 
represent the typical current model of an established profession and so provide an 
authoritative example and benchmark for other occupations embarking on professional 
projects (Etzioni 196 ?ʡ:ŽŚŶƐŽŶ ? ? ? ? ) ?  
 
Historically, pharmacists in their original role as compounders of medicines controlled an 
ĞǆĐůƵƐŝǀĞĨŝĞůĚŽĨŬŶŽǁůĞĚŐĞƚŚĂƚǁĂƐƐĞĞŶĂƐ ‘ŵǇƐƚŝĐĂů ?. However, as discussed in the previous 
ƐĞĐƚŝŽŶ ?ƚŚĞ  ‘ƚƌĂŶƐŝƚŝŽŶĂů ? ƐƚĂŐĞ ĨŽƌ ƚŚĞƉŚĂƌŵĂĐy profession (Hepler and Strand 1990) led to 
the profession of pharmacy to embark on a process of re-professionalisation (Edmund and 
Calnan 2001). Concerns over pharmacists ? deskilling and dissatisfaction with their public image 
as commeƌĐŝĂůůǇŵŽƚŝǀĂƚĞĚ ‘ƐŚŽƉŬĞĞƉĞƌƐ ? also influenced this process (Eaton and Webb 1979; 
Francke 1969; Hughes and McCann 2003). Professional initiatives have sought ways for 
pharmacists to move away from the mechanical aspect of dispensing and sale of retail 
products towards extending the pharmacists ? role in more patient-centred and advisory 
services (Cipolle et al 1998; Hepler and Strand 1990; Nuffield Committee of Inquiry into 
Pharmacy 1986; Noyce 2007; Roberts et al 2006; RPSGB 1996; RPSGB 1997a; Simpson 1997; 
Tully et al 2000). However, extending the role of community pharmacists has not always been 
welcomed by other professions such as medicine. The reasons for this have been because of 
the perceived potential threat to the autonomy of the medical profession and its contribution 
towards blurring of professional boundaries (Britten 2001; Hughes and McCann 2003; 
Macdonald 1995).  
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2.8 WŚĂƌŵĂĐŝƐƚƐ ?ĞǆƚĞŶĚĞĚ role activity and user attitudes   
Over the last 20 years, community pharmacists have diversified their practice to become 
involved with many services including health promotion activities, prevention of illness (e.g. 
smoking cessation, immunisation, travel services), contraception and sexual health advice, 
screening for ill health (e.g. blood pressure, blood glucose, cholesterol levels, Chlamydia 
screening), HIV prevention through syringe and needle exchange schemes and supporting 
patients with long-term conditions (e.g. diabetes, asthma, hypertension) to manage their 
conditions better (Anderson et al 2008; Noyce 2007). Anderson et al (2008) in their review on 
ƚŚĞĐŽŶƚƌŝďƵƚŝŽŶŽĨĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐǇƚŽŝŵƉƌŽǀŝŶŐƚŚĞƉƵďůŝĐ ?ƐŚĞĂůƚŚindicated that there 
is a substaŶƚŝĂů ďŽĚǇ ŽĨ ĞǀŝĚĞŶĐĞ ĨŽƌ ƉŚĂƌŵĂĐŝƐƚƐ ? positive contribution, both in the UK and 
internationally. Changes to UK legislation have provided opportunities for pharmacists to 
extend their role to prescribing activity. However, community pharmacist involvement is 
uncommon and overall pharmacist prescribing activity in other settings represents an 
extremely small proportion of total primary care prescribing (Guillaume et al 2008). Concerns 
have been raised by the medical profession to extending prescribing rights to those who may 
lack appropriate training in diagnosis (Avery and Pringle 2005). However, a study has found 
that the barriers to pharmacist prescribing tend to be logistical and organisational rather than 
arising from inter-professional tensions (Lloyd et al 2010).   
 
Despite the range of activities undertaken by community pharmacists, peoples ? ƵƐĞ of 
pharmacies remains predominantly for prescription supplies and purchase of OTC medicines 
(Anderson et al 2004). WĞŽƉůĞƐ ?ƉĞƌĐĞƉƚŝŽŶŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚ ?s role has been portrayed as one 
ŽĨ ‘ĚƌƵŐƐĞǆƉĞƌƚƐ ?ƌĂƚŚĞƌƚŚĂŶĞǆƉĞƌƚƐŽŶŚĞĂůƚŚĂŶd illness (Anderson et al 2004). Consumers 
have expressed high levels of satisfaction with services such as EHC and Chlamydia screening 
(Anderson et al 2004; Eades et al 2011). Consumer views of public health activities in 
community pharmacy indicate they view pharmacists as appropriate providers of public health 
advice but their lack of regular involvement in the patients health care means they hold mixed 
ǀŝĞǁƐŽŶƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĂďŝůŝƚǇƚŽĚŽƚŚŝƐ ?ŶĚĞƌƐŽŶĞƚĂů ? ? ? ? ?ĂĚĞƐĞƚĂů ? ? ? ? ) ?dŚĞŶĞĞĚ
for pharmacy services has been shown to be determinĞĚ ďǇ ƚŚĞ ŝŶĚŝǀŝĚƵĂů ?Ɛ ƐƵďũĞĐƚŝǀĞ
evaluation of the perceived value and appropriateness for the service (Hassell et al 1999). 
Patients have also expressed concern where the pharmacist would have access to selected 
information from medical records (Iverson et al 2001).There has been little research into 
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whether patients perceive a need for the MUR service or to what extent this is being accepted 
and valued by patients.  
2.8.1 ƌŝƚŝƋƵĞŽĨƉŚĂƌŵĂĐǇ ?ƐƌŽůĞĞǆƚĞŶƐŝŽŶ 
New patient-centred roles offer pharmacy the prospect of an enhanced professional status. 
However, it has been suggested that this can occur only if knowledge is utilised with the skill, 
judgement and experience necessary to practice at an appropriate level of competency as 
determined by academics, regulators and the public (Macdonald 1995; Mrtek and Catizone 
1989). Patient-ĐĞŶƚƌĞĚ ƌŽůĞƐ ŚĂǀĞ ƚŚĞ ƉŽƚĞŶƚŝĂů ĨŽƌ ŝŶĐƌĞĂƐŝŶŐ ƚŚĞ ůĞǀĞůŽĨ  ‘ŝŶĚĞƚĞƌŵŝŶĂĐǇ ? ŝŶ
pharmacists ? work. This refers to the component of the work which is based on specialist 
knowledge, its interpretation and the use of professional judgement. It contrasts with 
 ‘ƚĞĐŚŶŝĐĂůŝƚǇ ? ǁŚŝĐŚrefers to those aspects of the work which can be subject to routine, 
formulaic practices (Jamous and Peloille 1970). According to Jamous and Peloille (1970) 
professional status is associated with the capacity of occupations to maintain indeterminacy in 
their practice; increasing technicality is therefore associated with a reduction in professional 
status. Using medicine as an example, doctors are viewed as professionĂůƐ ĂƐ ƚŚĞǇ  ‘believe 
ǁŚĂƚƚŚĞǇĂƌĞĚŽŝŶŐ ?ĂŶĚƚƌƵƐƚ personal, over book knowledge (Freidson 1994).  
 
Dingwall and Wilson (1995:125) have argued that the social object of pharmacy is the 
 “ƐǇŵďŽůŝĐ ƚƌĂŶƐĨŽƌŵĂƚŝŽŶŽĨ ƚŚĞ ŝŶĞƌƚ ĐŚĞŵŝĐĂů ŝŶƚŽ ƚŚĞ ĚƌƵŐ ?. Harding and Taylor (1997) go 
ĨƵƌƚŚĞƌďǇĂĚĚŝƚŝŽŶĂůůǇƌĞĐŽŐŶŝƐŝŶŐƚŚĂƚƉŚĂƌŵĂĐŝƐƚƐƚƌĂŶƐĨŽƌŵƚŚĞƐĞŝŶƚŽ ‘medicines ? ?Harding 
and Taylor have highlighted problems associated with the extended role as a means of 
enhancing professional status and argue that re-professionalising strategies to extend the 
pharmacist ?Ɛ ƌŽůĞĂƌĞ “fundamentally flawed ? P 
 
 “The extended role, intended as a model for professional development, may ironically 
be considered to have a de-professionalising effect, in that by focusing on activities 
other than dispensing, the centrality to pharmacy of the dispensing process is not 
recognised. &ƵƌƚŚĞƌ ? ƚŚĞ ƐŽĐŝĂů ŽďũĞĐƚ ŽĨ ƉŚĂƌŵĂĐŝƐƚƐ ? ĂĐƚŝǀŝƚŝĞƐ ŝ ?Ğ ?ƚŚĞ ŵĞĚŝĐŝŶĞ ? ŶŽ
longer forms the focal point for many of the new roles ? ? 
(Harding and Taylor 1997:557) 
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The delegation of the dispensing task to other staff members means that pharmacy becomes 
ŶŽ ŵŽƌĞ ƚŚĂŶ ĂŶ  “exchange of prescription form and drug with no apparent input from a 
professional ?  ?,ĂƌĚŝŶŐ ĂŶĚ dĂǇůŽƌ  ? ? ? ? P557). They further argue there is no appreciation of 
professionalisation as a process. Success, which they view as being dependent upon promoting 
ƉŚĂƌŵĂĐŝƐƚƐ ? ĂĐƚŝǀŝƚŝĞƐ ĂƐ  ‘ŵǇƐƚŝĐĂů ? ĂŶĚ ƚŚĞŝƌ ŬŶŽǁůĞĚŐĞ ĂƐ  ‘esoteric ?, is eroded along with 
their professional identity. Furthermore, the routine nature of some of the services which have 
been implemented reduces the scope for professional judgement during patient / customer-
pharmacist interactions. This has led to extended services being ƌĞĚƵĐĞĚ ƚŽ  “no more than 
asking structured, formulaic questions ?  ?,ĂƌĚŝŶŐand Taylor 1997:556). The rationalisation of 
health services is discussed in the following section. 
 
2.9 The rationalisation of health services 
Policy analysis theory offers two main perspectives for policy implementation approaches. The 
 ‘top-down ? approach sees implementation as a rational process that can be pre-planned and 
controlled by the central planners responsible for developing policies. (Barrett and Fudge 
1981; Hogwood and Gunn 1984). The  ‘bottom-up ? approach (Barrett and Fudge 1981; Hjern 
and Porter 1981; Lipsky 2010) sees policy change as a much more dynamic and interactive 
process and emphasises the need to understand the ĐŽŶƚĞǆƚ ŽĨ ƉĞŽƉůĞ ?Ɛ ǁŽƌŬ ŝŶ ŽƌĚĞƌ ƚŽ
understand why policies do not achieve expected outcomes. For effective policy 
implementation to occur, a balance should be made ďĞƚǁĞĞŶ ƚŚĞ ĚĞĐŝƐŝŽŶĂů  ‘ƚŽƉ ĚŽǁŶ ?
perspective and action-ŽƌŝĞŶƚĞĚ  ‘ďŽƚƚŽŵƵƉ ? ?dŚŝƐ ŝƐƚǇƉŝĐĂůůǇĂnegotiative process, involving 
exchange and  ‘bargaining ? among a range of actors (Barrett and Fudge 1981).    
 
Health policies that are predominantly based upon rational theories of decision making have 
been argued to be flawed. North (1997) argues that this is because human cognition is unable 
to deal with the vast quantity of information that confronts policy makers and the resultant 
policy, oversimplifies complex processes. Ritzer goes further and has coined the term 
 ‘DĐŽŶĂůĚŝǌĂƚŝŽŶ ? ƚŽ ĚĞƐĐƌŝďĞ ŚŽǁ ƌŽƵƚŝŶĞ ƉƌŽĐĞƐƐĞƐ ĂŶĚƚŚĞŝƌ ƌĂƚŝŽŶĂů implementation not 
only affect policy, but are widespread in various institutions including politics, commerce, 
science and education, the leisure industry and even within the family (Ritzer 2008). Ritzer 
defines this process ĂƐƚŚĞ “McDonaldization of society ?which he defines as:  
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 “dhe process by which the principles of the fast-food restaurant are coming to 
dominate more and more sectors of American society as well as the rest of the world. ?  
(Ritzer 2008: 1).   
 
ZŝƚǌĞƌĐŚŽƐĞƚŚĞƚĞƌŵ ‘DĐŽŶĂůĚŝǌĂƚŝŽŶ ?ďĞĐĂƵƐĞƚŚĞƌĞƐƚĂƵƌĂŶƚĐŚĂŝŶDĐŽŶĂůĚƐƐĞƌǀĞƐĂƐĂ
contemporary example of such a process. Ritzer argues that economic success has come from 
the rationalisation process. Businesses like McDonalds, that have fashioned themselves on 
rational ways of working, have become successful because of greater consumer accessibility, 
convenience and uniformity of products and services (Ritzer 2008). Ritzer describes his 
McDonaldization model to include four intertwined dimensions: efficiency (choosing the 
optimum means to a given end), calculability (an emphasis on the number of products sold and 
the speed at which services are offered over their quality), predictability (the assurance that 
products and services will be the same over time and in all locations) and control through 
technologies which are constructed ultimately to replace people in order to eliminate 
uncertainty, unpredictability and inefficiency over the work performed (Ritzer 2008). Large 
scale manufacturing of pharmaceuticals over the past half century has had important 
implications for pharmacy practice and the professional ƌŽůĞ ŽĨ ƉŚĂƌŵĂĐŝƐƚƐ ? WŚĂƌŵĂĐŝƐƚƐ ?
activities themselves can also be viewed as increasingly becoming rationalised resulting in 
deskilling of the pharmacist. 
 
Ritzer does warn that although  ‘ƌĂƚŝŽŶĂůƐǇƐƚĞŵƐ ? appear to offer organisational success, they 
tend to spawn irrationalities that  “ůŝŵŝƚ ?ĞǀĞŶƚƵĂůůǇĐŽŵƉƌŽŵŝƐĞ and perhaps even undermine 
their rationality ?  ?ZŝƚǌĞƌ  ? ? ? ? P 141). He explains that this is predominantly the result of the 
whole process denying human reason in situations that require common-sense. A side effect of 
an over-rationalised system can lead to a deskilled workforce or worker burnout. 
Commentators have speculated that the dimensions of McDonaldization are evident in what 
has been referred to as the modern-ĚĂǇ  ‘DĐWŚĂƌŵĂĐǇ ? (Bush et al 2009; Harding and Taylor 
2000). Here, corporate focus is on standardising and rationalising the activities of pharmacies 
leading them to function more rationally, predictably and so more profitably. One irrational 
outcome however, was the subsequent deskilling of the ƉŚĂƌŵĂĐǇ ?Ɛworkforce. Harding and 
Taylor (2000) question ǁŚĞƚŚĞƌ ƚŚĞƌĞ ǁĂƐ Ă ŶĞĞĚ ĨŽƌ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ƵŶŝƋƵĞ ƐŬŝůůƐ ĂŶĚ
knowledge in this environment.  
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Pink (2009) also provides useful insights into how people ?Ɛ involvement and engagement in a 
service or activity is influenced by their motivation. He argues that the performance of many 
ƐŬŝůůĞĚƚĂƐŬƐƉƌŽǀŝĚĞƉĞŽƉůĞǁŝƚŚ “intrinsic reward ? ?dŚĂƚŝƐ ?ŚĞĞǆƉůĂŝŶƐ ?ƚŚĞũŽǇŽĨƚŚĞƚĂƐŬŝƐŝƚƐ
own reward. Pink identifies three elements underlying such intrinsic motivation: autonomy, 
the ability to choose how tasks are completed; mastery, the process of becoming adept at an 
activity and purpose, the desire to improve the world. Controversially, Pink argues that the 
introduction of external reward or punishment for not completing a task often leads to poorer 
performance. The reason for this is that the external reward led to a detrimental effect on the 
inherent intrinsic reward. Subjects lost intrinsic interest in the activity and so reduced their 
motivation to engage effectively. It is currently unknown to what extent pharmacists ? 
motivation is affected by the rewards or punishment they are subject to or to what extent the 
MUR service has been rationalised and what, if any, the irrational outcomes of these processes 
are. 
 
In this section, I have described how the profession of pharmacy has moved through three 
distinct periods as outlined by Hepler and Strand (1990) and how this has influenced the 
pharmacist ?s functions and professional practice. I have looked at the professionalising agenda 
that has produced an extended role for pharmacists and also the concerns expressed by some 
commentators about the implications of this agenda. The rationalisation of services that has 
come to dominate work has important implications for pharmacy. The  ‘top down ? rational 
approach to policy making without feedback on what is actually happening in practice 
potentially can lead to services to become irrational and ineffective. In this thesis, I provide a 
better understanding of these issues in relation to the MUR service. In the following section, I 
turn attention to the MUR service to highlight the different policy and professional 
perspectives that are being promoted. I explore the tensions between the different policy 
agendas for MURs, both as a means to increase adherence and so reduce avoidable medicine 
wastage versus the patient-centred and concordant model. I begin by providing a brief account 
of health policy development. 
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2.10 Health Policy and professional agendas   
There have been many attempts to define what a policy is, however, there is little agreement 
on the meaning of the word (Ham 2009). North (1997:23) describes a  ‘policy ? both as  “a 
statement of the current view of an issue and an attempt to standardise future action or 
responses in relation to that issue ? ?Health policy development and implementation involves 
complicated processes engaging civil servants, managers, elected members of an authority, 
professional bodies and pressure groups (Ham 2009). Furthermore, once a policy decision has 
been reached this can change or be adapted. This may arise following incremental adjustments 
following a review of the policy, feedback during its implementation or more unusually a major 
ĐŚĂŶŐĞ ŝŶ ƚŚĞƉŽůŝĐǇ ?ƐĚŝƌĞĐƚŝŽŶ (Ham 2009; North 1997). There may also be prioritisation of 
services based upon the cost and effectiveness of a service (Elliott and Payne 2005). UK health 
policy has undergone major reforms which have affected community pharmacy. Service 
development has become increasingly aligned with the political agenda of redesigning care 
around the patient and providing greater choice (DH 2000a; DH 2000b; DH 2003a; DH 2003b; 
DH 2005b; Forster and Gabe 2008; Ham 2009; Laine and Davidoff 1996) as well as personal 
responsibility through encouraging greater involvement of patients in their medicines 
management (Ham 2009; NICE 2009; North 1997). However, it has been argued that 
underlying these policy initiatives, there is a concern to reduce financial costs and shift the 
burden of responsibility for health care from the state onto the individual consumer; this 
sidesteps the responsibility for tackling the wider causes of ill health and inequality (Kendall 
and Moon 1997).  
 
Lipsky (2010) provides an analysis of actors on the front-line in public organisations. He defines 
 ‘street-level bureaucrats ? ĂƐ ƉƵďůŝĐ ƐĞƌǀŝĐĞ ǁŽƌŬĞƌƐ(such as police officers, teachers, health 
and social workers) who interact directly with people to deliver government policy. Actors who 
make policy decisions are rarely also responsible for its implementation (Ham 2010; Lipsky 
2010). Street-level bureaucrats are therefore often expected to carry out work that is 
rationalised or highly scripted to achieve the policy objectives. However, paradoxically, in 
practice, the tasks they are required to perform require improvisation and responsiveness to 
the individual case. Street-level bureaucrats have substantial discretion in the execution of 
their work but typically work in environments that are not conducive to the adequate 
performance of their jobs. They face high demand for their services and lack the organisational 
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and personal resources necessary to do the job effectively. This forces them to invent routines 
for mass processing to control the stress and complexity of day-to-day work.   
 
Lipsky (2010) argues that the decisions of street-level bureaucrats and the coping strategies 
they use, such as routinising and simplifying their job to deal with the uncertainties of their 
work, effectively became the public policies they carry out. The actions of these front-line 
workers have substantial and sometimes unexpected consequences for the actual direction 
and outcome of public policies. >ŝƉƐŬǇ ?ƐĂƌŐƵŵĞŶƚƐhave the potential for helping us to make 
sense of the impact of rational policy making on the relationship between service provider and 
consumer. There are no studies that have explored how the MUR policy is being interpreted 
and implemented in the real world setting of a community pharmacy and how this may impact 
on pharmacŝƐƚƐ ?ƉƌŽĨĞƐƐŝŽŶĂůŝƐĂƚŝŽŶ ?This study aims to provide insights that fill this gap. In the 
next section, I describe two perspectives that are influencing the direction of the MUR service. 
 
2.10.1  MUR policy perspectives  
One aim of MURs that has been promoted by the DH is that they should improve the  “clinical 
and cost-effectiveness of prescribed medicines thereby reducing the wastage of such drugs ? 
(DH 2005a: ? ) ? DhZƐ ŚĂǀĞ ĂůƐŽ ďĞĞŶ ĚĞƐĐƌŝďĞĚ ĂƐ Ă  “structured adherence-centred review 
(PSNC 2009). There is an assumption that patients are willing and able to undertake an MUR 
which would result in cost savings through better adherence to medicines and a reduction in 
avoidable waste. MURs have also been promoted as a concordance-based review (Clyne et al 
2008). Whilst this may be a more effective means of taking on board the perspectives of the 
patient, there is little known about how the service is operating or whether pharmacists are 
performing MURs based on the principles of concordance (NICE 2009; Pollock 2005; RPSGB 
1997b). In the following section, I discuss these differing perspectives to highlight the potential 
tensions that exist. The first MUR perspective that I consider is that of a political and 
professional agenda associated with biomedicine (Engel 1977; Nettleton 2006; North 1997) 
which seeks to promote adherence to medicine taking.  
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2.10.2 Compliance and adherence  
dŚĞ ƚĞƌŵƐ  ‘ĐŽŵƉůŝĂŶĐĞ ? ĂŶĚ  ‘ĂĚŚĞƌĞŶĐĞ ? ĂƌĞ ŽĨƚĞŶ ƵƐĞĚ ŝŶƚĞƌĐŚĂŶŐĞĂďůǇ ŝŶ ƚŚĞ medical 
consultation and patient satisfaction literature (Cribb and Barber 2005; Horne et al 2005; Lask 
2002; RPSGB 1997b) ?ŽŵƉůŝĂŶĐĞŝƐƚǇƉŝĐĂůůǇƵƐĞĚƚŽĚĞĨŝŶĞƚŚĞĞǆƚĞŶƚƚŽǁŚŝĐŚƚŚĞƉĂƚŝĞŶƚ ?Ɛ
ďĞŚĂǀŝŽƵƌ ŵĂƚĐŚĞƐ ƚŚĞ ƉƌĞƐĐƌŝďĞƌ ?Ɛ ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ  ?Conrad 1985; Hulka et al 1976). 
However, the use of the term is declining as it implies lack of patient involvement. Adherence, 
an alternative term, attempts to emphasise that the patient is free to decide whether to 
ĂĚŚĞƌĞƚŽƚŚĞĚŽĐƚŽƌ ?Ɛ recommendations and has ďĞĞŶĚĞƐĐƌŝďĞĚĂƐƚŚĞ ‘extent to which the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂǀŝŽƵƌ ŵĂƚĐŚĞƐ agreed recommendations from the prescriber ?  ?,ŽƌŶĞ Ğƚ Ăů
2005:33). Adherence to medicine taking is promoted as a means to avoid lost opportunities for 
health gain, unnecessary suffering and even death (DH 2001; Horne et al 2005; Pirmohamed et 
al 2004; Sackett and Snow 1979; Trueman et al 2010; Winterstein et al 2002). The 
consequences of non-adherence include a waste of scarce and expensive health care resource 
and also the incurring of personal and societal costs, for example, complications from chronic 
disease or formation of resistant infections (Ernst and Grizzle 2001; Horne et al 2005; Johnson 
and Bootman 1995; WHO 2003). One reason why there is an overt health policy strategy to 
ensure adherence is the costs associated with prescribed medicines. 
 
2.10.3 Medicines and the cost to the NHS 
Medication is the most common form of medical intervention provided by the NHS for the 
prevention and treatment of ill-health (Clyne et al 2008; Taskforce on Medicines Partnership 
2002). Approximately £10 billion per year is spent by the NHS on medicines which accounts for 
18% of NHS expenditure (Clyne et al 2008). In England, there has also been a steady increase in 
the number of prescription items dispensed in primary care: an increase of 58% over the last 
10 years (NHS Information centre 2010). Most reviews agree that between one third and a half 
of medicines prescribed long-term to treat chronic illnesses are not being taken as 
recommended (Horne et al 2005; RPSGB 1997b; WHO 2003). It has been estimated that 
annually over £100 million worth of dispensed NHS medicines go unused and are ultimately 
discarded (McGavock 1996; RPSGB 1997b; Trueman et al 2010). Interventions to improve 
medicine adherence have therefore been seen as a way to better manage health budgets 
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(WHO 2003). With the ever increasing costs associated with prescribed medicines, non-
adherence has major relevance to the health policy makers.  
 
2.10.4 Adherence to prescribed medicines  
Patient non-adherence has been classed as intentional, unintentional or both (Horne et al 
2005; Horne and Weinman 1999; NICE 2009). Unintentional non-adherence occurs when 
patients experience difficulty in following treatment recommendations due to individual 
constraints such as inadequate treatment understanding, forgetfulness or physical difficulties 
that prevent them from using their medication effectively. Problems of accessing prescriptions 
or the cost of medicines may be further causes of patient non-adherence. However, there is 
recognition that patients may intentionally decide not to take medications as instructed 
(Horne et al 2005; Horne and Weinman 1999; NICE 2009). This intentional non-adherence 
arises from beliefs, attitudes and expectations that influence ƉĂƚŝĞŶƚƐ ? motivation to begin and 
persist with the treatment regimen. These behaviours relate to how patients perceive their 
medicines and are further discussed in section 2.11.  
 
Despite extensive research into patient non-adherence, the most effective interventions to 
tackle these issues have not led to large improvements in adherence and treatment outcomes 
but such interventions are acknowledged as being costly (Elliott et al 2005; George et al 2008; 
Haynes et al 2002; Kripalani et al 2007; Pellegrino et al 2009). Many interventions are built 
predominately on an information deficit model (Heath 2003; Dunbar et al 1979) where it is 
assumed that ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂǀŝŽƵƌ ĐĂŶ ďĞ ĐŽƌƌĞĐƚĞĚ ďǇ ƉƌŽǀŝĚŝŶŐ ƚŚĞ ƌŝŐŚƚ ŝŶĨŽƌŵĂƚŝŽŶ ?
Combinations of educational and behavioural strategies have been considered to be most 
effective (George et al 2008; Horne et al 2005; Horne and Weinman 1999). Sackett et al (1985) 
acknowledged that the prescribing ŽĨĂŵĞĚŝĐŝŶĞŝƐĂ ‘ƚŚĞƌĂƉĞƵƚŝĐĞǆƉĞƌŝŵĞŶƚ ? ?ƚŚĞŽƵƚĐŽŵĞŽĨ
which is influenced by actions of the practitioner, in selecting an appropriate diagnosis and 
treatment, as well as the patient in adhering to the regimen. Current national guidelines on 
medication adherence have been provided to health care professionals in the UK to help 
patients become involved in making informed decisions about their medicines and how they 
can support patients to adhere to their prescribed treatment (NICE 2009). These guidelines 
recognise that professionals should identify whether the non-adherence is intentional or 
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unintentional and address these accordingly. The following section looks briefly at the role of 
health professionals in adherence related activities. 
 
2.10.5 Support from health care professionals  
The medical consultation between the patient and the prescriber has been shown to influence 
patient medicine taking behaviour (Cox et al 2007; Horne and Weinman 1999; Horne et al 
2005; NICE 2009; Pollock 2005; Stevenson et al 2004). Patients tend to adopt a passive role 
rarely offering their opinion or initiating discussion about any aspect of the treatment (Barry et 
al 2000; Barry et al 2001; Cox et al 2007; Makoul 1995; Pollock 2005; Stevenson et al 2004). 
Patients report their doctor to be their best source of information about medicines (Makoul 
1995). Some patients see their doctor as the only source of information about medicines 
(Britten 2008). Some people actively prefer the doctor to provide information and to trust 
what they consider to be expert judgement (Britten 2008; Lupton et al 1991).  
 
Community pharmacists may be suited to supporting patients with their medicines as it has 
ďĞĞŶ ĂƌŐƵĞĚ ƚŚĂƚ ƚŚĞƌĞ ŵĂǇ ďĞ ůĞƐƐ  ‘ƐŽĐŝĂů ĚŝƐƚĂŶĐĞ ? ďĞƚǁĞĞŶ ƉŚĂƌŵĂĐŝƐƚ ĂŶĚ ƉĂƚŝĞŶƚ ?
compared with patient and doctor (Blaxter and Britten 1996; Turner 1995). Therefore, there 
may be an opportunity for the patient to discuss medicine related problems with the 
pharmacist as a result of this more symmetrical relationship (Bissell and Traulsen 2005). 
>ŝŬĞǁŝƐĞ ? ƉŚĂƌŵĂĐŝƐƚƐ ŚĂǀĞ ďĞĞŶ ĚĞƐĐƌŝďĞĚ ĂƐ Ă  ‘ďƌŝĚŐĞ ?Žƌ  ‘ƚƌĂŶƐůĂƚŽƌ ? ďĞƚǁĞĞŶ ůĂǇ ĂŶĚ
professional care (Blaxter and Britten 1996). Despite this, people may not want additional 
information from the pharmacist because they feel that they have been given this by their 
doctor and some studies suggest that patients would much prefer to discuss their medicines 
with doctors rather than pharmacists (Stevenson et al 2004). Nevertheless, medication reviews 
have been described as a cornerstone of modern medicine management (Taskforce on 
Medicines Partnership 2002) and there is an increasing body of evidence supporting 
pharmacists undertaking medication review activity in the community.  
 
2.10.6 Medication reviews by pharmacists 
Before the advent of the 2005 pharmacy contract, a growing body of evidence suggested 
community pharmacists could play a greater ƌŽůĞ ŝŶ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ŵĂŶĂŐĞŵĞnt of their 
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medicines (Chen et al 1999a; Chen et al 1999b; Chen et al 2001; Hepler and Strand 1990;). 
Some studies showed improvements in adherence and clinical outcomes such as control of 
blood pressure (Blenkinsopp et al 2000; Lee et al 2006) and heart failure (Goodyer 1995). 
Other studies found the pharmacist intervention to be acceptable to the GP and were able to 
demonstrate cost savings (Krska et al 2001; Nathan et al 1999; Sorensen et al 2004; Sturgess et 
al 2003; Zermansky et al 2001). Domiciliary visits by pharmacists have also shown to lead to 
better compliance, drug storage practices and a reduced tendency for patients to hoard drugs 
(Begley et al 1997; Lowe et al 2000). An Australian study of home-based medication reviews 
demonstrated a reduction in hospital admissions of 25%, and also a reduction in out-of-
hospital deaths (Stewart et al 1998). Later studies also showed cost benefits of a pharmacist 
intervention with newly prescribed medicines (Elliott et al 2008). 
  
Despite this positive evidence, medication reviews by community pharmacists have come 
under increased scrutiny. One study published at the time when the MUR service was 
launched suggested that pharmacist medication reviews may have negative outcomes 
including increased hospital admissions, home visits by GPs and contribute to patient anxiety 
regarding their treatment (Holland et al 2005). Furthermore, in another study that explored 
patient-pharmacist discourse, pharmacists were found to provide advice that was not 
requested by the patient and that the medication review had the potential to threaten the 
ƉĂƚŝĞŶƚƐĂƐƐƵŵĞĚ “competence, integrity and self governance ? ?^ĂůƚĞƌĞƚĂů ? ? ? ? ) ?/ƚŚĂƐďĞĞŶ
suggested that medication review services by pharmacists should focus on at-risk populations 
rather than the older population in general (Lenaghan et al 2007).     
 
Prior to the start of the MUR service, a large randomised controlled trial (MEDMAN) was 
conducted, the results of which were particularly revealing (The Community Pharmacy 
Medicines Management Project Evaluation Team 2007). Patients with Coronary Heart Disease 
(CHD) were randomised to either a community pharmacy medicines management service 
 ?ĐŽŵƉƌŝƐĞĚ ŽĨ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ĂƐƐĞƐƐŝŶŐ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐĂƚŝŽŶĐŽŵƉůŝĂŶĐĞ ĂŶĚ ůŝĨĞƐƚǇůĞ  ?Ğ ?Ő ?
smoking habits, exercise and diet)) or their usual GP-based care. Findings from this study 
ƐŚŽǁĞĚ ƚŚĂƚ ƚŚĞ ŝŶƚĞƌǀĞŶƚŝŽŶ ĚŝĚ ŶŽƚ ĚĞŵŽŶƐƚƌĂƚĞ ĂŶǇ ƐŝŐŶŝĨŝĐĂŶƚ ĐŚĂŶŐĞ ŝŶ ƉĂƚŝĞŶƚƐ ?
management of CHD, as indicated by the number of patients prescribed aspirin, or reported 
lifestyle measures. However, the cost of the intervention was more than that of standard care 
(Scott et al 2007). The lack of observed change was explained by the high proportion of 
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patients already receiving appropriate treatment. The author suggested that this ceiling effect 
might have been avoided if pharmacists had targeted patients whose treatment was outside 
recommended guidelines.  
 
WĂƚŝĞŶƚƐ ? ǀŝĞǁƐ ǁĞƌĞ ĂůƐŽ ĞǆƉůŽƌĞĚ ĂƐ ƉĂƌƚ ŽĨ ƚŚĞ ƐĂŵĞ ƉƌŽũĞĐƚ ?  ƐƵƌǀĞǇ ŝŶĚŝĐĂƚĞĚ ƚŚĂƚ ƚŚĞ
pharmacist intervention was associated with a positive change in patient satisfaction and 
found that those who had the intervention were more willing than control patients to ask the 
pharmacist questions they felt unable or were unwilling to ask a GP. However, patients 
continued to prefer a GP-led service (Tinelli et al 2007). Interviews with 49 participants also 
indicated that patients hold positive views of the intervention (Bissell et al 2008). Pharmacists 
were found to provide a source of reassurance about illness and treatment. However, many 
respondents were unsure or had anxieties about pharmacists taking a more proactive role in 
making recommendations about changes to their treatment. In the following section, the 
international perspective on community pharmacists medication reviews is explored. 
 
2.10.7 Community pharmacy medication reviews: the international 
perspective 
^ĞǀĞƌĂů ĐŽƵŶƚƌŝĞƐ ŚĂǀĞ ĚĞǀĞůŽƉĞĚ ƚŚĞ ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ ƌŽůĞ ƚŽǁĂƌĚƐ ƌĞǀŝĞǁŝŶŐ
ƉĂƚŝĞŶƚƐ ? ƉƌĞƐĐƌŝďĞĚ ŵĞĚŝĐĂƚŝŽŶ ? ůŽŶŐƐŝĚĞ ƚŚĞ h< ? ƵƐƚƌĂůŝĂ ? ƚŚĞ hŶŝƚĞĚ ^ƚĂƚĞƐ  ?h^ ) ? EĞǁ
Zealand and more recently Switzerland have the most established services. However, there is 
recognition that these medication review services vary in their comprehensiveness, minimum 
competency requirements for pharmacists, levels of inter-professional collaboration and 
remuneration (Chen and De Neto Almeido 2007; McClure 2007; Roberts et al 2006). Patient 
views of these services have also been under researched.  
 
Introduced in 2001, the Australian Home Medicines Review (HMR) service is one of the longest 
established community pharmacy medication review service (Commonwealth Department of 
Health and Aged Care 2001). The HMR service was developed following negotiation by the 
pharmacy profession with the Australian Government to incorporate new, remunerated 
professional services into community pharmacies in order to better utilise the skills of 
pharmacists and for the community pharmacy network in Australia to remain viable (Roberts 
ĞƚĂů ? ? ? ? ) ?hŶůŝŬĞƚŚĞDhZƐĞƌǀŝĐĞ ?,DZƐĂƌĞƵŶĚĞƌƚĂŬĞŶǁŝƚŚŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐŚŽŵĞĂŶĚ'WƐ
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are remunerated for identifying patients for the service.  Greater collaboration between 
pharmacists and GPs, as seen in the HMR service, has been suggested to have more impact on 
improving patient outcomes, such as reductions in hospital admissions, than pharmacists 
working in relative isolation (Chen and De Neto Almeido 2007; Chen et al 1999a; Chen et al 
1999b; Chen et al 2001; Koshman et al 2008). However, like the MUR service, initial provision 
was slower than expected, with only 6.17% of GPs referring patients for a HMR up to May 
2003 (Rigby 2003) and only approximately 10% of the eligible general population receiving 
them (Roughead 2005). On-going facilitators for practice change have been identified and 
include improved relationships between pharmacists and GPs, better remuneration and 
pharmacy layout and improved team working (Roberts et al 2006).  
 
In the US, Medication Therapy Management (MTM) services provided by community 
pharmacists began to develop in the 1990s to assist GPs in managing clinical services and 
contain cost outcomes of drug therapy. MTM services have been described as a partnership 
between the pharmacist, the patient or their caregiver, and other health professionals and are 
designed to optimise therapeutic outcomes by improving adherence to medicines, enhance 
patient understanding of their medication and to reduce adverse drug events (DaVanzo et al 
2005; Thompson 2008). Community pharmacists in the US, as in many other developed 
countries, have historically been paid primarily for the dispensing and supply of medicines with 
the provision of information for prescription medicines typically supplied through patient 
information leaflets (Svarstad et al 2003). Formal MTM services were introduced more widely 
across the US in 2006 following reforms resulting from the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003 (Barnett et al 2009; Pellegrino et al 2009; 
Thompson 2008). This act required insurers to offer a MTM program to a target population of 
high-cost patients who are users of the ƐŽĐŝĂů ŝŶƐƵƌĂŶĐĞƉƌŽŐƌĂŵƐ ‘DĞĚŝĐĂƌĞ ?ĂŶĚ ‘DĞĚŝĐĂŝĚ ? ?
The targeted population include those patients receiving multiple medicines who are likely to 
spend more than US$ 4000 per year on these and those with several chronic conditions. These 
reforms have led to greater opportunities for community pharmacists to be reimbursed for 
medication management services (Pellegrino et al 2009; Barnett et al 2009).  
 
Few studies have quantified changes in the provision of pharmacist-provided MTM services 
over time. One study found that over a 7-year period, MTM had evolved from the provision of 
information for acute medications towards a more consultative service for patients receiving 
Chapter Two: Literature review  
28 
 
chronic medications (Barnett et al 2009). It has been suggested that this change is associated 
with increases in pharmacist reimbursement costs and pharmacist-estimated cost savings. 
However, it remains uncertain if this shift is a result of clinical need, documentation 
requirements, or reimbursement opportunities. Variations in the requirements of MTM 
programs have also been shown to exist between insurers as it is they who determine the 
education, skills and experience of MTM providers (Bluml 2005; Cameron 2005; DaVanzo et al 
2005). Nevertheless, each MTM service is designed to be a face-to-face consultation that is 
tailored to individual needs. It may involve assessment of physical and overall health status, 
and identification, assessment and resolution of medicine related problems as well as the 
monitoring of laboratory results if these are available. This, therefore, has the potential to be a 
more comprehensive review than the UK MUR service. The value of MTM services has yet to 
be fully assessed (The Lewin Group 2005). However, one study conducted in a clinic setting 
suggested that medication costs for older people could be reduced following a pharmacist 
MTM intervention (Stebbins et al 2005). Another study, that employed a pharmacist self-rated 
scale to measure the perceived value of MTM consultations, suggested that these services 
avoided GP and emergency room visits as well as hospital admissions (Barnett et al 2009).  
 
In New Zealand, Medicines Use Review and Adherence Support services (MURs) were 
introduced in 2007 and aimed to support adherence to medicines for selected patients (Lee et 
al 2009). Earlier community pharmacist involvement was through Pharmaceutical Review 
Services (PRS), which were funded by the Government from 1998 to 2004 and involved 
pharmacists undertaking a clinical review of medicines collaboratively with the patient and GP 
with access to clinical notes (Anon 2000). The New Zealand MUR has several similarities to the 
h< ŵŽĚĞů ? dŚĞ DhZ ŝƐ Ă ƐƚƌƵĐƚƵƌĞĚ ĐŽŶƐƵůƚĂƚŝŽŶ ŝŶǀŽůǀŝŶŐƌĞǀŝĞǁ ŽĨ Ă ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐĂƚŝŽŶ ?
identifying any practical or medication-related problems, and providing relevant information 
about these. Similar to the UK model, an MUR accreditation training course provided by the 
New Zealand College of Pharmacists must be completed before the service can be offered. 
One difference is that MURs are not nationally funded as they are in the UK and local schemes 
must be agreed with the local health authorities (Lee et al 2009). New Zealand MURs are 
reported to be provided in some parts of New Zealand however, there is a paucity of 
information on these services or patient views of them.   
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More recently Swiss community pharmacies have been given reimbursement opportunities to 
offer Polymedication-Checks that have been fashioned on the UK MUR (Messerli et al 2011) 
and other countries developing medication review services include Finland, Portugal, Canada 
and Germany (Blenkinsopp and Celino 2006; McClure 2007). In less developed countries there 
are less well evolved programmes and in these countries, insufficient training of professionals 
and lack of pharmacists have beĞŶĐŝƚĞĚĂƐďĂƌƌŝĞƌƐĨŽƌƉŚĂƌŵĂĐŝƐƚƐ ?ŝŶǀŽůǀĞŵĞŶƚŝŶŵĞĚŝĐĂƚŝŽŶ
review services (Silveira de Castro and Correr 2007). In this section, I have discussed 
community pharmacy medication reviews models occurring in other countries. The most 
effective of these appear to be those where there is greater collaboration between 
pharmacists and GPs built into the service, as in Australia. I have also considered the 
adherence-ĐĞŶƚƌĞĚ ĂŐĞŶĚĂ ĂŶĚ ĞǀŝĚĞŶĐĞ ĨŽƌ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ĐŽŶƚƌŝďƵƚŝŽŶ ƚŽ ƚŚŝƐ ƚŚƌŽƵŐŚ
patient medication reviews. However, as indicated, the effectiveness of these reviews has 
been challenged. The questions that are required to be asked as part of the MUR service are 
focused primarily to address unintentional non-ĂĚŚĞƌĞŶĐĞ ďǇ ƌĞŝŶĨŽƌĐŝŶŐ ƚŚĞ ƉƌĞƐĐƌŝďĞƌ ?Ɛ
instructions. Nevertheless, rĞƐƉĞĐƚĨŽƌƚŚĞƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞŝƐĂůƐŽƉƌŽŵŽƚĞĚĂƐƉĂƌƚŽĨƚŚĞ
MUR and this somewhat contrasting parallel agenda will be discussed further in the following 
section.   
 
2.11 MURs and the patient agenda 
The importance of recognisiŶŐ ƉĂƚŝĞŶƚƐ ? ďĞůŝĞĨƐ ĂŶĚ ƉƌĞĨĞƌĞŶĐĞƐ ĂďŽƵƚ ƚŚĞŝƌ ŵĞĚŝĐŝŶĞƐ ĂŶĚ
ƚŚĞŝƌ ĞĨĨĞĐƚ ŽŶ ƉĂƚŝĞŶƚƐ ? ďĞŚĂǀŝŽƵƌ ŚĂƐ ƐƚŝŵƵůĂƚĞĚ ƚŚĞ ƉƌŽŵŽƚŝŽŶ ŽĨ ŝŶƚĞƌǀĞŶƚŝŽŶƐ ƚŚĂƚ
ĞŶĐŽƵƌĂŐĞ ƉĂƚŝĞŶƚƐ ? ŝŶǀŽůǀĞŵĞŶƚ ŝŶ ƚŚĞŝƌ ĐĂƌĞ ĂŶĚ ĨŽƌ ƉĂƚŝĞŶƚ-centred services (Elliott et al 
2005; Haynes et al 2002; Kripalani et al 2007; Horne et al 2005; Horne and Weinman 1999; 
Laine and Davidoff 1996; NICE 2009; Vermeire et al 2001). WĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƚĂŬŝŶŐďĞŚĂǀŝŽƵƌ
and attitudes towards medicines is complex and I discuss these issues below. 
 
2.11.1  The complexity surrounding medicine taking   
Holme Hansen (1988) described modern drug therapy as being based upon technical-biological 
knowledge associated with the biomedical model of health care (Engel 1977; Nettleton 2006; 
North 1997) whereas patients' commonsense drug use is based on their experiences and 
evaluation. tŝůůŝĂŵƐĂŶĚĂůŶĂŶ ? ? ? ? ? )ĚĞƐĐƌŝďĞƚŚĞƉĂƚŝĞŶƚŵŽƌĞĂƐĂ ‘ĐŽŶƐƵŵĞƌ ?ƌĂƚŚĞƌƚŚĂŶ
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a passive recipient of care. Indeed, the rise of consumerism in the UK has been suggested to 
influence how health services are delivered (Hibbert et al 2002; Morgall and Almarsdo´ttir 
1999; Nettleton 2006; Rycroft-Malone et al 2001): 
 
 “The structure of lay thought and perceptions of modern medicine is complex, subtle 
and sophisticated, and individuals are not simply passive consumers who are duped by 
medical ideology.  Rather they are critical reflexive agents who are active in the face of 
modern medicine and technological developments ? 
(Williams and Calnan 1996:1613). 
 
WĂƚŝĞŶƚƐ ?ƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŝƌŝůůŶĞƐƐĂŶĚƌelated attitudes toward their medicines have been 
shown to affect the way they take their medicines (Vermeire et al 2001). Donovan and Blake 
(1992) questioned the concept of compliance as a paternalistic model of medical decision 
making. Their study involved observations of rheumatology clinic consultations and interviews 
with patients. They suggested that patients make reasoned decisions about their treatment 
that can be different from the treatment plan advised by the doctor. Many patients made 
 ‘reasoned ? decisions when they did not comply with their medicine regimen. For example, 
patients balanced their perceived need for relief from pain and stiffness with taking fewer 
tablets to reduce their fears of side effects. Apparently irrational acts of non-compliance (from 
the doctor's point of view) were found to be a very rational action when seen from the 
patient's perspective.  
 
ĚĂŵƐĞƚĂů ? ? ? ? ? )ĞǆƉůŽƌĞĚƉĂƚŝĞŶƚƐ ?ĂƚƚŝƚƵĚĞƐƚŽƚŚĞŝƌĂƐƚŚŵĂŵĞĚŝĐĂƚŝŽŶ ?dǁŽŵĂŝŶŐƌoups, 
 ‘ĚĞŶŝĞƌƐ ? ĂŶĚ  ‘ĂĐĐĞƉƚĞƌƐ ? of their condition, were found. Those who resisted their diagnosis 
were shown to rely on their reliever medication rather than take prophylactic medicines which 
they associated with having asthma. This was in contrast to those who accepted their 
diagnosis and used both the reliever and preventer as prescribed. In another study, Horne and 
Weinman (1999) suggested that the nature and perceived severity of a medical condition 
affects the level of adherence and that patients engaged in an implicit cost-benefit analysis 
when assessing whether and how to take a medicine. Patient attitudes towards medicines are 
further discussed in the following section. 
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2.11.2 Patient attitudes towards medicines  
When asked about their medicines, people tend to report concerns rather than positive views 
because of the taken-for-granted perspective about the necessity, effectiveness and safety of 
modern prescribed medicines (Britten 2008). Aversion to medicine taking has been found to 
ďĞ ǁŝĚĞƐƉƌĞĂĚ ĂŶĚ ƉĞŽƉůĞ ŽĨƚĞŶ ƚĂŬĞŵĞĚŝĐŝŶĞ ĂƐ Ă  ‘ůĂƐƚ ƌĞƐŽƌƚ ?  ?Britten et al 2004; Conrad 
1985; Donovan and Blake 1992; Gordon et al 2007; Pound et al 2005) despite acknowledging 
the necessity of their medicine to live as normal a life as possible (Townsend et al 2003). 
WĂƚŝĞŶƚƐ ? ĂǀĞƌƐŝŽŶ ƚŽ ŵĞĚŝĐŝŶĞs has been shown to affect their medicine taking behaviour. 
Patients report taking the perceived minimal effective dose, cut out doses from their 
prescribed regimens and stop taking the medicine altogether (Britten 1996; Pound et al 2005). 
 
People have concerns about taking medication generally, especially concerning the side-
effects, and the inconvenience of taking the medicine at the prescribed times and frequency 
(RPSGB 1997b; Bissell and Anderson 2003; Grime and Pollock 2003; Pound et al 2005). 
Medicine taking amongst the older population and those with long-term conditions, has been 
shown to be diverse and affected by perceptions of how effective medicines are, whether they 
are likely to lead to dependence and whether they cause side-effects (Britten 1996; Britten 
2008). This may lead to patients  ‘ƚĞƐƚŝŶŐ out ? their medicines and these issues are discussed 
below.  
 
2.11.3 Lay testing of prescribed medicines 
From the social science literature, it is clear that patients continually test out, form 
impressions and adjust their medicine taking according to their own set of health beliefs and 
ĚŽŶŽƚŵĞƌĞůǇĨŽůůŽǁ ‘ĚŽĐƚŽƌ ?ƐŽƌĚĞƌƐ ? ?ĂŶŶŝŶŐ ? ? ? ? ?ƌŝƚƚĞŶ ? ? ? ? ?ŽŚĞŶet al 2001; Pollock 
2001; Pound et al 2005; Townsend et al 2003). Once outside the surgery, patients will often 
modify or even reject their prescription medicine (Britten 2008). Patients might adhere to a 
regular regimen in treating one condition whilst adopting a flexible regimen for others 
(Banning 2008; Townsend et al  ? ? ? ? ) ? WĂƚŝĞŶƚƐ ? ĚĞĐŝƐŝŽŶƐ ƚŽ ƚĂŬĞ Žƌ ŶŽƚ ƚŽ ƚĂŬĞ Ă ŵĞĚŝcine 
ŚĂǀĞŶŽƚďĞĞŶƐŚŽǁŶƚŽĨŽůůŽǁŵĞĚŝĐĂůůŽŐŝĐ ?ďƵƚƚŽďĞďĂƐĞĚƵƉŽŶ ‘ƌĂƚŝŽŶĂů ?ĚĞĐŝƐŝŽŶƐǁŚĞŶ
viewed from the perspective of their individual beliefs and preferences. (Adams et al 1997; 
Conrad 1985; Donovan and Blake 1992; Donovan 1995; Nichter and Vuckovic 1994; Pollock 
2001). Patients ĐĂƌƌǇŽƵƚƚŚĞŝƌŽǁŶ ‘ĐŽƐƚ-ďĞŶĞĨŝƚ ? analysis of each treatment, weighing up the 
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costs and risks of each treatment against the benefits as they perceive them (Donovan and 
Blake 1992; Donovan 1995; Pollock 2001). People therefore tend to experiment with 
medicines as a resource to use in the most pragmatic and effective manner (Blaxter and 
Britten 1996; Donovan and Blake 1992; Donovan 1995).  
 
WŽƵŶĚĞƚĂů ?Ɛ(2005) analysis of lay experiences of medicine taking for chronic illnesses, noted 
ƚŚĂƚ ƉĞŽƉůĞ ?Ɛ ŵŽƚŝǀĂƚŝŽŶ ƚŽ ŵŝŶŝŵŝƐĞ ŵĞĚŝĐŝŶĞ ŝŶƚĂŬĞ ŝŶĐůƵĚĞĚ Ă ĚĞƐŝƌĞ ƚŽ ƌĞĚƵĐĞ adverse 
effects, addiction and to make the regimen more acceptable to their daily routines. Patients 
used medicines strategically to alleviate symptoms that they attributed to a disease. For 
example, they might omit doses if they intended to drink alcohol, replace or supplement 
medicines with non-pharmacological treatments or restrict medicine use for financial reasons. 
One of the key conclusions the author made was that people do not take their medicines as 
prescribed not because of failings in patients, doctors or systems, but because of concerns 
about the perceived toxicity of the medicines themselves. By examining what is known about 
lay evaluation of medicines, Britten (2008) has compiled an underlying list of questions that 
are asked by patients (Figure 4). 
 
The questions that patients may want answers to are often indeterminate in nature and 
require effective communication and interpretation on the part of the health care 
professional. The concordance model offers a way of developing the consultation so that the 
issues patients may wish to raise can be discussed in a more equal and meaningful way and 
this is discussed in the following section. 
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What will happen if I don't take anything for this problem? 
How can I manage this problem myself? 
Can I take a natural or non-pharmaceutical remedy for it? 
Is this medicine really necessary and, if so, what benefits will it bring? 
How can I teůůŝĨŝƚ ?ƐǁŽƌŬŝŶŐ ?
What is the minimum effective dose? 
What are the known side effects of this medicine? 
(How) will this medicine impact on my daily life? 
How much does it cost?   
 
 
Figure 4: PatientƐ ? questions about their medicines (Britten 2008: 58) 
2.11.4 Concordance  
Patient-centred approaches to health care consultations have become increasingly prominent 
to policy makers and professionals and stress the importance of undĞƌƐƚĂŶĚŝŶŐ ƉĂƚŝĞŶƚƐ ?
experience of their illness as well as relevant social and psychological factors (Laine and 
Davidoff 1996; Stevenson et al 2000a; Stevenson et al 2004). The concept of concordance has 
developed over the last decade as a means to enhance patient-centredness. This notion 
evolved following an investigation into the extent, causes and consequences of patient non-
ĐŽŵƉůŝĂŶĐĞ ǁŝƚŚ ƉƌĞƐĐƌŝďĞƌƐ ? ŝŶƐƚƌƵĐƚŝŽŶƐ ? dŚĞ ƚĞƌŵ ĂƉƉĞĂƌĞĚ ŝŶ Ă ƌĞƉŽƌƚ ďǇ ƚŚĞ ZŽǇĂů
Pharmaceutical Society of Great Britain (RPSGB) and was defined as: 
 
Concordance is based on the notion that the work of the prescriber and patient in the 
consultation is a negotiation between equals and the aim is therefore a therapeutic 
alliance between them. This alliance, may, in the end, include an agreement to differ. 
Its strength lies in a new assumption of respect for the patient's agenda and the 
creation of openness in the relationship, so that both doctor and patient together can 
proceed on the basis of reality and not of misunderstanding, distrust and concealment. 
 (RPSGB 1997b:8) 
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A core feature of a concordant consultation is that it enables a two way flow of information. It 
is assumed that professional understanding and appreciation of patient perspectives is a pre-
requisite for the professional to be able to assist the patient to make an informed choice about 
their treatment (Cribb and Barber 2005; NICE 2009; Pollock 2005). Non-compliance with 
medicines may be the outcome of a prescribing process that failed to take account of the 
ƉĂƚŝĞŶƚ ?ƐďĞůŝĞĨƐ ?ĞǆƉĞĐƚĂƚŝŽŶƐĂŶĚƉƌĞĨĞƌĞŶĐĞƐ  ?ŽŶŽǀĂŶ ? ? ? ? ?,Žƌne et al 2005; McGavock 
1996; NICE 2009). Roter et al (1998) conducted a meta-analysis of 153 studies which evaluated 
a range of interventions intended to improve compliance. The author suggested that 
interventions that addressed patient satisfaction, empowerment, understanding of illness, 
quality of life, functional status and psychological well-being would be most effective. 
Likewise, Vermeire et al (2001) suggested that the traditionally paternalistic approach to try to 
improve adherence to medicines should be abandoned in favour of a partnership where 
decisions about treatment are shared with the patient after being appropriately informed.  
 
Despite promoting greater patient autonomy, in practice, this has proved problematic (Dieppe 
and Horne 2002; Pollock 2005). The agenda has been shown to conflict with the traditional 
 ‘ĐŽŵƉůŝĂŶƚ ?  ?ĚŽĐƚŽƌ Žƌ ƉŚĂƌŵĂĐŝƐƚ ŬŶŽǁƐ ďĞƐƚ ) ŵŽĚĞů ŽĨ ŚĞĂůƚŚ ĐĂƌĞ (Pollock 2005). Some 
commentators have suggested that until doctors and health policy makers accept the patientƐ ? 
right to decide whether he or she will take a medicine, the change from compliance to 
concordance will be cosmetic and fundamentally, the paternalistic approach will remain but 
will be concealed (Dieppe and Horne 2002; Heath 2003; Leontowitsch et al 2005).  
 
In this section, I have discussed lay beliefs about medicines and how patients operate with 
different priorities and perspectives concerning their health and medicines. Concordance has 
been promoted as a means for patient-centredness and could form part of the pharmacist ?Ɛ 
role extension or professionalisation project. However, these perspectives conflict with the 
more dominant rational and adherence-centred model promoted to reduce costs associated 
with wasted medicines. This leads to questions about what perspective pharmacists are 
adopting when performing MURs in a  ‘real world ? setting of a community pharmacy. This 
thesis investigates the issue of how pharmacists are interpreting and implementing the MUR 
service and ŚŽǁǁĞůů ĐŽŵƉůĞǆ ŝƐƐƵĞƐŽĨƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐine taking are discussed within these 
consultations. In the following section, I will review the literature on the MUR service and 
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highlight current gaps in the literature in order to establish where our understanding of the 
MUR service lies. 
 
2.12 Research into MURs  
In this section, I discuss the research that has been undertaken into the MUR services. I start 
by discussing the view of GPs and other stakeholders before discussing what is known of 
ƉŚĂƌŵĂĐŝƐƚƐ ?ǀŝĞǁƐĂŶĚMUR implementation. I then examine the body of literature that has 
sought to evidence outcomes from the MUR and finally, detail what is known about patient 
views of MURs. I conclude this chapter by stating the aims and objectives of this study. 
 
2.12.1  GPs and stakeholder views  
Effective PCO coordination has been suggested as vital for delivering the benefits of the 2005 
contract to patients (Noyce 2007). Early studies indicated that PCOs viewed MURs as having 
considerable potential but raised concerns that there was slow adoption and implementation 
in pharmacies (Blenkinsopp et al 2007a; Blenkinsopp et al 2007b; Hall and Smith 2006). The 
majority of PCOs sampled in an evaluation of the pharmacy contract (Blenkinsopp et al 2007a), 
revealed they reported using newsletters and other publicity to encourage the roll out of MUR 
services amongst community pharmacists. However, few reported doing anything to involve 
patients. One PCO reported that only 50% of the pharmacies in their region were accredited to 
deliver MURs and so they had to be careful about managing public expectations. Concerns 
over the value of MURs have been raised in a recent Government pharmacy White Paper (DH 
2008). This has indicated that pharmacies are being remunerated for MURs which are not 
targeted at patients who may potentially benefit most. Recent changes to the MUR policy, 
including the introduction of national target groups, are to be implemented in October 2011 
(PSNC 2011e).   
 
GP views of MURs have been mixed but generally it has been found that their views are not 
positive (Blenkinsopp et al 2007a; Bradley et al 2008a; Elvey et al 2006; James et al 2007; 
Wilcock and Harding 2007). GPs have reported that they would view MURs to be more 
valuable if pharmacists focused on adherence and the reduction of waste from unused patient 
medicines (Celino et al 2007; Patel and Rosenbloom 2009; Wilcock and Harding 2007). 
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However, at present they largely consider MURs to provide little benefits to them or to 
patients and have expressed concerns over pharmacists advising patients, during an MUR, on 
clinical matters which GPs regard as inappropriate (Blenkinsopp et al 2007a; Bradley et al 
2008a; Celino et al 2007; Wilcock and Harding 2007).  
 
GPs have expressed negative views about pharmacists informing them about patient reported 
adverse drug reactions (ADRs) where they (GPs) consider them to be tolerable or inevitable. 
tŝůĐŽĐŬ ĂŶĚ ,ĂƌĚŝŶŐ  ? ? ? ? ? ) ŚĂǀĞ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ 'WƐ ŵĂǇ ďĞ ‘ŵŝƐƐŝŶŐ ƚŚĞ ƉŽŝŶƚ ? ŽĨ DhZƐ
because one would expect ADRs to be discussed by the pharmacist as part of a concordant 
approach to treatment. Other concerns expressed by GPs have included duplication of work, 
MURs being conducted in isolation from them, the potential increase in their workload which 
does not contribute to their Quality and Outcomes Framework (QOF) measures, and MUR 
forms being overcomplicated and unavailable in an electronic format (Alexander 2006; 
Blenkinsopp et al 2007a; Bradley et al 2008a). Relationships between GPs and pharmacists 
have been reported to have been negatively affected by MURs (Bradley et al 2008a). This has 
been seen as a barrier for pharmacists to undertake the service or implementing it effectively. 
This issue as well as ƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞ of MURs is discussed in the following section. 
 
2.12.2 PharmacistƐ ? perspectives of MURs  
Pharmacists ? ƉĞƌƐƉĞĐƚŝǀĞs of MURs have been more thoroughly investigated than patient 
views. Studies suggest that pharmacists perceive MURs to help improve patients 
understanding and correct use of medicines, have improved patient-pharmacist relations as 
well as increasing patient awareness of their accessibility (Alexander 2006; Bradley et al 2008a; 
Urban et al 2008). MURs are seen to provide an opportunity for an extended professional role, 
enabling ďĞƚƚĞƌ ƵƐĞ ŽĨ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ƐŬŝůůƐ ĂŶĚ ĂƐ Ă ǁĂǇ ƚŽ ĞŶŚĂŶĐĞ ƌĞůĂƚionships with 
patients (Cowley et al 2010; Harding and Wilcock 2010; Latif and Boardman 2008). However, 
despite support from most pharmacy contractors when they agreed to the 2005 pharmacy 
contract (Anon 2004), there have subsequently been concerns that contractors have lost out 
financially (Gidman 2010). The uptake of MURs was slow after the service was introduced with 
only 7% of available funding spent in the first year (Blenkinsopp et al 2007b; Blenkinsopp et al 
2008). This was viewed by some as giving PCOs a windfall to help fund the NHS financial deficit 
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(Gush 2006; Anon 2006a). Furthermore, several barriers have been reported to implementing 
and delivering the service.  
 
2.12.3 Barriers to extended role activities  
Many barriers have been acknowledged to comŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶǀŽůǀĞŵĞŶƚ ŝŶŵĞĚŝĐŝŶĞ
management services. These include a lack of time, a lack or poor use of staffing within the 
pharmacy and remuneration for undertaking such activities (Amsler et al 2001; Bradley et al 
2008b; Krska and Veitch 2001; Lounsbery et al 2009; Niquille et al 2010; Rutter et al 2000), a 
lack of awareness among other health care professionals and the general public about the 
pharmacist's skills and attributes (Krska and Veitch 2001; Rutter et al 2000), a lack of privacy or 
availability of a consultation room within the pharmacy (Amsler et al 2001), potential conflict 
with other health professionals (Bradshaw and Doucette 1998; Krska and Veitch 2001; Ruston 
2001; Mottram 1995; Wilcocks and Harding 2007) and issues around training (Bradley et al 
2008b; Ruston 2001).  
 
PŚĂƌŵĂĐŝƐƚƐ ?ĂƚƚŝƚƵĚĞƚŽǁĂƌĚƐextending their role has also been cited as a further barrier. One 
study of ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚƐ ? ĂƚƚŝƚƵĚĞƐ ƚŽǁĂƌds clinical medication reviews reported a 
perceived lack of mandate and legitimacy over this work and doubts about the adequacy of 
skills and experience to provide the service (Bryant et al 2010). The authors suggested that this 
may have resulted from a perceived lack of support from GPs, concerns over boundary 
encroachment and a lack of mandate from patients. A lack of readiness to change by 
community pharmacists and a perceived lack of workable strategies to adopt these newer 
roles have also been reported (Bryant et al 2009; Farris and Schopflocher 1999; Odedina et al 
1996). WŚĂƌŵĂĐŝƐƚƐ ? attitudes have also been proposed as barriers to becoming involved with 
health promotion activities and pharmacists have been described as being reactive rather than 
proactive in their approach (Anderson et al 2003).  
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2.12.4  MUR barriers 
Similar barriers to the effective implementation of the MUR service have also been reported 
and these are discussed below. 
 
2.12.4.1 Consultation room  
Early studies of MUR activity identified the lack of a consultation room as a barrier to 
conducting MURs (Ewen et al 2006; Hall and Smith 2006; Latif and Boardman 2008). One study 
found practical problems with consultation areas particularly in smaller pharmacies (Rapport 
et al 2009). The author suggested that while pharmacists may be keen to enhance their 
professional self-identity through the use of a consultation facility, the limitations of space 
meant they were typically  “shoehorned ?ĂŶĚĨŝůůĞĚǁŝƚŚƌĞƚĂŝůƐƚŽĐŬŝƚĞŵƐ ?dŚŝƐƚŚƌĞĂƚĞŶĞĚƚŚĞ
desired enhancement of professional status. In contrast, it was found that large multiple 
pharmacies were reported to have more comfortable and professional looking rooms.   
 
2.12.4.2 Pharmacists ? training and accreditation  
Pharmacists ? training and accreditation for undertaking MURs has been criticised for being a 
bureaucratic exercise which focuses on process rather than on consultation and the decision 
making skills needed for an effective service to patients (Alexander 2006; Foulsham et al 2006; 
Harding and Wilcock 2010; Wilcock and Harding 2008). In an early survey study of pharmacistƐ ? 
perceptions (Ewen et al 2006), two thirds of respondents reported that they thought the 
accreditation training prepared them for providing the service. However, half of the 
respondents at the time had not undertaken an MUR in their pharmacy. In a later study using 
qualitative interviews, most pharmacists reported the accreditation had not prepared them for 
face-to-face consultations or ways to keep the consultation within time constraints (Urban et 
al 2008). Another qualitative study that used focus groups and telephone interviews (Khideja 
2009) found that the range of accreditation training methods influenced what pharmacists 
understood the term MUR to mean. There have also been suggestions that pharmacists are 
unsure about the difference between MURs and a clinical medication review (Connelly 2007). 
However, it remains unclear from the literature how pharmacists are interpreting the MUR 
policy and how this is influencing their practice. 
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2.12.4.3 Time and staffing  
Lack of time, increase in workload and staffing pressures have been identified as barriers that 
pharmacists face when implementing MURs (Bradley et al 2008a; Foulsham et al 2006; Gidman 
2011; Latif and Boardman 2008; Rosenbloom and Graham 2008; Wang 2007). Most MURs 
have been reported to be incorporated into the daily work of the pharmacy without additional 
pharmacist cover (Blenkinsopp et al 2007a; Bradley et al 2008a). However, some pharmacists 
have reportedly stopped offering the service because of a lack of organisational support 
(Rosenbloom and Graham 2008). An MUR consultation has been estimated to average 51 
minutes in which 22 minutes is spent with the patient and the rest on preparation for the MUR 
and completing associated paperwork (Blenkinsopp et al 2007a). The pharmaciƐƚ ?Ɛ ĂďƐĞŶĐĞ
during an MUR has reported to have had a negative impact on patients waiting for their 
prescriptions (Blenkinsopp et al 2007a; Urban et al 2008). Concerns over the ƉŚĂƌŵĂĐŝƐƚƐ ?
inability to supervise sales of medicines during this time have also been raised (Moss 2007). In 
one study critiquing the original MUR form, pharmacists and GPs reported that this was too 
time consuming to complete, that not all sections were relevant and too much information 
was being recorded (Thomas et al 2007a). Some commentators raised concerns that MURs 
were being performed within an overly short time frame and this was devaluing the usefulness 
of the service (Anon 2006b; Goldstein et al 2006). To date no observational studies have been 
undertaken to contextualise the issues that pharmacists face when implementing the MUR 
service or the impact of this on ƉĂƚŝĞŶƚƐ ? views of the MUR consultation. 
 
2.12.4.4 Patient recruitment  
Pharmacists have reported recruitment of patients for MURs to be difficult and it remains 
uncůĞĂƌ ǁŚĞƚŚĞƌ ƚŚŝƐ ŝƐ ĚƵĞ ƚŽ Ă ůĂĐŬ ŽĨ ƉĂƚŝĞŶƚ ĚĞŵĂŶĚ Žƌ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶĂďŝůŝƚǇ ƚŽ
communicate the MUR as a useful and relevant service (Bassi and Wood 2009; Hall and Smith 
2006; Thomas et al 2007b). Some reports suggest that patients have been suspicious of the 
ƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶƚĞŶƚŝŽŶƐĂŶĚso have declined the invitation on the grounds that they felt no 
need for an MUR (Moss 2007; Urban et al 2007; Wang 2007). Appointment systems set up in 
pharmacies have been ƌĞƉŽƌƚĞĚƚŽ ĨĂŝůĚƵĞƚŽƉĂƚŝĞŶƚƐ ?ŶŽŶ-attendance, despite pharmacists 
using measures such as telephone reminders. This has led to pharmacists reporting feeling 
rejected and de-motivated to arrange further appointments (Blenkinsopp et al 2007a; Urban et 
al 2008). The problem of recruitment has led some commentators to suggest changing the 
ŶĂŵĞ ŽĨ ƚŚĞ ƐĞƌǀŝĐĞ ƚŽ  ‘ŵĞĚŝĐŝŶĞƐ ĐŚĞĐŬ-up ? Žƌ  ‘ŵĞĚŝĐŝŶĞƐ DKd ? ƚŽ ďĞƚƚĞƌ ĐŽŵŵƵŶŝĐĂƚĞ ƚŽ
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patients what an MUR involves (Donyai and Van den Berg 2006; Van den Berg and Donyai 
2009). However, because of the lack of research into patient perspectives and the way they 
are offered, it remains uncertain why patients decide to accept or decline the invitation.   
 
2.12.4.5 GPs perception as a barrier 
GPs lack of support for the MUR service appears to be a barrier to pharmacistƐ ?
implementation of the service. Over 80% of pharmacists providing MURs reported that the 
service had no effect on their relationship with local GPs. Only 12% of respondents indicated 
that it had improved their relationship with the GP (Blenkinsopp et al 2007a). Pharmacists 
reported that they felt GPs were cynical about the value of MURs and tended to see them 
merely as a way to increase pharmacist income (Urban et al 2008). Concerns have been raised 
about whether the GP was reviewing the MUR form and them not being including in the 
ƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůŶŽƚĞƐ. This has de-motivated some pharmacists who believed that the time 
and effort spent performing the MUR had been wasted (Anon 2006a; Harding and Wilcock 
2010; Trueman et al 2010; Urban et al 2008; Wilcock and Harding 2008).  
 
2.12.4.6 MUR pressure and targets   
The annual cap on MUR activity has been reported to contribute to organisations setting 
arbitrary targets which has led to several reports of pharmacists feeling pressurised to perform 
MURs (Bassi and Wood 2009; Blenkinsopp et al 2007a; Bradley et al 2008a; Harding and 
Wilcock 2010; Murphy 2007; McDonald et al 2010a; McDonald et al 2010b; Trueman et al 
2010; Urban et al 2008; Wilcock and Harding 2008). Organisational pressure within multiple 
pharmacies appears to be the main driver for MUR activity and may be one reason why there 
has been large variation in the number of MURs performed with fewer MURs conducted by 
independent pharmacies compared with multiples (Blenkinsopp et al 2007a, Bradley et al 
2008a; Harding and Wilcock 2010). The pressure that pharmacists are under to deliver an 
arbitrary target number of MURs has led to reports of pharmacists inviting patients who they 
think are on simpler medication regimes that can be performed quickly rather than those 
patients with more complex regimes who may benefit most (Bradley et al 2008a; Wilcock and 
Harding 2008; Harding and Wilcock 2010).  
 
WdƐ ŚĂǀĞ ĞǆƉƌĞƐƐĞĚ ǀŝĞǁƐ ƚŚĂƚ DhZƐ ĂƌĞ ŶŽƚ ďĞŝŶŐ ƚĂƌŐĞƚĞĚ ƚŽ  “local needs and patient 
priorities ?ĂŶĚƚŚĂƚƚŚĞƋƵĂůŝƚǇŽĨƌĞǀŝĞǁƐŝƐ “inconsistent ? ?, ? ? ? ? P29). The extent to which 
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ƚŚĞƐĞ ĐŽŵŵĞƌĐŝĂů ƉƌĞƐƐƵƌĞƐ ŚĂǀĞ ƵŶĚĞƌŵŝŶĞĚ ƉŚĂƌŵĂĐŝƐƚƐ ? ƉƌŽĨĞƐƐŝŽŶĂů ũƵĚŐĞŵĞŶƚ ĂŶĚ
autonomy over their work is yet to be determined as well as what effect this has had on 
patient outcomes. In this section, I have described some of the barriers faced by pharmacists 
delivering the MUR service. In the following section, I focus on the research that surrounds the 
value of the MUR. 
 
2.12.5  Evidencing the outcomes   
Patient outcomes resulting from MURs have been mixed. The most convincing outcomes have 
been from studies that have investigated a particular group of patients. MURs performed with 
patients with asthma have suggested the most benefit (Bagole et al 2007; Desborough et al 
2008; Portlock et al 2009). For example, WŽƌƚůŽĐŬ Ğƚ Ăů ?Ɛ  ? ? ? ? ? ) ƐƚƵĚǇ ŽĨ  ? ? ? ƉĂƚŝĞŶƚƐwith 
asthma identified that 30% of patients had not seen their GP or practice nurse for a review in 
the previous 12 months. The level of adherence to medicines in this group was lower than 
those who had an MUR. The two most common interventions that pharmacists made in the 
MUR were patient education and device check. In another study, Wilcock and Harding (2008) 
aimed to quantify the effects of performing an MUR on GP prescribing for patients with CHD. 
MUR forms (n = 1948) from 23 community pharmacies were reviewed as well as dispensing 
data from the patient ?s medication record (PMR). The study found over half of the MURs 
performed by the pharmacist (54%) had identified patients with an actual or potential risk of 
CVD. Of these, a quarter resulted in a prescribing recommendation of which over half 
appeared to have been acted upon by the GP. However, these studies do not reflect current 
practice as MURs are not typically restricted to patients with certain medical conditions. 
Furthermore, in several of these studies pharmacy staff were given additional training 
(Portlock et al 2009; Cree 2010) or were provided with additional supporting material, such as 
questions to assess asthma control, that tailored the MUR to the medical condition (Bagole et 
al 2007; Colquhoun 2010a; Colquhoun 2010b). These additional resources do not form part of 
the national MUR service. 
 
Studies that have not targeted particular groups of patients have shown more variation in their 
outcomes. A ƐƚƵĚǇ ďǇ zŽƵƐƐĞĨ Ğƚ Ăů  ? ? ? ? ? ) ĨŽƵŶĚ ŽŶůǇ  ?A? ŽĨ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ?
recommendations from an MUR appeared to have resulted in an intervention that eventually 
ůĞĚ ƚŽĂĐŚĂŶŐĞ ŝŶ ƚŚĞƉĂƚŝĞŶƚƐ ?ƉƌĞƐĐƌŝƉƚŝŽŶ ?,ŽǁĞǀĞƌ ? ŝŶĂŶŽƚŚĞƌ ƐƚƵĚǇ ƚǁŽthirds of MURs 
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(from a group of 120 patients) resulted in resolution of drug-related problems compared with 
just 3% in a control group (Mohammad 2008). The different criteria used by researchers to 
measure outcomes make comparisons between studies difficult. Moreover, studies conducted 
before 2007 investigated use of the original MUR form (Blenkinsopp et al 2007a; Bradley et al 
2008a; Mohammad 2008; Wilcock and Harding 2008) and this has now been replaced by the 
new version. One study that has tried to identify criteria for assessing the quality of MUR 
referral documentation used the original form and the author suggested that further piloting is 
needed against the new form (James et al 2008). There also appears to be wide variations in 
the completeness and legibility of MUR forms and disparity in the recommendations made to 
GPs (MacAdam and Sherwood 2011; NPA 2010; Ruda and Wood 2007). One study found that 
few MUR forms contained references relating to non-prescribed medicines or supplements 
which are supposed to be discussed as part of an MUR (John et al 2009).   
 
2.12.6 Patient perceptions of the MUR service   
Patient surveys have been used to investigate satisfaction with the MUR service. However, as 
with much of the methods that have measured patient satisfaction with pharmacy or health 
services, there is a lack of consistent instruments. Moreover, ƚŚĞĐŽŶĐĞƉƚŽĨ ‘ƐĂƚŝƐĨĂĐƚŝŽŶ ?ĨĂŝůƐ
to capture the problematic nature of health service delivery to patients who may not behave 
as a typical  ‘consumer ?. Satisfaction surveys may therefore be limited and may even lead to 
ŵŝƐůĞĂĚŝŶŐ  ‘ĞǀŝĚĞŶĐĞ ?(Avis et al 1997; Naik et al 2009). Several studies have attempted to 
determine ƚŽǁŚĂƚĞǆƚĞŶƚƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞŽĨƚŚĞŝƌŵĞĚŝĐŝŶĞƐŚĂĚŝŵƉƌŽǀĞĚĂƐĂƌĞƐƵůƚŽĨ
the MUR service. Statements such as  “I learned more about my medicine(s) after the MUR with 
ƚŚĞƉŚĂƌŵĂĐŝƐƚ ? have been used and have received positive responses (Patel and Lefteri 2009; 
Portlock et al 2009; Youssef 2008; Youssef 2009; Youssef et al 2010). Patients in these studies 
appeared to rate the MUR service highly (Bagole et al 2007; Kumwenda and James 2008; NPA 
2010; Portlock et al 2009; Youssef 2008; Youssef 2009; Youssef et al 2010) and in one study 
reported that they used the service to gain more confidence about their asthma treatment 
(Portlock et al 2009). However, it remained unclear how the interaction was handled and in 
what ways patients improved their confidence. Furthermore, these seemingly promising 
results do not explain how this was achieved, what patients had actually learnt or indeed if 
they wanted to know more at the beginning.  
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An ongoing national multidisciplinary audit involving four stakeholders (community pharmacy, 
general practice, PCOs and patients who had recently had an MUR) indicated that patients 
hold positive views of MURs (RPSGB 2010). From the 3016 returned patient surveys, half of the 
patients indicated they had received recommendations to change how they took their 
medicines and of these 90% were likely to make the change(s). Over three quarters indicated 
the MUR had improved their medicines knowledge and 85% of patients scored the MUR as 
high on a  ‘usefulness ? scale. However, there has been little investigation into why some 
patients report they do not find the MUR useful. This raises questions as to what is happening 
during the MUR consultation. Likewise, in other smaller surveys (Krska et al 2009; Patel and 
Lefteri 2009), there were indications that the MUR had not met patients ? needs about their 
medicines and that not all of their medicine problems had been discussed. With no direct 
observation of MURs, the authors suggest that more research is needed to find out why some 
patients who undertake an MUR are not deriving benefits. 
 
YƵĂůŝƚĂƚŝǀĞ ĂƉƉƌŽĂĐŚĞƐ ƚŽ ƚŚĞ ƐƚƵĚǇ ŽĨ ƉĂƚŝĞŶƚƐ ? ǀŝĞǁƐ ŚĂǀĞ provided richer insights 
(Blenkinsopp et al 2007a; Greenhill et al 2011; Iqbal and Wood 2010). Blenkinsopp et al 
(2007a )ĞǆƉůŽƌĞĚƉĂƚŝĞŶƚƐ ?ǀŝĞǁƐŽĨDhZƐƵƐŝŶŐƚǁŽĨŽĐƵƐŐƌŽƵƉƐǁŝƚŚ ? ?ƉĂƚŝĞŶƚƐǁŚŽŚĂĚĂŶ
MUR. Patients were identified by pharmacists through community pharmacies and were paid 
£50 for participating. The focus groups revealed that many patients took part in their MUR out 
ŽĨƉŽůŝƚĞŶĞƐƐǁŝƚŚƐŽŵĞŚĂǀŝŶŐĐŽŶĐĞƌŶƐĂďŽƵƚƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ǁŽƌŬůŽĂĚĂŶĚĂďŝůŝƚǇƚŽƐƉĞŶĚ
time with them. During the MUR, patients reported feeling being tested but talked favourably 
about the amount of time the pharmacist spent with them. However, the findings revealed 
that the majority of the patients would not volunteer for another annual MUR. Furthermore, 
Iqbal and Wood (2010) found through their telephone interviews with patients (n = 23) that 
over half found their MUR to be useful but only a minority could remember all of the 
recommendations made by the pharmacist.  
 
The lack of context in which MURs are carried out and insight into what happens before and 
during the MUR, limits the understanding one can achieve through survey and interview 
methods of enquiry. More recent work has reported on observations of pharmacist 
consultations more widely, including MURs, using the Calgary-Cambridge consultation guide 
(Greenhill et al 2011). This study indicated that some skills such as listening effectively, eliciting 
patient perspectives and creating a patient-centred consultation were poorly represented. 
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However, to my knowledge, there have been no studies investigating MURs as they happen in 
a community pharmacy setting and how these come about during the everyday activities of 
the pharmacy.  
 
2.13 Summary  
In this chapter, I have presented an overview of how historical developments in UK community 
pharmacy have led to initiatives to re-professionalise community pharmacist activities. I have 
also described the MUR service and the research that has been conducted in this area. 
Pharmacists potentially have a valuable contribution to make in medicines management 
services but the literature in this area is inconclusive. Few studies have highlighted outcomes 
from MURs and what patients take away from the consultation. There has been little research 
investigating live practice such as the processes that lead up to and shapes the MUR 
consultation, how the pharmacist within an MUR consultation identifies and addresses 
ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐĂƚŝŽn issues and whether MURs cater for individual patient beliefs, concerns  
and preferences. Consequently, there is a need for research that investigates the 
implementation of the MUR service within pharmacies and the behaviours of both pharmacist 
and support staff within a  ‘real world ? practice setting. Detailed below are my research aims 
and objectives. The following chapter describes the methodological approach undertaken and 
outlines the method for this study.   
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2.14 Research aims and objectives  
This research is timely as questions, both within and outside the profession, are being asked as 
to the value of communitǇƉŚĂƌŵĂĐŝƐƚƐ ?ŝŶǀŽůǀĞŵĞŶƚŝŶŵĞĚŝĐĂƚŝŽŶŵĂŶĂŐĞŵĞŶƚƐĞƌǀŝĐĞƐ ?,
2008; Holland et al 2005; McDonald et al 2010b; Salter et al 2007; Salter 2010; The Community 
Pharmacy Medicines Management Project Evaluation Team 2007). There is a lack of research 
that has ƐŽƵŐŚƚƚŽŝŶǀĞƐƚŝŐĂƚĞ ‘ůŝǀĞƉƌĂĐƚŝĐĞ ?ŽĨƉŚĂƌŵĂĐŝƐƚƐĚĞůŝǀĞƌŝŶŐMURs, has observed the 
MUR consultation and how patients interpret the service. The aims and objectives of this study 
therefore reflected these gaps in the literature and are detailed below:  
  
Research aims  
 
The aim of this research is to investigate patient and pharmacy staff perspectives of 
the MUR service and implementation in the real world setting of community 
pharmacy.  
 
Research objectives 
 
To observe and report how the MUR service is being implemented and managed 
alongside existing service provision. 
 
To describe what happens during an MUR and how the patient-pharmacist interaction 
is managed. 
 
To determine the views and perspectives of patients who had undertaken an MUR 
with the pharmacist and also those who declined the offer for an MUR. 
 
To better understand pharmacist and support staff perspectives of MURs and the 
challenges they face in practice. 
 
To investigate whether the aims of the MUR service to improve ƉĂƚŝĞŶƚƐ ?knowledge 
about their medicines and use are being realised in practice.  
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3. CHAPTER THREE Methodology and Methods 
CHAPTER THREE 
Methodology and Methods 
3.1 Introduction  
This chapter is divided into two parts: methodology and methods. In the first part, I discuss the 
methodological approach that underlies the research study. Methodology, as Grix contends, is 
essentially concerned with the logic of enquiry and:  
  
 “ Qin particular with investigating the potentialities and limitations of particular 
techniques or procedures. The term pertains to the science and study of methods and 
the assumptions about the ways in which knowledge is produced. ? 
(Grix 2002:179).  
 
With this in mind, in this section I begin by briefly outlining the ontological and epistemological 
position(s) underpinning this study and provide a rationale for using qualitative methods. 
Ethnographically-oriented fieldwork observations and interviews with participants were the 
two qualitative research methods that were chosen to answer the research aims and 
objectives and each method will be discussed. Consideration is also given to how the study 
demonstrated rigour. Finally, the ethical issues relating to the study are discussed. In the 
second part of this chapter, I provide a detailed description of the methods of data collection 
that were used, the decisions that informed the design of this study and a description of how 
the data was analysed. 
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3.2 Part One: Methodology  
3.2.1 Health services and pharmacy practice research  
Health services research has been defined by the Medical Research Council as: "the 
identification of the health care needs of communities and the study of the provision, 
effectiveness and use of health services ? ?ůĂƌŬĞĂŶĚ<ƵƌŝŶĐǌƵŬ ? ? ? ?:1675). This study aims to 
investigate patient and pharmacy staff perspectives of the MUR service and how this service is 
being managed in practice. It can therefore be considered pharmacy practice research. There 
are many different approaches to pharmacy practice research (Mays 1994; Smith 2002). 
Underlying each of these are differing philosophical assumptions about the nature of 
knowledge and how we can acquire this. Broadly, there are two contrasting approaches to 
health services research: positivist and interpretive (Blaikie 2010; Bowling 2009; Smith 2002) 
and these are discussed briefly below.  
 
3.2.2 Positivism and Interpretivism 
Positivistic and interpretive approaches hold different epistemologies which mean they hold 
different philosophical positions about the kinds of knowledge that are possible and claims 
about how what is assumed to exist can be known (Blaikie 2010). A positivist epistemology 
assumes that there is an objective reality, which can be measured, studied and understood 
largely through scientific investigation (Benton and Craib 2001). Much of the early pharmacy 
practice research held positivistic positions which like much early health research has been the 
dominant approach underpinning medical and scientific achievements (Benton and Craib 2001; 
Bond 2000; Smith 2002). However, positivistic approaches take less account of the role of 
social factors or individual subjectivity (Bowling 2009; Pope and Mays 2006; Smith 2002).  
 
Health services research has much to benefit from the knowledge generated through more 
interpretive strategies (Pope and Mays 2006; Stevenson et al 2000b). Interpretivist accounts 
hold that the study of social phenomena requires an understanding of the social world and 
how people have constructed and brought meaning to it. These interpretivist traditions were 
formed as a reaction to positivism and hold differing epistemological assumptions. They 
strongly believe that there is a fundamental difference between the subject matter of the 
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natural and social sciences (Benton and Craib 2001). Before positioning my own research on 
this landscape, I briefly describe below some relevant ontological issues.  
3.2.3 Ontological positions   
Ontology is concerned with the nature of what exists (Benton and Craib, 2001). The 
epistemological positions mentioned above are dependent upon the ontological viewpoint 
that is taken. For positivistic research, there is adherence to a realist ontology. This assumes 
that both natural and social phenomena have an existence that is independent of the human 
observer (Blaikie 2010). In contrast, the interpretivist tradition adheres more closely to an 
idealist ontology. This position assumes that we have no way of understanding the world other 
than through the lens of our own understanding and experience (Blaikie 2010).  
 
A useful amalgamation of both positions has been proposed, knoǁŶĂƐ ‘ƐƵďƚůĞƌĞĂůŝƐŵ ?ǁŚŝĐŚ
integrates insights of both idealist and realist ontologies (Hammersley 1992). As Hammersley 
proposes, individual subjective perceptions do not preclude the existence of an independent 
and observable reality (Hammersley 1992). The subtle realist position therefore shares with 
realism that it is possible for the researcher to acquire knowledge about the external world as 
it really is and this is independent of the human mind or subjectivity. However, Hammersley 
simultaneously holds that the researcher is unable to capture the social world and reflect this 
back to an audience like a mirror. Instead, he argues the researcher is constantly engaged with 
representations or constructions of the external world (Hammersley 1992).  
3.2.4 Ontological and epistemological assumptions underpinning the 
study  
For this study, an interpretivist epistemology was considered the most appropriate standpoint. 
As mentioned above, the interpretivist approach aims to understand individual events in 
relation to the individuals involved and to attempt to reconstruct the subjective experience of 
ƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐǁŝƚŚŽƵƚ ‘ĚŝƐƚŽƌƚŝŶŐ ?ƚŚĞǁŽƌůĚĂƌŽƵŶĚƚŚĞŵ ?ĞŶǌŝŶĂŶĚ>ŝŶĐŽůŶ 2008; Weber 
1949). The underlying purpose of this research rests on creating a deeper contextual 
understanding of the MUR service, the meanings and interpretations that the participants 
bring and to consider these in the totality or network of their own statements and beliefs.   
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This ontological viewpoint is one that aligns with the subtle realist position described above. 
This standpoint is increasingly being seen as a valuable approach to health care research 
(Murphy et al 1998) and one that resonates well with the present study. I do not preclude the 
existence of an independent and observable reality. Fieldwork observations in the  ‘real world ? 
would therefore be a way to attain firsthand knowledge of the phenomena that I aimed to 
research. Likewise, I accept that the observations undertaken and the information that the 
participants in the interviews revealed are not simple factual accounts. The research findings 
are based on interpretations and representations of events and that the knowledge about 
these phenomena is influenced by aspects of our social selves. Indeed, had my professional 
background not been as a pharmacist, or even if I had been from a different kind of society 
holding different ideologies, I may well have come to different conclusions. It is with this 
backdrop that I proceed to provide a methodological position for this study and a rationale for 
choosing my selected research methods.         
 
3.2.5 Qualitative research methods 
There have been widespread debates regarding the relative merits of quantitative and 
qualitative strategies for researching society (Hammersley 1992; Bryman 1988; Bryman 2008; 
Silverman 1997). Qualitative methods are exploratory, inductive in nature and are oriented to 
ĂŶƐǁĞƌŝŶŐ  ‘why ? ĂŶĚ  ‘how ? ƋƵĞƐƚŝŽŶƐ ǁŚĞƌĞĂƐ ƋƵĂŶƚŝƚĂƚŝǀĞ ŵĞƚŚŽĚƐ ďĞƚƚĞƌ ŝŶǀĞƐƚŝŐĂƚĞ
ƉƌŽĐĞƐƐĞƐ ƚŚĂƚ ĂƌĞ ƉĂƌƚŝĐƵůĂƌůǇ ĂƉƉƌŽƉƌŝĂƚĞ ƚŽ ĂŶƐǁĞƌŝŶŐ  ‘what ? Žƌ  ‘how many ? ƋƵĞƐƚŝŽŶƐ
(Bowling 2009; Bryman 2008). Bowling (2009) suggests that qualitative methods have 
advantage over quantitative methods in situations where there is little pre-existing knowledge, 
when the issues are sensitive or complex and where the maximum opportunity to pursue an 
exploratory approach is desired. As Silverman (1997) asserts, the choice of research method 
should aim to collect data that is most appropriate to answering the research aims and 
objectives.   
 
Qualitative research is a naturalistic method of enquiry which means that its strength lies in 
investigating people in their typical social environment with minimal disruption to the setting 
(Bryman 2008; Bowling 2009; Denzin and Lincoln 2005; Murphy et al 1998). There are 
numerous qualitative methods of enquiry including ethnography, grounded theory, case study, 
action research, phenomenology and ethnomethodology (Bowling 2009; Bryman 2008; 
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Charmaz 2006; Denzin and Lincoln 2005). Typically a qualitative approach attempts to 
understand the complexity of events when they are seen in context. It can therefore be used 
ƚŽĐůĂƌŝĨǇƚŚĞ “social, cultural and structural contexts associated with organisational problems 
and dilemmas ?  ?DŝůůĞƌ Ğƚ Ăů  ? ? ? ? P332). As Bryman states: qualitative reseaƌĐŚĞƌƐ  ‘express a 
commitment to viewing events and the social world through the eyes of the people that they 
study ? ?ƌǇŵĂŶ ? ? ? ? P385).  
 
The research method chosen for this study was determined by how much was known about 
MURs, how they were being implemented in pharmacies and how they were being received by 
patients in practice. It was clear from the literature that an in-depth understanding of the 
issues relating to the conduct of MURs within a pharmacy practice setting had not been 
established and that pĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞof the MUR consultation was scarce. Furthermore, 
investigating how the MUR policy was being realised in practice and what the views of the 
people directly involved with the service were, was a critical part of the study. A qualitative 
approach was therefore deemed suitable to provide these insights. 
 
In this section, I have described my ontological, epistemological and methodological position 
underpinning this research. In the following section, I discuss the two qualitative research 
methods that were adopted for this study: observations and interviews.   
 
3.2.6 Observational research 
Historically, the ethnographic method became prominent in the Western world in the late 
nineteenth and early twentieth century in order to study distant (usually non-Westernised) 
cultures. Ethnography primarily has its roots in anthropological research and is a method that 
ĂůůŽǁƐ ĚĂƚĂ ƚŽ ďĞ ĐŽůůĞĐƚĞĚ  ‘ĨŝƌƐƚŚĂŶĚ ? ƚŽ ƉƌŽǀŝĚĞ Ă ǀĞƌǇ ĚĞƚĂŝůĞĚ ? ŝŶ-depth description and 
analysis of everyday practices (Denzin and Lincoln 2008; Hammersley 1992; Lincoln and Guba 
1985; Lofland et al 2006; Murphy and Dingwall 2003a). Fieldwork observation is the classic 
method of enquiry for ethnographic research and is increasingly being used in health services 
research. According to Smith (2002:161) the objective of qualitative observational studies is to 
ƉƌŽǀŝĚĞĂŶŝŶƐŝŐŚƚŝŶƚŽƉĂƌƚŝĐŝƉĂŶƚƐ ?ďĞŚĂǀŝŽƵƌĂŶĚƚŽĐŽŶƐŝĚĞƌƚŚĞƐĞĂŐĂŝŶƐƚƚŚĞďĂĐŬŐƌŽƵŶĚŽĨ
 ‘ĐŽŶƐƚƌĂŝŶƚƐ ?ĚŝĨĨŝĐƵůƚŝĞƐŽƌĨĂĐŝůŝƚĂƚŝǀĞĂƐƉĞĐƚƐŽĨƚŚĞŝƌĞŶǀŝƌŽŶŵĞŶƚ ?.  
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Observational techniques are used to investigate social practices and typically require the 
researcher to spend considerable time in the field and sometimes to participate in the 
naturally occurring activities of the social grouping under study in order to generate rich data 
(Emerson 1981; Okely 2004; ^ŝůǀĞƌŵĂŶ  ? ? ? ? ) ? KďƐĞƌǀĂƚŝŽŶĂů ƌĞƐĞĂƌĐŚ ƚŚĂƚ ŝŶǀŽůǀĞƐ  ‘ŚĂŶŐŝŶŐ
ŽƵƚ ? ǁŝƚŚ ƚŚĞ ƉĞŽƉůĞ ĂŶĚ ƉŚĞŶŽŵĞŶĂ ƵŶĚĞƌ ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŝƐƐŽŵĞƚŝŵĞƐ ƌĞĨĞƌƌĞĚ ƚŽ ĂƐ
 ‘ƉĂƌƚŝĐŝƉĂŶƚ ŽďƐĞƌǀĂƚŝŽŶ ? ? ,ĞƌĞ ? ƚŚĞ ƌĞƐĞĂƌĐŚĞƌ ĂĐƚƐ ĂƐ ƚŚĞ ƉƌŝŵĂƌǇ ŝŶƐƚƌƵŵĞŶƚ Ĩor data 
collection and witnesses the events and phenomena they seek to understand personally and 
directly (Lofland et al 2006). The purpose of the participant observer has been succinctly 
summarised:  
 
 “dŚĞƉĂƌƚŝĐŝƉĂŶƚŽďƐĞƌǀĞƌŐĂƚŚĞƌƐĚĂƚĂďǇƉĂƌƚŝĐŝƉĂƚŝŶg in the daily life of the group or 
organization he studies. He watches the people he is studying to see what situations 
they ordinarily meet and how they behave in them. He enters into conversation with 
some or all of the participants in these situations and discovers their interpretations of 
ƚŚĞĞǀĞŶƚƐŚĞŚĂƐŽďƐĞƌǀĞĚ ? ?
(Becker 1958:652) 
 
Fieldwork observations provide the researcher with an opportunity to document actual events 
and behaviours within the context of how they happened. They allow for the generation of 
ƌŝĐŚ ĚĂƚĂ ĂŶĚ ĂŶ ĞǆƉůŽƌĂƚŝŽŶ ŽĨ  ‘ƌĞĂů ůŝĨĞ ? ďĞŚĂǀŝŽƵƌ ǁŝƚŚŽƵƚ ƌĞůǇŝŶŐ ƵƉŽŶ ĂĐĐŽƵŶƚƐ ďǇ ŽƚŚĞƌ
individuals (Bryman 2008; Lincoln and Guba 1985; Okely 1994; Lofland et al 2006). However, 
although observations cannot provide a simple copy of phenomena, they offer the potential 
ĨŽƌ ƚŚĞ ƉŚĞŶŽŵĞŶĂ ƵŶĚĞƌ ƐƚƵĚǇ ƚŽ ďĞ ƐƵďũĞĐƚ ƚŽ ĂŶĂůǇƐŝƐ ǁŝƚŚ Ă  ‘ƐŝŶŐůĞ ƚƌĂŶƐĨŽƌŵĂƚŝŽŶ ? Žƌ
representation by the researcher (Murphy and Dingwall 2003a). Other methods of inquiry such 
as interviewing have been said to involve at least two of these transformations: the researcher 
who chooses the question to ask and the respondent who reconstructs their original 
experience in the course of replying (Murphy and Dingwall 2003a). The minimisation of the 
chain of transformation is why observational research techniques have been described as the 
 “gold standard ? for qualitative research (Murphy and Dingwall 2003a). Furthermore, direct 
immersion into the everyday processes allow for a greater understanding of the rules, 
conventions and practices that govern the participants social worlds.    
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Observations are a useful method to explore health professional activities and behaviours 
(Smith 2002; Mays and Pope 1995). Non-participant observations in the pharmacy have been 
used to investigate OTC pharmacist-customer interactions in order to better understand 
customer views (Bissell et al 1997; Hassell et al 1998; Hibbert et al 2002; Wilson et al 1992). As 
mentioned in Chapter Two, there is little published research on the nature of MUR interactions. 
One study has used observations of MURs as part of a study of appointment-based 
consultations to analyse pharmacist-patient communication (Greenhill et al 2011). Observation 
methods have drawbacks including the time that it consumes and the resources that are 
required (Murphy et al 1998). Other issues raised include the heavy reliance upon the 
ƌĞƐĞĂƌĐŚĞƌ ?Ɛ ŝŶƚĞƌƉƌĞƚĂƚŝŽŶ ŽĨ ǁŚĂƚ ŚĂƐ ďĞĞŶ ŽďƐĞƌǀĞĚand the assumptions that the 
researcher brings; although this can be considered a strength given the skill and insightfulness 
ŽĨ ƚŚĞ ƌĞƐĞĂƌĐŚĞƌ  ?DŝůĞƐ ĂŶĚ ,ƵďĞƌŵĂŶ  ? ? ? ? ) ? ŚĂŶŐĞƐ ŝŶ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ďĞŚĂǀŝŽƵƌ ďĞĐĂƵƐĞ
they are aware of being observed can also be a drawback (Lincoln and Guba 1985; Smith 2002; 
Pope and Mays 1995). These issues are explored fully in Part Two of this chapter (section 3.3.7). 
In the following section I discuss structured and unstructured observation methods.   
 
3.2.6.1 Structured and unstructured observations 
Observations can be structured or unstructured. Emerson (1981) draws attention to the 
differences between the two. Structured observations are typically focused and selective and 
can be used to test hypotheses. The focus of structured observations is determined 
beforehand with a pre-specified procedure for what and when to observe. Observations here 
are predetermined into quantifiable pieces of information (e.g. type of behaviour, events) that 
can then be aggregated into variables allowing the data to be conceptualised in terms of 
frequency distributions of events under study (Emmerson 1981). This technique follows more 
closely the principles and assumptions of quantitative research. In contrast, unstructured 
observations are made without pre-determined categories or questions in mind. There is 
therefore no narrowing or restriction upon ƚŚĞ ŽďƐĞƌǀĞƌ ?Ɛ ƉĂƌƚŝĐŝƉĂƚŝŽŶ ŝŶ ƚŚĞ ƐĞƚƚŝŶŐ
(Emmerson 1981; Lofland et al 2006; Murphy and Dingwall 2003a). Silverman (1993) notes 
that one of the strengths of undertaking unstructured observation is that it avoids the 
premature definition of variables which may deflect attention away from social processes 
which are important to the participants themselves. Smith also contends that structured 
ŽďƐĞƌǀĂƚŝŽŶƐ  “grossly ignore the complexity ? ŽĨ ŝŶƚĞƌĂĐƚŝŽŶƐ  ?^ŵŝƚŚ1975:203) whereas 
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unstructured observations supƉŽƌƚ ƚŚĞ  ‘ŽƉĞŶ-ĞŶĚĞĚŶĞƐƐ ? ŽĨ ĨŝĞůĚ ƌĞƐĞĂƌĐŚ ŝŶ ŽƌĚĞƌ ƚŽ ƐƚƵĚǇ
matters where little is known.  
 
Unstructured observations were therefore used in this study as this was deemed the most 
appropriate way to answer the research aims and objectives. Careful consideration was given 
to the perspective or viewpoint I adopted during fieldwork. Researchers are typically open to 
two opposing, although not mutually exclusive, orientations when undertaking observation 
research. Davis (1973) metaphorically referred to these two stances as creatures. The first 
ŐƌŽƵƉ ? ƚŚĞ  ‘DĂƌƚŝĂŶƐ ? ? ĂƚƚĞŵƉƚ ƚŽ ĚŝƐƚĂŶĐĞ ƚŚĞŵƐĞůǀĞƐ ĨƌŽŵ ƚŚĞƐŽĐŝĂů ƐĞƚƚŝŶŐ ? ƐĞĞŬŝŶŐ ƚŽ
ƵŶĚĞƌƐƚĂŶĚǁŝƚŚĨƌĞƐŚĞǇĞƐƚŚĞƉŚĞŶŽŵĞŶĂƵŶĚĞƌƐƚƵĚǇ ?dŚĞƐĞĐŽŶĚ ?ƚŚĞ ‘ŽŶǀĞƌƚƐ ? ?ƐƚƌŝǀĞƚŽ
immerse themselves more deeply, and through this, develop intimate familiarity with the 
social setting. Lofland et al (2006) suggest that the distancing stance may be appropriate if 
there is existing familiarity with the setting; conversely, a researcher who is not familiar should 
employ mechanisms to reduce the distance between the participants and themselves. In Part 
Two of this chapter (section 3.3.7) I describe the perspective that I adopted. In this section, I 
have discussed the first research method that was used in this study. The second research 
method that was used was interviews with participants and this method of enquiry is 
discussed in the following section.    
 
3.2.7 Interviews  
Qualitative research interviews are used to discover what people think of the world they live in, 
to evaluate their experiences and to uncover why they behave the way they do (Murphy et al 
 ? ? ? ? ) ?DƵƌƉŚǇ ĂŶĚ ĐŽůůĞĂŐƵĞƐ ƉƵƚ ƚŚŝƐ ƐŝŵƉůǇǁŚĞŶ ƚŚĞǇƐƚĂƚĞĚ  “If you want to understand 
what people do, believe and think, ask them ?  ?DƵƌƉŚǇet al 1998:112). People possess self-
consciousness and are able to reflect on themselves, their situation and their relationships; 
interviews enable the investigation of these subjective experiences and attitudes (Kvale 1996). 
They are therefore particularly useful for getting the story bĞŚŝŶĚĂƉĂƌƚŝĐŝƉĂŶƚ ?ƐĞǆƉĞƌŝĞŶĐĞƐ ?
Qualitative interviews are also social encounters between two or more persons leading to 
ŶĞŐŽƚŝĂƚŝŽŶ ĨŽƌ ƚŚĞƉƵƌƉŽƐĞŽĨĂ  ‘ĨŽĐƵƐĞĚ ŝŶƚĞƌĂĐƚŝŽŶ ?ĂŶĚĂƌĞŽŶĞŽĨ ƚŚĞŵŽƐƚĐŽŵŵŽŶĂŶĚ
powerful ways that we can understand people (Silverman 1993; Fontana and Fray 2008). They 
ƚŚĞƌĞĨŽƌĞŽĨĨĞƌƚŚĞƉƌŽƐƉĞĐƚŽĨĂƵƚŚĞŶƚŝĐŝŶƐŝŐŚƚƐŝŶƚŽƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞ ?^ŝůǀĞƌŵĂŶ
1993).  
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Qualitative interviews have been used for a wide range of purposes and according to Smith 
(2002) are the most commonly employed approach in health and pharmacy practice research. 
Qualitative interviews have been used to explore various aspects of community pharmacy 
including how patients or customers have evaluated the services they have been offered 
(Anderson et al 2004; Bissell and Anderson 2003; Bissell et al 2008; Eades et al 2011; Morris et 
al 1997; Williamson et al 1992). However, there are limitations to using this method which will 
be expanded upon below. 
 
3.2.7.1 Interviews as a method of enquiry    
As with all research methods interviews do have limitations and they are not a simple neutral 
exchange of asking questions and getting answers. Scheurich (1995) points out that the 
interviewer is a person who is historically and contextually located, with personal conscious 
and unconscious motives, desires and biases. Moreover the researcher does not have direct 
ĂĐĐĞƐƐ ƚŽ ĂŶŽƚŚĞƌ ?Ɛ ĞǆƉĞƌŝĞŶĐĞ ďƵƚ ? ĂƐ ZŝĞƐƐŵĂŶ  ? ? ? ? ? P ? ) ĐůĂŝŵƐ:  “we deal with ambiguous 
representations of it ? ?Interviews are artefacts that rely upon the interviewer and interviewee 
to co-construct the experience. As a consequence interviews do not offer a literal description 
ŽĨ ƚŚĞ ƌĞƐƉŽŶĚĞŶƚ ?Ɛ ƌĞĂůŝƚǇ ? dŚĞǇ ĚŽ ŚŽǁĞǀĞƌ ƉƌŽǀŝĚĞa situated account that reflects each 
ƉĂƌƚǇ ?Ɛ ĞǆƉĞĐƚĂƚŝons and experiences (Dingwall 1997; Goffman 1983; Murphy et al 1998; 
Silverman 1993). 
 
3.2.7.2 Types of interviews  
There are a range of interview methods and techniques. One of the most common methods is 
the one-to-one encounter between the researcher and interviewee. Group discussions with 
ƉĂƌƚŝĐŝƉĂŶƚƐ Žƌ  ‘ĨŽĐƵƐ ŐƌŽƵƉƐ ? ĐĂƉŝƚĂůŝƐĞ ŽŶ ƚŚĞ ĚǇŶĂŵŝĐƐ ŽĨ ĐŽŵŵƵŶŝĐĂƚŝŽŶ ďĞƚǁĞĞŶ ƚŚĞ
research participants. The interaction that occurs is a crucial feature because the interaction 
between participants highlights their view of the world, the language they use about an issue 
and their values and beliefs about a situation (Kitzinger 1995). This enables the researcher to 
exploit peer interaction and explore the dynamics of the discussion that occurs between 
participants in ways that are not possible with one-to-one interviews (Greenbaum 1998; 
Kitzinger 1995). However, the one-to-one interview method was chosen for this study as this 
provided opportunities to explore in-depth individual experiences and perspectives.  
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3.2.7.3 Structured, unstructured and the semi-structured interview  
Interviews, according to Fontana and Fray (2008), can range from being structured, semi-
structured or unstructured. There are also a range of interview forms that can be used to 
ŝŶǀĞƐƚŝŐĂƚĞ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ƉĞrspectives or biographical accounts such as the biographical 
narrative, biographical narrative integrative method and free association narrative interview 
(Hollway and Jefferson 2000; Riessman 1993). Structured interviews involve asking 
respondents the same series of pre-defined questions to which participants have a limited set 
of response categories. Within these interviews the researcher treats respondents in a like 
manner, aiming to be as neutral as possible with little flexibility in his or her approach. In 
contrast, unstructured interviews, sometimes referred to as in-depth or open ended 
interviews, attempt to elicit the views and issues of greatest significance to the participant 
without imposing any personal notions that may limit the field of enquiry (Fontana and Fray 
2008; Pope and Mays 1995).  
 
The semi-structured approach is one which allows flexibility within the interview while 
ensuring that each interview covers a range of core topics (Bryman 2008; Fontana and Fray 
2008; Smith 2002). A list of questions sometimes known as an interview or topic guide is 
usually employed to achieve this (Bowling 2009; Bryman 2008). Additional questions may be 
asked which allows the researcher to probe or follow up leads mentioned by the participant. 
The semi-structured interview also allows scope for the participant to raise issues of personal 
relevance and concern and has been recommended in situations where there is a fairly clear 
focus to the interview (Bryman 2008; Smith 2002). The semi-structured approach was deemed 
the most appropriate method for these reasons when interviewing participants about the 
MURs service.  
 
In the preceding sections, I have described the two research methods used in this study: 
observations and interviews. The combination of both methods is an effective method for 
ƉĞŶĞƚƌĂƚŝŶŐ ĂŶĚ ƵŶĚĞƌƐƚĂŶĚŝŶŐ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ƉĞƌƐƉĞĐƚŝǀĞƐ ? ŽŵƉĂƌĂƚŝǀĞůǇ ĨĞǁ ĐŽŵŵƵŶŝƚǇ
pharmacy practice studies have combined observation and interview techniques. 
Observational data have been recognised as a valuable means of checking the credibility of 
ƌĞƐƉŽŶĚĞŶƚƐ ?ĂĐĐŽƵŶƚƐĂƚŝŶƚĞƌǀŝĞǁ ?ŽǁůŝŶŐ ? ? ? ? ?sŽǇƐĞǇ ? ? ? ? ) ?dŚŝƐĐŽŵďŝŶĂƚŝŽŶŽĨƌĞƐĞĂƌĐŚ
ŵĞƚŚŽĚƐ ĐĂŶ ƉƌŽǀŝĚĞ ǀĂůƵĂďůĞ ŝŶƐŝŐŚƚƐ ŝŶƚŽ ƉĂƚŝĞŶƚƐ ? ƉĞƌĐĞŝǀĞĚ  ‘ŶĞĞĚ ? ĂŶĚ ƉĞƌƐƉĞĐƚŝǀĞƐ ŽĨ
pharmacy services. The application of observations and interview techniques in this study 
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aimed to develop a deeper understanding of the complexities surrounding the MUR service 
and to enhance the validity of the conclusions (Bryman 2008; Smith 2002). I now turn 
attention to discussing the concept of rigour in qualitative studies and how this was achieved 
in the present study.  
 
3.2.8 Rigour and qualitative enquiry  
Qualitative research has been criticised for lacking scientific rigour (Pope and Mays 1995). 
Pope and Mays (1995) list three commonly heard criticisms. The first is that qualitative 
research is simply an assembly of anecdotes that are subject to researcher bias; secondly, 
qualitative research lacks reproducibility and lastly, qualitative research lacks generalisability.  
In the following section, I discuss the concept of rigour as it applies to qualitative research. I 
will initially discuss the two concepts that have been associated with ensuring rigour in 
quantitative studies: validity and reliability. 
 
3.2.8.1 Validity and reliability  
Reliability has been defined as whether a research study is replicable or the extent to which 
results are consistent over time and provide an accurate representation of the total population 
under study (Golafshani 2003). Validity refers to whether the means of measurement are 
accurate and whether they are actually measuring what they are intended to measure 
(Golafshani 2003). Both terms are essential criteria for demonstrating rigour in quantitative 
research. However, these measures have been criticised in their applicability to qualitative 
research (Golafshani 2003; Lincoln and Guba 1985; Marshall 1985). dŚĞƚĞƌŵ ‘ƚrustworthiness ? 
has been used for issues conventionally discussed in terms of validity and reliability. However, 
it is acknowledged that trustworthiness is always negotiable and open-ended and is not a 
matter for claiming final proof (Seale 1999). Lincoln and Guba (1986) have presented criteria 
ƚŚĂƚ ĂƌĞ ŵŽƌĞ ĂƉƉůŝĐĂďůĞ ǁŚĞŶ ĂƐƐĞƐƐŝŶŐ ƚŚĞ  ‘ƌŝŐŽƵƌ ? ŽĨ Ă ƋƵĂůŝƚĂƚŝǀĞ ƌĞƐĞĂƌĐŚ ƐƚƵĚǇ ? dŚĞƐĞ
include the concepts of credibility and transferability (Lincoln and Guba 1986).  
 
The credibility of a study relies upon the ability of the researcher to be sensitive to the data 
and the extent to which the findings that are presented are convincing to the reader (Creswell 
and Miller 2000). The measures undertaken in this study combine periods of direct 
observation of the phenomena and interviews with the participants under study. The 
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comparison or triangulation of different data sources has been acknowledged as a means to 
improve the credibility of qualitative research (Lincloln and Guba 1985). Another way of 
establishing the credibility of findings is to actively search for evidence that does not support 
the themes being generated (the deviant case). In grounded theory, in particular, the deviant 
case is used to challenge and extend theory and explanation so that all of the data is 
accounted for (Bryman 2008; Charmaz 2006). The inclusion of disconfirming or negative 
evidence points to an awareness of, and sensitivity to, the multiple perspectives that are 
experienced by the participants (Miles and Huberman 1994).  
 
Transferability is the extent to which the findings are transferable to other settings. This 
construct does not aim for random sampling and probabilistic reasoning which are commonly 
associated with the generalisability of quantitative research. In this study, there are no claims 
about statistical representation or generalisation to a larger population. The use of a 
qualitative study design is for the purpose of understanding and explaining. Eisner (1991:58) 
ĐŽŶƚĞŶĚƐ ƚŚĂƚ Ă ŐŽŽĚ ƋƵĂůŝƚĂƚŝǀĞ ƐƚƵĚǇ ĐĂŶ ŚĞůƉ ƵƐ  “understand a situation that would 
otherwise be enigmatic or confusing ? ?dŚĞƉƌŝŶĐŝƉůĞĂŝŵŽĨƚŚŝƐƐƚƵĚǇǁĂƐƚŽĂĐŚŝĞǀĞĂďĞƚƚĞƌ
understanding of what people think of MURs and consider how the service is integrated into 
the daily working practice of pharmacy. Nevertheless, Murphy et al (1998) have argued that 
although direct comparability between settings is impossible, some similarities do exist. In 
order for the reader to evaluate the possibility of such transfer, the researcher must provide a 
ĚĞƚĂŝůĞĚƉŽƌƚƌĂŝƚŽƌ ‘ƚŚŝĐŬĚĞƐĐƌŝƉƚŝŽŶ ?ŽĨƚŚĞŽƌŝŐŝŶĂůƐĞƚƚŝŶŐŝŶǁŚŝĐŚƚŚĞƌĞƐĞĂƌĐŚŝƐĐŽŶĚƵĐƚĞĚ 
(Geertz 2000).  
  
In this section, I have reviewed the different criteria which help ensures the quality, integrity, 
and relevance of qualitative research. These are important concepts that allow the reader to 
determine the rigour of this study. In the next section, I discuss the ethical issues arising from 
this study.     
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3.2.9 Ethical issues 
Ethical theory can be seen to fall into two broad and distinct, but not mutually exclusive, 
approaches. These are the consequentialist and deontological approach (Murphy and Dingwall 
2001). Consequentialist principles focus on the outcomes of the research and stress that 
research can be justified if outcomes outweigh any potential harm. A risk-benefit analysis 
strategy is therefore applied. This approach contrasts with deontological principles which focus 
on the inherent rights of the research participants. This means that there is respect for 
peoples ? values and autonomy but also that people should be treated equally (Beauchamp et 
al 1982). The operationalisation of these principles has led to a set of guidelines which are now 
widely accepted by research governance committees and institutions (Murphy and Dingwall 
2001). One prominent guideline is that participants are to be adequately informed about their 
involvement in research and to have time to consider written information about the study and 
whether they want to participate. This posed problems of investigating MURs as they happen 
in a  ‘real world ? practice setting. Full details of the methods used in this study are outlined in 
Part Two of this chapter. However, I detail below some decisions that resulted from ethical 
issues arising from this study.       
 
3.2.9.1 Ethical decisions in the field  
In a qualitative research study, overcoming ethical conduct cannot be guaranteed simply by 
requiring all participants to sign a consent form. Rather, it has been recognised that the 
researcher should identify and minimise or eliminate any risks to participants (Murphy et al 
1998). Several ethical implications arose from observing both shop floor interactions and ad 
hoc MURs. It has been acknowledged thĂƚ ŝŶ  ‘complex and mobile settings it may be 
impractical to seek consent from everyone involved ? ?DƵƌƉŚǇĂŶĚŝŶŐǁĂůů ? ? ? ? P ? ? ? ) ?In this 
study, the placing of posters in the pharmacy aimed to promote awareness of the research 
among patients and customers.  
 
Previous research and personal experience indicated that patients were mainly being recruited 
by an ad hoc direct invitation (Hall and Smith 2006; Latif and Boardman 2008; Moss 2007; 
Urban et al 2007; Wang 2007). This meant that patients were being put  ‘ŽŶ ƚŚĞ ƐƉŽƚ ? ?
Consideration was given to whether patients may be put under pressure, both by the 
pharmacist in requesting an MUR, a service with which they were unfamiliar and not expecting, 
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and then by the further request to take part in the research. Research governance 
requirements usually call for patients to be adequately informed and to have time to consider 
written information about the study and whether they want to participate. This posed 
ƉƌŽďůĞŵƐĂƐ ƚŚĞƉƌŝŵĂƌǇŽďũĞĐƚŝǀĞǁĂƐ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ  ‘ůŝǀĞ ƉƌĂĐƚŝĐĞ ? ? /ŶǀĞƐƚŝŐĂƚŝŶŐDhZƐthat 
were being performed on an ad hoc basis would mean that patients would not have the time 
to read or reflect on all of the information provided. This is normally considered a prerequisite 
by research ethics committees for properly informed consent.   
 
Fully informed consent is sometimes acknowledged as being impractical in advance of a 
qualitative research study (Murphy et al 1998). dŽĂĚĚƌĞƐƐƚŚĞŝƐƐƵĞŽĨƉĂƚŝĞŶƚƐďĞŝŶŐ ‘ƉƵƚŽŶ
ƚŚĞƐƉŽƚ ?ƚŚĞƉŚĂƌŵĂĐŝƐƚŽƌƐƚĂĨĨŵĞŵďĞƌ ŝŶǀŝted the patient for an MUR and if they agreed, 
the pharmacist invited them to take part in the study and introduced the researcher who then 
provided a verbal summary. Video or audio-recording the MUR would have provided an 
objective record of the consultation (DuFon 2002). However, compromises were made as it 
was felt that this would be too intrusive and might cause anxiety to patients. This was because 
most patients would not be expecting an MUR and therefore would not have had adequate 
time to consider paƌƚŝĐŝƉĂƚŝŶŐŝŶƚŚĞƐƚƵĚǇ ?dŽƉƌŽƚĞĐƚƉĂƚŝĞŶƚƐ ?ƌŝŐŚƚŽĨƐĞůĨ-determination, the 
option to withdraw from the study was given including the deletion of all notes relating to the 
observed MUR. Patients were also given the option to reply by post should they wish to 
decline the invitation for their follow-up interview (Latif et al 2010).   
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3.3 Part Two: Methods 
3.3.1 Introduction  
In the second part of this chapter, I provide a detailed account of the methods used in this 
study. I detail how I recruited the study pharmacies, the process that was undertaken during 
fieldwork and how the participants were recruited. Lastly, a description of the data 
management and analysis is given.      
 
3.3.2 Ethical and Research and Development approvals   
This project was approved by the Nottingham Research Ethics Committee on 9th July 2008 (ref 
08/H04080/92). Research and Development (R&D) approval was obtained from 
Nottinghamshire County Teaching PCT. Indemnity sponsorship arrangements were obtained 
from the University of Nottingham. Approval letters for this study can be found in Appendix 
Three.  
3.3.3 Overview of proposed plan of fieldwork 
Following ethical and R&D approval, two pharmacies, a multiple and an independent, were 
recruited purposefully via personal contacts. Consent was obtained from the pharmacists and 
support staff for five weeks of observations in each pharmacy. One-week placements were 
arranged over a 12-month period between November 2008 and October 2009. 
Ethnographically oriented unstructured observation methods notes were made of all 
pharmacy activities, including all activities relating to MURs. All pharmacists and support staff 
were requested to identify and invite patients for MURs as per normal practice and to 
introduce the research to all those who accepted the offer of an MUR. All such patients agreed 
to be included in the research and for their MUR to be observed.  
 
After the MUR, patients were invited to take part in an interview about their experience. Each 
placement week was therefore followed by a period of approximately three weeks for 
reflection, arrangement and conduct of interviews with patients. This allowed data collection 
and analysis phases to proceed in parallel. At the end of the observational period within the 
pharmacies, pharmacists and staff were invited to take part in interviews about their 
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experience of the MUR service. In the next section, a detailed description of methods is given 
starting with consideration of issues about the recruitment of the study pharmacies         
 
3.3.4 Pharmacy recruitment planning   
Deciding upon the sample of pharmacies to research was an important step in the design of 
this study. It was clearly not practical or efficient to qualitatively explore large populations and 
so consideration was given to the number of pharmacies that would be approached. This study 
could have been undertaken in one pharmacy. However, two pharmacies were selected which 
allowed for the incorporation of a comparative dimension to the study findings.  The choice of 
pharmacies aimed to investigate MURs in two contrasting and diverse settings to enable the 
collection of the richest possible data (Lofland et al 2006). Although other pharmacy 
parameters could have been used, such as levels of affluence, urban or rural locations or size 
of pharmacy, the decision to explore in a multiple and independent was influenced by existing 
research indicating that there were marked differences in implementation issues between the 
two (Blenkinsopp et al 2007a; Bradley et al 2008a). There were several reasons why the 
decision was taken to conduct this study in two rather than in several pharmacies. Recruitment 
of community pharmacies to the study was anticipated to be challenging. The literature 
indicated that independents, in particular, have lower MUR adoption rates (Blenkinsopp et al 
2007a; Bradley et al 2008a). Indeed, the independent pharmacy recruited for this study was 
the only one, out of the ten pharmacies approached, that met the minimum selection criteria 
for this study. This is discussed further in the following section.  
 
Undertaking a qualitative study in only two pharmacies had several methodological 
advantages. The aim of quantitative sampling is different to the approach taken in a qualitative 
sample. Whereas the former aims to draw on a representative sample of the population, so 
that the results then can be generalized back to the population, the essence of the latter is to 
achieve an in-depth holistic understanding of complex social phenomena which is aimed at 
studying people in their natural settings (Marshall 1996). This enables explanation and 
understanding of how people experience the world and how it works and not merely recording 
how often something happens (Hammersley 1992; Bryman 1988; Bryman 2008; Silverman 
1997). This study, like many other qualitative studies, was not designed to be generalisable to 
the larger population (Golafshani 2003) or to describe the service provision in several different 
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settings. Rather, the study sought an opportunity to learn and understand about the MUR 
service as it naturally occurs in the real world practice of community pharmacy. The aim 
therefore was so to develop a detailed knowledge of two extended case studies rather than 
more superficial knowledge of a larger number of pharmacy sites.  The extended time spent in 
each pharmacy allowed for the recording of a more naturalistic attitude of staff in the 
pharmacies as they increasingly became use to the presence of the researcher. Furthermore, 
undertaking qualitative observations typically results in a large amount of data being collected 
and this was evident in the present study. Careful consideration of how many pharmacies that 
took part was needed to avoid the volume of data collected becoming unmanageable. It is 
however, acknowledged that adopting only two study sites has limitations and this issue is 
discussed in Chapter Eight (section 8.5.2). 
 
Inclusion into the study was dependent upon the pharmacy actively providing the MUR service 
to patients. Easterbrook and Matthews (1992) found that the main reason for studies being 
abandoned was difficulty in recruiting participants. Careful consideration was therefore given 
to the minimum number of MURs undertaken by pharmacies to ensure recruitment of a 
reasonable number of participants to the study. It was anticipated that 30 to 40 patients would 
ďĞƌĞĐƌƵŝƚĞĚĂŶĚƚŚĂƚƚŚŝƐǁŽƵůĚďĞƐƵĨĨŝĐŝĞŶƚƚŽĂůůŽǁĂǁŝĚĞƌĂŶŐĞŽĨƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞƐƚŽ
be incorporated within the study. Pharmacies conducting a minimum of three MURs per week 
were considered for inclusion. With pharmacies anticipated to perform at least three MURs a 
week, ten weeks of planned observations would allow for the targeted number of 30-40 
participants. As a contingency, a third pharmacy would have been used if MUR activity and 
patient recruitment proved to be less than anticipated in the initially selected pharmacies. The 
extended period of fieldwork observations also intended to reduce the extent to which 
participants modified their behaviour as a result of a heightened awareness of the observer 
and allowed familiarity with the people and the setting.   
 
3.3.5 Recruitment and access 
Gaining access to the field has been described as the most difficult phase in the entire process 
of an ethnographic study (Agar 1996; Gobo 2008; Lofland et al 2006; Murphy et al 1992; Van 
Maanen and Kolb 1985). In primary care settings this can be complex, requiring the 
recruitment of organisations, practitioners and patients. Murphy et al (1992) point to two 
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broad categories of stakeholders or groups who might be affected by a proposed research 
study: the participants who are directly involved in the research process and external 
stakeholders who are not directly involved but who may be  ‘ŐĂƚĞŬĞĞƉĞƌƐ ?ƚŽĂŶŽƌŐĂŶŝƐĂƚŝŽŶĂů
setting. ZĞŵĂƌŬŝŶŐŽŶ ‘ŐĞƚƚŝŶŐƉĂƐƚƚŚĞŐĂƚĞŬĞĞƉĞƌƐ ? ?sĂŶDĂĂŶĞŶĂŶĚ<ŽůďŽbserve that:  
 
 “Most fieldworkers would probably agree that gaining access to most organizational 
settings is not a matter to be taken lightly but one that involves some combination of 
strategic planning, hard work and dumb luck ?.  
(Van Maanen and Kolb 1985:11).  
 
Individualised approaches were used to identify and negotiate with the external stakeholders 
of the multiple and independent pharmacies and these are discussed below.    
 
3.3.5.1 Recruitment and access: the multiple  
One chain pharmacy was approached through local contacts. This was a pragmatic choice and 
an approach that can facilitate access to study participants (Agar 1996; Murphy et al 1992; Van 
Maanen and Kolb 1985). Permission was sought from the CŽŵƉĂŶǇ ?ƐůŝŶŝĐĂů^ĞƌǀŝĐĞƐDanager 
who had overall responsibility for the provision of clinical services within the pharmacies. 
Through a process of negotiation and assurances of anonymity for the Company, a pharmacy 
was selected and permission was sought from the manager and pharmacist to conduct the 
study. Pharmacies that the researcher had previously worked in regularly or extensively were 
avoided to reduce the potential of being mistaken, by pharmacy staff, for the pharmacist on 
duty. The pharmacy selected was one that I had previously worked in as a pharmacist. 
However, this had been on an occasional basis and several years previously. A visit to the 
pharmacy was made prior to the start of the study in order to further explain the details of the 
study to the pharmacy staff.  
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3.3.5.2 Recruitment and access: the independent  
A list of all the independent pharmacies that were in the Nottingham and Nottingham county 
PCT areas was used to identify five pharmacies that were performing MURs.  Identification of 
the pharmacies was aided by local pharmacist contacts who suggested pharmacies that were 
actively offering the service to patients. Five invitation letters were sent during August 2008 
inviting the pharmacy to the study (Appendix Four). All five pharmacies were contacted by 
telephone several days later to see whether they were willing to partake in the study. All five 
pharmacies reported either not regularly performing MURs at the minimum of three MURs per 
week or reported being  ‘too busy ? to participate. Another five independent pharmacies were 
ideŶƚŝĨŝĞĚ ? ƚŚŝƐ ƚŝŵĞ ďǇ Ă ŵĞŵďĞƌ ŽĨ ƚŚĞ hŶŝǀĞƌƐŝƚǇ ?Ɛ ƉŚĂƌŵĂĐǇ ĂĐĂĚĞŵŝĐ ƚĞĂŵ ǁŚŽ ǁĂƐ
involved with undergraduate community pharmacy placements. Again recruitment letters 
were sent and the pharmacies subsequently contacted. Only one pharmacy was performing 
the minimum number of MURs required for inclusion to the study and expressed interest in 
taking part in the study. As with the multiple, an assurance of anonymity was provided for the 
pharmacy. A visit was also made prior to the start of the study to further explain the details of 
the study to the pharmacy staff.  
 
3.3.6 Pharmacy staff recruitment  
An important aim of this research was to investigate how the MUR service was being 
integrated amongst the other services offered at the pharmacy. This meant that all staff 
involved with pharmacy activities were eligible and were invited to take part in the study. 
Suspicions, lack of adequate information or inaccurate assumptions have been suggested as 
reasons why participants decline to take part in research studies (Agar 1996; Murphy et al 
1992). A central objective during the recruitment period and during the initial stages was to 
ƚŚĞƌĞĨŽƌĞĂǀŽŝĚǁŚĂƚŚĂƐďĞĞŶĚĞƐĐƌŝďĞĚĂƐ ‘ŝƌƌĂƚŝŽŶĂů ?ƌĞĨƵƐĂůƐ ?DƵƌƉŚǇĞƚĂů ? ? ? ? ) ?dŚŝƐǁĂƐ
achieved through explaining to each participant what the study involved and identifying and 
discussing any concerns that participants may have had about the study. Pharmacists and 
support staff were provided with an assurance of anonymity and that a non-judgemental 
approach would be taken when observing their activities. A participant information sheet was 
provided to all participants and written consent to take part in the study was obtained 
(Appendix Five).  No staff member declined to take part in the study. 
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3.3.7 Observations  
One week before the study began, pharmacies were requested to display study posters 
prominently within the relevant pharmacy areas to promote patient awareness of the study 
(Appendix Six). Fieldwork observation in the multiple and independent were alternated in 
order to facilitate comparison of the findings between the two pharmacies. Observations were 
made during the pharmacies ? opening hours and at weekends if the pharmacist indicated that 
there was a possibility that MURs would be conducted. In the following section, I discuss the 
role adopted in the field, how field notes were recorded and the process involved in observing 
the MURs. 
 
3.3.7.1 The role of the researcher  
Careful consideration was given to constructing the role that I would eventually adopt in 
relation to the fieldwork setting, pharmacy staff and patients. Gold (1958) classifies four roles 
that could be adopted within the field which include the complete participant, participant-as-
observer, observer-as-participant and the complete observer. The complete or covert 
participant is described as a fully functioning member of the social setting and as such the 
ƌĞƐĞĂƌĐŚĞƌ ?Ɛ ŝĚĞŶƚŝƚǇ ŝƐ ƵŶŬŶŽǁŶ ƚŽ ƚŚĞ ŵĞŵďĞƌƐ ? dŚĞ ƉĂƌƚŝĐŝƉĂŶƚ-as-observer adopts the 
same role as a complete participant; however their identity is overt and is known to the 
members of the social setting.  These two positions were untenable since, as part of the study, 
I wanted to observe MURs between the pharmacist and patient. An observer-as-participant 
role was therefore adopted. This provided flexibility and involvement within the research 
setting when this was necessary but aimed to minimise participation in the social activities of 
the pharmacy. 
 
My professional identity was also carefully considered when the pharmacist introduced me to 
patients. The identity of researchers with a professional background is a particular concern 
when performing research in this area as respondents who are asked to take part in research 
about the use of medicines may feel they are being tested (Stevenson et al 2000b). The 
researcher was therefore ŝŶƚƌŽĚƵĐĞĚ ƚŽ ƉĂƚŝĞŶƚƐ ĂƐ Ă  ‘ƐƚƵĚĞŶƚfrom the hŶŝǀĞƌƐŝƚǇ ? ? dŚŝƐ
facilitated participants to talk with more freedom without feeling guarded.  
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3.3.7.2 Reflexivity  
The concept of reflexivity is concerned with the impact the researchers prior assumptions, 
viewpoints and framework have on the research findings (Schwandt 1997) or more generally 
the reciprocal impact of the researcher and the research field (Denscombe 2003). My 
professional background as a pharmacist will have shaped what was observed and my 
interpretations of those observations. It was therefore critical to understand how my 
background influenced the phenomena that I perceived and the way in which data were 
gathered and analysed. This was achieved through ongoing reflections upon my personal 
impressions and feelings which were recorded in personal memos and with regular discussions 
with supervisors.  
 
My dual identity as a researcher and as a pharmacist offered several advantages. I used my 
contacts within the field to gain easier access and membership to the group as I could 
converse about pharmacy issues. However, this sometimes led to unexpected tensions which 
became evident during fieldwork. It was decided at the beginning that I would introduce 
myself to the pharmacist and staff as both a pharmacist and researcher and it was made clear 
from the outset that I would undertake no pharmacist or other pharmacy work activities. I 
ǁŽƵůĚƚŚĞƌĞĨŽƌĞďĞĐŽŶƐŝĚĞƌĞĚŝŶƚŚŝƐƌĞƐƉĞĐƚĂƐĂŶŽƵƚƐŝĚĞƌŽƌĂ ‘ƉƌŽĨĞƐƐŝŽŶĂůƐƚƌĂŶŐĞƌ ?ǁŚŽ
was detached from the work commitments of the group (Agar 1996). This, however, did not 
mean that I had no influence on the setting or participants. On the contrary, because of my 
presence within the pharmacy I noticed what is commonly referred to as the  ‘,ĂǁƚŚŽƌŶĞ
eĨĨĞĐƚ ? ?
 
3.3.7.3 The Hawthorne effect 
The Hawthorne effect typically arises from the awareness of research participants that they 
ĂƌĞďĞŝŶŐƐƚƵĚŝĞĚǁŚŝĐŚůĞĂĚƐƚŽĐŚĂŶŐĞƐŝŶƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ďĞŚĂǀŝŽƵƌ ?ƵƐƵĂůůǇĨŽƌƚŚĞďĞƚƚĞƌ ?
This leads to the participants responding to the conditions of the data collection process rather 
than the phenomena the researcher is intending to study (Pope and Mays 1995; Smith 2002; 
Stevenson et al 2000a; Stevenson et al 2000b). This was most noticeable when the pharmacists 
in both pharmacies occasionally apologised on days when no MURs were performed. My 
presence as an observer appeared to encourage MUR activity despite requesting that 
pharmacy staff should identify and invite patients for MURs as per normal practice. This 
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occurred more frequently in the independent pharmacy where there was less organisational 
pressure than the multiple to perform MURs. 
 
Observing the patient-pharmacist interaction may have also altered what would have normally 
occurred. To minimise the influence of the researcher on the behaviour of the participants, 
fieldwork observations were spread over a period of 12 months and it was anticipated that 
during this time the pharmacists would become accustomed to being observed. Although my 
presence appeared to encourage MUR activity or at least pharmacist awareness of MURs, I felt 
the impact was minimal. As Strong (1979: ? ? ? )ĐŽŶƚĞŶĚƐ  “the daily business of life has to get 
done ?. On reflecting upon my background as a pharmacist, I was aware that I would already be 
accustomed to the environment and so have some level of  ‘field blindness ?. A  ‘DĂƌƚŝĂŶ ?ƐƚĂŶĐĞ
(Davis 1973) was sought when observing the routine activities that occur in the pharmacy. 
However, for most of the time it waƐŶĞĐĞƐƐĂƌǇƚŽĂĚŽƉƚƚŚĞ ‘ŽŶǀĞƌƚ ? stance (Davis 1973) in 
order to observe and better understand DhZƐĨƌŽŵƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ ?ǀiewpoint.     
 
3.3.7.4 Field notes 
Observations were made of all pharmacy activities including dispensing prescription medicines, 
OTC consultations and sales as well as MUR consultations. Observation notes were also made 
ŽĨ ƚŚĞ ƉŚĂƌŵĂĐǇ ?Ɛ ǁŽƌŬŝŶŐ ĞŶǀŝƌŽŶŵĞŶƚ ? ĞǀĞŶƚƐ ĂŶĚ ƉĞŽƉůĞ ? ǁŽƌŬ ƉĂƚƚĞƌŶƐ ? ĐŽŶǀĞƌƐĂƚŝŽŶƐ
between patients and staff members and all activities relating to MURs. Recording field notes 
without drawing attention to this activity is a common problem experienced by ethnographers 
(Agar 1996; Gobo 2008; Lofland et al 2006; Smith 2002). Recording field notes was, as far as 
possible, done inconspicuously to avoid raising staff anxieties, self-consciousness or even 
threatening access arrangements. Field notes were recorded by pen and paper and 
occasionally through use of a personal digital recording device when outside the pharmacy. 
Memo writing was a critical aspect of recording findings. Key words and phrases used by 
participants were recorded during fieldwork and a full account of the observations were 
written up and reflected upon as soon as practicable. This provided a running log of 
observations. Casual or  “informal discussions ? (Lofland et al 2006: 88) which involved asking 
questions in situ, helped to clarify and confirm observations. These too were later 
reconstructed from memory and recorded. The removal of identifiable information was made 
at the earliest possible stage substituting names for pseudonyms and altering non-relevant 
information.   
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3.3.8 Recruitment of patients   
WŚĂƌŵĂĐŝƐƚƐĂŶĚƐƚĂĨĨǁĞƌĞĂƐŬĞĚƚŽĐĂƌƌǇŽŶƚŚĞŝƌĚĂŝůǇĂĐƚŝǀŝƚŝĞƐĂƐ ‘ŶŽƌŵĂů ?ĚƵƌŝŶŐƚŚĞĐŽƵƌƐĞ
of the fieldwork observations. Observing this process allowed valuable contextual data and 
information about the decisions that were made leading up to offering an MUR to a patient. All 
pharmacists and support staff were requested to identify and invite patients for MURs as per 
normal practice and to introduce the research to all those who accepted the offer of an MUR. 
All such patients agreed to be included in the research and for their MUR to be observed, at 
which point I was introduced to explain what was involved. Despite a few occasions where the 
pharmacist had forgotten to introduce me to the patient, I was able to  ‘Ɛŝƚ ŝŶ ? ŽŶ all MURs 
taking place when I was observing in the pharmacy.   
 
3.3.8.1 Patient exclusion criteria  
Patients who were not eligible for an MUR and those under the age of 18 were excluded. No 
patients under 18 were offered an MUR by the pharmacist or staff during the study period. 
Since translation resources were not available, it was decided that interviews would only be 
conducted in English and so patients who were insufficiently fluent in the English language 
would also be excluded. Ultimately, no patients were actually excluded on this basis. 
 
3.3.9 Observations of MURs  
Before the MUR, a verbal summary of the research aims along with an information sheet was 
provided to the participant (Appendix Seven). Written consent for allowing the MUR to be 
observed was taken before the MUR began (Appendix Seven). On a few occasions when the 
pharmacist had already started the consultation written consent was taken after the MUR. The 
researcher sat in the corner of the consultation room viewing both patient and pharmacist 
during the MUR and made written notes of the MUR consultation. Audio or video recording 
the MUR consultation would have provided verbatim data. Nevertheless, it was decided that 
hand written notes would be used to record the MUR consultation because this method was 
deemed to be the least intrusive (Latif et al 2010).   
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During the MUR, linguistic (e.g. content of talk / coherence) and extra-linguistic (e.g. speaking 
rate, interruptions) features were noted. Non-verbal commuŶŝĐĂƚŝŽŶ ? ƐƵĐŚ ĂƐ ƉĂƚŝĞŶƚ ?Ɛ
expression and body language, were also recorded as were the physical proximity and layout 
of the room. After the MUR, observations were made of the patient and pharmacist and how 
they both resumed their respective roles when they left the consultation room. Informal 
discussions between the pharmacist and support staff were also recorded after an MUR to 
provide further contextual insights. 
 
Patients were invited for an interview about their experience of the MUR once the pharmacist 
had ended the consultation and had left the consultation room. If patients expressed interest, 
they were contacted several days later by telephone and asked if they were willing to continue 
with the study. If so, an interview was arranged. Participants were given the option to reply by 
post (using a pre-paid envelope that was supplied) should they subsequently decide to decline 
the invitation for an interview.  
 
3.3.10  Arrangement of patient interviews 
Interviews with patients were arranged and conducted after each ǁĞĞŬ ?ƐŽďƐĞƌǀĂƚŝŽŶƐǁŝƚŚŝŶ
the pharmacy. Options were offered to conduct the interview ǁŝƚŚŝŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŚŽŵĞ ?Ăƚ
the pharmacy or if they wished at another convenient location and at a time according to their 
preference and convenience. All interviews took place at the pharmacies except for two that 
were conducted at the University of Nottingham. Checks were made to ensure participants 
were willing to continue to take part in the study and that there was continued acceptance for 
me to use the collected MUR observational data. Written consent was taken before the 
interview and permission to audio-record the interview was sought (Appendix Seven). Patients 
were reminded that they were not obliged to respond to any questions they were not 
comfortable with and that the interview could be terminated at any time they wished.    
 
3.3.10.1 Interview format and topic guide  
Semi-structured interviews were conducted to investigate patient experiences of the MUR 
consultation. This allowed the opportunity to consider the interview in relation to the 
ŽďƐĞƌǀĂƚŝŽŶƐ ? ůƐŽ ĚŝƐĐƵƐƐĞĚ ǁĞƌĞ ƉĂƚŝĞŶƚƐ ? ďĞůŝĞĨƐ ? ĐŽŶĞƌŶƐ ĂŶĚ ƵŶĚĞƌƐƚĂŶĚŝŶŐ ĂďŽƵƚ ƚŚĞŝƌ
medicines and the wider involvement of pharmacists and GPs in their health care. Using open 
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ended questions and a conversational style, the interviews aimed, as far as possible, to avoid 
ŝŵƉŽƐŝŶŐ ƚŚĞ ƌĞƐĞĂƌĐŚĞƌ ?Ɛframework of meanings onto patient accounts (Britten 1999). A 
topic guide was initially developed following a literature review. It was then developed and 
tailored to the specific details and context of the MUR which preceded it (Appendix Eight). The 
topic guide was therefore used to stimulate an open discussion of topics and issues that were 
ŵŽƐƚ ƐĂůŝĞŶƚ ĨŽƌ ƌĞƐƉŽŶĚĞŶƚƐ ƌĂƚŚĞƌ ƚŚĂŶ ƚŽ ŝŵƉŽƐĞ ƚŚĞ ƌĞƐĞĂƌĐŚĞƌ ?Ɛ ĨƌĂŵĞǁŽƌŬ Žf 
understanding (Charmaz 2006). This inductive approach is considered to be good qualitative 
practice (Charmaz 2006; Ziebland and McPherson 2006). After the interview, personal 
reflections were recorded on how the interview went. For example, how nervous, confident or 
relaxed the participant appeared. 
 
3.3.11  Patients declining the invitation for an MUR 
Patients who declined the invitation for an MUR were also approached after their interaction 
with the pharmacist or support staff and offered an interview regarding the reasons why they 
declined. It was anticipated that these interviews would be shorter (as the patient did not have 
an MUR) and so a telephone, instead of a face-to face interview, was proposed. Patients were 
informed that they did not need to decide immediately and an information sheet including the 
ƌĞƐĞĂƌĐŚĞƌ ?ƐĐŽŶƚĂĐƚĚĞƚĂŝůƐǁĞƌĞƐƵƉƉůŝĞĚƐŚŽƵůĚƚŚĞǇǁŝƐŚƚŽƚĂŬĞƉĂƌƚŝŶƚŚĞƐƚƵĚǇ (Appendix 
Seven). Patients were given the option to reply by post should they wish not to be contacted 
further. For patients who agreed to take part, a semi-structured telephone interview was 
arranged at a time that was convenient to them. Permission was sought for the interview to be 
audio recorded. Oral consent was taken before the interview commenced and the patient was 
requested to post a written copy of the consent form back to the researcher in a pre-paid 
envelope.  
 
3.3.12 Pharmacist and pharmacy staff interviews  
After the observational fieldwork had been completed, pharmacists and support staff were 
invited to take part in an interview to explore their perceptions of the MUR service. One 
pharmacist interview occurred after the 4th week of observation within the pharmacy as there 
was a concern that she would shortly leave employment. Topic guides were developed to 
explore pharmacist and support staff perceptions of the MUR service (Appendix Eight). As with 
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the patient interviews, staff interviews were individually tailored to clarify, confirm and extend 
the observational data. Interviews were semi-structured and took place at a time and location 
that was convenient to the participants. Written consent was taken before the start of the 
interview and permission sought for the interview to be audio-recorded. All pharmacist 
interviews, except one, were conducted at the pharmaciƐƚ ?Ɛ ǁŽƌŬ ƉůĂĐĞ ? KŶĞ ƉŚĂƌŵĂĐŝƐƚ
interview took place in their home. All support staff interviews occurred at the pharmacy 
where they worked except for two; these were conducted at the University of Nottingham. 
 
3.3.13  Protocol changes 
It is rare to find qualitative projects without unforeseeable problems and there were many 
instances where I had to make adjustments to the planned strategy during my time in the field. 
Three modifications to the research protocol were required and made during fieldwork. One 
protocol change was the addition of a telephone interview option for patients who had 
completed an MUR. Originally it was anticipated that all interviews would be arranged face-to-
face. However, during fieldwork it was found that this was not always practicable and so a 
telephone option was incorporated into the study design. Another protocol amendment 
involved withdrawing the planned focus groups or interviews with the local GPs in order to 
focus on those areas that were considered under-researched. The final protocol amendment 
was seeking permission to employ a professional transcriber to aid transcription of some of the 
interviews. Protocol amendment approval letters can be found in Appendix Three. 
  
3.3.14  Data management 
The alternation of fieldwork periods in each pharmacy along with regular patient interviews 
facilitated an iterative process of data collection and analysis. Full accounts of all the 
observations were written up and all of the interviews with patients and pharmacy staff were 
transcribed verbatim. N-Vivo8, a leading qualitative data analysis software programme, was 
used as a tool for the storage and management of the multiple forms of data sources. Richards 
and Richards provide a comprehensive overview of the advantages and disadvantages of using 
qualitative software packages (Richards and Richards 1998; Richards and Richards 1991). A 
point worthy of note here is that no software can perform qualitative data analysis which must 
still be done by the researcher and this process is described in the next section. 
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3.3.14.1 Data analysis 
Data analysis started during the early stages of data collection. The principle of constant 
comparison was used as a framework for thematic analysis (Creswell 2007). This is a widely 
applicable method for identifying, analysing and reporting patterns and themes within the 
data and may be judged appropriate when the research question has a relatively narrow focus 
(Ziebland and McPherson 2006). Analysis began with repeated listening to the interviews and 
reading and re-reading the observation notes. Sections of the data representing an idea, 
opinion or attitude were categorised as statements or words which were collected under 
ĚŝĨĨĞƌĞŶƚŚĞĂĚŝŶŐƐŽƌ ‘ĐŽĚĞƐ ? ?WŽƉĞĞƚĂů ? ? ? ? ) ?Codes were created as far as possible in terms 
of the categories and concepts of the research participants. As more information was added to 
the code, these were constantly compared to the original data source to ensure it was 
grounded in the data. Regular meetings with supervisors provided multiple perspectives and 
interpretations. This enabled more credible identification of key concepts and themes.   
 
Once all of the observation notes and interview data had been coded the  ‘one sheet of paper ? 
(OSOP) analysis as described by Ziebland and McPherson (2006) was used to progress the 
analysis of the data. This involved reading through each code category in turn and noting, on 
one piece of paper, all the issues that were raised by the coded extracts. Axial coding was used 
in order to further analyse the data. Axial coding has been described as putting the fractured 
data back together in new ways by  “making connections between a category and its 
subcategory ? ?Strauss and Corbin 1990:97). This facilitated comparison of similar categories to 
ĨŝŶĚŽƵƚ ‘ǁŚĂƚ ?ƐŐŽŝŶŐŽŶ ŝŶƚŚĞĚĂƚĂ ? ?ŝĞďůĂŶĚĂŶĚDĐWŚĞƌƐŽŶ ? ? ? ? ? ) ?dŚŝƐprocess involved 
making connections between categories and subcategories in order to create a more precise 
and complete explanation about the phenomena under study. The OSOP method allowed 
negative evidence or deviant cases that did not fit into the emerging story, to be identified. 
These were paid particular attention and were accounted for in the analysis. There were 
constant reflections throughout this whole process as well as conferring with supervisors 
which encouraged the application of an attitude of critical appraisal towards the findings. The 
analysis was enriched by going back to the literature to see where and how other research and 
theories fitted and how it could further inform the analysis and testing of findings.    
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In this chapter, a detailed description of the methodology and methods used in this study has 
been provided. The following four chapters will present the findings of this study.  
 
Chapter Four: The Pharmacy 
74 
 
4 CHAPTER FOUR The Pharmacy 
CHAPTER FOUR 
The Pharmacy 
4.1 Introduction  
In the following four chapters, I present the results of this study. This chapter will focus on the 
pharmacy environment and contextualise how patients act within this and how they use the 
services of the pharmacy. The findings from the observations of the MUR consultations 
themselves will be reported in Chapter Five. The inferences made from these two chapters will 
lay the foundation for Chapters Six and Seven which provide further explanatory insights into 
the perspectives of patients and pharmacy staff of the MUR service.    
 
In this chapter, /  ‘ƐĞƚ ƚŚĞ ƐĐĞŶĞ ? ďǇ ƉƌŽǀŝĚŝŶŐ ĂŶ ŽǀĞƌǀŝĞǁ ŽĨ ƚŚĞ ƌĂŶŐĞ ŽĨ ƐĞƌǀŝĐĞƐ ĂŶĚ
interactions from the two pharmacies and contextualise how the MUR service was being 
implemented in the midst of these activities. This is important to understanding how the MUR 
service was received and viewed by patients. A  ‘thick description ? (Geertz 2000) of the two 
study sites will initially be provided and then the different patient-pharmacist interactions that 
were observed will be discussed. A description of how the pharmacies had implemented the 
DhZƐĞƌǀŝĐĞǁŝůůƚŚĞŶĨŽůůŽǁƚŽŐĞƚŚĞƌǁŝƚŚĨŝŶĚŝŶŐƐŽŶƉŚĂƌŵĂĐŝƐƚƐ ?ŵŽƚŝǀĂƚŝŽŶƚŽĞŶŐĂŐĞǁŝƚŚ
MURs. Next, the initial processes of the MUR will be reported including the way patients were 
identified and invited for an MUR and the preparations that the pharmacist had to make 
before the start will then be described. The chapter will conclude by presenting the 
observations made after the MUR, in particular, the workload that mounted during the 
ƉŚĂƌŵĂĐŝƐƚƐ ?ĂďƐĞŶĐĞ ?dŚŝƐĐŚĂƉƚĞƌƚŚĞƌĞĨŽƌĞƉƌŽǀŝĚĞƐĂďĂĐŬĚƌŽƉƚŽŚŽǁƚŚĞDhZƐĞƌǀŝĐĞĨŝƚƐ
into the overall running of the pharmacy and so enables the service to be better put into 
perspective. To begin, the following sections will describe each of the two pharmacy settings. 
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4.2 Multiple pharmacy study site  
The multiple pharmacy was located in a relatively affluent town, situated along a busy high 
street, much of which is pedestrianised. Several GP surgeries were located within a short walk 
of the pharmacy. The pharmacy was medium-sized compared to other pharmacies that form 
part of the organisation and was open weekdays and Saturday from 9am to 5.30pm. When 
entering the pharmacy there were many noticeable professional looking promotional displays. 
The pharmacy sold a wide range of retail merchandise including cosmetics, toiletries, baby / 
child, electrical and gift items. 
 
The health care counter was found to the side of the dispensary from which customers could 
buy health care products either through self selection or by asking a MCA for more potent 
 ‘Wharmacy only ? medicines that were located behind the medicines counter out, of reach of 
the public. A variety of health related posters, leaflets and books was displayed around the 
dispensary including the promotion of the MUR service. The dispensary was located at the rear 
of the shop and dispensed approximately 1600 to 1700 prescription items a week. Pharmacy 
staff working within the dispensary were clearly visible preparing prescription medicines when 
viewed from the shop floor. Two pharmacists were employed at the pharmacy. One was full-
time and had recently qualified as a pharmacist. The other worked part-time and had been 
practising for over 20 years. This arrangement changed midway through the study when an 
ACT joined the team and the pharmacist hours reduced accordingly. Two dispensers were 
employed to assist the pharmacist in the dispensary and two medicines counter assistants 
managed requests for OTC medicines. A trainee pharmacist (pre-registration graduate) also 
worked in the pharmacy.     
  
Whilst this was a medium-sized retail shop, pharmacy activities were concentrated in a 
relatively small area in and around the dispensary (Figure 5). The dispensing area did not 
naturally lend itself to private discussions as people could be overheard when speaking to the 
pharmacy staff. A number of staff target boards located within the dispensary, stair ways, 
offices and the tea room area displayed how well or poorly the pharmacy was performing. A 
target board for MURs was displayed in the dispensary. The consultation room was located a 
short distance away from the dispensary and had been specially installed to provide MURs. 
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The room was well lit and contained no furnishings except for two chairs and a small table. The 
room was seldom used other than for MUR consultations.  
 
 
 
 
Figure 5: Schematic diagram of the multiple pharmacy  
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4.3 Independent pharmacy study site 
The independent pharmacy was located in a similarly affluent but residential suburb. The 
community was served mainly through a single GP practice located across the road from the 
pharmacy. The pharmacy opening hours were similar to that of the multiple, but closed at 
midday on Saturday. Inside, the size of the shop floor was smaller than the multiple and so was 
the range of retail items stocked. Retail items were individually priced with the name of the 
pharmacy on the price sticker. Retail items sold from the pharmacy included cosmetics, 
toiletries and nappies with jewellery and greeting cards on standalone displays. Unlike the 
multiple, there were no target boards displayed in the dispensary or other areas of the 
pharmacy.  
 
Health care products could be found near to and on top of the health care counter which was 
located to the rear of the shop and manned by a MCA. Medicines were available on open 
displays. However, as in the multiple, Pharmacy-only medicines were kept behind the 
medicines counter out of reach of customers. The dispensary was situated behind the 
medicines counter toward the rear and on a raised platform. When viewed from the shop floor, 
the heads and shoulders of the staff working in the dispensary could be seen but not the 
dispensing process. The number of prescription items that was dispensed was approximately 
the same as in the multiple pharmacy (1600-1700 per week). Only one pharmacist was 
employed in the pharmacy with a regular locum pharmacist or the pharmacist-owner covering 
any days off. The pharmacist had worked for the owner for several years and was both the 
pharmacist and manager of the pharmacy. Support staff included three dispensers and one 
MCA. Job roles appeared to be less rigid and compartmentalised than in the multiple. This 
meant that dispensers were occasionally seen serving customers on the medicines counter.  
 
Being in a smaller catchment area with less passing trade, the staff appeared to be more 
acquainted with the relatively fewer people who entered the pharmacy compared with the 
ŵƵůƚŝƉůĞ ?dŚĞŝŶĚĞƉĞŶĚĞŶƚƉŚĂƌŵĂĐǇ ?ƐƐŽĨƚĞƌĨƵƌŶŝƐŚŝŶŐƐ such as a carpeted floor, chairs with 
cushions for patients to sit on and the soft sound of a radio playing in the background created 
a more homely, less formal, atmosphere. As in the multiple, there was no obvious place for 
patients and pharmacists to sit and have a private discussion (Figure 6). The consultation area 
where MURs were performed was located next to the dispensary and had been adapted from 
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an existing general purpose office. The room had a window with net curtains allowing privacy 
and was again rarely used for discussions with patients other than MUR consultations. The 
room was large enough for two people to sit around the computer screen. However, when 
three people were sitting in the room, for example when the pharmacist had invited two 
patients together for an MUR (husband and wife), access to the door was restricted and the 
room appeared cramp. Other items in the room included a water cooler, shop merchandise 
and display items as well as several piles of invoices that had been placed on shelves.  
 
 
 
 
Figure 6: Schematic diagram of the independent pharmacy 
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4.4 Pharmacy and pharmacist activities  
In order to better understand the context in which MURs were offered and undertaken in 
practice it is helpful to consider this in relation to the other patient services that were provided 
by the pharmacies. Dispensing prescriptions and managing requests for OTC products to treat 
ŵŝŶŽƌĂŝůŵĞŶƚƐǁĞƌĞƚŚĞŵĂŝŶƐƚĂǇǁŽƌŬŽĨƚŚĞƉŚĂƌŵĂĐǇ ?ƐŚĞĂůƚŚ care areas and pharmacists 
were heaǀŝůǇ ĐŽŵŵŝƚƚĞĚ ƚŽ ƚŚĞƐĞ ĂĐƚŝǀŝƚŝĞƐ ? hŶĚĞƌƐƚĂŶĚŝŶŐ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶǀŽůǀĞŵĞŶƚ ŝŶ
these activities is fundamental to how they managed and delivered the MUR service. 
Pharmacists and support staff involvement in the activities of the pharmacy is described in the 
following three sections. 
 
4.4.1 Pharmacist involvement in dispensing prescriptions  
While the dispensing staff managed the bulk of the assembly work, the pharmacist was 
observed to be involved in all aspects of the dispensing process from receiving prescriptions 
from patients or their representatives, producing labels, selecting the medicines from the 
shelves and accuracy checking the final assembled prescription. In both pharmacies, these 
processes were markedly routinised. In the multiple, the proximity and visibility of the 
pharmacist to patients meant that they were engaged consistently with bringing in and 
handing out prescriptions. The pace of work of the pharmacists was dependent upon the rate 
at which prescriptions were presented at the pharmacy:  
 
Around 10 am there seemed to be a rush of people to the dispensary. There were 4 to 5 
patients or their representatives around this area. Jane [pharmacist] who was bringing 
ŝŶƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶƐƐĂŝĚƚŽƚŚĞƉĂƚŝĞŶƚ “/ ?ǀĞŐŽƚĨŽƵƌŽƌĨŝǀĞŝŶĨƌŽŶƚ ?ŝƚǁŝůůďĞ about 15 
ŵŝŶƵƚĞƐ ? ? dŚĞ ŵĂůĞ ƉĂƚŝĞŶƚ  ?ĂŐĞĚ ĂƌŽƵŶĚ  ? ? ) ĚŝĚ ŶŽƚ ƐĞĞŵƚŽ ŵŝŶĚ ĂŶĚ ǁĞŶƚ ? dŚĞ
ƉĂƚŝĞŶƚďĞŚŝŶĚŚŝŵǁĂƐŶĞǆƚĂŶĚ:ĂŶĞƐĂŝĚ “ŚŽǁůŽŶŐǁŝůůǇŽƵŐŝǀĞƵƐ ?ĂŶǇŽƵŐŝǀĞƵƐ
ĂďŽƵƚ ? ?ƚŽ ? ?ŵŝŶƵƚĞƐ ? ? ?:ĂŶĞƚŚĞŶƚŽŽŬĂƉƌĞƐĐƌŝƉƚŝŽŶĐŚĂƌŐĞĨ ŽŵƚŚĞŵĂŶ ?,Ăǀing 
ďƌŽƵŐŚƚŝŶƚŚƌĞĞŽƌĨŽƵƌƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶƚŚŝƐǁĂǇ:ĂŶĞĂƐŬĞĚ:ĞĨĨ ?ƐĂůĞƐĂƐƐŝƐƚĂŶƚ ? “ĐĂŶ
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ǇŽƵŐŽƵƉƐƚĂŝƌƐĂŶĚĨŝŶĚĂƌŽů ?ĚŝƐƉĞŶƐĞƌ ?ǁĞ ?ǀĞŐŽƚĂƌƵƐŚŽŶ ? ?ĨƚĞƌĂĨĞǁŵŽŵĞŶƚƐ
Carol appeared and started dispensing the items.
1
   
Observation Wk. 5 Multiple     
 
Pharmacists appeared to have little control over their own work flow and so MURs were 
pragmatically accommodated during times when the pharmacy was less busy. Similar 
circumstances were evident in the independent. The pharmacist here was not only responsible 
for accuracy checking of prescriptions brought into the pharmacy, but also prescription 
supplies to several nursing homes:  
 
In the morning, there were lots of boxes of delivery items on the floor of the dispensary. 
dŚĞ  ‘ŶƵƌƐŝŶŐ ŚŽŵĞ ďĞŶĐŚ ? ǁĂƐoverflowing onto the floor with prescription items in 
ƚƌĂǇƐ QƚŚĞ ĚŝƐƉĞŶƐŝŶŐ ďĞŶĐŚĞƐ ǁĞƌĞ ĂůƐŽ ŶŽƚŝĐĞĂďůǇ ĐůƵƚƚĞƌĞĚ ǁŝƚŚ ƉƌĞƐĐƌŝƉƚŝŽŶƐ ƚŚĂƚ
ŚĂĚďĞĞŶĚŝƐƉĞŶƐĞĚĨŽƌƚŚĞŶƵƌƐŝŶŐŚŽŵĞƐ Q 
Observation Wk. 5 Independent 
 
Supplies of prescriptions to nursing homes took priority over most other pharmacy activities 
including MURs. Likewise, prescriptions that were to be delivered to patients ? homes also took 
priority. This was because the delivery driver would often wait in the dispensary for the 
pharmacist to complete accuracy checking of the prescriptions before they could be delivered: 
     
Rebecca has a certain workload that others depend upon. In particular the driver, John, 
who comes to the pharmacy midmorning for deliveries. He requires prescriptions to be 
ready for him to deliver. If items that are to be delivered are not ready he will 
ǁĂŝƚ Q:ŽŚŶŚĂƐƚǁŽŽƚŚĞƌƉŚĂƌŵĂĐŝĞƐƚŽƐĞƌǀĞĂůŽŶŐƐŝĚĞƚŚŝƐŽŶĞ ?ZĞďĞĐĐĂŝƐĂǁĂƌĞŽĨ
this and so when he is present she prioritises this work so that he is not standing 
around waitinŐ QdŚĞƌĞĚŽĞƐƐĞĞŵƚŽďĞƉƌĞƐƐƵƌĞƚŽĞŶƐƵƌĞƚŚŝŶŐƐĂƌĞƌĞĂĚǇ ĨŽƌ:ŽŚŶ ?
ŚŝƐǁŽƌŬŝƐĚĞƉĞŶĚĞŶƚƵƉŽŶZĞďĞĐĐĂ Q^ŚĞĚŽĞƐŵĞŶƚŝŽŶďĞĨŽƌĞŚĞůĞĂǀĞƐƚŚĂƚƐŚĞŚĂƐ
not checked the nursing home yet and so instructs him to return.   
Observation Wk. 3 Independent 
                                                          
1
 The extracts from the observation notes that are presented in this thesis are taken from detailed notes 
written up after each observation, rather than verbatim quotes. Pseudonyms have been used in quoted 
ĞǆƚƌĂĐƚƐƚŽŵĂŝŶƚĂŝŶƌĞƐƉŽŶĚĞŶƚƐ ?ĂŶŽŶǇŵŝƚǇ ? 
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Pharmacists work was predominantly reactive and there was often no planning for MUR 
activity. MURs within both pharmacies were therefore offered to patients when convenient to 
the pharmacist. Therefore most MURs were performed opportunistically and ad hoc. The 
extent to which pharmacists could engage with non-dispensing activities, such as MURs, was in 
part determined by the number of prescriptions received. The lack of patient-induced demand 
for MURs meant that when the pharmacist was busy dispensing prescriptions, MUR activity 
was abandoned with no obvious consequences to the care of patients:  
 
In the afternoon Jane [senior pharmacist] decided that the work load was too much as 
ƚŚĞƌĞ ǁĂƐ Ɛƚŝůů  ‘W^ ?2 prescriptions to do. She told Kate [junior ƉŚĂƌŵĂĐŝƐƚ ? ƚŚĂƚ  “ǁe 
ŶĞĞĚ ƚŽ ĐĂƚĐŚ ƵƉ ĂŶĚ ƐŽ ũƵƐƚ ďŽŽŬ DhZ ĂƉƉŽŝŶƚŵĞŶƚƐ ? ? dŚĞƌĞ ǁĂƐ ŶŽ ŶĞŐŽƚŝĂƚŝŽŶ ?
Subsequently no MURs were performed that afternoon. The front dispensing bench had 
several tubs containing prescriptions to be checked by the pharmacist. Overall the 
pharmacist appeared busy in the afternoon with ĚŝƐƉĞŶƐŝŶŐĂŶĚĐŚĞĐŬŝŶŐ Q^ƉĞĂŬŝŶŐƚŽ
Jane later that afternoon, she mentioned that three MURs had been booked [for that 
day]. However the patients had not turned up for appointments... 
Observation Wk. 2 Multiple 
 
The importance that pharmacists attached to performing MURs seemed to be significantly 
lower than the more immĞĚŝĂƚĞ ĂŶĚ  ‘ƌĞĂĐƚŝǀĞ ? ƐĞƌǀŝĐĞƐ ƐƵĐŚ ĂƐ ĚŝƐƉĞŶƐŝŶŐ ƉƌĞƐĐƌŝƉƚŝŽŶƐ ĂŶĚ
responding to OTC requests for advice. Appointments were seen as a way to manage work 
load better but as the extract above indicates, patients were reported not to turn up to these.  
 
Dispensing activity occupied much of the pharmacists time. However, their availability to 
provide advice to all support staff was critical to the smooth running of the dispensary:  
 
A lady (aged around 50) ĐĂŵĞ ŝŶ ƚŽ ƚŚĞ ĚŝƐƉĞŶƐŝŶŐ ĂƌĞĂ Q:ĂŶĞ  ?ƉŚĂƌŵĂĐŝƐƚ ? ǁĂƐ
working on the front with Dawn [disƉĞŶƐĞƌ ? ?dŚĞůĂĚǇƐĂŝĚƚŽĂǁŶ “I'm running out of 
ŵǇ ƉƌĞŐĂďĂůŝŶ ? ? ĂǁŶ ĂƐŬĞĚ ĨŽƌ ƚŚĞ ůĂĚǇ ?Ɛ ŶĂŵĞ ĂŶĚ ďƌŽƵŐŚƚ ƵƉ ŚĞƌ WMR [patient 
medication record]. Dawn haǀŝŶŐ ůŽŽŬĞĚ ŽŶ ƚŚĞ ƌĞĐŽƌĚ ƐĂŝĚ  “you should have more 
ƚŚĂŶĂǁĞĞŬ ůĞĨƚ ?. Jane who was standing beside Dawn then looked at the computer 
                                                          
2
 W^ƐƚĂŶĚƐ ĨŽƌ  ‘ƉƌĞƐĐƌŝƉƚŝŽŶĐŽůůĞĐƚŝŽŶƐĞƌǀŝĐĞ ? ?dŚŝƐ ƐĞƌǀŝĐĞ ŝŶǀŽůǀĞƐĐŽůůĞĐƚŝŶŐƉƌĞƐĐƌŝƉƚŝŽŶƐ ĨƌŽŵƚŚĞ
'WƐƵƌŐĞƌǇŽŶƚŚĞƉĂƚŝĞŶƚƐ ?ďĞŚĂůĨĂŶĚƉƌĞ-preparing them before the patient arrives at the pharmacy.   
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screen and took over from Dawn who then went into the back of the dispensary.  This 
was perhaps because it was the pharmacist who was perceived to deal with this 
ƐŝƚƵĂƚŝŽŶ ?:ĂŶĞƐĂŝĚ “ǇŽƵǁŝůůŶĞĞĚƚŽŽƌĚĞƌĂƉƌĞƐĐƌŝƉƚŝŽŶ ?ŝĨǁĞĚŽƐƵƉƉůǇŝƚ ?ƚŚĞŶƚŚĞǇ
 ?'W ƐƵƌŐĞƌǇ ? ǁŽŶ ?ƚ ŐŝǀĞ ŝƚ  ?ƉƌĞƐĐƌŝƉƚŝŽŶ ? ĂŶĚ ƐŽ ǁĞ ?ůů ď  ƐƚƵĐŬ ? QƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ǁĂƐ
able to identify when the prescription was dispensed, how many were being used and 
so how many were left. This was accurate to the day. The patient accepted what the 
ƉŚĂƌŵĂĐŝƐƚƐĂŝĚĂŶĚůĞĨƚ Q 
Observation Wk. 4 Multiple 
 
Ambiguities or issues that dispensers were unable to tackle themselves were discussed with or 
handed to the pharmacist who was seen as a problem solver. In the above case it was the 
pharmacist who decided what the patient should do. Interestingly, the pharmacist referred the 
patient to the GP surgery instead of contacting the GP surgery personally to resolve the matter. 
The pharmacist ?Ɛ remit and involvement with the patient ?s care will be further explored in 
section 4.4.4.1. However, the smooth operation of dispensing activities was dependent upon a 
pharmacist being present. When the pharmacist was absent during an MUR, activities in the 
ĚŝƐƉĞŶƐĂƌǇĂƉƉĞĂƌĞĚƚŽ ‘ŐƌŝŶĚƚŽĂŚĂůƚ ? ?dŚŝƐƉŽŝŶƚŝƐĞǆƉĂŶĚĞĚĨƵƌƚŚĞƌǁŚĞŶƚŚĞfindings from 
the observations taken after the MUR consultations are reported (section 4.8). Likewise, some 
dispensing activities in the multiple were solely managed by the pharmacists. Such activities 
included supplies of medicines to patients experiencing drug addiction (often referred by the 
ƐƚĂĨĨĂƐ ‘ĂĚĚŝĐƚƐ ? ) ?Such patients would normally attend daily and be requested by dispensers to 
wait until the pharmacist was available. They often took priority over other patients or their 
representatives who were waiting to collect their prescription: 
 
Two of the regular addicts (man and a woman in their thirties) came in to the 
ƉŚĂƌŵĂĐǇ QdŚĞƌĞ ŝƐ ĂŶ ŽůĚĞƌ ǁŽŵĂŶ ƐŝƚƚŝŶŐ ĚŽǁŶ ŽŶ ƚŚĞ ĐŚĂŝƌ ǁĂŝƚŝŶŐ ĨŽƌ ŚĞƌ
ƉƌĞƐĐƌŝƉƚŝŽŶ QdŚĞ ŵĂŶ ƐĂƚ ŶĞǆƚ ƚŽ ŚĞƌ QdŚĞ ǁŽŵĂŶ ĂĚĚŝĐƚ ůĞĂŶƐ ŽǀĞƌ ƚŚĞ ĨƌŽŶƚ
dispensing area and picks up a pharmacy dispensing stamp, and stamps it on the bench.  
dŚĞŵĂŶƐĂŝĚ  “ƚŚĞǇ ?ůůďůĂŵĞŵĞĨŽƌƚŚĂƚ ? ? ?,ŝƐǀŽŝĐĞ ŝƐ ůŽƵĚĂŶĚŝƐŽǀĞƌŚĞĂƌĚďǇ:ĂŶĞ
[pharmacist] who comes out from the back of the dispensary and acknowledges them 
ďǇƐĂǇŝŶŐ “ŚŝǇĂ ? ?dŚĞŵĂŶƌĞƐƉŽŶĚƐ P “ŚĂǀĞǇŽƵŶŽƚĚŽŶĞƚŚĞŵǇĞƚ ? ?He says this twice 
ƚŽǁŚŝĐŚ:ĂŶĞƌĞƉůŝĞĚ “ũƵƐƚĨŝŶŝƐŚŝŶŐƚŚĞŵŽĨĨ ? Q 
Observation Wk. 2 Multiple 
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The times that patients with drug addiction came in for their supply of medication varied and 
there was an expectation that they would be served without delay. The reliance therefore 
upon the pharmacist being available for these patients and for other dispensing services meant 
that in the multiple, there was an acknowledgment that two pharmacists were normally 
required to be on duty in order for any MUR activity to take place. This allowed one 
pharmacist to be available for  ‘ƌŽƵƚŝŶĞ ?services. However, in the independent there was no 
ƐƵĐŚ ‘ůƵǆƵƌǇ ?ŽĨĂƐĞĐŽŶĚƉŚĂƌŵĂĐŝƐƚĂŶĚƐŽDhZĂĐƚŝǀŝƚǇǁĂƐŽďƐĞƌǀĞĚƚŽďĞĨŝƚƚĞĚĂƌŽƵŶĚthe 
existing service provision.  
 
4.4.2 Pharmacist activities over-the-counter (OTC)  
Sales of OTC medicines to treat minor ailments were routinely undertaken by MCAs who 
advised patients directly. OTC medicines could be requested by patients by name or supplied 
through ĂƌĞĐŽŵŵĞŶĚĂƚŝŽŶ ?WŚĂƌŵĂĐŝƐƚƐ ?ŝnvolvement occurred when counter staff felt more 
specialist advice was required or if there was a request to speak to the pharmacist directly: 
 
During the afternoon a woman of about 35 years came in with a toddler.  She 
approached the chemist counter and spoke to Cath [MCA].  She explained that her child 
ŚĂĚ  “ĨĞůů ĚŽǁŶ ĂŶĚ Śŝƚ ŚŝƐ ŚĞĂĚ ? ? ĂƚŚ ĂƐŬĞĚ  “ŚŽǁ ŽůĚ ŝƐ ŚĞ ? ƚŽ ǁŚŝĐŚ ƚŚĞ ǁŽŵĂŶ
ƌĞƉůŝĞĚ  “ ? ? ŵŽŶƚŚƐ ? ? ĂƚŚ ƐĂŝĚ  “/ ?ůů ƐƉĞĂŬ ƚŽ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ? ? ĂƚŚ walked into the 
dispensary and asked Rebecca what to recomŵĞŶĚ ? ZĞďĞĐĐĂ ƚŽůĚ ĂƚŚ  “ĚŽŶ ?ƚ ŐŝǀĞ
Calpol as it may masks the signs of something more serious, do you want me to have a 
ůŽŽŬ ? ?ĂƚŚƌĞƉůŝĞĚ ‘ǇĞƐ ? QĨƚĞƌĂĨĞǁŵŽŵĞŶƚƐZĞďĞĐĐĂĐĂŵĞĚŽǁŶŽƵƚĂŶĚƚŚĞ ůĂĚǇ
ĞǆƉůĂŝŶĞĚƚŚĂƚ “ŚĞŚĂĚĨĂůůĞŶĚŽǁŶĂŶĚŚƵƌƚŚŝƐŚĞĂĚ ? Q ZĞďĞĐĐĂƐĂŝĚ “ŚĞůŽŽŬƐK< ?ĂƐ/
ǁĂƐƐĂǇŝŶŐƚŽĂƚŚ ?ĚŽŶ ?ƚŐŝǀĞŚŝŵĂůƉŽůĂƐƉĂŝŶŝƐĂŐŽŽĚŝŶĚŝĐĂƚŽƌƚŚĂƚƐŽŵĞƚŚŝŶŐŝƐ
wrong, he seems okay at ƚŚĞŵŽŵĞŶƚ ?ũƵƐƚŬĞĞƉĂŶĞǇĞŽŶŚŝŵ ? Q 
Observation Wk. 4 Independent 
 
In both pharmacies, MCAs typically directed customers to the pharmacist when the customer 
sought a recommendation for a baby or child, when a patient reported a medical condition or 
took a medication or regarding certain medicines seen as the responsibility of the pharmacist 
(e.g. supplied of EHC, anti-migraine and obesity medicines). In these situations the customer 
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was asked to wait until the pharmacist became available which was usually a short while after 
the request to be seen. Patients appeared to use the pharmacist as an accessible source of 
information. As with dispensing activities described earlier, the need for the pharmacist to be 
available was also applicable to certain sales of OTC medicines. With support staff potentially 
requiring the pharmacists input at any time, MURs were seen by some support staff as 
problematic in circumstances when the pharmacist was needed.      
 
4.4.3 Pharmacist engagement in management and administrative roles  
Pharmacists in both settings were observed undertaking managerial and administrative roles 
alongside the responsibilities already described. In the independent pharmacy, the pharmacist 
ǁĂƐ ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ ĂĐƚŝǀŝƚŝĞƐ ƐƵĐŚ ĂƐ  ‘ďĂŶŬŝŶŐ ƚŚĞ ƚĂŬŝŶŐs ? ? ƉĂǇŵĞŶƚ ŽĨ ǁĂŐĞƐ ĂŶĚ
arrangement of staff holidays. Administrative tasks were often done amid health care activities: 
  
Rebecca [pharmacist] spent time banking. She has created a spreadsheet with help 
from her brother and fiancé. It is a simple chart with takings from the pharmacy and 
costs. Rebecca was entering the takings into the dispensary computer screen. This was 
done in between prescriptions. She mentioned to me, in an informal discussion, that 
ƐŚĞŝƐĂďŽƵƚ “ƚŚƌĞĞǁĞĞŬƐďĞŚŝŶĚŝŶďĂŶŬŝŶŐ ? Q 
Observation Wk. 1 Independent 
 
Within the multiple pharmacy, pharmacists too had managerial responsibilities. The more 
experienced pharmacist was responsible for organising staffing, completing paperwork 
associated with claiming payment for services provided from the pharmacy, completing audits 
and other miscellaneous activities arising from the day-to-day running of a community 
pharmacy. The time needed to undertake these activities was on the whole unscheduled and 
had to be accommodated within the working hours of the day. Pharmacists were expected to 
undertake these duties as part of their role. However, as they were carried out in between the 
everyday provision of services to the public there appeared to be little free time to plan for 
DhZƐ ?dŚĞ  ‘ĨŝƌĞ ĨŝŐŚƚŝŶŐ ?ŵĞŶƚĂůŝƚǇĂĚŽƉƚĞĚ ŝŶďŽƚŚƉŚĂƌŵĂĐŝĞƐ ?ǁŚĞƌĞƚŚĞŵŽƌĞƵƌŐĞŶƚĂŶĚ
pressing activities took priority, left little room for lower priority activities such as MURs.      
 
Chapter Four: The Pharmacy 
85 
 
Pharmacists were observed to have little control over their workload both in its intensity and 
variety. Pharmacists were integral to the processes that allowed the dispensary and retail 
medicines counter ƚŽ ĨƵŶĐƚŝŽŶ ĞĨĨŝĐŝĞŶƚůǇ ? tŝƚŚ ŶŽ ĂĚĚŝƚŝŽŶĂů ƐƚĂĨĨŝŶŐ ? ƉŚĂƌŵĂĐŝƐƚƐ ?
pragmatically accommodated MUR activity into their workload. In the following three sections, 
I turn attention to the various patient-pharmacist interactions that occurred on the shop floor 
of the pharmacy. This will lay the foundation for Chapter Six, where patient experiences and 
expectations of pharmacy services will be presented. Investigating shop floor interactions will 
also facilitate comparison of patient-pharmacist interactions during MURs and other 
interactions in the pharmacy.    
 
4.4.4 Prescription medicines and pharmacist counselling  
Observations of patient behaviour revealed that most came to the dispensary to fill 
prescriptions and they could frequently be seen waiting for them. Patients were occasionally 
seen taking their prescription elsewhere if the medicine was not stocked by the pharmacy:   
 
ŵŝĚĚůĞĂŐĞĚŵĂůĞƉĂƚŝĞŶƚŚĂŶĚƐĂƉƌĞƐĐƌŝƉƚŝŽŶƚŽŽƌŽƚŚǇ ?ĚŝƐƉĞŶƐĞƌ ? ?^ŚĞƐĂǇƐ “ǁĞ
ĚŽŶ ?ƚ ŚĂǀĞ ƚŚŝƐ ŽŶĞ ŝŶ ? / ĐĂŶ ŽƌĚĞƌ ŝƚ ĨŽƌ ǇŽƵ ĨŽƌ ƚŚŝƐ ĂĨƚĞƌŶŽŽŶ ? ?  WĂƚŝĞŶƚ ƚĂŬĞƐ ƚŚĞ
ƉƌĞƐĐƌŝƉƚŝŽŶ ďĂĐŬ ĂŶĚ ƐĂǇƐ  “/ ?ůů ŐŽ ƐŽŵĞǁŚĞƌĞ ĞůƐĞ ? ?ŽƌŽƚŚǇƐĂǇƐ  “K< ? ? dŚŝƐ ĚŝĚ ŶŽƚ
ƐĞĞŵƚŽďŽƚŚĞƌƚŚĞƉĂƚŝĞŶƚƚŽŽŵƵĐŚ ?,ĞĐĂŶƉĞƌŚĂƉƐŐŽƚŽĂŶŽƚŚĞƌƉŚĂƌŵĂĐǇ Q 
Observation Wk. 1 Multiple 
 
Patients appeared accustomed to the supply driven environment that the pharmacies offered. 
Prescriptions in bags which were ready for collection could be seen from the shop floor. This 
reinforced the pharmacy as a place geared towards filling prescriptions rather than discussing 
them or allowing consideration of other issues that the patient may want to discuss. The 
ŵƵůƚŝƉůĞƉŚĂƌŵĂĐǇĚŝƐƉůĂǇĞĚƉƌŽŵŝŶĞŶƚ ‘/E ?ĂŶĚ ‘K>>d ?ƐŝŐŶƐĚŝƌĞĐƚŝŶŐƉĂƚŝĞŶƚƐƚŽǁŚĞƌĞƚŽ
present their prescription and where to collect. Likewise, within the independent patients 
were seen to observe their prescriptions going into the dispensary and minutes later are 
presented to them complete. When patients were offered an MUR this was largely unexpected. 
Patient views of how they felt about being invited for an MUR are discussed in Chapter Six 
section 6.4.2. 
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When patients or their representatives arrived in the pharmacy, initial interactions were 
mostly with pharmacy support ƐƚĂĨĨĂŶĚŝŶƚĞƌĂĐƚŝŽŶƐǁĞƌĞĨƌĞƋƵĞŶƚůǇĂďŽƵƚǁŚĞŶƚŚĞƉĂƚŝĞŶƚƐ ?
prescription would be ready to collect. Phrases such as  “are you waiting or calling back? ?,  “ŝƚ ?ůů
be 10 minutes, do you have any shopping to do? ? were frequently used by the pharmacy staff. 
Patients collecting medicines were seen providing their name and address to confirm the 
prescription belonged to them. After confirming these details the prescription was handed to 
the patient which concluded the interaction. Most interactions observed followed this 
etiquette with the assumption that patients did not have problems with or were content with 
their supplied medicines. When the pharmacist or staff sought to provide advice, patient-staff 
interactions were brief; the information provided was typically generic in nature and often well 
scripted: 
 
ZĞďĞĐĐĂ ?ƉŚĂƌŵĂĐŝƐƚ ? PdŚŝƐŝƐĂŶĞǁŝƚĞŵŝƐŶ ?ƚŝƚ?  
Patient:  Yes [mentions it is for his shoulder].  
Rebecca: Yes, yes, ok then [patient describes his shoulder pain. However Rebecca, by 
turning sideways provides a cue that she is ready to go back to the dispensary]. 
Rebecca: It can cause drowsiness.  
PaƚŝĞŶƚ PdŚĂƚ ?ƐǁŚĂƚƚŚĞĚŽĐƚŽƌƐĂŝĚ ?/ƐƚŚĞƌĞĞŶŽƵŐŚƚŽůĂƐƚŵĞĨŽƌĂĨŽƌƚŶŝŐŚƚ ? 
Rebecca: If you take less than 8 a day, then yes.  Bye. 
Observation Wk. 2 Independent   
 
The above extract illustrates a unilateral approach to counselling (Pilnick 2003). This has been 
described as a routine way of providing information about medicines in accordance with the 
standard clinic protocol and which does not acknowledge, or is sensitive to, prior client 
knowledge (Pilnick 2003). Information about drowsiness was transmitted without first 
establishing whether the patient understood or was knowledgeable about this. Advice on 
ŶĞǁůǇ ƉƌĞƐĐƌŝďĞĚ ŵĞĚŝĐŝŶĞƐ Žƌ ĐŚĂŶŐĞƐ ƚŽ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞƐ ĚŽƐĞƐ ƚŚĂƚ ŚĂĚ ďĞĞŶ
identified by pharmacy staff were often communicated to patients in an instructional manner. 
Interactions of this kind were frequently short with information imparted to the patient with 
little two-way communication:   
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[I observed a male patient aged about 75, asking for his prescription].  
:ĂŶĞ  ?ƉŚĂƌŵĂĐŝƐƚ ? PdŚĞƌĞ ?Ɛa note on your prescription that your metformin [diabetic 
medicine] has been reduced from three times a day to twice a day. Is that right? 
Patient: Yes.  
Jane: Do you know about that? 
Patient: Yes.  
Jane: I wanted to make sure.  
Observation Wk 3 Multiple  
 
Although patients were free to ask questions of the pharmacist or whoever was giving out the 
prescription, the routine purpose of this encounter was to supply the medicine and so the 
scope for providing advice to patients was limited. Patients appeared comfortable with, or at 
least to accept, this arrangement and any instructions given. Questions asked by the 
ƉŚĂƌŵĂĐŝƐƚƐƵĐŚĂƐ “have you had this before? ? ? “has the doctor gone through this with you? ?
Žƌ  “do you know your dose of [medicine] has been increased? ? ƌĞĐĞŝǀĞĚ ŵŝŶŝŵĂů ƌĞƐƉŽŶƐĞƐ
from patients. There was little exploration by the pharmacist of patients ? understanding or use 
of their medicines in this interaction. Moreover, observations of the trainee pharmacist 
revealed that their training and socialisation was predominantly in the assembly of dispensed 
prescriptions: 
  
Producing labels for walk-in prescriptions, producing labels for PCS prescriptions, 
finding the medicine on the shelf and placing a sticker on the box, putting away stock, 
filling up, date checking, disposing of unwanted medicines, bringing in and handing out 
prescriptions to patients, often without talking to patients other than asking for their 
ŶĂŵĞƐĂŶĚĂĚĚƌĞƐƐĞƐ ?dŚŝƐǁŚĂƚŵĂĚĞƵƉƚŚĞƚƌĂŝŶĞĞƉŚĂƌŵĂĐŝƐƚ ?ƐĐŽƌĞĂĐƚŝǀŝƚŝĞƐ Q 
Observation Wk. 4 Multiple  
 
WŚĂƌŵĂĐŝƐƚƐ ? ŝŶƚĞƌĂĐƚŝŽŶƐǁŝƚŚƉĂƚŝĞŶƚƐǁĞƌĞŵŝŶŝŵĂů ? Occasionally the prescription was seen 
ƚŽďĞŚĂŶĚĞĚƚŽƉĂƚŝĞŶƚƐ ?ƌĞƉƌĞƐĞŶƚĂƚŝǀĞƐ ?WĂƚŝĞŶƚƐĚŝĚŚĂǀĞƚŚĞŽƉƉŽƌƚƵŶŝƚǇƚŽĂƐŬƋƵĞƐƚŝŽŶƐ
during this encounter and most of these were observed to be about clarifying the practicalities 
of taking the medicine. Answers from pharmacists were brief, focused and tailored to what 
had been asked with little exploration of the issue. In the main, pharmacists reinforced the 
ĚŽĐƚŽƌƐ ? ŝŶƐƚƌƵĐƚŝŽŶƐ ǁŚĞŶ providing advice on prescribed medicines. The information or 
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advice giving role, as will be discussed in section 4.4.5, differed when pharmacists were 
observed to provide advice during OTC consultations. Here, pharmacists appeared to have a 
stronger sense of autonomy over their work resulting in their interactions with patients being 
more conversational and patient-centred.  
 
4.4.4.1 Pharmacist remit and autonomy  
Most of the prescriptions presented by patients at the pharmacy were unproblematic. 
However, occasionally patients did present with prescriptions with anomalies. Most of these 
cases concerned a medicine that the patient was expecting but which had not been issued on 
the prescription. Patients were usually referred back to the GP surgery in order to rectify the 
problem: 
 
A man (aged around 70) asked about his medicines that he had collected from the 
pharmacy earlier that day. Referring to his paper prescription order slip he mentions 
that the surgery has not put tramadol [painkiller] on his prescripƚŝŽŶ Q:ĂŶĞ ůŽŽŬƐ
through a pile of completed prescriptions and  finds the prescription in question and 
ƐŚŽǁƐƚŚŝƐƚŽƚŚĞƉĂƚŝĞŶƚ QƐŚĞƐĂǇƐƚŚĂƚƚŚĞƐƵƌŐĞƌǇŚĂƐ “ŶŽƚƉƵƚƚŚĞƚƌĂŵĂĚŽůŽŶƚŚĞ
ƉƌĞƐĐƌŝƉƚŝŽŶ ? ?^ŚĞŽĨĨĞƌƐ ƚŽƉŚŽƚŽĐŽƉǇĂůů ƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶƐ ĨŽƌ ƚŚĞ patient to show to 
ƚŚĞƐƵƌŐĞƌǇ “ĂƐĞǀŝĚĞŶĐĞ ? ?dŚĞƉĂƚŝĞŶƚĂĐĐĞƉƚƐƚŚĞŽĨĨĞƌ ?dŚĞƚƌĂŵĂĚŽůǁĂƐŶŽƚŽŶƚŚĞ
ƉƌĞƐĐƌŝƉƚŝŽŶ ĂŶĚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ĚŝĚ ŶŽƚ ƐƵƉƉůǇ ƚŚŝƐ QdŚĞ ŵĂŶ ǁĞŶƚ ĂǁĂǇ ǁŝƚŚ Ă
photocopy of the prescriptions presumably back to the surgery to get a prescription for 
ŚŝƐƚƌĂŵĂĚŽů Q 
Observation Wk. 2 Multiple 
  
Pharmacists communicated to patients through their actions that they were heavily reliant 
upon exactly what had been issued or written on the prescription. Pharmacists were observed 
to be cautious about making any changes to prescriptions without being authorised to do so by 
whoever had prescribed the patients ? medicine. On occasions, the pharmacist would take 
ŽǁŶĞƌƐŚŝƉĂŶĚĐŽŶƚĂĐƚƚŚĞƐƵƌŐĞƌǇŽŶƚŚĞƉĂƚŝĞŶƚƐ ?ďĞŚĂůĨ P 
  
During the afternoon, Rebecca [pharmacist] whilst labelling a prescription noticed that 
the patient had a prescription for 54 tablets of prednisolone with a dose of 8 tablets a 
ĚĂǇ ?^ŚĞǁŽŶĚĞƌĞĚŝĨƚŚŝƐǁĂƐĂǁĞĞŬ ?ƐƐƵƉƉůǇĂŶĚĂƐŬĞĚƚŚĞƉĂƚŝĞŶƚǁŚŽǁĂƐƵŶƐƵƌĞ ?
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Rebecca said that she woulĚ “ĐŚĞĐŬ ? ?^ŚĞƌĂŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐƐƵƌŐĞƌǇĂŶĚƐĂŝĚƚŚĂƚƐŚĞ
needs to talk to the doctor about the amount of prednisolone prescribed. The 
ƌĞĐĞƉƚŝŽŶŝƐƚŵĞŶƚŝŽŶĞĚƚŚĂƚƚŚĞĚŽĐƚŽƌŚĂĚƉƵƚŝŶŚŝƐ ‘ŶŽƚĞƐ ? P ?ĚĂǇƐŽĨĂŶƚŝďŝŽƚŝĐƐĂŶĚ
seven days of prednisolone. Rebecca on hearing this said that she would give 56 
ŝŶƐƚĞĂĚ ŽĨ  ? ? ĂŶĚ ƐĂŝĚ ŽŶ ƚŚĞ ƉŚŽŶĞ ƐŵŝůŝŶŐ  “ŽŶ ǇŽƵƌ ŚĞĂĚ ďĞ ŝƚ ? ? dŚŝƐ ǁĂƐ ĂŶ
indication that responsibility rested with the surgery and not her. Commenting on this 
after she mentioned to me and ƐĂŝĚ ƚŚĂƚ  “community pharmacists ĐĂŶ ?ƚ change the 
quantity of the items, even if it ?Ɛ ƚǁŽ ? ?
Observation Wk. 3 Independent   
 
Pharmacists were not often seen to exercise personal judgement relying instead on referring 
patients back to the GP or contacting the surgery ƚŚĞŵƐĞůǀĞƐ ? WŚĂƌŵĂĐŝƐƚƐ ? ůĂĐŬ ŽĨ
ĐŽŵŵƵŶŝĐĂƚŝŽŶ ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ 'W Žƌ ŽƚŚĞƌ ŚĞĂůƚŚ care provider meant that they often 
ƌĞůŝĞĚ ƵƉŽŶ ƉĂƚŝĞŶƚƐ ƚŽ ƌĞƚƵƌŶ ƚŽ ƚŚĞ 'W ƚŽ ƌĞƐŽůǀĞ ƚŚĞ ŝƐƐƵĞ ? dŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ŵŝŶĚƐĞƚ ĂŶĚ
approach to responding to patient problems with their medicines had important implications 
for how they dealt with medication issues during the MUR.  
4.4.5 Pharmacist-customer interactions over-the-counter (OTC)  
The wide range of medicines and retail products available from the pharmacies meant that 
there was an apparent freedom for customers to take the initiative and ask about a variety of 
health issues. In doing so, OTC interactions tended to be more conversational than interactions 
when handing out medicines and were focused and tailored to what the customer had 
requested:  
A woman aged around 55 years came to the dispensing counter. 
Customer: Which is better? [Holds up two antifungal products]. 
Jane [Pharmacist]: Is the inside moist or dry?  
ƵƐƚŽŵĞƌ P/ƚ ?ƐĚƌǇ ? 
:ĂŶĞ P/ƚ ?ƐďĞƐƚƚŽŐŽĨŽƌƚŚĞĐƌĞĂŵ ?if it was moist you could have used the powder to 
ĚƌǇŝƚƵƉ ?ŝĨŝƚ ?ƐĚƌǇƵƐĞƚŚĞĐƌĞĂŵ ? 
Customer: Do you want to look? [Jane goes around the front of the dispensary]. 
Jane: It looks moist, so use the powder. The powder will dry it out, and you can use it in 
the socks as well.    
Observation Wk.3 Multiple  
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Despite working in a retail environment, pharmacists did not appear to be influenced by 
commercial interest. Pharmacists relied on their own experience and personal preference 
when choosing to recommend a medicine for patients. One pharmacist was observed referring 
Ă ĐƵƐƚŽŵĞƌ ƚŽ Ă  ‘ĐŽŵƉĞƚŝƚŽƌ ? ǁŚĞŶ Ă ĐĞƌƚĂŝŶ ƉƌŽĚƵĐƚ ǁĂƐ ŶŽƚĂǀĂŝůĂďůĞ ĚĞƐƉŝƚĞ ƚŚĞƌĞ ďĞŝŶŐ
alternatives available to her: 
 
ƵƐƚŽŵĞƌ ?ŵĂŶĂŐĞĚĂďŽƵƚ ? ? ? P/ ?ǀĞŐŽƚĂƌƚŚƌŝƚŝƐŝŶŵǇůĞŐĂŶĚĨŽŽƚ ?ŝƐthere anything?  
Jane [Pharmacist]: Arnica gel is good [Jane walks over with the customer and looks on 
ƐŚĞůĨ ? ?tĞ ?ǀĞŐŽƚƚŚĞĐƌĞĂŵďƵƚŶŽƚƚŚĞŐĞů ?dŚĞŐĞůŝƐďĞƚƚĞƌ ?ŐŽƚŽ,ŽůůĂŶĚĂŶĚĂƌƌĞƚƚ
and ask for the gel. [Customer leaves. On walking back to the dispensary Jane said to 
ŵĞ  “ŵǇ ŚƵƐďĂŶĚ ƵƐĞƐ ƚŚĂƚ ? ĂŶĚ / ?ǀĞ ƵƐĞĚ ŝƚ ĂŶĚ ŝƚƐ ƋƵŝƚĞ ŐŽŽĚ ? ƚŚĞ ŐĞů ŝƐ ďĞƚƚĞƌ ĨŽƌ
Śŝŵ Q ? ? 
Observation Wk. 3 Multiple 
 
OTC interactions appeared to be more open and conversational in nature than counselling on 
prescribed medicines. In fielding enquiries directly from customers, the pharmacist often 
ŶĞĞĚĞĚƚŽĞƐƚĂďůŝƐŚƐŽŵĞƚŚŝŶŐĂďŽƵƚƚŚĞĐƵƐƚŽŵĞƌ ?ƐĐŝƌĐƵŵƐƚĂŶĐĞƐĂŶĚĂŶƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨ
the problem before recommending a treatment. The interactional focus was more person-
centred and consumer-led as the following extract illustrates: 
 
[A woman aged around 50 approaches the dispensary and asks to speak to someone 
about a new anti-obesity drug].  
Customer: How does it work? 
Rebecca [Pharmacist]: It removes the excess fat from the diet.   
CƵƐƚŽŵĞƌ P/ƚŐŽĞƐƐƚƌĂŝŐŚƚƚŚƌŽƵŐŚĚŽĞƐŝƚ ? ?zĞƐ ? ?/ĚŽŶ ?ƚǁĂŶƚƚŽƵƐĞŝƚƚŚĞŶďĞĐĂƵƐĞ/
use cod liver oil.   
Rebecca: When do you take the cod liver oil? 
Customer: In the morning. 
Rebecca: And when do you have your breakfast? 
Customer: Straight after [the cod liver oil]. 
Rebecca: Well you can take these after an hour after breakfast. Have your cod liver oil 
first and then your breakfast and then about an hour later take the capsule. 
ƵƐƚŽŵĞƌ P/ĚŽŶ ?ƚŚĂǀĞƚŽƚĂŬĞŝƚŝŶƚŚĞŵŽƌŶŝŶŐĚŽ/ ? 
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Rebecca: No. You can take it at lunchtime and in the evening Q 
Customer: Fine, do I need to tell the doctors? 
ZĞďĞĐĐĂ PEŽ ?ǇŽƵĐĂŶũƵƐƚďƵǇŝƚ Q 
[Discussion continues, after which patient purchases the medicine]. 
Observation Wk. 5 Independent 
  
The extract illustrates that the pharmacist was prepared to support the patient to make an 
ĂĚũƵƐƚŵĞŶƚ ƚŽ ƚŚĞ ĚŽƐĞ ŽĨ ƚŚĞ ŵĞĚŝĐŝŶĞ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ǁŽŵĂŶ ?Ɛ ŶĞĞĚƐ ?However, the 
ƉŚĂƌŵĂĐŝƐƚ ŶĞŐůĞĐƚĞĚ ƚŽ ĞŶƋƵŝƌĞ ŝŶƚŽ ƚŚĞ ǁŽŵĂŶ ?Ɛ ůŝĨĞƐƚǇůĞŽƌ ŽƚŚĞƌ ŵĂƚƚĞƌƐ ƚŚĂƚ ŵĂǇ ŚĂǀĞ
been relevant to her weight management. Nevertheless, many OTC interactions served to 
address specific customer-initiated requests for advice and resembled what Pilnick describes 
as a  ‘ƐƚĞƉǁŝƐĞ ? ĐŽƵŶƐĞlling approach. This has been described as an approach to patient 
counselling that provides a means for explicitly negotiating issues of knowledge and resultant 
competence. Knowledge and competence are explored in the encounter and the responses to 
these sequences which are received from patients or carers are potentially the most indicative 
of active involvement in the counselling process (Pilnick 2003). OTC interactions served to 
address specific customer-initiated requests for advice. The shop-floor environment allowed 
this but was not conducive for more detailed discussions.  
 
4.4.6 Summary  
Patient-pharmacist shop floor interactions were predominantly initiated by patients requiring 
a prescription to be filled or through a customer enquiry. Opportunities for the pharmacist to 
invite or enable the provision of additional support or advice on prescribed medicines were 
limited. The real life constraints of a busy dispensary meant that patient-pharmacist 
encounters were brief. Pharmacists were not expected, nor did they feel they had the remit to 
provide counselling that went beyond simple aĚ ŚŽĐ ĂĚǀŝĐĞ ĂŶĚ ĐŽŶĨŝƌŵŝŶŐ ƚŚĞ ĚŽĐƚŽƌƐ ?
instructions. Overall, the pharmacist ?Ɛ involvement with the patient ?s prescribed medicines 
was a technically oriented role with little scope for any indeterminacy.   
 
Observations of OTC interactions found that pharmacists could provide customised 
information in responding to patient requests for advice about minor ailments. In these 
circumstances, patients appeared both familiar with, and accepted, the role of the pharmacist 
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as an accessible adviser. The autonomy and willingness of the pharmacists to accommodate 
patient preferences during OTC discussions was in contrast to interactions when handing out 
ĚŝƐƉĞŶƐĞĚ ŵĞĚŝĐŝŶĞƐ ǁŚĞƌĞ ƉĂƚŝĞŶƚƐ ? ŝŶĨŽƌŵĂƚŝŽŶneeds were assumed to have been 
addressed by the GP. Nevertheless, problems were usually specific and there were no obvious 
opportunities to discuss wider health issues. In the rest of this chapter, I will focus upon how 
the MUR service was being implemented in the study pharmacies. I will begin by reporting on 
what appeared to lie behind pharmacist motivation to perform MURs and, in particular, the 
ŝŵƉĂĐƚŽĨƚĂƌŐĞƚƐŽŶƉŚĂƌŵĂĐŝƐƚƐ ?ĞŶŐĂŐĞŵĞŶƚ ? 
 
4.5 MUR targets  
Pharmacist motivation to undertake MUR activity was primarily target driven with the multiple 
pharmacy displaying stronger signs of a target-driven culture than the independent. Within the 
ŝŶĚĞƉĞŶĚĞŶƚƚŚĞƉŚĂƌŵĂĐŝƐƚǁĂƐĂǁĂƌĞŽĨƚŚĞŽǁŶĞƌ ?Ɛ ŝŶƚĞŶƚŝŽŶƚŽƉĞƌĨŽƌŵDhZƐ ?,ŽǁĞǀĞƌ
the pharmacist was not overly concerned with the number they needed to perform. Likewise, 
the locum pharmacist working at the independent was not observed carrying out any MURs 
during fieldwork observations. She revealed in informal discussions that she did not perceive 
undertaking MURs as part of her role when working at the independent, leaving this to the 
pharmacist who regularly worked there. Within the multiple the situation was markedly 
different. The cap of 400 MURs was viewed as a target. An MUR  ‘support pack ? was available 
ĂŶĚ ŝŶĐůƵĚĞĚ ŐƵŝĚĂŶĐĞ ŽŶ ǁĂǇƐ ŝŶ ǁŚŝĐŚ DhZƐ ĐŽƵůĚ ďĞ ĚŽŶĞ  “efficiently and effectively ? ?
Inside the pack, recommendations were made on how to achieve the target which included 
suggestions for performing two MURs a day in order to spread the workload so that the 
ƉŚĂƌŵĂĐǇ ĐĂŶ ĐĂƌƌǇ ŽŶ  “business as usual ? ? tŝƚŚŝŶ ƚŚĞ ĚŝƐƉĞŶƐĂƌǇ there was a prominently 
displayed MUR target board detailing how many MURs had been performed in that financial 
year and how many were required to reach the target of 400: 
 
The MUR target board which had numbers from 400 to 1 was in three different colours, 
red, amber and green.  The red was to the beginning and the green towards the end 
numbers.  They crossed out the numbers as they perform the MURs, and they had 
ĐƌŽƐƐĞĚŽƵƚĂƉƉƌŽǆŝŵĂƚĞůǇ ? ? ?DhZƐ QKŶƚŚĞƐŝĚĞŽĨƚŚĞĐŚĂƌƚǁĂƐĂďŽǆƚŚĂƚǁĂƐĨŽƌ
the number that was needed to be achieved weekly to meet 400. 
Observation Wk. 4 Multiple   
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In the multiple, the pharmacists periodically talked about how many MURs they had 
performed. On one occasion the pharmacists discussed that they needed to perform 50 a 
month over the next 4 months to reach 400. In an informal discussion with the manager, she 
indicated that they were behind on MURs and that she wanted to be in a position next year 
that by  “January they should have completed the 400 ?. Tea room conversations about MURs 
between the manager and other non-pharmacy staff members also emphasised targeted 
measures. The manager in response to the question of how many had already been performed 
ĐŽŵŵĞŶƚĞĚƚŚĂƚ “ƚŚĞǇ ?ǀĞŐŽƚ ? ? ?ŽƌƐŽŵĞƚŚŝŶŐƚŽŐŽ ?. Pharmacists revealed, during informal 
discussions, that they felt pressurised to meet MUR targets. Reports were also available that 
showed a list of the CŽŵƉĂŶǇ ?ƐŶĞŝŐŚďŽƵƌŝŶŐƉŚĂƌŵĂĐŝĞƐ ?dŚĞƌĞƉŽƌƚƐŚŽǁĞĚŚŽǁŵĂŶǇDhZƐ
had been performed in each of these pharmacies and again was colour coded with green / 
amber and red. On one occasion a box of merchandise was received from  ‘,ĞĂĚ Kffice ? in 
which were T-shirts and other material promoting the service. ůƚŚŽƵŐŚ ƚŚĞ ƉŚĂƌŵĂĐǇ ?Ɛ
manager was a non-pharmacist she nevertheless recognised the importance of achieving the 
maximum allowance. This was demonstrated from the start of my observations:   
 
/Ŷ ƚŚĞ ŵŽƌŶŝŶŐ ƚŚĞ ƉŚĂƌŵĂĐǇ ?Ɛ ŵĂŶĂŐĞƌ ĂƉƉƌŽĂĐŚĞĚ ƚŚĞ ĚŝƐƉĞŶƐĂƌǇ ĂŶĚ / ƚŽŽŬ ƚŚĞ
opportunity to introduce myself to her. I briefly explained the purpose of my project 
ǁŚŝĐŚ ƐŚĞ ƌĞƉůŝĞĚ  “iƚ ?s not just about the numbers I want them to be of quality not 
ƋƵĂŶƚŝƚǇ ?. She followed this up immediately by saying  “but they still should do 400, but 
ƚŚĞǇƐŚŽƵůĚďĞƋƵĂůŝƚǇ ?. 
Observation Wk. 1 Multiple 
  
As can be seen from the extract the manager had a clear measurable target that needed to be 
reached but acknowledged that there should also be benefit to the patient. Pressure to attain 
400 MURs was seen to come mostly from the area manager who periodically visited the 
pharmacy. In one discussion the pharmacist mentioned that they had done seven MURs today 
ĂŶĚǁŝůů  “hopefully get 400 by April ? ĨŽƌǁŚŝĐŚƚŚĞĂƌĞĂŵĂŶĂŐĞƌƌĞƉůŝĞĚǁŝƚŚĂŚĂůĨ-hearted 
ƐŵŝůĞ “no you will get 400 by April ? ?KŶĞǀŝƐŝƚŝŶŐƚƌĂŝŶĞĞƉŚĂƌŵĂĐŝƐƚ from the US commented 
upon the service and how it was being delivered:  
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 “Pharmacists therefore do MURs to avoid the negative reaction rather than doing it for 
ƐŽŵĞƚŚŝŶŐƉŽƐŝƚŝǀĞ ? ? 
Observation Wk. 1 Multiple 
 
Pharmacist appeared to be motivated by the desire to avoid negative repercussions rather 
than because they perceived this as something positive for their patients. This issue is further 
discussed in Chapter Seven section 7.3.7. The following two sections will present the findings 
relating to how patients were identified and invited and the reasons patients gave when they 
declined the invitation for an MUR.   
 
4.6 Identifying and inviting patients for an MUR 
Patients seldom asked for an MUR and so were identified by pharmacy staff and offered an 
MUR during the time they came to the pharmacy to have their prescription filled. Most 
patients were therefore recruited ad hoc and were asked either by the pharmacist or support 
ƐƚĂĨĨŝĨƚŚĞǇŚĂĚƚŝŵĞƚŽƐƉĂƌĞƚŽ “go through their medicines ? ?ŽƚŚƉŚĂƌŵĂĐŝĞƐŚĂĚƉƌĞǀiously 
tried making appointments with patients but these were seen to be problematic when staff 
reported that many patients did not attend. Particularly in the independent, patients whom 
the staff appeared to have a good relationship were typically selected for MURs. When a 
candidate was identified, the deciding factor did not appear to be whether the patient could 
potentially benefit from an MUR but rather if they had completed an MUR within the previous 
12 months and so they were not considered eligible for another.  
 
When patients were invited to take part in an MUR, staff did this by asking whether they 
ǁŽƵůĚ ůŝŬĞĂŵĞĚŝĐĂƚŝŽŶƌĞǀŝĞǁǁŚĞƌĞƚŚĞƉŚĂƌŵĂĐŝƐƚǁŝůů  “check your medicines ? ?dŚĞDhZ
ǁĂƐƉƌŽŵŽƚĞĚĂƐĂƋƵŝĐŬĐŚĂƚƚŚĂƚ “complements what the doctor does ? ?KŶĞĚŝƐƉĞŶƐĞƌŝŶƚŚĞ
multiple mentioned how she persuaded patients: 
 
/Ŷ Ă ŶĂƚƵƌĂůŝƐƚŝĐ ŝŶƚĞƌǀŝĞǁ ǁŝƚŚ ĂǁŶ  ?ĚŝƐƉĞŶƐĞƌ ? ĂŶĚ:ĂŶĞ  ?ƉŚĂƌŵĂĐŝƐƚ ? QĂǁŶ
revealed when offering a patient an MUR:  “/ĚŽŶ ?ƚŐŝǀĞƚŚĞŵĂŶŽƉƚŝŽŶ ?/ũƵƐƚƐĂǇ ‘have 
you got 5 minutes for the pharmaciƐƚƚŽƐƉĞĂŬƚŽǇŽƵ ? ?. 
Observation Wk. 3 Multiple 
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Patients appeared to accept the invitation for an MUR because they were asked by the 
pharmacist or support staff with whom they had a good relationship. Most patients did not 
seem to have been previously aware of the service and some responded with surprise. Some 
patients questioned how long it would take or mentioned that they had already had a review 
ǁŝƚŚ ƚŚĞŝƌ 'W ? WĂƚŝĞŶƚƐ ? ƌĞƐƉŽŶƐĞ ƚŽ DhZƐ ĚŝĚ ŶŽƚ ƐĞĞŵ ƚŽďĞ ƐƚƌŽŶŐůǇ ŵŽƚŝǀĂƚĞĚ ďǇ ƐĞůĨ
interest or the prospect of personal benefit. MUR activity occurred in the consultation room 
and was hidden from public view; the MUR was therefore not an activity that patients were 
familiar with or expected to be offered by the pharmacy.  
 
Patients on the prescription collection service (PCS) were particularly targeted as their 
prescriptions were assembled and stamped indicating the patient was a candidate for an MUR: 
 
I spoke to Kate who said that generally PCS patients are identified first.  When 
dispensing their prescriptions the PMR is checked and they see if the MUR is due and if 
ƚŚĞǇ ?ǀĞŶŽƚŚĂĚŽŶĞƚŚĞŶƚŚĞǇĂƌĞĂƐŬĞĚ ?dŚŝƐŝƐƚŚĞŶƌĞĐŽƌĚĞĚŽŶƚŚĞŝƌWDZ ? 
Observation Wk. 1 Multiple 
 
As the extract illustrates, patients were selected by screening when their last MUR happened. 
There was little evidence for a needs-based assessment through talking to patients and 
identifying whether an MUR was required. Moreover, some patients groups who may 
potentially benefited more appeared to be actively avoided: 
 
Kate then revealed that she does not like doing MURs on patients who have depressive 
or ƉƐǇĐŚŽůŽŐŝĐĂů ŝůůŶĞƐƐĂƐ ŝƚ ŝƐ  “difficult to talk to patŝĞŶƚƐ ŝĨ ƚŚĞǇ ?ǀĞŐŽƚĚĞƉƌĞƐƐŝŽŶ ? ?
She also added ƚŚĂƚŝĨƚŚĞǇ ?ƌĞŽŶŵĞdication for mental illness, they would probably be 
under specialist care. 
Observation Wk. 4 Multiple  
 
The avoidance of patients who had certain medical conditions was expressed by four of the 
five pharmacists in their interviews and this is discussed further in Chapter Seven. One 
pharmacist commented in an informal discussion that she avoided performing MURs on 
patients who appeared confused: 
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I asked if Jane [pharmacist] had ever had any feedback from a medicines use review 
and she said that she had not. She said that most patients come in for reasƐƵƌĂŶĐĞ “I 
ĚŽŶ ?ƚŐĞƚinvolved ?/ƵƐƵĂůůǇƐĂǇƐĞĞƚŚĞĚŽĐƚŽƌ ?. She did not feel that it was her place to 
make recommendations. ^ŚĞ ƚŚĞŶ ƐĂŝĚ  “I won ?ƚ ĚŽ ƚŚĞŵ ŝĨ ƚŚĞǇ ĂƌĞ ĐŽŶĨƵƐĞĚ ? ? This 
surprised me as she acknowledged that these were the ones that needed it. She then 
said to me they ǁŽƵůĚ ƉƌŽďĂďůǇ  “ƚĂŬĞ ŚĂůĨ ĂŶ ŚŽƵƌ ĂŶĚ ƚŚĂƚ ƚŚĞǇ ?ůl probably end up 
ŵŽƌĞĐŽŶĨƵƐĞĚ ?.  
Observation Wk. 5 Multiple 
 
The findings from staff interviews will explore further the approach staff took when identifying 
patients for an MUR. However, it is worthy of note here that patients who may potentially 
benefit most were not actively being identified and this potentially limited the benefits of the 
service to patients. Another method that was found to be employed by the multiple was to 
send out invitation letters directly to patients. This was of a generic nature indicating to 
patients that they may benefit from a free  “check-up ? on their medicines. The letter did 
specify the terms under which the patient would qualify for an MUR. Although I did not know 
the number of letters sent out to patients by the Company, two patients were observed 
bringing in the letter and showing the pharmacist. However, on one of these occasions it was 
apparent that the letter had caused confusion:  
 
In the morning a woman (aged about 70) came in with a letter (she was accompanied 
by a man of about the same age). The woman explained that the letter had arrived in 
the post and was about a medicines use review. She showed the letter to Jane 
[pharmacist] who checkĞĚŚĞƌWDZĂŶĚƐĂŝĚƚŽƚŚĞŵ “ǇŽƵ ?ǀĞŚĂĚǇŽƵƌƐĚŽŶĞ ?ĂŶĚ “ŝƚ ?Ɛ
ŶŽƚŶŽǁĚƵĞƚŝůůŶĞǆƚ:ƵůǇ ? ?
Observation Wk. 1 Multiple 
 
Although the woman did not appear annoyed at having received the letter, the extract 
illustrates that she had been unaware of when or whether she had had an MUR. Another 
ƉĂƚŝĞŶƚ ǁĂƐ ĂƐŬĞĚ ďǇ ƚŚĞ ƐĂŵĞ ƉŚĂƌŵĂĐŝƐƚ ŽŶ ƚŚĞ ƐĂŵĞ ĚĂǇ  “Have we reviewed your 
medication? ? ƚŽ ǁŚŝĐŚ ƚŚĞ ƉĂƚŝĞŶƚ ƌĞƐƉŽŶĚĞĚ ďǇ Ă ĐŽŶĨƵƐĞĚ ůŽŽŬ. This was followed 
ŝŵŵĞĚŝĂƚĞůǇ ďǇ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ƐĂǇŝŶŐ  “Have we taken you in there? ? ƉŽŝŶƚŝŶŐ ƚŽ ƚŚĞ
consultation area, to ǁŚŝĐŚƚŚĞŵĂŶƌĞƐƉŽŶĚĞĚ “Yes, I enjoyed it ? ? 
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In most cases, support staff did not appear to be informed of what the outcomes of MURs 
were; this was not due to the information being confidential but rather the benefits to patients 
were not emphasised to them to any great degree after the MUR:    
 
After the MUR Grace [dispenser] said  “it waƐŶ ?ƚ ƌĞĂůůǇ Ă ďŝŐ ƌĞǀŝĞǁ ǁĂƐ ŝƚ ?. The 
ƉŚĂƌŵĂĐŝƐƚƌĞƉůŝĞĚ “ŶŽƚƌĞĂůůǇ ?ŚĞŬŶĞǁƐŽŵĞďƵƚŚĂĚĨŽƌŐŽƚƚĞŶǁŚǇŚĞǁĂƐƚĂŬŝŶŐŚŝƐ
cholesterol tablets ?ƐŽƚŚĂƚǁĂƐŐŽŽĚ ? ?dŚĞƉŚĂƌŵĂĐŝƐƚƚŚĞŶƚƵƌŶĞĚƚŽŵĞĂŶĚƐĂŝĚ  “/
ƐƵƉƉŽƐĞƚŚĂƚ ?ƐƚŚĞƌĞĂƐŽŶǁŚǇǇŽƵĚŽƚŚĞƐĞDhZƐ ? ? 
Observation Wk. 2 Independent 
 
Support staff who were involved with recruiting patients for MURs were largely unaware of 
the intended purpose or potential benefits an MUR could bring to patients. Interviews with 
dispensers and MCAs confirmed their lack of awareness of what occurs during an MUR and 
this may have contributed to the vague way they offered the service to patients. These issues 
will be further discussed in Chapter Seven.  
 
4.7 Pharmacist preparation before the MUR  
Pharmacists within both the multiple and independent pharmacies were observed making 
preparations before the MUR. In the multiple, the paper based MUR form and lack of access to 
the computerised patients medication record (PMR) in the consultation room meant that the 
pharmacist needed to print the patient medication history prior to each MUR that was 
performed. The consultation room in the independent was equipped with a computer and so 
the MUR form was available electronically. In the independent, the consultation room was 
multi-purposed and so often ŝƚŶĞĞĚĞĚƚŽďĞ  ‘ƐĞƚƵƉ ?ďĞĨŽƌĞĂŶ MUR. People working within 
the room would be told to leave and the tables cleared of any clutter before the patient could 
be invited in. Chairs would also have to be arranged within the room and sometimes brought 
ŝŶĨƌŽŵƚŚĞƉŚĂƌŵĂĐǇ ?ƐƐŚŽƉĨůŽŽƌ P
 
 QZĞďĞĐĐĂůĞĚŚŝŵƚŽƚŚĞĐŽŶƐƵůƚĂƚŝŽŶƌŽŽŵ ?,ĞŚĂĚĂůŝƚƚůĞƚƌŽƵďůĞŐĞƚƚŝŶŐƵƉthe step 
ŝŶƚŽ ƚŚĞĚŝƐƉĞŶƐĂƌǇ QdŚĞƌĞǁĞƌĞ  ? ĐŚĂŝƌƐ ŝŶ ƚŚĞƌŽŽŵƚŚĞǇďŽƚŚŚĂĚǁŚĞĞůƐ ?ZĞďĞĐĐĂ
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ďƌŽƵŐŚƚƵƉƚŚĞǁŝĐŬĞƌĐŚĂŝƌ ĨƌŽŵƚŚĞƐŚŽƉĨůŽŽƌ QĞĐĂƵƐĞƚŚĞĐŚĂŝƌǁĂƐƋƵŝƚĞďŝŐǁĞ
momentarily had problems shutting the door.  
Observation Wk. 2 Independent   
 
Preparing the consultation area before the MUR took a few moments but supported the 
notion that the pharmacy was not set up to perform MURs as a routine activity. Within the 
multiple, there were also issues of the number of patients who could sit in the consultation 
room. There were frequently only two chairs within the room which meant that if two people 
were invited or decided to sit in, another chair would need to be brought in. This generally was 
not problematic. However, it did present a hindrance on one occasion when I took a woman to 
the consultation area with her and her husband, to obtain consent to observe the MUR:   
 
I walk her over to the consultation area and she asks if her husband can sit in as well, I 
agreed and say that I would need another chair. Not wanting to trouble me, he said 
ƚŚĂƚ “ŝƚĚŽĞƐŶ ?ƚŵĂƚƚĞƌ ?. We went in and he remained outside Q  
Observation Wk. 2 Multiple    
 
The details of what occurred during the MUR will be presented in the following chapter. The 
following section will report on the observations made after the pharmacist had completed 
the MUR, left the room and returned to the dispensary.  
 
4.8 Observations after the MUR 
Once the MUR had been completed the pharmacists were observed returning to the 
dispensary to be greeted with several prescriptions that were ready to be checked and patient 
queries that had accumulated whilst the pharmacist had been away. With pharmacists so 
heavily involved with the dispensing process, the ACT working in the multiple did not appear to 
free up pharmacists time. The trainee pharmacist commented during an informal discussion 
that the ACT does not help maintain work flow ĂƐƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶ “still needs a clinical check ? ?
Problems with work piling up were more noticeable when the pharmacist worked alone. The 
following extract illustrates the reception the pharmacist in the independent received having 
spent 40 minutes completing two consecutive MURs:   
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TŚĞ ŵŽŽĚ ǁĂƐ ƉĂƌƚŝĐƵůĂƌůǇ  ‘ĐŽůĚ ? and unreceptive. Lucy [dispenser] ƐĂŝĚ  “ǁĞ ?ƌĞ ŶŽƚ
ĚŽŝŶŐĂŶǇŵŽƌĞ ? ? Q>ƵĐǇŚĂĚďĞĞŶƋƵŝƚĞŬĞĞŶŝŶŝƚŝĂůůǇƚŽƌĞĐƌƵŝƚƉĂƚŝĞŶƚƐ QĂŶĚŚĂĚďĞĞŶ
ŝŶǀŽůǀĞĚ ŝŶ ŝĚĞŶƚŝĨǇŝŶŐ ƚŚĞ ĐŽƵƉůĞ ũƵƐƚ ƐĞĞŶ QdŚĞƌĞ ǁĞƌĞ ĞŵƉƚǇ ďŽǆĞƐ ŽŶ ƚŚĞ ĨůŽŽƌ ?
boxes of stock yet to be put away and the general feel of the dispensary was that it was 
disorganised. The amount of yellow tubs indicated that patients had either decided to 
ĐĂůůďĂĐŬŽƌŚĂĚďĞĞŶĂƐŬĞĚƚŽĐĂůůďĂĐŬ ?ƚŚĞĐŚĞĐŬŝŶŐďĞŶĐŚǁĂƐĨƵůůŽĨƚƵďƐ Q 
Observation Wk. 3 Independent    
 
dŚĞ  ‘ĨƌŽƐƚǇ ? ƌĞĐĞƉƚŝŽŶǁĂƐ ůĂƚĞƌ ĨŽƵŶĚ ƚŽďĞĚƵĞ ƚŽƚŚĞƉƌŽďůĞŵƐ ĨĂĐĞĚďǇ ƚŚĞƐƵpport staff 
because of the volume of patients who had been waiting for their prescriptions. Pharmacists in 
the multiple also had to contend with similar situations when they were the sole pharmacist 
performing MURs. The findings from the pharmacist interviews are presented in Chapter 
Seven. The next section will briefly discuss how the information collected during the MUR was 
ƵƐĞĚĚƵƌŝŶŐƚŚĞĚŝƐƉĞŶƐŝŶŐŽĨƉĂƚŝĞŶƚ ?ƐƉƌĞƐĐƌŝƉƚŝŽŶƐ ? 
 
4.9 The use of information collected during the MUR  
Information collected during the MUR was not seen to be referred to in either pharmacy 
during the provision of dispensing prescriptions or other services for patients. Within the 
multiple, completed paper MUR records were often placed in a large pile of completed forms 
ready to be filed in alphabetical order into folders that were kept on a dispensary shelf. 
Despite the MUR regulations stating that patients should receive a copy of the MUR form, 
there were indications that this did not always happen: 
 
They [MUR folders] were in alphabetical order, so the first folder was marked A-F, the 
second G-DĞƚĐ Q/ŶŽƚŝĐĞƚŚĂƚǁŝƚŚŝŶƚŚĞĨŽůĚĞƌƐƚŚĞƌĞǁĞƌĞƐŽŵĞDhZƐǁŝƚŚƚƌŝƉůŝĐĂƚĞ
pages which indicated that the patient had not received their copy of the MUR form.  
Kate [pharmacist] said she usually gives the patient a copy of the form ƚŚĞƌĞĂŶĚƚŚĞŶ Q 
Observation Wk. 4 Multiple    
 
In an informal discussion with the second pharmacist she ƌĞǀĞĂůĞĚƚŚĂƚ “We used to send out 
the patient ?s copy. Then we asked the patient whether they wanted one and now we just keep 
it ? ? dŚĞ ŽŶůǇ ŝŶĨŽƌŵĂƚŝŽŶ ƉůĂĐĞĚ ŽŶ ƚŚĞ ƉĂƚŝĞŶƚ ?s PMR was the date the review had been 
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undertaken. In the independent, MUR forms were completed electronically. However, these 
were not seen to be referred to during the dispensing process. In an informal discussion the 
owner mentioned that the MUR provided a record of what was discussed and recommended. 
Despite this the only data that was seen to be referred to in both pharmacies was the date on 
which the patient had their previous MUR so that they did not offer the patient another until it 
was due. Likewise, there were no instances where the pharmacist was observed discussing 
with any patient an MUR that had been conducted previously. Some patients visited the 
pharmacy in subsequent observation weeks. There was no evidence to suggest they were 
treated any differently to other patients or were observed to have any follow-up discussion 
resulting from an MUR.    
 
4.10 Summary 
This chapter has provided a contextual backdrop to how MURs were being incorporated 
alongside the other activities of the pharmacy. Fieldwork observations highlighted 
ƉŚĂƌŵĂĐŝƐƚƐ ? ĂĐĐĞƐƐŝďůĞ ĂŶĚ ƌĞĂĐƚŝǀĞ ŶĂƚƵƌĞ ƚŽ ƌĞƋƵĞƐƚƐ ĨƌŽŵ ƉĂƚŝĞŶƚƐ ? customers and 
pharmacy support staff that enabled the services of the pharmacy to run efficiently. 
WŚĂƌŵĂĐŝƐƚƐ ?ĚƵƚŝĞƐǁĞƌĞƐĞĞŶƚŽŚĂǀĞĂŚŝŐŚĚĞŐƌĞĞŽĨƚĞĐŚŶŝĐĂůŝƚǇĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞŵǁŝƚŚ
most of their time being oriented around the dispensing process. Given the nature of their 
routine work, there was little need for the exercise of professional judgement. When the 
pharmacy was less busy the pharmacists were seen to be catching up with administrative and 
ŵĂŶĂŐĞŵĞŶƚ ƌĞƐƉŽŶƐŝďŝůŝƚŝĞƐ ? /Ŷ ƉƌĂĐƚŝĐĞ ? ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ǁŽƌŬůŽĂĚ ǁĂƐ ďĞŝŶŐ ĚŝĐƚĂƚĞĚ ƚŽ
them and they were seen to have little control over the intensity or variety of work tasks that 
were presented. Pharmacists therefore pragmatically accommodated the MUR service in 
between their existing service provision.  
 
The observations also highlighted how patients tended to use the pharmacy. This was for the 
collection of their prescriptions and for advice on treating minor ailments. Most patient-
pharmacist interactions within the pharmacy occurred on the shop-ĨůŽŽƌ ǁŝƚŚ ƉŚĂƌŵĂĐŝƐƚƐ ?
advice about prescribed medicines typically given in an instructionaů ŵĂŶŶĞƌ ? WŚĂƌŵĂĐŝƐƚƐ ?
discussions with customers about the treatment of minor ailments were found to have more 
of a two-way dialogue. This greater level of engagement reflectĞĚ ƚŚĞĐƵƐƚŽŵĞƌ ?Ɛpro-active 
approach to seeking treatment and the greater scope for pharmacists to exercise professional 
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judgement in relation to OTC medicines and recommendations. However, opportunities for 
the pharmacist to discuss prescribed medicines with patients were limited and pharmacists 
were cautious about making suggestions ŽƌƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐƚŚĂƚĚĞǀŝĂƚĞĚĨƌŽŵƚŚĞĚŽĐƚŽƌ ?Ɛ
instructions. They preferred instead to refer patients back to the GP to resolve any issues. The 
pharmacy was therefore observed to be a place where patients received, rather than discussed, 
their prescribed medicines. As will be seen in Chapter Six, patients constructed their views of 
MURs based upon their existing expectations and experience of the roles and responsibilities 
of the pharmacist.   
 
This chapter also revealed how MURs were being managed and implemented in the study 
pharmacies. Most MURs were observed to be performed opportunistically when convenient to 
the pharmacist and when the pharmacy was not busy. The process of identifying patients for 
an MUR did not appear to be tapered according to patient need or benefit but based upon the 
minimum selection criteria. These processes did not actively seek to ascertain whether 
patients could potentially benefit from an MUR; nor was the core message that the MUR 
should be an activity for the sole benefit of the patient effectively conveyed. Moreover, the 
primary motivation for pharmacists to conduct MURs, particularly in the multiple, was driven 
by Company targets and financial interests. Various strategies had been adopted by the 
management to encourage pharmacists to engage with the service. The most noticeable effect 
of these strategies was the perceived pressure that was placed on pharmacists to achieve a 
targeted number of MURs. This had a significant impact in the way MURs were viewed and 
performed by pharmacy staff and is further discussed in Chapter Seven.  
  
dŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ ĂďƐĞŶĐĞ ĚƵƌŝŶŐ ĂŶ DhZ ŵĞĂŶƚ ƚŚĂƚ ŝŶ ƉƌĂĐƚŝĐĞ ? ǁŽƌŬ flow was impeded 
during this period. Problems with work piling up were more noticeable when only one 
pharmacist was on duty. It was against this backdrop that MURs were being accommodated. 
MURs were observed to be a proactive activity which meant that, other than the pressures to 
achieve the MUR target, they could be undertaken at the convenience of the pharmacist and 
not necessarily to that of the patient. Lastly, there was little referral to previous MURs when a 
new MUR was performed or referral when providing other services from the pharmacy such as 
dispensing of patient prescriptions. The MUR was effectively a  ‘ƐƚĂŶĚĂůŽŶĞ ?Ɛervice rather than 
one that made a contribution to the other care provided in the pharmacy.  
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This chapter has illustrated some of the difficulties that pharmacists faced in implementing the 
MUR service. The next chapter will detail what happened during the MUR and how the 
patient-pharmacist interaction was managed.  
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5 CHAPTER FIVE The MURs 
CHAPTER FIVE 
The MUR 
 
5.1 Introduction  
In this chapter, I present the findings from the 54 MURs that were observed and outline how 
the MUR was performed and structured. I investigate how the MUR was introduced to the 
patient, the nature of the information exchanged during the patient-pharmacist interaction 
and how complex issues that arose during the MUR were managed. Lastly, I present how the 
MUR was concluded.  
 
5.2 Participants and characteristics of MURs 
In total, 54 MURs were observed (33 from the multiple and 21 from the independent). 
Demographic data for these patients and some characteristics of the MUR consultations are 
presented in Table 1. 
 
5.3 Structure of the MUR consultation   
Four pharmacists, two from each pharmacy were observed undertaking MUR consultations. 
Although, each pharmacist adopted different approaches, similar patterns were identified 
through the analysis of the MURs. As part of the MUR service, a nationally standardised form 
was required to be completed during the consultation (Appendix Two). Information that the 
pharmacist was expected to elicit from the patient and record on the form included whether 
they used the medicine as prescribed, whether they knew what they were using the medicine 
for, if the formulation of the medicine was appropriate and reported side effects. The format 
of the form was  ‘tick-box ? which allowed for a yes / no response for each response. Paper MUR 
forms were used within the multiple and a computer-based electronic form in the independent.  
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Table 1: Demographic data and some characteristics of the MUR consultations (n = 54)   
 
 
Outcome measure 
 
Independent 
Pharmacy 
 
 
Multiple 
Pharmacy 
Number of MURs observed 21 33 
Patient Gender 
 
Men 
Women 
 
 
7 
14 
 
 
8 
25 
Mean age of patients (range) 65 (46-81) 72 (40-89) 
Method of invitation 
 
Ad hoc 
Appointment 
 
 
17 
4 
 
 
31 
2 
Mean number of medicines per patient1 
(range) 
8 (2-17) 6 (2-11) 
Number of MURs conducted by pharmacists 
 
Jane  (Employee pharmacist) 
Kate (Employee pharmacist) 
 
Rebecca (Managing Pharmacist) 
Rose (Owner and pharmacist) 
 
 
- 
- 
 
20 
1 
 
 
19 
14 
 
- 
- 
Number of patients interviewed 
 
Number of patients reporting in the 
interview having had an MUR previously 
17 
 
 
5 
17 
 
 
7 
 
1
This is the total number of prescribed and OTC medicines (including herbal and vitamin supplements) 
that the patient reported taking during the MUR and at interview. On a few occasions the patient had 
revealed at their interview a medicine that had not been identified by the pharmacist during the MUR. A 
full list of medications recorded can be found in Appendix Nine.  
 
The structure of the MURs broadly followed a pattern directed by the pharmacist asking the 
patient questions that enabled completion of the MUR form. The consultation would typically 
begin with an initial statement from the pharmacist explaining what they intended to do and 
what the MUR involved. A question-answer sequence would then follow where the pharmacist 
would ask the patient questions to enable the MUR form to be completed and lastly, the 
pharmacist would make a summary statement to conclude the MUR. In the following sections, 
these processes are described in more detail.  
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5.3.1 Introducing the MUR  
Once both the pharmacist and patient were seated in the consultation room, the pharmacists 
began with an initial statement explaining the purpose of the MUR and what this would 
involve. This set the agenda and provided a cue for what patients could expect to happen 
during the encounter:  
 
ZĞďĞĐĐĂ PdŚŝƐƐŚŽƵůĚďĞŶŝĐĞĂŶĚƋƵŝĐŬ ? ŝƚ ?ƐĐĂůůĞĚĂŵĞĚŝĐŝŶĞƐƵƐĞ ƌĞǀŝĞǁĂŶĚǁĞŐŽ
ƚŚƌŽƵŐŚ ǁŚĂƚ ǇŽƵ ?ƌĞ ŽŶ ?  DǇ ŶĂŵĞ ŝƐ ZĞďĞĐĐĂ ǇŽƵ ?ǀĞ ƉƌŽďĂďůǇ ƐĞĞŶ ŵĞ ?  zŽƵ ?ƌĞ ŽŶ
three medicines is that right? 
  MUR 11- Cilla 55yr F. Independent  
 
Kate: This is ƚŽ ĐŚĞĐŬ ǇŽƵƌ ŵĞĚŝĐŝŶĞƐ ƚŚĂƚ ǇŽƵ ?ƌĞ ŽŶĂŶĚ ƚŚĂƚ ƚŚĞǇ ?ƌĞ ŶŽƚ ŝŶƚĞƌĂĐƚŝŶŐ
with anything over-the-ĐŽƵŶƚĞƌ Q 
MUR 30 - Michael 65yr M. Multiple 
 
The activity and purpose of the MUR appeared to be determined by the pharmacist from the 
onset. On several occasions the pharmacists mentioned that the MUR would not take up too 
ŵƵĐŚŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐƚŝŵĞ ?ƐĚŝƐĐƵƐƐĞĚŝŶƚŚĞƉƌĞǀŝŽƵƐĐŚĂƉƚĞƌ  ?section 4.6), the pharmacy 
staff typically invited patients for an MUR using general or unspecific statements relating to 
 “going through ? or  “checking ? the patients ? medicines. Occasionally, the pharmacists would 
indicate in their opening explanation that the MUR was to check whether the patient 
understood the medicines they were taking and resolve any problems they had. However, 
many patients did not appear to have time to reflect on what the pharmacist had said or take 
the opportunity to speak and set out their own agenda. Pharmacists did sometimes indicate to 
the patient that MURs should be a routine activity, the reason why this had not been achieved 
was sometimes explained to patients:    
 
:ĂŶĞ P dŚŝƐ ŝƐ ĐĂůůĞĚ Ă ŵĞĚŝĐŝŶĞƐ ƵƐĞ ƌĞǀŝĞǁ ĐŚĞĐŬ ƵƉ ? ŝƚ ?Ɛ ĚŽŶĞ ƌĞŐƵůĂƌůǇ ďƵƚ ŝƚ ?Ɛ ŶŽƚ
always quiet enough to do it. 
Konnie: Yes. 
:ĂŶĞ PtĞĐĂŶƐŝŐŶǇŽƵŽĨĨĂŶĚŐŽƚŚƌŽƵŐŚǇŽƵƌŵĞĚŝĐŝŶĞƐ Q 
MUR 19 - Konnie 40yr F. Multiple 
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Rose: We should be doing this with all our patients, but I have not had time.  
dĞƌƌŝĞ PdŚĂƚ ?ƐĨŝŶĞ ? 
MUR 7 - Terrie 54yr F. Independent 
 
As these extracts illustrate, pharmacists occasionally mentioned to patients that MURs were 
an activity that the pharmacy should be performing but because of time constraints this was 
not always possible. In these cases, the MUR was therefore framed as an activity that occurred 
when convenient to the pharmacy rather than at the convenience of, or in response to, the 
clinical need of the patient. The purpose that patients later attributed to their MUR was in part 
constructed through the description that the pharmacist provided at the beginning of the 
consultation and this is further explored in the following chapter (section 6.4.3). Some patients 
ŚĂǀŝŶŐŚĞĂƌĚƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐĚĞƐĐƌŝƉƚŝŽŶŽĨƚŚĞDhZƉƌĞ-empted the activity by mentioning 
they already had a review with their doctors:  
 
^ƵŵŵĞƌ P/ ?ǀĞũƵƐƚŚĂĚĂƌĞǀŝĞǁĂƚŵǇĚŽĐƚŽƌƐ ? 
Jane: It complementƐǁŚĂƚƚŚĞĚŽĐƚŽƌĚŽĞƐ ?tĞůŽŽŬĂƚǁŚĂƚŵĞĚŝĐĂƚŝŽŶǇŽƵ ?ƌĞŽŶĂƚ
ŚŽŵĞĂŶĚǇŽƵƌƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŵ ?/ ?ůůĚŽŝƚĂƐƋƵŝĐŬĂƐ/ĐĂŶ ? 
MUR 22 - Summer 62yr F. Multiple 
 
,ŽǁĂƌĚ P/ ?ǀĞũƵƐƚƚŽůĚǇŽƵƌĨƌŝĞŶĚŚĞƌĞĂŶĚ/ŚĂǀĞĂƌĞǀŝĞǁǁŝƚŚƚŚĞŚŽƐƉŝƚĂůĞǀĞƌǇƚŚƌĞĞ 
months. 
ZĞďĞĐĐĂ PtĞŶĞĞĚƚŽĐŚĞĐŬŚŽǁŽƌǁŚǇǇŽƵ ?ƌĞƚĂŬŝŶŐŝƚ ? ? ?
MUR 20 - Howard 52yr M. Independent 
 
A few patients challenged the reason for their MUR mentioning they already had a medication 
review with their doctor.  In these cases, the pharmacist sidelined their concern and continued 
the MUR unabated. Pharmacists justified the MUR to patients based upon their own purpose 
and agenda. Likewise, on occasions when the patient revealed that they had previously had an 
MUR, the pharmacist would assume that patients knew the purpose of the exercise. They 
again did not consider whether the MUR was necessary or established whether this was going 
to benefit the patient:  
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 ?ĂǁŶ ?ĚŝƐƉĞŶƐĞƌ )ŚĂĚŝŶǀŝƚĞĚƚŚĞƉĂƚŝĞŶƚĨŽƌĂŶDhZƚŽǁŚŝĐŚƚŚĞůĂĚǇƌĞƐƉŽŶĚĞĚ ‘/ ?ǀĞ
had ŽŶĞ ? ?ĂǁŶƚŽůĚ<ĂƚĞ ?ƉŚĂƌŵĂĐŝƐƚ ? P  “/ƚ ?ƐďĞĞŶĂǇĞĂƌƐŝŶĐ ƚŚĞ ůĂƐƚŽŶĞ ?ƚŽǁŚŝĐŚ
<ĂƚĞƌĞƉůŝĞĚƚŽƚŚĞƉĂƚŝĞŶƚ  “tĞĚŽ ŝƚĞǀĞƌǇǇĞĂƌ ? ?WĂƚŝĞŶƚĂŶĚƉŚĂƌŵĂĐŝƐƚŐŽ ŝŶƚŽƚŚĞ
consultation room]. 
<ĂƚĞ P zŽƵ ?ǀĞ ŚĂĚ ŽŶĞ ďĞĨŽƌĞ ? ƐŽ ǇŽƵ ŬŶŽǁ ǁŚĂƚ ƚŽ ĞǆƉĞĐƚ ?  :ƵƐƚ ƚŽ ŐŽ through your 
tablets.  
ƵƚƵŵŶ P/ ?ǀĞŚĂĚŝƚďĞĨŽƌĞ ? 
<ĂƚĞ P/ƐĞĞƚŚĂƚǇŽƵ ?ƌĞƚĂŬŝŶŐďůŽŽĚƉƌĞƐƐƵƌĞƚĂďůĞƚƐ Q 
MUR 33 -  ‘ƵƚƵŵŶ ? ? ?Ǉƌ& ?DƵůƚŝƉůĞ    
 
Jane: This is an annual review. 
Mia: I did it before. 
Jane: So we're just updating then. 
   MUR 32 -  ‘DŝĂ ? ? ?Ǉr F. Multiple 
Where patients indicated that they had taken part in an MUR before, this utterance was seen 
to inform the pharmacist rather than taken as a cue to explore whether another MUR was 
necessary. In response to the knowledge that the patient previously had undertaken an MUR, 
pharmacists were not observed to investigate or follow up any earlier actions resulting from 
these. Fieldwork observations found that within the multiple, completed MUR records were 
filed in the dispensary and pharmacists were not observed referring to these. Instead, 
pharmacists printed a copy of the patients ? PMR which enabled them to see a list of the 
ƉĂƚŝĞŶƚƐ ?ĐƵƌƌĞŶƚŵĞĚŝĐĂƚŝŽŶƐ ?Given that pharmacists typically did not refer to previous MURs, 
there were rarely any review or follow-through actions from previous consultations. Only on 
one occasion was the pharmacist observed to refer to a previous MUR. This was on hearing 
ƚŚĂƚƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐĂůĐŽŶĚŝƚŝŽŶŚĂĚĐŚĂŶŐĞĚ P 
 
Rebecca:  So you had your MUR in March.  
Morris: I ŚĂĚŶ ?ƚ ƐƚĂƌƚĞĚ ǁŝƚŚ ŵǇ ŚĞĂƌƚ ƉƌŽďůĞŵƐ ƚŚĞŶ  ?ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ůŽŽŬƐ Ăƚ ƚŚĞ
previous MUR]. 
Rebecca:  This is your old one [MUR form] you said that the pump leaked?  
DŽƌƌŝƐ P ?dŚĞƉĂƚŝĞŶƚĞǆƉůĂŝŶƐƚŚĂƚŚĞĚŽĞƐŶ ?ƚŶĞĞĚƚŚĞƉƵŵƉĂŶǇŵŽƌĞĂƐŚĞŚĂƐŚĂĚĂ
stent to aůůĞǀŝĂƚĞŚŝƐĂŶŐŝŶĂ ? ?ƌŝůůŝĂŶƚŝƚǁĂƐ Q
MUR 10 - Morris 79yr M. Independent   
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On the whole, the pharmacist ?Ɛ introduction to the MUR set out their agenda for the MUR but 
did not invite patients to set theirs. One case emphasised the extent to which the agenda for 
the MUR activity was dominated by the pharmacist. Here, Rebecca had invited a patient for a 
blood pressure check as well as an MUR. However, it was noticed that the patient recently had 
an MUR:   
 
Brian: ...[The patient explains that he has had codeine and has a problem. He also 
takes Naprosyn and asks if this should be taken with food. He asks when to take the 
omeprazole]. 
ZĞďĞĐĐĂ PdŚĞEĂƉƌŽƐǇŶ ?ƐĂĨƚĞƌ ?ĨŽŽĚ ?ĂŶĚƚĂŬĞƚŚĞŽŵĞƉƌĂǌŽůĞŶŽƚĂƚƚŚĞƐĂŵĞƚŝŵĞĂƐ
the Naprosyn.  When are you suffering most from the heartburn? 
ƌŝĂŶ PDĞĂůƚŝŵĞƐ Q 
Rebecca: [Rebecca looks at the computer] It seems we have done one [MUR] already 
this year. Unless there is a reason, ŝƚ ?ƐƌĞĂůůǇŽŶůǇĚŽŶĞǇĞĂƌůǇ ?
ƌŝĂŶ P/ŵŝŐŚƚŚĂǀĞŚĂĚŽŶĞĚƵƌŝŶŐŵǇďŝƌƚŚĚĂǇ Q ?ZĞďĞĐĐĂƚƵƌŶƐƚŽŵĞ ĂŶĚƐĂǇ “ĨĂůƐĞ
ĂůĂƌŵ/ ?ŵĂĨƌĂŝĚ ? ? 
[Rebecca immediately abandons the MUR and proceeds to take blood pressure]. 
Observation Wk 3 Independent 
 
On realising that the patient had a previous MUR within the last twelve months, Rebecca 
abruptly stopped the medicine consultation. The national policy guidelines on how frequently 
MURs can be performed appeared to prevent Rebecca from continuing this consultation. The 
ƉĂƚŝĞŶƚ ?ƐŚĞĂƌƚďƵƌŶŽƌĐŽĚĞŝŶĞƉƌŽďůĞŵǁĂƐĐŽŶƐĞƋƵĞŶƚůǇŶŽƚexplored.  
 
DŽƐƚƉĂƚŝĞŶƚƐ ?ĂƉƉĞĂƌĞĚĐŽŵĨŽrtable with, or at least accepted, what the pharmacist had said 
during the introduction. The pharmacist would follow their introductory statements by next 
confirming what medication the patient was taking. This would prepare them to discuss with 
the patient each medicine in a systematic way. This process will be described in the next 
section.  
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5.3.2 Sequencing of the MUR   
The unspecific agenda provided by the pharmacist for the MUR activity meant that few health 
or medication related issues were initiated by the patient during the MUR. Consultations were 
immediately led from the onset by the pharmacist asking a series of closed questions to 
complete the MUR form. This resulted in a question-answer sequence where the pharmacist 
would ask the patient questions about their prescribed and OTC medicines. This enabled the 
MUR form to be completed quickly.  
 
5.3.2.1 Establishing the patients medication 
Pharmacists adopted differing approaches to establish the patients ? current medicine regimen. 
This depended upon whether the pharmacist was completing a paper or an electronic MUR 
form. In the multiple, paper forms were available. Pharmacists would refer to a pre-printed 
PMR as a guide to what had been prescribed. The pharmacists would therefore either start by 
talking about one medicine or confirm with the patient all of their current medicines so they 
could be talked about sequentially: 
 
:ĂŶĞ P  QEŽǁ ǇŽƵ ?ƌĞ ŽŶ ƉĂƌĂĐĞƚĂŵŽů ? ^ůŽǁ < ? ǀĂůƐĂƌƚĂŶ ? &ŽƌƚŝƉŝŶĞ ? ƐŝŵǀĂƐƚĂƚŝŶ ĂŶĚ
Calcichew [this is Calcichew D3 forte].  You have six items yes?  
Nicola: Yep. 
:ĂŶĞ P QtĞ ?ůůŐŽƚŚƌŽƵŐŚǇŽƵƌŵĞĚŝĐŝŶĞƐŽŶĞďǇŽŶĞ ? 
MUR 31- Nicola 68yr F. Multiple 
 
Once medications had been identified, the consultation then proceeded with the pharmacist 
asking questions about each one in turn to complete the MUR form.  
 
In the independent, the MUR form was available electronically. Rebecca was required to select 
medications from the PMR and then transfer the details onto the MUR form. Unlike the paper 
based version, this process saved the pharmacist having to type each medicine directly onto 
the form. However, there were a few instances where this process hindered the pharmacist 
from exploring opportunities to address patient concerns that arose during this stage. As the 
following extract illustrates, some patients revealed information that was not followed 
ƚŚƌŽƵŐŚƐŝŶĐĞZĞďĞĐĐĂ ?Ɛ ŝŵŵĞĚŝĂƚĞƉƌĞŽĐĐƵƉĂƚŝŽŶǁĂƐ ƚŽĞƐƚĂďůŝƐŚĂ ůŝƐƚŽĨŵĞĚŝĐŝŶĞ ĨŽƌ ƚŚĞ
MUR form:  
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ZĞďĞĐĐĂ P QtĞ ?ƌĞŐŽŝŶŐƚŽůŽŽŬĂƚĞǀĞƌǇƚŚŝŶŐǇŽƵ ?ƌĞŽŶ QƐŽǇŽƵ ?ƌĞŽŶĨĞůŽĚŝƉŝŶĞ ? ? ? ?Ɛ ? 
Annabel: Yes. 
Rebecca: Was it increased to 10? 
ŶŶĂďĞů P/ƚ ?ƐĐŽŵĞĚŽǁŶƚŽ ? ? ?ĂƐ/ĨĞůƚĚƌĞĂĚĨƵůĂŶĚ/ŐŽƚŚĞĂĚĂĐŚĞƐƐŽŝƚĐĂŵĞĚŽǁŶ
to 2.5. 
Rebecca: Right, the omeprazole, and the cetirizine you take that... 
MUR 17 - Annabel 61yr F. Independent   
 
ZĞďĞĐĐĂ ?ƐĂŝŵĂƚƚŚĞŝŶŝƚial stage was to select current medication details and transfer these to 
the MUR form. On seeing the higher strength of felodipine she enquired about this. In 
responding, the patient made an offer to address a potential concern in stating a side effect 
from her tablets. Since the pharmacist did not respond immediately to take up the initiative to 
explore the issue further, the window of opportunity to explore this concern was closed. The 
opportunity to discuss the side effect from the felodipine did not present itself later when the 
pharmacist returned to ask about that medicine: 
 
Rebecca: The felodipine, do you take that every day?  
Annabel: Yes 
ZĞďĞĐĐĂ P dŚĞ ŽŵĞƉƌĂǌŽůĞ ǇŽƵ ?ƌĞ ŽŶ ƚŚĂƚ ŽŶĞ ƚǁŝĐĞ Ă ĚĂǇ ? ? ? ? / ?ǀĞ ƉƵƚ ŚĞƌĞ ƚŚĂƚ ƚŚĞ
doctors reduced the felodipine; ǇŽƵ ŬŶŽǁ ǁŚĂƚ ǇŽƵ ?ƌĞ ĚŽŝŶŐ ?  ?ŶŶĂďĞů ƚĂůŬƐ ĂďŽƵƚ
ŚƵƐďĂŶĚ ?ƐŚŽƐƉŝƚĂůǀŝƐŝƚ ? ?
ZĞďĞĐĐĂ P QǇŽƵĚŽŶ ?ƚŚĂǀĞĂŶǇƐŝĚĞĞĨĨĞĐƚƐ ? 
Annabel: No 
ZĞďĞĐĐĂ P^ŽƚŚĞƌĞĂƌĞŶŽŝƐƐƵĞƐƚŽƐŚĂƌĞǁŝƚŚǇŽƵƌĚŽĐƚŽƌ Q 
MUR 17 Annabel 61yr F. Independent 
 
The previous brief reference to the doctor reducing the dose of felodipine was not raised and 
the chance to fully explore and address this potentially significant subject was lost. The 
question-answer sequence will be further discussed in the next section.  
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5.3.2.2 Seeking answers to fill in the MUR  
The closed question-answer sequence was typical and formed the body of the MUR. 
Pharmacists were observed asking the patient to confirm whether the medication they took 
was the same as that which was on the medication record, if they knew what this was for, if 
side effects were reported by the patient and if they could swallow or take their prescribed 
medicine. This was the information needed to complete the MUR form. During the question-
answer sequence, patients typically offered minimal responses to the closed nature of the 
ƉŚĂƌŵĂĐŝƐƚ ?ƐƋƵĞƐƚŝŽŶƐ P 
 
Jane: The feldene, how often do you use it? (Patient says that she uses it when she gets 
arthritis in her neck). 
:ĂŶĞ P^ŽǇŽƵŬŶŽǁǁŚĂƚŝƚ ?ƐĨŽƌ ? 
Iris: Yes. 
:ĂŶĞ PzŽƵĚŽŶ ?ƚŐĞƚĂŶǇŝƌƌŝƚĂƚion?  
Iris: No. 
:ĂŶĞ PdŚĞĐĞƚŝƌŝǌŝŶĞǇŽƵŬŶŽǁǁŚĂƚƚŚĂƚ ?ƐĨŽƌ ? 
/ƌŝƐ PƌĂƐŚ Q ? 
MUR 11- Iris 65yr F. Multiple     
 
As this extract illustrates, pharmacists through their questioning checked whether patients 
knew what the medicine was for and identified potential side effects from medicines and 
enquired whether these were present. Most of the patients knew what their medicine had 
been prescribed for, had few problematic side effects and had little to no issues administering 
their medicines. The pharmacists asked about each medicine sequentially. Jane, an employee 
pharmacist working in the multiple, was observed to have the most mechanistic approach 
compared with the other pharmacists. In an informal discussion after one observed MUR, she 
commented that she performed her MURs in such a way that the patients were  “in and out ? ?
As will be discussed further in Chapter SĞǀĞŶ ?:ĂŶĞǁĂƐƚŚĞŵŽƌĞƐĞŶŝŽƌƉŚĂƌŵĂĐŝƐƚĂŶĚ ‘ďŽƌĞ
ƚŚĞďƌƵŶƚ ?ǁŚĞŶƚŚĞƚĂƌŐĞƚĞĚŶƵŵďĞƌŽĨDhZƐǁĂƐŶŽƚĂĐŚŝĞǀĞĚ ? 
 
Occasionally patients seized the opportunity to discuss extraneous issues such as the 
treatment of minor ailment. Pharmacists typically closed down such requests preferring to 
resolve them through discussions on the shop floor:  
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 ?:ĂŶĞĞŶƋƵŝƌĞƐĂďŽƵƚƚŚĞƉĂƚŝĞŶƚ ?ƐhŶŝƉŚǇůůŝŶĞƚĂďůĞƚƐ ? 
MiĂ P Q/ǁĂŶƚƐŽŵĞĐŽƵŐŚŵĞĚŝĐŝŶĞ ?
Jane: Is it a dry cough or is it on your chest or throat? 
Mia: Both.       
:ĂŶĞ P/ ?ůůǁƌŝƚĞĚŽǁŶƚŚĞŶĂŵĞŶŽǁŝŶĐĂƐĞ/ŶĞĞĚƚŽƌƵƐŚŽƵƚ ? ?:ĂŶĞǁƌŝƚĞƐŽŶĂďŝƚŽĨ
ƉĂƉĞƌ QŚĂŶĚƐƚŚŝƐƚŽƚŚĞůĂĚǇ ? ? 
Jane: You alright swallowing the Uniphylline?  
   MUR 32 - Mia 66yr F. Multiple 
 
ZĞďĞĐĐĂ P  Q/ ŚĂǀĞ Ă ůŝƐƚ ŽĨ ĨŽƵƌ ŵĞĚŝĐŝŶĞƐ  ?ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ůŝƐƚƐ ƚŚĞƐĞ ? ? ĚŽ ǇŽƵ ƚĂŬĞ
anything else?  
Renata: No, but I will tell you, I have bridges rubbing on my face (she explains that it is 
uncomfortaďůĞ ) Q 
ZĞďĞĐĐĂ QŝĨƚŚĂƚ ?ƐǁŚĂƚǇŽƵ ?ƌĞŽŶ ?ǁĞ ?ǀĞŐŽƚZŝŶƐƚĞĂĚWĂƐƚŝůůĞƐŽƌŽŶũĞůůĂ ?ǁĞ ?ůůŚĂǀĞĂ
ƋƵŝĐŬůŽŽŬŽŶƚŚĞǁĂǇŽƵƚ Q 
MUR 13 - Renata 81yr F. Independent    
 
OTC recommendations were typically dealt with after the MUR and when the patient had left 
the consultation room. Although OTC medicines are to be recorded as part of the MUR, 
discussions regarding the management of minor ailments are not. The completion of the MUR 
form appeared to take precedence over these enquiries. 
 
When pharmacists asked patients whether they were taking the medicine and whether they 
understood why the medicine had been prescribed, patients offered little challenge to the 
ƉŚĂƌŵĂĐŝƐƚƐ ?ƋƵĞƐƚŝŽŶƐĂŶĚĂƉƉĞĂƌĞĚƚŽĂŶƐǁĞƌƚŚĞŵƐƚƌĂŝŐŚƚĨŽƌǁĂƌĚůǇ P 
 
Rose: Does the patient take the medication [Preservative free eye drops] as prescribed? 
[Pharmacist reads off the MUR form]. 
Terrie: I do, I use it every 2 hours. 
ZŽƐĞ PdŚĂƚ ?ƐŶŽƚŽŶŽƵƌƌĞĐŽƌĚƐƐŽ/ ?ůůƉƵƚ  ‘every 2 hours ?.  Does the patient know why 
they are using the medication? [Again reads off the MUR form]. 
Terrie: Yes.  
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Rose: Why? I need to ask you [she says this softly but in a firm manner]. 
Terrie: I had an acoustic tumour and it protects the cornea following the acoustic 
neuroma.  
ZŽƐĞ P/ ?ůůƉƵƚŝŶŚĞƌĞ ?ĚƌŽƉƐƉƌŽǀŝĚĞƚĞĂƌƐĂŶĚƉƌŽƚĞĐƚŝŽŶ ?ĂŶĚ/ĚŽŶ ?ƚŶĞĞĚƚŽŐŝǀĞĂŶǇ
ŝŶĨŽƌŵĂƚŝŽŶ ?ĂŶĚŝƚ ?ƐĂƉƉƌŽƉƌŝĂƚĞ ? 
Terrie: Very. 
MUR 7 - Terrie 54yr F. Independent 
 
Rose was the owner of the independent, and was observed undertaking only a single MUR. 
She frequently mentioned to me that pharmacistƐ ŵĂĚĞ ƚŚĞ ƐĞƌǀŝĐĞ  “too clinical ? P  “/ƚ ?Ɛ Ăůů
about compliance and concordance ? ?ZŽƐĞǁĂƐŽďƐĞƌǀĞĚƚŽŚĂǀĞĂŶŽǀĞƌƚƐƚƌĂƚĞŐǇ, similar to 
Jane, which focused on seeking answers directly to complete the MUR form. As illustrated 
above, the use of the statement  “I need to ask you ? enabled Rose to dominate the 
consultation and serve her agenda to complete the MUR form. A common trait that was 
observed in many MURs was the selective interpretation in what pharmacists recorded. In the 
preceding extract Rose had simplified the patient ?Ɛ account of the use of the eye drops in 
order to succinctly record the information on the form. Patients were often told that the 
ƉƵƌƉŽƐĞŽĨƚŚĞDhZǁĂƐƚŽ “check ?ƚŚĞŝƌŵĞĚŝĐŝŶĞƐ ?In their manner of asking and recording 
information, the pharmacists were seen to be merely monitoring what had been prescribed:  
 
ZĞďĞĐĐĂ P QŽǇŽƵŬŶŽǁǁŚǇǇŽƵ ?ƌĞƚĂŬŝŶŐƚŚĞƐŝŵǀĂƐƚĂƚŝŶ ? 
Geri: For the uh high cholesterol.  
ZĞďĞĐĐĂ P/ƚ ?ƐĂŶĞǁŽŶĞŝƐŶ ?ƚŝƚ ? 
'Ğƌŝ P/ ?ŵŚŽƉŝŶŐƚŽĐŽŵĞŽĨĨƚŚĂƚ ? 
Rebecca: You knoǁǁŚǇǇŽƵ ?ƌĞƚĂŬŝŶŐƚŚĞĨĞůŽĚŝƉŝŶĞ ?
'Ğƌŝ P,ŝŐŚďůŽŽĚƉƌĞƐƐƵƌĞ Q 
MUR 12 - Geri 74yr F. Independent   
 
This extract further illustrates the way pharmacists overlooked patients perspectives of their 
medicines. As will be detailed later, more indeterminate matters (ŝŶƚŚŝƐĐĂƐĞ ?'Ğƌŝ ?ƐĚĞƐŝƌĞƚŽ
 “come off ? ŚĞƌ ĐŚŽůĞƐƚĞƌŽů ƚĂďůĞƚƐ) were sidelined in favour of the next routine question. 
However, not all MURs followed this simple question-answer sequence. In the independent, 
the MURs performed appeared to be less hurried affairs than in the multiple. Invited patients 
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appeared to have developed good relationships with pharmacy staff through their regular use 
of the pharmacy. Most patients in the independent were offered a cup of tea at the beginning 
or during the MUR which several accepted and this created a more relaxed atmosphere. 
 
During most MURs, ƉŚĂƌŵĂĐŝƐƚƐĨŽĐƵƐĞĚƵƉŽŶƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐǁŝƚŚůŝƚƚůĞĞǆƉůŽƌĂƚŝŽŶŽĨƚŚĞ
illness that they were used to treat. Pharmacists used the question-answer sequence in order 
to check that patients were using the medication as intended by the prescriber. However, they 
were frequently observed embedding advice about side effects on medicines in their discourse 
with patients:   
 
Kate: ..With the ramipril you can sometimes get a dry cough, do you get this? 
ƵƚƵŵŶ PEŽ ?ŽŶůǇǁŚĞŶ/ ?ǀĞŐŽƚĂĐŽůĚ ? 
Kate: And the amlodipine can sometimes cause ankle swelling.  
ƵƚƵŵŶ P/ŽŶůǇŐĞƚƚŚĂƚǁŚĞŶ/ŐĞƚĂƌƚŚƌŝƚŝƐ Q 
MUR 33 - Autumn 85yr F. Multiple    
 
Kate sometimes enquired ĂďŽƵƚƚŚĞƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůĐŽŶĚŝƚŝŽŶƐƵĐŚĂƐǁŚĞƚŚĞƌƚŚĞƉĂƚŝĞŶƚ ?Ɛ
ďůŽŽĚƉƌĞƐƐƵƌĞǁĂƐ “stable ? ?In informal discussions it was revealed that she found that simply 
asking the requisite questions in a systematic way was clumsy and commented that she aimed 
ĨŽƌĂ “conversation ?ǁith the patient. In order to achieve this she would try to group medicines 
for a particular condition together.  
 
Pharmacists routinely dominated the MUR consultation with nearly half of all patients 
observed not to ask any questions during the encounter. The number of questions that were 
asked by both the patients and pharmacists are presented in Table 2. Although these were 
polite encounters, pharmacists did not facilitate opportunities for the consultation to be 
centred on what the patient might have found useful or interesting. The MUR was therefore 
not focused on how the patient could better manage their illness with the aid of medicines but 
whether the medicines were being used in a way that was acceptable to the pharmacist. All 
pharmacists were observed to fill in the MUR form whilst simultaneously talking to patients. 
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Table 2: Questions asked by pharmacists and patients in 54 MURs 
 
 
Outcome measure 
 
Independent 
Pharmacy 
 
Multiple 
Pharmacy 
 
Mean number of questions asked by the pharmacist 
during the MUR1 
 
 
10 
 
 
 
14 
 
Number of patients who did not ask any questions 
during the MUR 
 
Of the remaining patients, average number of 
questions asked per patients (range) 
 
12 (57%) 
 
 
2 (1-4) 
 
13 (39%) 
 
 
3 (1-92) 
 
 
1
The number of direct questions asked by pharmacists is presented here. However, pharmacists also 
used statements in an interrogative fashion to confirm that patients were taking a particular medicine or 
taking a particular dose. These have not been included in the count.  
2
There was one MUR where a patient and a carer were both present. Nine questions were asked; the 
carer asked five questions (one about his own health) and the patient asked four questions.  
 
 
Patients did not appear to mind this even when this need to record the information displaced 
ƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐĂƚƚĞŶƚŝŽŶĨƌŽŵƚŚĞŵƐĞůǀĞƐ P
 
ǀĞ P  ?dŚĞ ƉĂƚŝĞŶƚ ĞǆƉůĂŝŶƐ ƚŚĂƚ ƐŚĞ ŚĂƐ ŵĂƌŬƐ ŽŶ ŚĞƌ ůĞŐƐ ? QĂŶĚ ƚŚĞƌĞ ?Ɛ Ă ďŝƚ ŽŶ ŵǇ
ďŽĚǇ ?ŝƚ ?ƐŶŽƚŝƚĐŚǇ ? 
ǀĞ ?ƐŚƵƐďĂŶĚ P/ƚ ?ƐƵƉĂŶĚĚŽǁŶǁŝƚŚƚĞŵƉĞƌĂƚƵƌĞ ? 
ǀĞ P / ƚŚŽƵŐŚƚ / ?Ě ŐŽƚ Q ?/ ?ůů ůet you get on [patient indicates that she is disturbing 
ƉŚĂƌŵĂĐŝƐƚĂƐƐŚĞŝƐƚǇƉŝŶŐ Q ? ? 
ZĞďĞĐĐĂ PzŽƵĐĂŶƚĞůůŵĞ Q 
MUR 2 - Eve 75yr F. Independent  
 
As the extract shows, the patient politely stopped the flow of the conversation as she observed 
the pharmacist was busy typing on the computer. Although the pharmacist did invite the 
patient to continue her focus remained on the computer.  
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5.3.2.3 Information exchanges  
The following three sections will investigate information exchanges during the MUR. 
PharmacisƚƐ ƚĞŶĚĞĚƚŽƵƐĞĂ  ‘ƵŶŝůĂƚĞƌĂů ?ĂƉƉƌŽĂĐŚƚŽƉĂƚŝĞŶƚĐŽƵŶƐĞůůŝŶŐ  ?WŝůŶŝĐŬ  ? ? ? ? )ǁŚŝĐŚ
involved delivering advice without first establishing whether the client is knowledgeable about 
the issue in question. Information was delivered in a way that was similar to their interaction 
with patients while handing out dispensed medicines. Pharmacists were seen to provide advice 
when they thought the medicine could be taken in a better way. For example, pharmacists 
ĂĚǀŝƐĞĚ ƚĂŬŝŶŐ ĂƐƉŝƌŝŶ  “after food ? ƚŽ ƉƌĞǀĞŶƚ ŝŶĚŝŐĞƐtion or asked patients who were on 
medicines to reduce cholesterol and which had the potential to cause muscle ache, whether 
they suffered from such side effects. In the relatively few instances in which patients 
requested advice or information, the pharmaĐŝƐƚƐ ?did appeared to respond adequately:   
 
ZĞŶĂƚĂ P/ŚĂǀĞƐŽŵĞĂŶƚŝŚŝƐƚĂŵŝŶĞƐ QƚŚĂƚ ?ƐŽŬŝƐŶ ?ƚŝƚǁŝƚŚƚŚĞĐŽ-proxamol?  
ZĞďĞĐĐĂ P /Ĩ ƚŚĞǇ ?ƌĞ ƚŚĞ ŽŶĞ-a-ĚĂǇ ŽŶĞƐ ƚŚĞŶ ƚŚĞǇ ?ƌĞ ĨŝŶĞ ǁŝƚŚ ĞǀĞƌǇƚŚŝŶŐ ƚŚĂƚ ǇŽƵ ?ƌĞ
ŽŶ QŝĨǇŽƵŚĂǀĞĚƌǇĞǇĞƐ ?ĂŶĚǇŽƵĨŝŶĚƚŚĂƚǇŽƵare using the drops more, than it might 
be the antihistamines that are doing that.   
ZĞŶĂƚĂ PdŚĂƚ ?ƐǁŽƌƚŚŬŶŽǁŝŶŐ Q 
MUR 13 - Renata 81yr F. Independent   
 
Occasionally there was evidence to suggest that patients responded positively to the 
information provided indicating that they found this useful. Like the example above, these 
situations were predominantly about practical advice on a particular issue for which the 
patient sought clarification. For example, several patients enquired about whether doses of 
different medicines could be taken at the same time. The structured format of the MUR 
consultation did not naturally facilitate this and patients appeared to have to seize 
opportunities to ask their questions. For example Nicola, the only patient who was observed to 
ĂƐŬ ĨŽƌ Ă  ‘ƌĞǀŝĞǁ ? ?had to wait until the end of the consultation in order to ask her own 
question:  
 
:ĂŶĞ P QŽǇŽƵŚĂǀĞĂŶǇƋƵĞƐƚŝŽŶƐ ? 
Nicola: In the morning, I take all three together.    
Jane: [Looks at the MUR] The Slow K, Fortipine and the Calcichew. 
Nicola: I take them all in the morning. 
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:ĂŶĞ PdŚĞǇ ?ƌĞĂůů ĨŝŶĞƚŽ ƚĂŬĞĂůů ƚŽŐĞƚŚĞƌ ? ŝƐƚŚĂƚĂůƌŝŐŚƚ ?ŽǇŽƵŚĂǀĞĂŶǇƋƵĞƌŝĞƐŽŶ
your health? 
EŝĐŽůĂ PdŚĂƚ ?ƐǁŚĂƚ/ǁĂŶƚĞĚƚŽĐŚĞĐŬ Q ?ƚĂůŬƐďƌŝĞĨůǇƚĂůŬƐĂďŽƵƚĂƚƵŵŽƵƌƚŚĂƚƐŚĞŚĂƐ
had]. 
Pharmacist P'ƌĞĂƚ ?ƐŽǇŽƵ ?ƌĞŐĞƚƚŝŶŐŽŶĨŝŶĞ ?/ ?ůůƉƵƚƚŚŝƐŽŶǇŽƵƌƌĞĐŽƌĚ ?ƚŚĂƚǇŽƵ ?ǀĞŚĂĚ
ŽŶĞĂŶĚ/ ?ůůƐĞĞǇŽƵ ? 
MUR 31- Nicola 68yr F. Multiple 
 
dŚĞƌĞŵŽǀĂůŽĨƚŚĞƋƵĞƐƚŝŽŶ ‘What would the patient like to get out of the review? ?ĨƌŽŵƚŚĞ
 ‘sĞƌƐŝŽŶ  ? ?DhZ ĨŽƌŵdenied patients an opportunity to set their agenda at the start of the 
consultation. ĞƐƉŝƚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĚŽŵŝŶĂŶĐĞŽǀĞƌƚŚĞĐŽŶƐƵůƚĂƚŝŽŶ ?ĞŶƋƵŝƌŝŶŐĂďŽƵƚƉĂƚŝĞŶƚ ?Ɛ
medicines encouraged patients to ƚĞůů ƚŚĞ  ‘ƐƚŽƌǇ ? ďĞŚŝŶĚ ǁŚǇ Žƌ ŚŽǁ Ă ŵĞĚŝĐŝŶĞ ŚĂĚ ďĞĞŶ
initiated. However, pŚĂƌŵĂĐŝƐƚƐǁĞƌĞĐĂƵƚŝŽƵƐŽĨƉƌǇŝŶŐŝŶƚŽƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůĂĨĨĂŝƌƐ:  
  
ZĞďĞĐĐĂ P QĂŶĚǇŽƵŵĞŶƚŝŽŶĞĚƚŚĂƚŝƚ ?ƐĞǀĞƌǇƐŝǆǁĞĞŬƐ ?ŽŵĞƚĂ ? 
Connie P zĞƐ ĞǀĞƌǇ Ɛŝǆ ǁĞĞŬƐ ĂŶĚ / ?ŵ ŵĂŶĂŐĞĚ ďǇ ƚŚĞ  ?ŶĂŵĞƐ ŚŽƐƉŝƚĂů ? ďƌĞĂƐƚ ĐĂŶĐĞƌ
clinic.  I used to get Zoladex from the hospital.  
ZĞďĞĐĐĂ P/ĚŽŶ ?ƚǁĂŶƚƚŽƉƌǇĂŶĚĞǆĐƵƐĞŵĞŝĨ/ŚĂǀĞŶ ?ƚŐŽƚƚŚĞũŝƐƚŽƌĂŶǇƚŚŝŶŐ ? ?WĂƚŝĞŶƚ
tells pharmacist about the cancer pain that she is experiencing and pain from her 
ostomyelitis].  
ZĞďĞĐĐĂ P^ŽǇŽƵ ?ƌĞĐĂŶĐĞƌŝƐŽĨƚŚĞƉĞůǀis and spine? 
Connie: Yes, and I needed some heavy painkillers. 
Rebecca: When I first saw your Oxynorm dose I thought it was high.  
Connie PdŚĞŽƚŚĞƌůĂĚǇƉŚĂƌŵĂĐŝƐƚ QƚŚŽƵŐŚƚƚŚĂƚ/ǁĂƐĂĚƌƵŐĚĞĂůĞƌďƵƚ/ŶĞĞĚƚŚĞŵ ? 
ZĞďĞĐĐĂ PƐŽǇŽƵ ?ƌĞŽŶKǆǇŶŽƌŵ ?ĨŝǀĞĞvery two hours? 
MUR 21  W Connie 49 yr F. Independent  
  
On several occasions, such as above, patients spoke of their illness and pharmacists took the 
opportunity to obtain relevant information. However, they typically directed the conversation 
back to filling in the MUR form. The format of the MUR discouraged wider discussions of the 
ƉĂƚŝĞŶƚƐ ?ŚĞĂůƚŚĂŶĚŝůůŶĞƐƐ:   
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Rose: The Gaviscon, do you take two-spoons at night? [Pharmacist enquires why] 
dĞƌƌŝĞ PzĞƐ QĨŽƌƐŝůĞŶƚƌĞĨůƵǆ ?/ƚŽĐĐƵƌƐǁŚĞŶƚŝŶǇƉĂƌƚŝĐůĞƐŽĨ acid make their way up the 
ŽĞƐŽƉŚĂŐƵƐ ?ĚĂŵĂŐŝŶŐƚŚĞǀŽĐĂůĐŚŽƌĚƐ QdŚĞǇĚŽŶ ?ƚŬŶŽǁŝĨŝƚ ?ƐƐŝůĞŶƚƌĞĨůƵǆŽƌĂŶƵůĐĞƌ ?
ZŽƐĞ P/ ?ŵŐŽŝŶŐƚŽƉƵƚŚĞƌĞ ‘ŶĞƌǀĞƐŶŽƚŬŝĐŬŝŶŐŝŶƉƌŽƉĞƌůǇ ? ?/ĚŽŶ ?ƚŶĞĞĚƚŽŐŝǀĞǇŽƵĂŶǇ
more information, but you probably know that it forms a raft on the contents of your 
ƐƚŽŵĂĐŚĂŶĚƐŽŝƚƉƌĞǀĞŶƚƐƚŚĞƌĞĨůƵǆ Q ?ŽŶǀĞƌƐĂƚŝŽŶƚƵƌŶƐƚŽƚŚĞŶĞǆƚŵĞĚŝĐŝŶĞ ? ? 
MUR 7  W Terrie 54yr F. Independent  
 
dŚĞĂďŽǀĞĞǆƚƌĂĐƚŝůůƵƐƚƌĂƚĞƐƚŚĂƚƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐĐŽŶǀĞƌƐĂƚŝŽŶĂůƚƵƌŶĂŝŵĞĚƚŽƉƌŽŵŽƚĞher 
agenda of completing the MUR form rather than adapting her response directly to what the 
patient said. Rose appeared to lack curiosity about the uncertainty expressed by the patient 
about her diagnosis and failed to explore this. Adhering to the questions listed on the MUR 
form meant that the opportunity was lost for a discussion that the patient might have found 
useful. Instead the pharmacist remained focused on the medicine and her remit to provide 
information about how the medicine worked rather than tailoring the conversation so that it 
was more patient-centred. Most patients appeared to accept the information provided by the 
pharmacist about a particular topic. Only on a couple of occasions did patients resist the 
ƉŚĂƌŵĂĐŝƐƚ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐŽƌĂĚǀŝĐĞ P
 
Kate: tŝƚŚƌĂŵŝƉƌŝůŝƚ ?ƐďĞƚƚĞƌŝĨǇŽƵƚĂŬĞŝƚŝŶƚŚĞŵŽƌŶŝŶŐ ? 
Anthony: I usually take ramipril and eye drops at night. 
Kate: Better off taking it in the morning. Your blood pressure is higher in the morning 
ƐŽŝƚ ?ƐŵŽƌĞĞĨĨĞĐƚŝǀĞ ?
Anthony: I take the ramipril ŝŶƚŚĞĞǀĞŶŝŶŐƐŽ/ĚŽŶ ?ƚĨŽƌŐĞƚ ?^Ž/ŬŶŽǁǁŚĂƚ/ ?ŵĚŽŝŶŐ ? 
<ĂƚĞ P ^Ž ůŽŶŐ ĂƐ ǇŽƵ ĚŽŶ ?ƚ ĨŽƌŐĞƚ ? /ƚ ?Ɛ ďĞƚƚĞƌ ƚŽ ƚĂŬĞ ŝƚŝŶ ƚŚĞ ŵŽƌŶŝŶŐ ? dĂŬĞ ŝƚ ĂĨƚĞƌ
breakfast. 
Anthony: Probably throws me out [mumbles to himself].  
 MUR 5 - Anthony 74 yr M.  Multiple    
 
In this MUR Kate was persistent that patient took his ramipril medicine in the morning. Her 
position remained unchanged despite the patient providing a logical argument as to why he 
took his medicine in the evening: in this case he took his ramipril when he administered his eye 
drop. Kate did not appear to acknowledge this preferring instead to adhere to her 
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pharmacological understanding of how she thought the medicine worked best instead of 
ƌĞƐƉŽŶĚŝŶŐĂŶĚƚĂŝůŽƌŝŶŐŚĞƌƌĞƐƉŽŶƐĞĂĐĐŽƌĚŝŶŐƚŽƚŚĞƉĂƚŝĞŶƚƐ ? circumstances. 
 
5.3.2.4 Circumventing indeterminacy in the MUR  
It became apparent during some MURs that patients used their medicines differently to the 
way they had been instructed by the doctor. Patients were observed to adjust their medicine 
taking accordŝŶŐƚŽƚŚĞŝƌŽǁŶƐĞƚŽĨŚĞĂůƚŚďĞůŝĞĨƐĂŶĚĚŝĚŶŽƚŵĞƌĞůǇĨŽůůŽǁ ‘ĚŽĐƚŽƌ ?ƐŽƌĚĞƌƐ ? ?
However, when enquiring how the patient took their medicines, pharmacists tended to close 
down or circumvent circumstances where the patients had deviated from the prescribed 
ĐŽƵƌƐĞ ?dŚĞǇƚǇƉŝĐĂůůǇĂĚĚƌĞƐƐĞĚƚŚĞƐĞŝƐƐƵĞƐďǇƌĞŝŶĨŽƌĐŝŶŐƚŚĞƉƌĞƐĐƌŝďĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ P 
 
Jane: The flecainide [used to treat heart arrhythmias], you take two twice a day? 
Konnie: I take one twice a day. 
:ĂŶĞ PdŚĞĚŽĐƚŽƌ ?ƐŐŽƚǇŽƵĚŽǁŶĂƐƚǁŽƚǁŝĐe a day [looks at the prescription]. 
Konnie: I take one in the morning and one at night. 
:ĂŶĞ PzŽƵŶĞĞĚƚŽŚĂǀĞĂǁŽƌĚǁŝƚŚƚŚĞĚŽĐƚŽƌ Q 
MUR 19 - Konnie 40yr F. Multiple 
 
ƐƚŚĞƌ P Q/ĨŝŶĚƐŽŵĞƚŝŵĞƐĂƚŶŝŐŚƚŝĨ/ƚĂŬĞƚŚƌĞĞƉĂƌĂĐĞƚĂŵŽůĨŽƌƚŚĞƉĂŝŶŝƚǁŽƌŬƐ ?and 
takes away the pain]. 
ZĞďĞĐĐĂ PzŽƵƐŚŽƵůĚŶ ?ƚƌĞĂůůǇĚŽƚŚĂƚ ? 
Esther: I find if I take three when the pain is bad it gets me to sleep. 
ZĞďĞĐĐĂ PtĞůů ?ŝƚ ?ƐďĞƐƚƚŽƚĂŬĞƚǁŽ ? 
ƐƚŚĞƌ P/ĚŽŶ ?ƚĚŽŝƚŽĨƚĞŶ ? 
Rebecca: The fluoxetine, are you taking that 2 a day? 
ƐƚŚĞƌ P/ ?ǀĞĐƵƚŝƚĚŽǁŶƚŽŽŶĞĂĚĂǇ ?ďƵƚŝĨ/ĨĞĞůĚŽǁŶ/ƐƚĞƉŝƚƵƉƚŽƚǁŽĂĚĂǇ ?/ĂĚũƵƐƚ
ŝƚƚŽǁŚĂƚ/ĨĞĞůůŝŬĞ Q 
Rebecca: And doctor [names doctor] is happy with that? 
Esther: Yes. 
ZĞďĞĐĐĂ P/ ?ůůƉƵƚŽŶŚĞƌĞ ?ƚǇƉĞƐŽŶĐŽŵƉƵƚĞƌ ? ‘ĚŽĐƚŽƌŝƐĂǁĂƌĞƚŚĂt patient changes the 
ĚŽƐĞ ? ?dŚĞŵĂŝŶƚŚŝŶŐŝƐƚŚĂƚƚŚĞĚŽĐƚŽƌŝƐĂǁĂƌĞ ?/ƚŚŝŶŬƚŚĂƚ ?ƐĨŝŶĞ. 
MUR 18 - Esther 61yr F. Independent   
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As the extracts illustrate the pharmacists dealt with more complex issues in a succinct and an 
apparently superficial manner to allow the review to continue. Pharmacists would frequently 
record the issue on the MUR form and the advice given to indicate that the matter had been 
highlighted and addressed. Patients sometimes provided assurances that their doctor was 
aware of the deviation from the prescribed dose which appeared to appease the pharmacist. 
The consequence of this was that there was rarely any agreed change to the way the patient 
used their medicines. Another area of indeterminacy that arose during several MURs was 
when patients expressed aversion to taking medicines. The grounds for these concerns were 
rarely explored or uncovered and at times they were ignored totally by the pharmacist:  
 
<ĂƚĞ P Q/ ?ŵƐƵƌƉƌŝƐĞĚƚŚĞǇ ?ǀĞŶŽƚƉƵƚǇŽƵŽŶůĂŶƐŽƉƌĂǌŽůĞ Q 
Megan: To be honest I ĚŽŶ ?ƚǁĂŶƚƚŽƚĂŬĞĂŶǇŵŽƌĞ Q/ ?ŵĨĞĚƵƉ ?/ ?ŵŶŽƚĂƉŝůůƚĂŬĞƌ ƚ
Ăůů Q 
Kate: Do you retain water? 
DĞŐĂŶ P zĞƐ QŽŶĐĞ / ?ǀĞ ŐŽƚ ŽĨĨ ƚŽ ƐůĞĞƉ ? ƚŚĞŶ ŝƚ ?Ɛ ƚŝŵĞ ƚŽ ŐĞ  ƵƉ ĂŐĂŝŶ  ?ƚŽ ŐŽ ƚŽ ƚŚĞ
ƚŽŝůĞƚ Q ? ? 
Kate: The Calcichew? 
DĞŐĂŶ PdŚĂƚ/ĚŽŶ ?ƚŵŝŶĚƚĂŬŝŶŐ ?ƚŚĞƌĞƐƚ/could put them in the bin.  
<ĂƚĞ PŽǇŽƵƚĂŬĞƉĂƌĂĐĞƚĂŵŽů Q 
MUR 9 - Megan 73yr F. Multiple 
 
 
Jane: Do you have any questions? 
ŚĂƌůŝĞ P/ĚŽŶ ?ƚůŝŬĞŵĞĚŝĐŝŶĞƐ ?/ĚŽŶ ?ƚůŝŬĞƚĂŬŝŶŐƚŚĞŵǀŽůƵŶƚĂƌŝůǇ ? 
Jane: OK. 
ŚĂƌůŝĞ P QƚŚĞǇŵŝŐŚƚƚĂŬĞƚŚĞƌĂŵŝƉƌŝůŽĨĨ ? 
Jane: Might take you off that one, seems good one less to take. OK any questions or 
concerns? [Patient does not respond] so I will sign you off then. 
MUR 4 - Charlie 68yr M. Multiple    
 
Pharmacists tended to show little curiosity as to why patients had an aversion to taking 
medicines. Patients desire to be self-reliant and not dependent on their medicines was at odds 
with the professional view the pharmacists held about adherence to prescribed medicines. On 
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the few occasions when the pharmacists did respond to ƉĂƚŝĞŶƚƐ ? ĐŽŶĐĞƌŶƐ ĂďŽƵƚ ƚŚĞŝƌ
ĂǀĞƌƐŝŽŶ ƚŽ ŵĞĚŝĐŝŶĞ ƚĂŬŝŶŐ ƚŚĞǇ ƚĞŶĚĞĚ ƚŽ ĂĚŽƉƚ Ă  ‘ďŝŽŵĞĚŝĐĂů ŵŽĚĞů ? ĂƉƉƌŽĂĐŚ ƚŽ ƚŚĞ
situation. This meant that pharmacists focused ƉƌŝŵĂƌŝůǇŽŶƉĂƚŝĞŶƚƐ ?ĂĚŚĞƌĞŶĐĞƚŽŵĞĚŝĐŝŶĞƐ P
 
Rebecca: So why come off the temazepam? [If it is working]. 
WŽůůǇ PdŚĞǇ ?ƌĞĂĚĚŝĐƚŝǀĞ ?ĂŶĚ/ĚŽŶ ?ƚǁĂŶƚƚŽ ?ǁŚĞŶ/ĚŽŶ ?ƚƚĂŬĞŝƚƚŚĞŶ/ĚŽŶ ?ƚƐůĞĞƉ 
ZĞďĞĐĐĂ PŝƐĐƵƐƐŝƚǁŝƚŚƚŚĞĚŽĐƚŽƌ ?ďƵƚŝĨŝƚ ?ƐǁŽƌŬŝŶŐƚŚĞŶǁŚǇŶŽƚŬĞĞƉĐĂƌƌǇŝŶŐŽŶ ? Q 
MUR 16 - Polly 58yr F. Independent   
 
'Ğƌŝ P/ĚŽŶ ?ƚůŝŬĞƚĂŬŝŶŐƚĂďůĞƚƐ ?/ǁŝƐŚ/ĚŝĚŶ ?ƚ ? 
ZĞďĞĐĐĂ PdŚĞŵĂŝŶƌĞĂƐŽŶǁŚǇǇŽƵ ?ƌĞŽŶƚŚĞƐĞ ?ďůŽŽĚƉƌĞƐƐƵƌĞŵĞĚŝĐŝŶĞƐĂŶĚƚĂďůĞƚƐ
for prevention of osteoporosis] is to prevent you from going onto other things [more 
ŵĞĚŝĐŝŶĞƐ ?ĂŶĚƚŽƉƌĞǀĞŶƚǇŽƵĨƌŽŵŐĞƚƚŝŶŐǁŽƌƐĞ Q 
MUR 12 - Geri 74yr F. Independent    
 
All pharmacists appeared to lack awareness of lay perceptions of health and medicines sticking 
instead to their well versed pharmacological knowledge. Despite more complex patient 
concerns being circumvented, MURs did expose pharmacists to individual patients for greater 
length of time compared with their  ‘traditional ? interactions that occurred on the shop floor.  
 
5.3.2.5 Lack of medical information  
WŚĂƌŵĂĐŝƐƚƐ ? ůĂĐŬ ŽĨ ŝŶǀŽůǀĞŵĞŶƚ ŝŶ ŝŶĚĞƚĞƌŵŝŶĂƚĞ ŝƐƐƵĞƐ ŵĂǇ ŚĂǀĞ ƌĞƐƵůƚĞĚ Ĩƌom a lack of 
medical background about the patient. Observations of MURs revealed that pharmacists 
ƐŽŵĞƚŝŵĞƐ ŚĂĚ ƚŽ ĐŽŶƚĞŶĚ ǁŝƚŚ ŚĂǀŝŶŐ ŝŶĐŽŵƉůĞƚĞ ŝŶĨŽƌŵĂƚŝŽŶ ĂďŽƵƚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐĂů
condition and the medicines that they took. Pharmacists therefore relied on the patient to 
ŝŶĨŽƌŵ ƚŚĞŵ ? dŚŝƐ ŚĂĚ ƚŚĞ ƉŽƚĞŶƚŝĂů ĨŽƌ ƚŚĞ DhZ ƚŽ ŝŵƉƌŽǀĞ ĂŶĚ ĞǆƚĞŶĚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ?
knowledge of the patient: 
 
Rebecca: How long have you been on the anti-TNF? 
Howard: Two and a bit years [Rebecca types the response onto computer] 
RĞďĞĐĐĂ P/ƚ ?ƐĂŶŽƚŚĞƌƌĞĂƐŽŶ ?ŝƐŐŽŽĚĨŽƌƵƐƚŽŬŶŽǁĂƐ/ĚŝĚŶ ?ƚŬŶŽǁƵŶƚŝůǇŽƵƚŽůĚŵĞ Q 
MUR 20 - Howard 52yr M. Independent 
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:ĂŶĞ P QŶĚǇŽƵ ?ƌĞƐƚĂƌƚŝŶŐŽŶďĞŶĚƌŽĨůƵƌĂǌŝĚĞ ? 
ƐŚůĞǇ PEŽ ?ƚŚĂƚǁĂƐŽŶĐĞĂĚĂǇ Q
:ĂŶĞ PŶĚǇŽƵ ?ƌĞƐƚĂƌƚŝŶŐŽŶůŝƐŝŶŽƉƌŝů ? 
Ashley: ,ĞƐĂŝĚƚŚĂƚŽŶĞ ?ƐŐŽŝŶŐƚŽŝŶĐƌĞĂƐĞ ?ŵǇďůŽŽĚƉƌĞƐƐƵƌĞŬĞĞƉƐŐŽŝŶŐƵƉ ?ŚĞƐĂŝĚ
ŝƚ ?ƐƚŚĞǁŝŶĞ. 
  MUR 27 - Ashley 67yr M. Multiple    
 
It was clear from the MURs that pharmacists relied upon their knowledge of medicines to 
make inferences about illness for which the patient was being treated. They also relied upon 
the patient to reinforce gaps in their knowledge ŽĨƚŚĞŝŶĚŝǀŝĚƵĂů ?ƐŵĞĚŝĐĂůŚŝƐƚŽƌǇ ? 
 
5.3.2.6 WĂƚŝĞŶƚƐ ?ĚŝƐƉŽƐŝƚŝŽŶĚƵƌŝŶŐƚŚĞDhZ 
As indicated, most patients appeared to feel comfortable in the consultation and were 
unperturbed about discussing their medicines-related issues with the pharmacist. A few 
patients expressed appreciation for the hospitality that the pharmacy provided; this was more 
noticeable in the independent:  
 
ZĞďĞĐĐĂ PzŽƵ ?ƌĞďŽƚŚŐŽŝŶŐƐŽǁĞůů ?ƐĞĞǇŽƵŶĞǆƚǇĞĂƌ Q 
Adam: This is how private patients are treated [says this to wife]. 
MUR 3 - Adam 79yr M. Independent   
 
[There is an interruption by Lucy (dispenser) who brings in the tea] 
ĂŝƐǇ P/ ?ǀĞďĞĞŶŐŝǀĞŶƚŚĞŽŶĐĞŽǀĞƌ ?>ƵĐǇŚĂŶĚs Daisy tea]. 
MUR 1  W Daisy 79yr F. Independent)   
 
Most patients appeared at ease with answering the pharmacist ?Ɛ questions. However, a few 
patients appeared to become confused when asked questions about their medications: 
 
ZĞďĞĐĐĂ P  QŶĚ ƚŚĞ ƐŝŵǀĂƐƚĂƚŝŶ ĚŽ ǇŽƵ ŬŶŽǁǁŚǇ ǇŽƵ ?ƌĞ ƚĂŬŝŶŐ ƚŚĂƚ ?  ?dŚĞ ƉĂƚŝĞŶƚ ŝƐ
hesitant and does not respond, he seems to have become flustered at the question].  
ZĞďĞĐĐĂ PdŚĂƚ ?ƐĨŽƌǇŽƵƌĐŚŽůĞƐƚĞƌŽů ?/ ?ůůƉƵƚƐŽŵĞŚŝŶƚƐŽ ŚĞƌĞ ?ƚŚĞDhZĨŽƌŵ ?ƐŽƚŚĂƚ
ǇŽƵĐĂŶƌĞŵĞŵďĞƌ Q 
MUR 6 - Wilson 75yr M. Independent   
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Such episodes of confusion appeared to last only a few moments and may result from the 
 ‘ŵŽŶŝƚŽƌŝŶŐ ? Žƌ  ‘ƚĞƐƚŝŶŐ ? ĞůĞŵĞŶƚ ƚŚĂƚ ƉĂƚŝĞŶƚƐ ƌĞƉŽƌƚĞĚ ĚƵƌŝŶŐ ƚŚĞŝƌ ŝŶƚĞƌǀŝĞǁƐ ? dŚŝƐis 
explored further in Chapter Six (section 6.4.3). Furthermore, there were a couple of patients 
who did not appear at ease during the MUR. One patient from the multiple appeared very 
anxious from the start of his MUR and gave a minimal response to the ƉŚĂƌŵĂĐŝƐƚ ?ƐƋƵĞƐƚŝŽŶƐ: 
 
[The patient looks very afraid and ŝƐƐŵŝůŝŶŐŶĞƌǀŽƵƐůǇ ?,ŝƐĂƌŵƐĂƌĞĨŽůĚĞĚ Q ? 
Kate: How often do you get the blood pressure checked? Is it stable at the moment? 
Jimmy: Yes [continues to smile awkwardly]. 
Kate PtŝƚŚƚŚĞƌĂŵŝƉƌŝůƐŽŵĞƚŝŵĞƐǇŽƵĐĂŶŐĞƚĂĚƌǇĐŽƵŐŚ ?ǇŽƵĚŽŶ ?ƚŐĞƚĂŶǇƚŚŝŶŐůŝŬĞ 
that?  
Jimmy PEŽ ?dŚĞůĂƐƚƚŝŵĞ/ŐŽƚƚŚĞĨůƵǁĂƐǁŚĞŶ/ǁĂƐĂƚĞĞŶĂŐĞƌ ?EŽǁ/ ?ŵ ? ? ?ŶĞƌǀŽƵƐ
laugh]. 
<ĂƚĞ PzŽƵ ?ǀĞŐŽƚĂŐŽŽĚŝŵŵƵŶĞƐǇƐƚĞŵ ?ŚŽƉĞŝƚŬĞĞƉƐůŝŬĞƚŚĂƚ ? 
MUR 21 - Jimmy 71 yr M. Multiple 
 
ƐĐĂŶďĞƐĞĞŶĨƌŽŵƚŚĞĞǆƚƌĂĐƚ<ĂƚĞ ?ƐƵƐĞŽĨĐůŽƐĞĚƋƵĞstions called for minimal responses 
ĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?<ĂƚĞ ?ƐĞŶƋƵŝƌǇŝŶƚŽǁŚĞƚŚĞƌƚŚĞƉĂƚŝĞŶƚ ?ƐƌĂŵŝƉƌŝůǁĂƐĐĂƵƐŝŶŐa side effect 
appeared to have been misunderstood by the patient. His response indicated that he had 
associated the enquiry about the cough for an enquiry about when he last had the flu. Kate 
instead of clarifying her question agreed with the patient to allow the MUR to continue. 
Having asked her questions, Kate concluded the review swiftly. Afterwards I mentioned that 
the patient looked nervŽƵƐƚŽǁŚŝĐŚƐŚĞƌĞƉůŝĞĚ P “he's very sweet and I didn't want to confuse 
him ? ? 
 
5.3.2.7 Interruptions 
Ten out of the 54 MURs consultations were interrupted by support staff. This happened to all 
four of the pharmacists during their MUR consultations with patients. The most common 
reason for the interruption was that the pharmacist was required to clinically check a 
prescription for a patient who was waiting: 
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DŝĐŚĂĞů PDǇďůŽŽĚƉƌĞƐƐƵƌĞǁĂƐƵƉ Q 
[There is a knock at the door, it is Dawn [dispenser] and she has a prescription in a tub 
to be checked]. 
Kate: Is Jane [pharmacist] not down yet? 
ĂǁŶ P EŽ ƐŚĞ ?Ɛ ĚŽŝŶŐ ^ŽƉŚŝĞ ?Ɛ  ?employee trainee pharmacist] review [I take the 
medicine and the prescription and hand this to Kate who puts it on the table and looks 
at the medicine and the prescription and puts her initials on the label. She hands this 
back to me to give to Dawn. The consultation continues and the patient continues to 
talk about his blood pressure. He did not seem to mind the interruption].  
  MUR 30 - Michael 65yr M. Multiple    
 
 ?dŚĞƌĞ ?Ɛ Ă ŬŶŽĐŬ Ăƚ ƚŚĞ ĚŽŽƌ ĂŶĚ ,ĞůĞŶ  ?ĚŝƐƉĞŶƐĞƌ ? ŚĂƐ Ă ǇĞůůŽǁ ďĂƐŬĞƚ ǁŝƚŚ Ă
ƉƌĞƐĐƌŝƉƚŝŽŶ ĨŽƌ ZĞďĞĐĐĂ  ?ƉŚĂƌŵĂĐŝƐƚ ? ƚŽ ĐŚĞĐŬ ? ,ĞůĞŶ ŵĞŶƚŝŽŶƐ ƚŽ ZĞďĞĐĐĂ  “ƐŚĞ ?Ɛ
ǁĂŝƚŝŶŐ ?ŝŶĚŝĐĂƚŝŶŐƚŚĞƉĂƚŝĞŶƚŽŶƚŚĞ shop floor is waiting for her prescription]. 
ZĞďĞĐĐĂ PhƐƵĂůůǇǁĞĚŽŶ ?ƚůŝŬĞƚŽďĞŝŶƚĞƌƌƵƉƚĞĚ ?ŝƚŵƵƐƚďĞďƵƐǇ ?ƐĂǇƐƚŚŝƐƚŽƉĂƚŝĞŶƚ ? ? 
WŽůůǇ P ŽŶ ?ƚ ǁŽƌƌǇ ? ǇŽƵ ŬŶŽǁ ŵĞ ǁĞůů ĞŶŽƵŐŚ ? /ƚ ?Ɛ ŶŽƚ ŐŽŶŶĂ ďŽƚŚĞƌ ŵĞ ?  ?ZĞďĞĐĐĂ
completes checking the prescription which is for an inhaler. She mentions to Helen the 
dosage to be relayed to the patient. Helen leaves]. 
Rebecca: Where were we?  
MUR 16  W Polly 58yr F. Independent   
 
Pharmacists accommodated interruptions as they were aware of the consequences of their 
absence on other pharmacy services. MCA also interrupted MURs to seek advice:     
 
Rebecca: and the Fybogel sachets? 
Primrose: I'm trying not to take those. 
Rebecca: Fine OK [There is a knock at the door and Cath [MCA] asks if she could sell 
some Phytex paint. This was for a customer who had requested the item the day 
previously and which Rebecca had subsequently ordered. Rebecca agrees]. 
ZĞďĞĐĐĂ P / ?ŵ ũƵƐƚ ƚƌǇŝŶŐƚŽ ĨŝŶĚŵŽƌƉŚŝŶĞ  ?ŽŶƚŚĞŵĞĚŝĐĂƚŝŽŶƌĞĐŽƌĚ ? ?ŽŚǇĞƐ ŝƚǁĂƐĂ
long time ago... 
MUR 19  W Polly 56 yr F. Independent   
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On two occasions Rebecca left the consultation room altogether to respond to the request of 
ƚŚĞ ĚŝƐƉĞŶƐĞƌ ƚŽ  “do some [prescription] checks ? ĂŶĚ ƌĞƚƵƌŶĞĚ Ă ĨĞǁ ŵŽŵĞŶƚƐ ůĂƚĞƌ ƚŽ
continue the review. Patients did not appear to mind the interruptions and appeared happy to 
continue their review once the pharmacist was able to return their focus back to the 
consultation. Further interruptions occurred when the pharmacist was required to refer to a 
reference book. No reference books or patient information leaflets were kept in either the 
multiple or independent consultation rooms and so were unavailable if the pharmacist needed 
them:   
 
ZĞďĞĐĐĂ P QŽǇŽƵŬŶŽǁǁŚĂƚƚŚĞƐƚƌĞŶŐƚŚŽĨŝƚŝƐ ?ŽŵĞƚĂ ? 
Connie: [patient indicates he is not sure] 
ZĞďĞĐĐĂ P / ?ůů ũƵƐƚ ŐĞƚ ŵǇ ƌĞĨĞƌĞŶĐĞ  ?ZĞďĞĐĐĂ ůĞĂǀĞƐ ƚŚĞ ĐŽŶƐƵůƚĂƚŝŽŶ ĂƌĞĂ Q ZĞďĞĐĐĂ
returns with the BNF a few moments later] 
Rebecca: SŽǇŽƵ ?ƌĞŽŶKǆǇŶŽƌŵ Q 
MUR 21- Connie 49yr F. Independent 
 
<ĂƚĞ Q I see you take amantadine 
ĂĚǇ PŝƐƚŚĂƚŽŶĞĨŽƌWĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ? 
<ĂƚĞ P/ĚŽŶ ?ƚŬŶŽǁ ? ? ?
[Kate then aƐŬĞĚŵĞƚŽŐĞƚƚŚĞE& Q/ ůĞĨƚƚŚĞƌŽŽŵĨŽƌĂĨĞǁŵŽŵĞŶƚƐĂŶĚǁĞŶƚƚŽ
the dispensary and asked for the BNF. When I returned, the conversation turned to 
ŐůƵĐŽƐĂŵŝŶĞ ? Q 
  MUR 17 - Cady 74yr F. Multiple   
 
Patients whose MUR had been interrupted did not express any resentment or appeared to 
mind. The pharmacist was prepared to tolerate interruptions to their consultations indicating 
their desire to maintain the flow of dispensing and shop floor services. Such interruptions 
signalled to the nature and status of the MUR consultation and how pharmacists were 
pragmatically accommodating the service. In the following section, I consider the MUR in 
relation to other services provided from the pharmacy.    
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5.3.2.8 MURs: a distinct activity  
As discussed in the previous chapter (section 4.9), the information collected during the MUR 
was poorly integrated into the provision of dispensing prescriptions or other services. Referral 
back to previous MURs was rare and so any matters arising from the MUR that the pharmacist 
felt subsequently required attention during the dispensing process, were recorded directly 
ŽŶƚŽ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ PMR. For example, a ƉĂƚŝĞŶƚ ?Ɛ ƌĞƋƵĞƐƚ ĨŽƌ  ‘ůŽŽƐĞ ? ƚĂďůĞƚƐ ŝŶƐƚĞĂĚ of a 
standard blister pack was recorded by the pharmacist on the PMR as a reminder to staff, for 
ǁŚĞŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŶĞǆƚ ŵĞĚŝĐŝŶĞ ǁĂƐ ĚŝƐƉĞŶƐĞĚ ? dŚĞ ĚĞƚĂĐŚŵĞŶƚ ŽĨ DhZ ĂĐƚŝǀŝƚǇ ĨƌŽŵ
routine dispensing work was made apparent on one occasion when a patient revealed during 
her MUR that she had copious amounts of ƚŚĞŵĞĚŝĐŝŶĞ ‘Polytar liquid ?at home: 
 
ZĞďĞĐĐĂ PŶĚĂůůƚŚĞůŽƚŝŽŶƐ ?ǇŽƵ ?ƌĞK<ƚŽĂƉƉůǇƚŚĞŵ ? 
Polly: Yes. I tick everything else [besides the Polytar] but they still give me the Polytar. 
/ ?ǀĞŐŽƚďŽƚƚůĞƐŽĨƚŚĞƐƚƵĨĨĂƚŚŽŵĞ ? 
ZĞďĞĐĐĂ PDĞŶƚŝŽŶŝƚƚŽƵƐŽƌǁĞĐĂŶƉƵƚ ‘ŶŽƚĚŝƐƉĞŶƐĞĚ ?ďeside it [on the prescription]. 
WŽůůǇ P /ĚŽŶ ?ƚ ƚŝĐŬ ŝƚ ?ŶĞǀĞƌ ? ƚŚĞǇ ƐƚŝůůŐŝǀĞ ŝƚ ?ƵƚŶŽǁƚŚĂƚ / ?ǀĞ ƐĂŝĚ ƚŚŝƐ ƚŚĞǇƉƌŽďĂďůǇ
ǁŽŶ ?ƚĚŽŝƚ ?ůĂƵŐŚ ? ? 
MUR 16 - Polly 58yr F. Independent   
 
As the extract illustrates, Rebecca was informed that the patient had an excess supply of the 
medicated shampoo at home. Despite this, on returning to the dispensary and finding the 
patient ?s prescription ready to be accuracy checked, Rebecca proceeded and supplied the 
medicines including the Polytar liquid. Once the patient had left the pharmacy, I enquired 
whether she had been supplied the Polytar; instantly recognising what she had done, Rebecca 
put her hand to her mouth indicating surprise that she had supplied the Polytar. MURs were 
isolated events with little integration ŝŶƚŽ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƌŽƵƚŝŶĞ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ĐĂƌĞ ĚƵƌŝŶŐ
ĚŝƐƉĞŶƐŝŶŐŽƌĂŶǇǁŝĚĞƌůŝĂŝƐŽŶǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?Ɛ'W ? WŚĂƌŵĂĐŝƐƚƐ ?ǀŝĞǁƐŽŶƚŚĞŝŶƚĞŐƌĂƚŝŽŶŽĨ
information collected during MUR with dispensing are explored in Chapter Seven (section 7.5). 
The final section will consider how the MUR was concluded.    
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5.3.3 Ending the MUR consultation  
The MUR consultations ended once the pharmacist had completed the MUR form. At the end 
of their consultation, half of the patients were provided with the opportunity to ask questions 
about their medicines or their health. Jane was the most consistent in asking this with three 
quarters of her patients being invited to raise concerns:  
 
Jane: Do you have any concerns about your medicines? Any concerns about your health?  
Oprah: No. 
:ĂŶĞ P/ ?ůůƐŝŐŶǇŽƵŽĨĨŽŶƚŚĞĐŽŵƉƵƚĞƌƚŚĞŶĂŶĚǁĞ ?ƌĞĚŽŶĞĨŽƌƚŚĞǇĞĂƌ ? 
MUR 12 - Oprah 89yr F. Multiple    
 
Rebecca: Do you want to know anything more? 
tŝůƐŽŶ P/ ?ŵƋƵŝƚĞŚĂƉƉǇ ? 
ZĞďĞĐĐĂ P /ƚǁĂƐ ůŽŶŐĞƌ ůĂƐƚ ƚŝŵĞ ?ƚŚĞ ĨŽƌŵ ?Ɛ  ? ‘Version 2 ?] shorter now so that we talk 
ĂďŽƵƚǁŚĂƚŶĞĞĚƐƚŽďĞƐŽƌƚĞĚŽƵƚ ?dŚŝƐŝƐƚŚĞĂĐƚŝŽŶƐŚĞĞƚ ?ƚŚĂƚ ?ƐĨŽƌŵĞ ?ǁĞĚŝĚƚŚĞ
ƌĞǀŝĞǁĂŶĚĞǀĞƌǇƚŚŝŶŐŝƐĨŝŶĞ Q 
MUR 6 - Wilson 75yr M. Independent   
 
Few patients opted to take up this invitation. Most patients were recruited to take part in an 
MUR on an unexpected and ad hoc basis and may not have had sufficient time to think of 
concerns and questions they may have had about their medicines (Table One). As a result, 
some patients reported feeling unprepared for the consultation. The consequences of this will 
be explored further in the following chapter (section 6.4.2). When patients did take the 
opportunity to ask questions these were not always fully addressed within the MUR:   
 
Jane: Have you have any concerns about your medicines at all? 
<ŽŶŶŝĞ PƐ/ŝŶĐƌĞĂƐĞĚƚŚĞĚŽƐĞ ?ŽĨĐŝƚĂůŽƉƌĂŵ ?/ŐĞƚƐŚĂŬǇ Q 
:ĂŶĞ P/ƚƵƐƵĂůůǇƚĂŬĞƐĂĐŽƵƉůĞŽĨǁĞĞŬƐƚŽƐĞƚƚůĞ ?ƚŚĂƚ ?ƐƋƵŝƚĞŝŶƚĞƌĞƐƚŝŶŐĨŽƌŵĞƚŽŚĞĂƌ
that. Do you have any other problems? 
Konnie: I want to stop smoking. 
:ĂŶĞ P /ƚ ?ƐĚŝĨĨŝĐƵůƚ  ?:ĂŶĞĂdvises Konnie not want to be over ambitious as her dose of 
ĂŶƚŝĚĞƉƌĞƐƐĂŶƚƐŝƐƐƚŝůůďĞŝŶŐŝŶĐƌĞĂƐĞĚĂŶĚƚŚĂƚƐŚĞƐŚŽƵůĚǁĂŝƚƵŶƚŝůƐŚĞŝƐƐƚĂďŝůŝƐĞĚ ? Q
Chapter Five: The MUR 
128 
 
zŽƵŶĞĞĚƚŽďĞƉƐǇĐŚŽůŽŐŝĐĂůůǇƉƌĞƉĂƌĞĚĨŽƌŝƚ ?/ƚŚŝŶŬǇŽƵ ?ƌĞĚŽŝŶŐƚŚĞƌŝŐŚƚƚŚŝŶŐ ?tĂŝƚ
for everything ƚŽƐĞƚƚůĞĚŽǁŶ ?KŬĂǇ/ ?ůůŵĂƌŬǇŽƵŽĨĨ Q 
MUR 19 - Konnie 40yr F. Multiple 
 
Jane showed little curiosity to explore further into the patient ?s side effect from her citalopram. 
dŚĞ ƐĐŽƉĞ ĨŽƌ ŵĂŶĂŐŝŶŐ Žƌ ďĞŝŶŐ ĂďůĞ ƚŽ ŝŶĨůƵĞŶĐĞ ƚŚĞ ĐĂƌĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƉƌĞƐĐribed 
ŵĞĚŝĐŝŶĞƐ ǁĂƐ ůŝŵŝƚĞĚ ? >ŝŬĞǁŝƐĞ ? ĂůƚŚŽƵŐŚ ƐǇŵƉĂƚŚĞƚŝĐ ƚŽ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƌĞƋƵĞƐƚ ƚŽ ƐƚŽƉ
smoking, Jane had not suggested a further review of this or had invited the patient back once 
ƐŚĞ ŚĂĚ ďĞĞŶ  “stabilised ? ? /Ŷ ĐŽŶƚƌĂƐƚ ƚŽ :ĂŶĞ ? <ĂƚĞ ƌĂƌĞůǇ ƉƌŽǀŝĚĞĚpatients with the 
opportunity to ask questions at the end of the MUR:  
 
Kate: Do you take anything over-the-counter?   
Faith: No. 
<ĂƚĞ PdŚĂƚ ?ƐƉƌĞƚƚǇŵƵĐŚŝƚ ?ǇŽƵĚŽŶ ?ƚƚĂŬĞĂŶǇƚŚŝŶŐĞůƐĞ ? 
Faith: No. 
<ĂƚĞ P ^Ž ǇŽƵ ŬŶŽǁ ǁŚĂƚ ǇŽƵ ?ƌĞ ĚŽŝŶŐ ǁŝƚŚ ǇŽƵƌ ŵĞĚŝĐĂƚŝŽŶ ? ĂŶĚ ǇŽƵ ?ǀĞ ŚĂĚ ǇŽƵƌ
ĂŶŶƵĂůĐŚĞĐŬƵƉ ?ĂŶĚ/ ?ůůůĞĂǀĞŝƚƚŽŵǇĐŽůůĞĂŐƵĞ Q ?WŚĂƌŵĂĐŝƐƚůĞĂǀĞƐ ?. 
MUR 20  W Faith 88yr F. Multiple 
  
As the extract illustrates Kate assumed at the end of most of her MURs, that the patient was 
sufficiently knowledgeable about her medicines to allow her bring an end to the consultation. 
Most MURs ended with few outcomes for patients and when a problem with medicines did 
arise, this was often dealt with by referring the patient back to the GP. Kate occasionally 
provided the patient with a copy of the MUR form or informed them that this would be posted 
to them. However, on most occasions Jane and Kate took the MUR form away with them. They 
did so ŝŶŽƌĚĞƌƚŽĐŽŵƉůĞƚĞƚŚĞƉĂƚŝĞŶƚĂŶĚƉƌĞƐĐƌŝďĞƌ ?ƐĚĞƚĂŝůƐ that appear on the MUR form 
(Appendix Two). Jane rarely offered patients a copy of the MUR form. She mentioned, in an 
informal discussion, that she did not have time to fill out the paperwork during the 
consultation aŶĚ ĚŝĚ ŶŽƚ ŽĨĨĞƌ ƚŽ ƉŽƐƚ ƚŚĞƐĞ ĂƐ ƐŚĞ ĨŽƵŶĚ ƚŚŝƐ ĐƌĞĂƚĞĚ Ă  “backlog ? of MUR 
forms. Patients therefore did not always receive a copy of the MUR form. In the independent, 
Rebecca usually printed the electronic copy of the MUR form once the consultation ended. She 
offered the form to the patient which most accepted.  
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5.4 Summary  
In this chapter, I have presented the findings from the 54 MURs that were observed during 
fieldwork. All the pharmacists adhered to a format for conducting MURs which was largely 
determined by the structure of the MUR form. Pharmacists enquired into patiĞŶƚƐ ? ƌĞƉŽƌƚĞĚ
adherence with each of their medicines, their understanding of what the medicine was for, 
reported side effects and whether the patient was able to administer the medicine successfully. 
Patients did not ask many questions but when they did, the pharmacist appeared to respond 
to these adequately. The MUR service had enabled the pharmacists to talk about medicine-
related issues which would have otherwise not have been actively discussed with the patient. 
ŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚĞ  ‘ƵƐƵĂů ? ĐĂƌĞ ƚŚĞ ƉĂƚŝĞnt received on the shop floor this interaction was 
private and more comprehensive. Most patients appeared comfortable during the MUR and 
ƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐĞŶƋƵŝƌǇ ŝŶƚŽƚŚĞŝƌƵƐĞŽĨŵĞĚŝĐŝŶĞƐĂůůŽǁĞĚƚŚĞƐĐŽƉĞ ĨŽƌƐŽŵĞƉĂƚŝĞŶƚƐƚŽ
discuss other and sometimes sensitive topics privately.   
 
ůƚŚŽƵŐŚ ƉŚĂƌŵĂĐŝƐƚƐ ĨŝůůĞĚ ƚŚĞŝƌ ŽďůŝŐĂƚŝŽŶ ŽĨ ĂƐŬŝŶŐ ƚŚĞ ƋƵĞƐƚŝŽŶƐ ĂďŽƵƚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
medicines use, they appeared to be subordinated ƚŽ ƚŚĞ  ‘ƚĞĐŚŶŽůŽŐǇ ? ŽĨ ƚŚĞ DhZ ĨŽƌŵ ?
Pharmacists dominated the consultation through their professional discourse providing 
information in an instructional manner in a way that was similar to their interaction with 
patients while handing out dispensed medicines. Questions such as to whether the patient 
could swallow tablets, when there was no reason to suspect they could not, meant that 
pharmacists failed to tailor the MUR to the individual patient. Pharmacists tended to take an 
inflexible view in circumstances where medication was being used in ways other than had 
been prescribed. They chose not to speak to the GP directly but relied on the patient to do this. 
This reduced the scope for possible inter-professional collaborative work or for pharmacists to 
ĞŶŚĂŶĐĞ ƚŚĞ ƉƵďůŝĐ ?Ɛ ǀŝĞǁ ŽĨ ƚŚĞŝƌ ƉƌŽĨĞƐƐŝŽŶĂů ƌŽůĞ ? dŚĞ ƐƵŐŐĞƐƚŝŽŶƐ ĂŶĚ ŝŶĨŽƌŵĂƚŝŽŶ ƚŚĞǇ 
ŝŵƉĂƌƚĞĚ ǁĂƐ ƚŽ  ‘ĐŽƌƌĞĐƚ ? ƉĂƚŝĞŶƚƐ ? ƵƐĞ ŽĨ ŵĞĚŝĐŝŶĞƐ ƌĂƚŚĞƌ ƚŚĂŶ ƚŽ ƵŶĚĞƌƐƚĂŶĚ ƚŚĞŝƌ
perspectives and assist them to make an informed choice about the individual use of their 
medicines.    
 
/ŶƌĞƐƉŽŶĚŝŶŐƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐƋƵĞƐƚŝŽŶƐ, patients often contextualised their medicine use 
by speaking about their illness. However, pharmacists rarely responded to the opportunity to 
ĞǆƉůŽƌĞŽƌůĞĂƌŶĂďŽƵƚƚŚĞŶĂƚƵƌĞŽƌƐŝŐŶŝĨŝĐĂŶĐĞŽĨƉĂƚŝĞŶƚƐ ?ƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞŝƌŵĞĚŝĐŝŶĞƐ
and illness. There was a lack of evidence that pharmacists were aware of lay beliefs about 
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medicines. For example when patients overtly expressed an aversion to taking medicines, 
exploring the grounds for these concerns was not undertaken but rather pharmacists mainly 
exhorted patients to take their medicines as prescribed. Because of the narrow scope of the 
DhZ ?ƉŚĂƌŵĂĐŝƐƚƐĨŽĐƵƐĞĚƉƌĞĚŽŵŝŶĂŶƚůǇŽŶŵĞĚŝĐŝŶĞƐĂŶĚƌĞůŝĞĚŚĞĂǀŝůǇŽŶƚŚĞƉƌĞƐĐƌŝďĞƌ ?Ɛ
instructions to circumvent or close down more indeterminate or contentious medicine-related 
matters.  
 
During the MURs patients concurred with or minimally acknowledged the pharmacist's 
utterances and the closed format of the consultation, left patients little scope for a more open 
discussion of their health and medicines. The pharmacist somewhat superficially confirmed 
that the patient was taking their medicines and were content when the patient agreed, when 
asked, if they knew what they were for. Patients did sometimes seize opportunities to ask 
questions, though these were mainly about practical issues for which they sought reassurance. 
Patients expressed varying degrees of individual need, yet pharmacists treated them in a 
standard ĨĂƐŚŝŽŶ ? dŚŝƐ ůĞĨƚ ĂŶ ŝŵƉƌĞƐƐŝŽŶ ƚŚĂƚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ǁĂƐ  ‘ĐŚĞĐŬŝŶŐ ? Žƌ  ‘ŵŽŶŝƚŽƌŝŶŐ ?
patients medicine use. MURs were driven by professional conceptions of what should be 
achieved and there was little evidence of the consultation being responsive to patient cues or 
ƚŽŚĞůƉƉĂƚŝĞŶƚƐŝĚĞŶƚŝĨǇŝƐƐƵĞƐƚŚĂƚǁŽƵůĚďĞŶĞĨŝƚĨƌŽŵƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ŝŶƉƵƚ ?WĂƚŝĞŶƚƐǁĞƌĞ
not asked at the beginning what they wanted from the MUR. The lack of freedom to set their 
own agenda led them to be passive recipients of the service. The next chapter will develop the 
ƚŽƉŝĐƐŝŶƚƌŽĚƵĐĞĚŝŶƚŚŝƐĂŶĚƚŚĞƉƌĞǀŝŽƵƐĐŚĂƉƚĞƌƚŽĞǆƉůŽƌĞƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞƐŽf the MUR. 
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6 CHAPTER SIX Patient perspectives of MURs 
CHAPTER SIX 
Patient perspectives of MURs 
6.1 Introduction 
This chapter builds on the previous two by presenting the findings from the patient interviews. 
I begin by considering the context in which the participants visited the pharmacy and why they 
decided to accept or decline the invitation for an MUR. Following this, I describe how they 
perceived the MUR experience and how they contextualised this within their wider health care 
needs. I then investigate patient accounts further by identifying whether or not the aims of the 
service are being realised. Lastly, the suggestions made by the participants for improving the 
service are presented. Patients provided a range of views about the MUR service. Sometimes 
patients liked certain aspects of the MUR service whilst disliking others: a complex picture 
therefore developed and the different perspectives are represented in this chapter.   
 
6.2 Participants  
Thirty four patients (11 men and 23 women) who were observed having an MUR and three 
patients (one man and two women) who had declined the offer were interviewed. Interviews 
with patients typically took place a week after their observed MUR or their declination of an 
MUR. All but two interviews took place at the pharmacy where the MUR was performed, with 
the remaining two taking place at the University of Nottingham. Patients who had declined the 
invitation were interviewed by telephone which lasted between 10 to 20 minutes. Patient 
interviews about their experience of their MUR lasted between 20 minutes and one and a 
quarter hours (typically 45 minutes) and all were audio recorded.  
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6.3 The patient and the pharmacy 
6.3.1 Frequency of and reasons for pharmacy use  
Patients reported visiting the pharmacy between a few times a week to once every two 
months and used this particular pharmacy for pragmatic reasons such as close proximity to 
where they lived. The pharmacy was perceived as the place to collect their prescribed 
medicines but respondents also mentioned visiting the pharmacy to obtain OTC medicines and 
advice for treating their minor ailments such as sore throats or flu. Some patient accounts 
recognised the dual nature of the pharmacy to provide both professional and retail services: 
  
ZĞƐĞĂƌĐŚĞƌ P Q,ow often do you use the pharmacy when you pop in? 
ZĞŶŝƚĂ PtĞůůĞǀĞƌǇƚŝŵĞ/ ?ǀĞŐŽƚĂƉƌĞƐĐƌŝƉƚŝŽŶƌĞĂůůǇ Q ?ƚŚĞǇĚŽĂƚŽŽƚŚďƌƵƐŚǁŚŝĐŚ/ĐĂŶ
only get in here as well. 
Patient interview 9 - 53yr F. Independent   
 
EŝĐŽůĂ PtĞůů/ ?ŵŝŶŚĞƌĞƉƌŽďĂďůǇĞǀĞƌǇĚĂǇ ?ĐŽƵƉůĞŽĨƚŝŵĞƐĂǁĞĞŬ Q/am a bugger for 
ďĂƌŐĂŝŶƐ ?ŝĨƚŚĞƌĞ ?ƐĂďĂƌŐĂŝŶ/ ?ůůƉŝĐŬŝƚƵƉ Q 
Patient interview 16 - 68yr F. Multiple 
 
Whilst obtaining prescribed medicines was the main reason for using the pharmacy, patients 
also bought OTC medicines and retail items. This finding, although seemingly obvious, is 
ŝŵƉŽƌƚĂŶƚĂƐƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨǁŚĂƚƚŚĞƉŚĂƌŵĂĐǇĂŶĚƚŚĞƉŚĂƌŵĂĐŝƐƚŽĨĨĞƌĞĚĚŝĚŶŽƚ
include the MUR service or descriptions of any similarly related activities. The following two 
sections explore this further and considers patient expectations of the pharmacist and views 
on the pharmacist ?Ɛ role in relation to prescribed medicines.           
 
6.3.2 Patient expectations of the pharmacist  
Most patients viewed the pharmacist as a useful contact and felt that it was comforting to 
know that they were available when they needed them. Several patients commented that the 
ƉŚĂƌŵĂĐŝƐƚĐŽƵůĚƉƌŽǀŝĚĞ “confidential ?ĂŶĚ “unbiased ?ŽƉŝŶŝŽŶƐĂŶĚŝŶĨŽƌŵĂƚŝŽŶ P
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ƐŚůĞǇ P Q ?ĚŽĐƚŽƌƐ ? ǁĞ ŶĞĞĚ ƚŚĞŵ ĂŶĚ ƚŚĞǇ ?ǀĞ ŐŽƚ ƚŽ ďĞ ƚŚĞƌĞ ? ďƵƚ ƚŚĞǇ ĚŽŶ ?ƚ ĂůǁĂǇƐ
taůŬ ƚŚĞ ƐĂŵĞ ůĂŶŐƵĂŐĞ ĂƐ :ŽĞ ƉƵďůŝĐ QƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ? ŝĨ ǇŽƵ ?ǀĞ ďĞĞŶ ƚĂŬŝŶŐ ǇŽƵƌ
ƉƌĞƐĐƌŝƉƚŝŽŶƚŚĞƌĞƌĞŐƵůĂƌůǇ ?ƚŚĞǇďĞĐŽŵĞ ‘ŵŽƌŶŝŶŐ ?ǇŽƵĂůƌŝŐŚƚ ? ?ĚŽĐƚŽƌ ?ƐŶŽƚůŝŬĞƚŚĂƚ ?
dŚĞƌĞǇŽƵ ?ǀĞŐŽƚ ? ?ŵŝŶƵƚĞƐ ?ƐŝƚĚŽǁŶ ?ƚĞůůŵĞ ?/ ?ůůĚŽƚŚŝƐ Q ?ƉŚĂƌŵĂĐŝƐƚƐ ?ƚŚĞǇ ?ƌĞƚŚĞre 
ĂŶĚ ƚŚĞǇ ?ƌĞ ĞĂƐŝĞƌ ƚŽ ƚĂůŬ ƚŽ ĂŶĚ ĐŽŵŵƵŶŝĐĂƚĞ ǁŝƚŚ QǇŽƵ ďĂƐŝĐĂůůǇ ĨĞĞů ǇŽƵ ?ǀĞ ŐŽƚ Ă
ĨƌŝĞŶĚĨŽƌůŝĨĞ Q 
Patient interview 14 - 67yr M. Multiple    
 
ZĞƐĞĂƌĐŚĞƌ P Qthat sort of relationship do you have with the pharmacist? 
ĂŝƐǇ PzĞƐ / ?ŵĂůƌŝŐŚƚǁŝƚŚZĞďĞĐĐĂ ? I mean, if you want to ask her any questions you 
can. I believe if you wanted to ask her something confidential she would keep it 
ƐĞĐƌĞƚŝǀĞŝƚǁŽƵůĚŶ ?ƚďĞƐƉƌĞĂĚĂƌŽƵŶĚ Q 
 Patient interview 2 - 79yr F. Independent 
 
The pharmacist was viewed as a trusted and accessible source of information, someone who 
was less busy than the GP and who could be approached informally but also confidentially. 
Some patients commented that they used the services of the pharmacist when they perceived 
that the issue over their medicine or health was not significant enough to bother the GP. 
Pharmacists were seen to help decide whether or not it was necessary for the patient to 
consult their GP and so prevent them from making a wrong judgement:  
 
,ĂƌƌǇ P  QƐŽ ƌĂƚŚĞƌ ƚŚĂŶǁĂƐƚĞthe doĐƚŽƌ ?Ɛ ƚŝŵĞ ? ŝĨ / ĐŽŵĞŚĞƌĞĂŶĚƐŚĞ ?ůů ƐĂǇ  “go to 
your doctors ? ? ƚŚĂƚ ?Ɛ ĨŝŶĞ / ĂĐĐĞƉƚ ƚŚĂƚ ? ĂŶĚ ǇŽƵ ŐŽ QƐŚĞŵŝŐŚƚ ũƵƐƚ ƐĂǇ  “oh take this 
ĂŶĚǇŽƵ ?ůůďĞĂůƌŝŐŚƚ ? Q/ǁŽƵůĚĂĐĐĞƉƚǁŚĂƚƐŚĞƐĂŝĚ ? 
Patient interview 1 - 75yr M. Independent   
 
Other than the MUR, patients did not describe ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ role to extend to private 
discussions in the consultation room. The fieldwork observations supported this with MURs 
being the only ƌĞĂƐŽŶĨŽƌƉŚĂƌŵĂĐŝƐƚƐŚĂǀŝŶŐĂ ‘ƐŝƚĚŽǁŶ ?ĚŝƐĐƵƐƐŝŽŶǁŝƚŚĂƉĂƚŝĞŶƚ about their 
medicines. The MUR was therefore viewed as an unusual activity for patients in the pharmacy. 
Patients were asked about the advice they sought from the pharmacist. Their responses 
indicated that the pharmacists ? ƉĞƌĐĞŝǀĞĚmandate was strong when providing advice on 
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treating minor ailments and on which OTC medicines could be safely used with prescribed 
medicines: 
 
ZĞƐĞĂƌĐŚĞƌ P QWhat sort of advice do you ask in the pharmacy? 
tŝůƐŽŶ PtĞůůŝƚ ?ƐƵƐƵĂůůǇƌĞůĂƚĞĚƚŽƚŚĞĚƌƵŐƐ ?/Ĩ/ ?ŵĚŽŝŶŐƚŚŝƐ ?ǁŝůůŝƚƌĞĂĐƚǁŝƚŚƐŽ and 
ƐŽ QŽŶĐĞŵǇǁŝĨĞŐŽƚĂƌĂƐŚŽŶƚŚĞďĂĐŬŽĨŚĞƌŶĞĐŬ ?^ŚĞĐĂŵĞŝŶĂŶĚĂƐŬĞĚĨŽƌĂĚǀŝĐĞ ?
they know her medication here; advised her what to get. It worked very well. 
Patient interview 4 - 75yr M. Independent 
 
Pharmacists ?remit for providing advice on prescribed medicines was more limited and these 
existing perceptions influenced how useful they perceived the MUR service.  
 
6.3.3 Pharmacists ? role in relation to prescribed medicines  
/ŶĐŽŶƚƌĂƐƚƚŽƉĂƚŝĞŶƚƐ ?ƉŽƐŝƚŝǀĞǀŝĞǁƐĂďŽƵƚƚŚĞƉŚĂƌŵĂĐŝƐƚ ?s ability to provide advice on the 
treatment of minor ailments, the extent of their involvement with ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛprescribed 
medicines was perceived to be confined to a supply role: 
 
ZĞƐĞĂƌĐŚĞƌ P QǁŚŽĚŽǇŽƵƚŚŝŶŬŚĂƐƚŚĞŵĂŝŶĂƵƚŚŽƌŝƚǇ [over prescribed medicines]? 
Daisy: tĞůůŝƚ ?ƐŐŽƚƚŽďĞƚŚĞĚŽĐƚŽƌŚĂƐŶ ?ƚŝƚ Q/ŵĞĂŶ ?ƐŚĞ ?ƐƚŚĞŽŶly one that knows all 
ƚŚĞŝůůŶĞƐƐĞƐĂŶĚĞǀĞƌǇƚŚŝŶŐ ?^ŚĞ ?ƐŐŽƚǇŽƵƌŵĞĚŝĐĂůƌĞĐŽƌĚƐŚĂƐŶ ?ƚƐŚĞ ?
  Patient interview 2 - 79yr F. Independent   
 
When asked who they thought had the main authority over their prescribed medicines, most 
patients indicated that it was the GP / doctor who was responsible for prescribing for the 
illness and who also had access to their medical records. Nearly all patients perceived that the 
pharmacist held a subordinate position to the medical profession. The pharmacist was 
acknowledged to be an expert about medicines rather than prescribing or managing the 
ƉĂƚŝĞŶƚ ?Ɛillness. Nevertheless, the pharmacist was seen by some as an important failsafe to 
ensure patients were aware of changes to medicine regimens or in the event that the GP had 
made an error: 
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ŚĂƌůŝĞ P Q/ ƚŚŽƵŐŚƚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ŚĂĚ ƚǁŽ ƌŽůĞƐ ƌĞĂůůǇ ? KŶĞ ƚŽ ĚŝƐƉĞŶƐĞ ǁŚĂƚ ƚŚĞ
ĚŽĐƚŽƌƉƌĞƐĐƌŝďĞĚ QƚŚĞƐĞĐŽŶĚǁĂƐƐŽƌƚŽĨ ‘ǁƌŽŶŐ-ƐƚŽƉ ?ũƵƐƚŝŶĐĂƐĞŝƚǁĂƐŽďǀŝŽƵƐƚŚĂƚ
the dŽĐƚŽƌ ŚĂĚ ŐŽƚ ŝƚ ǁƌŽŶŐ Q/ ŵĞĂŶ ĂŶĞĐĚŽƚĂů ĞǀŝĚĞŶĐĞ ǁŽƵůĚ ƐƵŐŐĞƐƚ ƚŚĂƚ ŝƚ ĚŽĞƐ
occur sometimes. 
Patient interview 4 - 68yr M. Multiple    
 
Pharmacists were perceived to be lower in the professional hierarchy, being consulted for 
issues that were perceived to be too trivial to warrant a visit to the GP. The use of the 
pharmacist provided patients with an alternate source of professional advice. In extending the 
professional hierarchy, one patient who was receiving specialist care from a rheumatology 
clinic felt that his GP lacked sufficient knowledge to treat his pain: 
 
,ŽǁĂƌĚ P  Q/ƚ ?ƐƉƵƌĞůǇďĞĐĂƵƐĞƚŚĞ'WƉƌŽďĂďůǇǁŽƵůĚŶ ?ƚŬŶŽǁǁŚĂƚƚŽĚŽ ?ďĞĐĂƵƐĞŽĨ
ƚŚĞĐŽŵďŝŶĂƚŝŽŶƐ ?ŽĨŵĞĚŝĐĂƚŝŽŶƐ ? Q/ŐŽƐƚƌĂŝŐŚƚƚŽƚŚĞŚŽƐƉŝƚĂů ?ŝƚ ?ƐĞĂƐŝĞƌ Q 
ZĞƐĞĂƌĐŚĞƌ P Qzou wouldn't even consider going to your GP first? 
Howard: No unless it's out of hours. 
   Patient interview 16 - 52yr M. Independent 
    
dŚŝƐĞǆƚƌĂĐƚŝƐƌĞǀĞĂůŝŶŐĂƐƚŚĞƉĂƚŝĞŶƚ ?ƐĐŚŽŝĐĞŽĨŚĞĂůƚŚƉƌŽĨĞƐƐŝŽŶĂůǁĂƐĚĞƚĞƌŵŝŶĞĚďǇƚŚĞŝƌ
perception of who would be best to help theŵ ?dŚĞƐƉĞĐŝĂůŝƐƚŶĂƚƵƌĞŽĨ,ŽǁĂƌĚ ?Ɛ ƚƌĞĂƚŵĞŶƚ
meant that he saw the GP as subordinate to his consultant in the professional hierarchy. 
Likewise, patients perceived the pharmacist role to be subordinate to that of the GP. As we 
shall see, the perceived rolĞ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ŚĞůĚ ŚĂĚ ŝŵƉŽƌƚĂŶƚ ŝŵƉůŝĐĂƚŝŽŶƐǁŚĞŶ ƉĂƚŝĞŶƚƐ ?
constructed their experience and attached value to the MUR service. Significantly, the 
patŝĞŶƚ ?Ɛ depiction of what they expected from the pharmacist did not include reference to 
them reviewing prescribed medicines. These attitudes were evident when the patients were 
asked about their awareness of the MUR service.  
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6.4 Patients perceptions of MURs 
6.4.1 Awareness of the MUR service  
Patient awareness of what the MURs could potentially offer them was poor. Although the 
MUR service had been available since 2005, patients who had not previously been approached 
had not heard of, or were only vaguely aware of, the service: 
 
ZĞƐĞĂƌĐŚĞƌ P Q,ave you heard about these medicines use review before? 
Terrie: No. I havĞŶ ?ƚ Q 
ZĞƐĞĂƌĐŚĞƌ P/ƚŚŝŶŬƚŚĞƌĞĂƌĞƉƌŽďĂďůǇƉŽƐƚĞƌƐŽƵƚ Q 
dĞƌƌŝĞ PzŽƵĚŽŶ ?ƚůŽŽŬĂĐƚƵĂůůǇ ?/ŵĞĂŶŝĨǇŽƵ ?ƌĞŝŶǀŽůǀĞĚǁŝƚŚŝƚǇŽƵůŽŽŬ ?ďƵƚǇŽƵŬŶŽǁ
ǁŚĞŶǇŽƵ ?ƌĞƐŽƌƚŽĨĨŽĐƵƐĞĚ ?ŝŶĂŚƵƌƌǇ ?ǇŽƵǁĂŶƚǇŽƵƌƉƌĞƐĐƌŝƉƚŝŽŶ Q/ǁŽƵůĚŶ ?ƚŚĞƐŝƚĂƚĞ
to ask if I needed any sort of wider information. 
Patient interview 3 - 54yr F. Independent 
 
Most patients who had not previously had an MUR lacked awareness of the service or 
confused the service with other services provided from the pharmacy such as minor ailments 
services
3
. However, not all patients were unaware of MURs. A couple of patients reported 
seeing advertisements in the pharmacy or had spoken to others who had a review: 
 
ZĞƐĞĂƌĐŚĞƌ P Q,ave you ever heard about the service? 
ůŝƐŽŶ PzĞƐ Q/ǁŽŶĚĞƌĞĚǁŚǇ/ŚĂǀĞŶ ?ƚŚĂĚŽŶĞĂĐƚƵĂůůǇ QĞǀĞƌǇŽŶĞǁĂƐŚĂǀŝŶŐŽŶĞ Q 
Researcher: Where did you hear this from? 
ůŝƐŽŶ PKŚ/ĚŽŶ ?ƚŬŶŽǁ ?/ƚŚŝŶŬ / ũƵƐƚƉŝĐŬĞĚŝƚƵƉŽŶƚŚĞŐƌĂƉĞǀŝŶĞǇŽƵŬŶŽǁ ?ĨƌŝĞŶĚƐ
ǁŚŽ ?ǀĞŚĂĚŝƚĂŶĚ/ ?ǀĞƐĞĞŶƐŝŐŶƐĂďŽƵƚŝƚ/ƚŚŝŶŬ Q 
ZĞƐĞĂƌĐŚĞƌ P Q/ƐƚŚĞƌĞĂŶǇƌĞĂƐŽŶ why ǇŽƵĚŝĚŶ ?ƚĐŽŵĞĂŶĚĂƐŬĨŽƌĂƌĞǀŝĞǁŚĞƌĞ ?
Alison: Um, ďĞĐĂƵƐĞ / ĚŝĚŶ ?ƚ ƚŚŝŶŬ / ŶĞĞĚĞĚ ŽŶĞ ƌĞĂůůǇ / ŐƵĞƐƐ ? /ƐĞĞ ƚŚĞ ĚŽĐƚŽƌ ƋƵŝƚĞ
ŽĨƚĞŶ Q 
  Patient interview 7 - 46yr F. Independent 
                                                          
3
 The minor ailment scheme is an Enhanced service that allows patients to consult the community 
pharmacist rather than the GP for a defined list of minor ailments. The scheme allows patients who are 
exempt from NHS prescription charges to receive treatment from an agreed local formulary free of 
charge from the pharmacy. 
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ZĞƐĞĂƌĐŚĞƌ P Q^ŽǇŽƵ ?ǀĞĂĐƚƵĂůůǇŚĞĂƌĚĂďŽƵƚŵĞĚŝĐŝŶĞƐƵĞƌĞǀŝĞǁƐ ? 
Summer: /ĚŝĚ ?ĐĂŶ ?ƚƌĞŵĞŵďĞƌ ?ƉƌŽďĂďůǇĂƚƚŚĞĐŽƵŶƚĞƌ ? 
ZĞƐĞĂƌĐŚĞƌ P QBƵƚǇŽƵ ?ǀĞŶĞǀĞƌŚĂĚŽŶĞŝŶƚŚĞƉĂƐƚ ?
Summer: No, /ŚĂǀĞŶ ?ƚŚĂĚŽŶĞ ?/ũƵƐƚŵĂĚĞĂŵĞŶƚĂůŶŽƚĞďĞĐĂƵƐĞŝĨ/ŚĂĚŶ ?ƚŐŽŶĞŝŶƚŽ
my doctor, I perhaps would have requested one. 
Patient interview 12- 62yr F. Multiple 
 
Twelve out of 37 patients who were interviewed reported having had a prior MUR. However, 
when asked about their previous MUR, most patients could remember few, if any, details:  
 
Researcher: Do you remember about [previous MUR]? 
Wilson: /ĐĂŶ ?ƚŽĨĨŚĂŶĚ ?/ƐĞĞŵƚŽŐĞƚƌŽƉĞĚŝŶƚŽƐŽŵĂŶǇƚŚŝŶŐƐ Q 
ZĞƐĞĂƌĐŚĞƌ P Qtere you aware that the pharmacy actually offers these reviews to you? 
tŝůƐŽŶ PEŽ/ǁĂƐŶ ?ƚ ?ŝƚ ?ƐƵƐĞĨƵůƚŽŬŶŽǁƚŚĂƚ ?/ǁĂƐŶ ?ƚĂǁĂƌĞŽĨŝƚƚŝůůŝƚŚĂƉƉĞŶĞĚ ? 
Patient interview 4 - 75yr M. Independent 
 
Patients who had reported having a previous MUR did not portray this as an opportunity to 
discuss concerns or medication issues with the pharmacist. This is unsurprising given the fact 
that their previous MUR consultation may have also been dominated by the pharmacist asking 
closed questions. Most MURs were brief encounters taken up with the completion of the MUR 
form and pharmacists did not communicate effectively to the patient that the MUR was 
supposed to be for their benefit. Before exploring patient views of the MUR, the next section 
focuses on participant views on being invited or the reasons why they chose to decline the 
invitation for an MUR. 
 
6.4.2 The invitation  
6.4.2.1 Reasons for accepting an MUR  
Patients were asked to describe how the pharmacist or the pharmacy staff invited them for an 
MUR. Their accounts supported the observations. Patients reported being asked if they were 
willing or wanted to participate in an DhZĂŶĚŝĨƚŚĞǇŚĂĚƐŽŵĞ “time to spare ? P
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Researcher: Do you remember how you were approached initially? 
Primrose: The lady came up to me and said would I mind going through my medication 
with um the pharmacist and just to kind of make sure that we both knew why this 
medication was being prescribed. And it was just something that um chemists are 
having to do now. 
Patient interview 17 - 56yr F. Independent 
 
Most patients were invited in an ad hoc way when collecting their prescription. However, this 
meant that patients did not expect to sit down and discuss their medicines with the 
pharmacist:    
 
Researcher: Were you expecting a review? 
ůŝƐŽŶ PEŽ QũƵƐƚƉŝĐŬŝŶŐƵƉŵǇŵĞĚŝĐŝŶĞƐ ? 
  Patient interview 7 - 46yr F. Independent   
 
Nick: No [laugh] no, Jane [pharmacist] just collared me [laughter].   
Patient interview 13 - 80yr M. Multiple 
 
One patient described how her particular MUR invitation came about: 
 
WŽůůǇ PtĞůů /ĐĂŵĞŝŶŚĞƌĞƚŽĐŽůůĞĐƚŵǇŽƌĚŝŶĂƌǇƉƌĞƐĐƌŝƉƚŝŽŶ QĂŶĚ/ŚĂĚǁŝƚŚŵĞŵǇ
ƐƉŽŶƐŽƌĨŽƌŵĨŽƌŵǇ ‘ZĂĐĞĨŽƌ>ŝĨĞ ?ĂŶĚ/ĂƐŬĞĚŝĨĂŶǇŽŶĞǁŽƵůĚďĞƉƌĞƉĂƌĞĚƚŽƐƉŽŶƐŽƌ
ŵĞ Q>ƵĐǇ  ?ĚŝƐƉĞŶƐĞƌ ?ƐĂŝĚ  ‘/ ?ůůĚŽǇŽƵĂƐǁŽƉ ? /ĨǇŽƵĚŽƚŚĞƌĞǀŝĞǁĨŽƌŵĞ / ?ůů ƐƉŽŶƐŽƌ
ǇŽƵƌZĂĐĞĨŽƌůŝĨĞ ? ?^ŽƚŚĂƚ ?ƐŚŽǁŝƚĐĂŵĞƚŽďĞ Q/ǁĂƐďƌŽƵŐŚƚŝŶŚĞƌĞĂŶĚ/ǁĂƐŽĨĨĞƌĞĚ
ĂĐƵƉŽĨƚĞĂ Q 
Patient interview 15 - 58yr F. Independent   
 
The extract illustrates the opportunistic approach pharmacy staff took in order to recruit 
patients for an MUR. The ad hoc approach used by the pharmacy staff appeared to take a 
couple of patients by surprise. They revealed that because they were caught unaware they 
unthinkingly agreed to the invitation:    
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ZĞƐĞĂƌĐŚĞƌ P Qtere you expecting a review last Friday? 
YƵĞĞŶŝĞ PEŽ ?ŶŽ/ǁĂƐĐŽŵƉůĞƚĞůǇŐŽďƐŵĂĐŬĞĚǁŚĞŶƐŚĞĂƐŬĞĚŵĞ Q/ĚŽŶ ?ƚŬŶŽǁǁŚǇ/
ƐĂŝĚǇĞƐ ?/ũƵƐƚƐĂŝĚǇĞƐĂƵƚŽŵĂƚŝĐĂůůǇ/ƚŚŝŶŬ ?ǇĞĂŚ Q/ƚŚŝŶŬƐŚĞƚŚƌĞǁŵĞĂďŝƚƐŽ/ũƵƐƚ
said yes automatically and had no idea what was coming. 
Patient interview 10 - 81yr F. Multiple 
 
Not all patients were positive in response to the offer of an MUR. Some reported that if they 
did not have the time they would have declined the invitation:  
 
ReseĂƌĐŚĞƌ P QtŽƵůĚǇŽƵŚĂǀĞƉƌĞĨĞƌƌĞĚŵĂǇďĞƐŽŵĞƉƌŝŽƌŶŽƚŝĐĞĂďŽƵƚƚŚĞƌĞǀŝĞǁ ? 
DŽǇĂ P EŽ ? ŶŽ ĚŽĞƐŶ ?ƚ ŵĂƚƚĞƌ ƌĞĂůůǇ ? ŝĨ ǁĞ ŚĂĚŶ ?ƚ ŚĂĚ ƚŝŵĞ ƚŚĂƚ ĚĂǇ ? ƚŚĞŶ ǁĞ ǁŽƵld 
ŚĂǀĞ ƐĂŝĚ  “well I'ŵ ƐŽƌƌǇ ďƵƚ ŝƚ ?Ɛ ŶŽƚ ĐŽŶǀĞŶŝĞŶƚ ?ĂŶĚ ƚŚĞŶ ǁĞ ?Ě ŚĂǀĞ ƚŽ ĐŽŵĞ ďĂĐŬ
some other time. 
Patient interview 10 - 79yr F. Independent   
 
Although most patients felt that the ad hoc approach taken by the pharmacy was acceptable 
some indicated that they would have liked some prior notice: 
  
<ŽŶŶŝĞ P Q/ǁĂƐŬŝŶĚŽĨŶŽƚĞǆƉĞĐƚŝŶŐŝƚ QŝĨŝƚ ?ƐƐƵƉƉŽƐed be beneficial for us, we need to 
ďĞŐŝǀĞŶĂďŝƚŽĨƚŝŵĞĂďŽƵƚǁŚĂƚǁĞǁĂŶƚƚŽŬŶŽǁ Q/ǁŽƵůĚŚĂǀĞĂƐŬĞĚĂďŽƵƚŵǇĂŶƚŝ-
depressants, can I take them together? Does it matter what time of the day I take 
ƚŚĞŵ ? QĂůƚŚŽƵŐŚ ŵǇ ĚŽĐƚŽƌ ?Ɛ ǀĞƌǇ ŐŽŽĚ ? ƐŚĞ ũƵƐƚ ŐŝǀĞƐ ǇŽƵ ƚŚĞ ƉƌĞƐĐƌŝƉƚŝŽŶ QǁŚĂƚ
ǁŽƵůĚŚĂƉƉĞŶŝĨ /ǁĂŶƚĞĚƚŽŚĂůĨƚŚĞĚŽƐĂŐĞ Q/ĐĂŶ ?ƚƌĞĂůůǇŵĂŬĞĂŶĂƉƉŽŝŶƚŵĞŶƚƚŽ
ũƵƐƚŐŽĂŶĚĂƐŬŵǇĚŽĐƚŽƌƚŚŝƐ ?zŽƵŬŝŶĚŽĨǁĂŝƚƵŶƚŝůƚŚĞŶĞǆƚƚŝŵĞĂŶĚƚŚĞŶ ?ŝĨǇŽƵ ?ƌĞ
going in for something else you forget.   
Patient interview 11 - 40yr F. Multiple 
 
The lack of prior notice appeared to unsettle a few patients who then felt less engaged to talk 
to the pharmacist during the MUR. Konnie, in particular, recognised that the MUR was 
supposed to benefit her and revealed questions that she would have liked to have asked the 
pharmacist if she had been given the opportunity to think about the review beforehand. As the 
extract illustrates, these were complex issues which were not addressed through the 
structured format of the MUR consultation.  
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When patients were asked why they accepted the invitation for an MUR they reported a range 
of reasons. Most patients reported being indifferent when asked how they felt about being 
invited for an MUR. They generally accepted the invitation because they were asked by the 
pharmacist or staff with whom they had a good relationship. Even though patient awareness 
of the MUR service was poor, patients did not appear to feel threatened by the invitation: 
 
Researcher: Why did you agree to that review, was there any reason? 
Eve: No, I just thought she asked. 
Patient interview 5 - 75yr F. Independent   
 
 
ZĞƐĞĂƌĐŚĞƌ P QďƵƚǁŚǇĚŝĚǇŽƵĂŐƌĞĞ ? 
/ƌŝƐ PtĞůů/ƐƵƉƉŽƐĞ/ĂŐƌĞĞĚ ?ƵŚ/ĚŽŶ ?ƚƌĞĂůůǇŬŶŽǁ ?ƐƵƉƉŽƐĞďĞĐĂƵƐĞƐŚĞĂƐŬĞĚŵĞƚŚĞ
question [laughs ? Q/ƐƵƉƉŽƐĞŝƚ ?ƐŐŽŽd. I mean she said to me some people are probably 
ƚĂŬŝŶŐŵĞĚŝĐŝŶĞƐĂŶĚƚŚĞǇĚŽŶ ?ƚĞǀĞŶŬŶŽǁǁŚĂƚƚŚĞǇ ?ƌĞƚĂŬŝŶŐƚŚĞŵĨŽƌ ?^Ž/ƚŚŝŶŬŝƚ
could be quite useful really. 
Patient interview 7- 65yr F. Multiple    
 
Patients generally appeared to accept the invitation for MURs because they felt obligated or 
were willing to help the pharmacist. Several patients had the impression that the MUR was an 
activity the pharmacy needed to undertake. In accepting the invitation for the MUR their 
responses did not seem to be strongly motivated by self interest or the prospect of personal 
benefit. Several patients accepted the invitation because they were curious or acknowledged 
that it was good to keep up to date with their knowledge of their medicines. A couple of 
respondents revealed that they welcomed the opportunity to raise a concern about specific 
issues with their medicines:   
 
Researcher: Why did you agree? 
Howard: Just out of interest, you know to keep up my own knowledge and make sure I 
ŚĂĚŶ ?ƚŵŝƐƐĞĚĂŶǇƚŚŝŶŐ Q 
Patient interview 16 - 52yr M. Independent 
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Researcher: What do you think their intention was at the time? 
^ƵŵŵĞƌ PhŵƚŽƌĞǀŝĞǁƚŚĞŵĞĚŝĐŝŶĞƐƚŚĂƚ/ ?ŵŽŶ ?/ǁĂƐƋƵŝƚĞŚĂƉƉǇƚŽĚŽƚŚĂƚ ‘ĐĂƵƐĞ
/ ?ǀĞũƵƐƚŚĂĚĂƌĞǀŝĞǁǁŝƚŚŵǇĚŽĐƚŽƌĂŶĚ/ŚĂǀĞŽŶĞŽƌƚǁŽŝƐƐƵĞƐƚŚĂƚ / ?ve had with my 
ŵĞĚŝĐĂƚŝŽŶ ŝŶ ƚĞƌŵƐ ŽĨ ƐŝĚĞ ĞĨĨĞĐƚƐ Q ?ƐŽ / ǁĂƐ ƋƵŝƚĞ ŝŶƚĞƌĞƐƚĞĚ ĂĐƚƵĂůůǇ ŽŶ ǇŽƵƌ
[pharmacist] take on my medication. 
Patient interview 12 - 62yr F. Multiple 
 
The MUR was seen by these patients as an unexpected encounter but one which was a 
welcome chance to refresh their knowledge or gain some insight about a particular issue about 
their medicines. Although patients were comfortable accepting the offer for an MUR at this 
pharmacy, several reported that they would be less comfortable or would decline the offer if 
they went elsewhere to a pharmacy they were less familiar with. The relationship with the 
staff therefore appeared to be an important factor for patients to accept the invitation for an 
MUR:  
 
ŽŵĨŽƌƚ P Q/ ǁŽƵůĚ ŚĂǀĞ ĨĞůƚ ŵŽƌĞ Ăƚ ŚŽŵĞhere than going into a strange one 
 ?ƉŚĂƌŵĂĐǇ ?ĂŶĚĚŝƐĐƵƐƐŝŶŐĂůůŵǇƵŵƚŚŝŶŐƐǇŽƵŬŶŽǁ Q/ŶŽƚƐĂǇŝŶŐ/ǁŽƵůĚŶ ?ƚĚŽŝƚ ?ďƵƚ
/ ?ĚďĞŵŽƌĞƚŚŝŶŬŝŶŐǁŚĂƚƐŚŽƵůĚ/ƐĂǇ ?ǁŚĂƚƐŚĂůů/ĚŽ ?ŶŽƚďĞŝŶŐŝŶǁŝƚŚƐŽŵĞŽŶĞƚŚĂƚ
ŬŶŽǁƐŵĞĂƐǁĞůůĂƐ/ŬŶŽǁƚŚĞŵ Q 
 Patient interview 15 - 72yr F. Multiple  
 
ƐŚůĞǇ P Q/f I walked into [name of another pharmacy] for example, took my prescription 
ŝŶĂŶĚŚĞĂƐŬĞĚŵĞƚŽĚŽĂƉƌĞƐĐƌŝƉƚŝŽŶƌĞǀŝĞǁ ? ŝĨ / ?ĚŐŽƚŶŽƉƌŽďůĞŵƐ/ ?ĚƐĂǇ  “ŶŽ/ ?ŵ
ŶŽƚďŽƚŚĞƌĞĚƚŚĂŶŬƐ ? ĂŶĚĐŽŵĞŽƵƚĐĂƵƐĞ ?/ǁŽƵůĚŶ ?ƚŬŶŽǁǁŚŽ/ǁĂƐƚĂůŬŝŶŐƚŽ Q 
Patient interview 14 - 67yr M. Multiple 
 
Only one patient (Nicola) was observed to ask the pharmacy staff for an MUR. When asked 
why she did this, she mentioned specific concerns about her medicines that she felt the 
pharmacist could answer:   
  
Researcher: Why did you ask for a review? 
EŝĐŽůĂ P ĞĐĂƵƐĞ ƚŚĞǇ ?ƌĞ ŽĨĨĞƌŝŶŐ ŝƚ QƚŚĂƚ ?Ɛ ƚŚĞ ŽŶůǇ ƌĞĂƐŽŶ QĂŶĚ ũƵƐƚ ǁĂŶƚ ƚŽ ŵĂŬĞ
ƐƵƌĞ QŝĨ/ĐŽƵůĚƚĂŬĞƚŚĞŵin one go in the morning, in one go at dinner and one go at 
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night rather than individually QƐŽ/ƚŚŽƵŐŚƚ/ ?ĚũƵƐƚĐŚĞĐŬ Q/ũƵƐƚƌĞĐĞŶƚůǇƐƚĂƌƚĞĚƚĂŬŝŶŐ
ƉĂƌĂĐĞƚĂŵŽůƐ Q/ĚŝĚĂƐŬƚŚĞĚŽĐƚŽƌŝĨ/ĐŽƵůĚƚĂŬĞƵƉƚŽƐŝǆĂŶĚƐŚĞƐĂŝĚĞŝŐŚƚ ?ƐŽ/ũƵƐƚ
ǁĂŶƚĞĚ ƚŽ ŵĂŬĞ ƐƵƌĞ ǁŝƚŚ ƚŚĞ ŽƚŚĞƌ ƚĂďůĞƚƐ ? / ƚŚŽƵŐŚƚ ƚŚĞƌĞ ?Ɛ ŶŽƚŚŝŶŐ ǁƌŽŶŐ ǁŝƚŚ
having it confirmed, a second opinion if you like [laughs] I wouldn't want my doctor to 
know that [laughter]. 
Patient interview 16 - 68yr F. Multiple 
 
Nicola saw the MUR as an opportunity to address her concerns about her medicines and this 
was a means to provide reassurance. Significantly, she revealed that she did not want the 
ĚŽĐƚŽƌƚŽŬŶŽǁƚŚŝƐ ĨŽƌ ĨĞĂƌ ƚŚĂƚŚĞƌĚŽĐƚŽƌŵĂǇďĞĐŽŵĞ  “upset ? ?Some patients recognised 
that there was potential for the MUR to cause tension between the GP and pharmacist which 
could impact on professional boundaries and responsibilities and this is discussed further in 
section 6.4.5. As they were not widely aware of the service and given their existing 
ƉƌĞĐŽŶĐĞƉƚŝŽŶƐ ĂŶĚ ĞǆƉĞƌŝĞŶĐĞ ŽĨ ƉŚĂƌŵĂĐǇ ƐĞƌǀŝĐĞƐ ? ƉĂƚŝĞŶƚƐ ? ƌĞĂƐŽŶƐ ĨŽƌ ĂĐĐĞƉƚŝŶŐ ƚŚĞ
invitation for an MUR was rarely based upon an understanding or awareness that the overall 
aim of the service was to improve their knowledge and use of medicines. 
 
6.4.2.2 Patients ? reasons for declining the invitation for an MUR 
Having explored patientƐ ? reasons for accepting the invitation for an MUR, further insights 
ĂďŽƵƚ ƉĂƚŝĞŶƚƐ ? ƉĞƌĐĞƉƚŝŽŶƐof the MUR service were gained through considering why some 
declined the offer. Eight patients were observed to decline the offer of an MUR: one patient 
from the independent and seven from the multiple. In the pharmacy, two stated that they did 
so due to a lack of time and three refused outright without reason. However, interviews with 
the remaining three revealed a more complex picture. Despite previously having had an MUR, 
one patient was observed declining the offer from the pharmacist because he perceived this 
would result in more medication. In his interview he revealed that he could not remember 
many details of his previous MUR other than being asked whether he was taking the 
medication, how he felt about them and if he was happy with the service from the pharmacy. 
HĞƌĞƉŽƌƚĞĚďĞŝŶŐ  “very impressed ?ǁŝƚŚƉŚĂƌŵĂĐǇƐĞƌǀŝĐĞƐĂŶĚƚŚĞĂĚǀŝĐĞ ƚŚĂƚŚĞƌĞĐĞŝǀĞĚ
from the pharmacy. Nevertheless, he revealed that his main reason for declining the invitation 
was because he had recently been diagnosed with throat cancer and was overwhelmed by his 
personal circumstances. He therefore just wanted his prescription filled: 
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ĂĐŚ P Q/ƐĂŝĚ ‘/ ?ǀĞŐŽƚŽŶĞŽƌƚǁŽƚŚŝŶŐƐŽŶŵǇŵŝŶĚĂƚƚŚĞŵŽŵĞŶƚ ?Ănd I wanted to 
ďĂƐŝĐĂůůǇŐĞƚ ŝŶ ?ŐĞƚŵǇƉƌĞƐĐƌŝƉƚŝŽŶĂŶĚŐĞƚŽƵƚ QďĞůŝĞǀĞŵĞ ?ƐŚĞ ?ƐĂĐŚĂƌŵŝŶŐǇŽƵŶŐ
ůĂĚǇĂŶĚ/ůŝŬĞŚĞƌĐŽŵƉĂŶǇƐŽƚŚĞƌĞǁĂƐŶŽƉƌŽďůĞŵ ?/ƚǁĂƐũƵƐƚƚŚĞĨĂĐƚƚŚĂƚ/ ?ǀĞďĞĞŶ
ƌĞĐĞŶƚůǇƚŽůĚ/ ?ǀĞŐŽƚĐĂŶĐĞƌŽĨƚŚĞƚŚƌŽĂƚ QƐŽ ?/ ?ǀĞŚĂĚŵǇ ŝŶĚĨƵll of other things. 
   Patient decliner 1 - 70yr M. Independent 
 
Zach mentioned in his interview that he would be happy to take part in an MUR when things 
ŚĂĚƐĞƚƚůĞĚĂŶĚ “if it helps the system run smoothly ? ?dŚĞŽƚŚĞƌƚǁŽƉĂƚŝĞŶƚƐĚĞĐůŝŶĞĚƚŚĞDhZ
reporting to the pharmacy staff they had previously completed a  “review with the doctor ? ?
During the interview, it transpired that one of these patients said that the two medications 
that she was taking (Hormone Replacement Therapy (HRT) tablets and ranitidine) were not 
 “important ?ĞŶŽƵŐŚƚŽǁĂƌƌĂŶƚĂƌĞǀŝĞǁ P
  
ZĞƐĞĂƌĐŚĞƌ P Q,ŽǁĚŝĚǇŽƵĨĞĞůďĞŝŶŐĂƐŬĞĚĂďŽƵƚŚĂǀŝŶŐŽŶĞ ?DhZ ? ? 
yĞŶĂ PtĞůů /ĚŝĚŶ ?ƚ ƚŚŝŶŬ ƚŚĞƌĞǁĂƐĂŶĞĞĚďĞĐĂƵƐĞ / ?ŵŶŽƚŽŶĂŶǇƐŽƌƚŽĨ ŝŵƉŽƌƚĂŶƚ
ŵĞĚŝĐĂƚŝŽŶƐ ŝĨ ǇŽƵ ůŝŬĞ Q/ ?ŵ ŶŽƚ ŽŶ ĂŶǇƚŚŝŶŐ ƐŽƌƚ ŽĨ ĨŽƌ blood pressure. If I had 
something like that I would have a review. 
Researcher: Is that why you declined the offer? 
Xena: Yes. 
   Patient decliner 1 - 66yr F. Multiple  
 
Xena felt the MUR was a good idea in principle and appropriate that pharmacists should be 
involved in MUR activity. However, she felt that these would be more useful for patients on 
ŵŽƌĞ  “important medications ? ? tŚĞŶ ĂƐŬĞĚ ǁŚĞƚŚĞƌ ƐŚĞ ŚĂĚ ĂŶǇ ĐŽŶĐĞƌŶƐ ĂďŽƵƚ ŚĞƌ
medicines, she revealed that some supplies of her ranitidine did not seem as efficacious as 
others: 
 
yĞŶĂ P dŚĞ ŽŶůǇ ƚŚŝŶŐ ƚŚĂƚ ĐŽŶĐĞƌŶƐ ŵĞ ŝƐ / ?ǀĞ ďĞĞŶ ƚŽ ĚŝĨĨĞƌĞŶƚ ƉŚĂƌŵĂĐŝĞƐ ĂŶĚ ƚŚĞ
ƚĂďůĞƚƐƐĞĞŵŶŽƚĂƐŐŽŽĚŝŶŽŶĞĂƐĂŶŽƚŚĞƌ Q 
Researcher: Do you think that this would have been an issue that you would have 
discussed with the pharmacist? 
Xena: Yeah, actually probably would. Yes. 
Patient decliner 1 - 66yr F. Multiple 
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The extract illustrates that Xena had not realised until the interview what the MUR could offer 
her. The approach taken by the pharmacy staff had therefore not conveyed this effectively 
enough. TŚĞ ƚŚŝƌĚ ƉĂƚŝĞŶƚ ǁŚŽ ǁĂƐ ŝŶƚĞƌǀŝĞǁĞĚ ĚĞƐĐƌŝďĞĚ ƚŚĞ ƌĞǀŝĞǁ ĂƐ  “bureaucratic ? ?
Observations in the pharmacy revealed that the invitation made by the pharmacy staff was 
typical of how other patients were approached. However, this patient revealed in her 
ŝŶƚĞƌǀŝĞǁƚŚĂƚƐŚĞĚŝĚŶŽƚǁĂŶƚĂŶ “extra layer ?ŽĨŝŶǀŽůǀĞŵĞŶƚ ?
 
ĂƌĂ P  Q/ ?ŵŶŽƚƉĂƌƚŝĐƵůĂƌůǇ ŝŵƉƌĞƐƐĞĚǁŝƚŚĂŶǇďŽĚǇǁŚŽ/ĨĞĞů ŝƐƉƵƚƚŝŶŐƉƌĞƐƐƵƌĞŽŶ
ŵĞ Q/ ĚŽŶ ?ƚ ǁĂŶƚ ĂŶŽƚŚĞƌ ůĞǀĞů ǁŚĞƌĞ / ŚĂǀĞ ƚŽ ƐĞĞ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ĂƐ ǁĞůů QƚŚĞƌĞ
seemed to be tŚĂƚƐůŝŐŚƚƉƌĞƐƐƵƌĞ ?ǇŽƵŬŶŽǁ ? “ƚŚŝƐŝƐǁŚĂƚǁĞĚŽŶŽǁ ?ǇŽƵŬŶŽǁ ? “this 
is NHS rĞŐƵůĂƚŝŽŶƐ ? ?ǇŽƵŬŶŽǁ “so we reĂůůǇŽƵŐŚƚƚŽďĞĚŽŝŶŐƚŚŝƐŶŽǁ ? ?ƚŚĂƚ ?ƐŚŽǁ/
felt about it. 
Patient decliner 2 - 53yrs F. Multiple  
 
Zara expressed noticeable resentment about the pressure she felt over the way she was 
offered the MUR. Another important factor was that she did not live near the pharmacy and it 
was not made clear whether she would have the MUR immediately or later via an 
appointment. When asked whether she thought that she was the type of person who would 
benefit from having an MUR she clarified:  
 
ĂƌĂ PEŽ ?ĨŽƌŽŶĞƚŚŝŶŐ/ ?ŵŶŽƚŝŶƚĞƌĞƐƚĞĚĂŶĚĂŶŽƚŚĞƌƚŚŝŶŐ/ŬŶŽǁ/ ?ŵŽŶůǇŽŶďůŽŽĚ
ƉƌĞƐƐƵƌĞĂŶĚĐŚŽůĞƐƚĞƌŽů  ?ƚĂďůĞƚƐ ? Qŝƚ ?ƐďĞƚƚĞƌĨŽƌŵĞƚŽƚĂŬĞŵǇďůŽŽĚƉƌĞssure in the 
morning and my cholesterol in the evening. I know that already and if I get any side 
ĞĨĨĞĐƚƐ Q/ǁŝůůŐŽĂŶĚƐĞĞƐŽŵĞďŽĚǇ QƚŚƌŽƵŐŚŵǇŽǁŶĐŚŽŝĐĞ ?ƚŽŵĞŝƚ ?ƐĂďŝƚůŝŬĞŚĂƌĚ
selling through the telephone. 
Patient decliner 2 - 53yrs F. Multiple 
 
Zara agreed in principle that the MUR was a good idea but felt the additional involvement 
from the pharmacist, for her personally, was unnecessary. She mentioned that a pharmacist 
ƐŚŽƵůĚďĞĂǀĂŝůĂďůĞŝĨĂƉĂƚŝĞŶƚǁĂŶƚĞĚƚŽĚŝƐĐƵƐƐ “something medical ? ?^ŚĞĚŝd recognise that 
the MUR could be beneficial for some, such as young mothers or for older people who find it 
ĚŝĨĨŝĐƵůƚƚŽƐĞĞƚŚĞĚŽĐƚŽƌ ?,ŽǁĞǀĞƌ ?ƐŚĞǁĂƐŶŽƚŽŶĞǁŚŽƉĂƐƐŝǀĞůǇĂĐĐĞƉƚĞĚƚŚĞ ‘ƐƚĂƚƵƐƋƵŽ ? P
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Zara: As I said, iƚ ?s probably a good idea for some ƉĞŽƉůĞ ĂŶĚ ƉĞƌŚĂƉƐ ŝƚ ?Ɛ Ă ƌŽƵƚĞ
ĂƌŽƵŶĚ ŝĨ ǇŽƵ ĐĂŶ ?ƚ ŐĞƚ ŝŶ ƚŽ ƐĞĞ ƚŚĞ ĚŽĐƚŽƌ Žƌ ǁŚĂƚĞǀĞƌ ? Ƶƚ / ƚĞŶĚ ƚŽ ďĞ ĂŶƚŝ-
establishment anyway so the least I get involved with them the better [laughs]. 
Patient decliner 2 - 53yrs F. Multiple 
 
Zara acknowledged the MUR could be useful for some patients but held strong personal views 
ŶŽƚ ƚŽ ďĞ  ‘ĐĂũŽůĞĚ ? ŝŶƚŽ ĂĐĐĞƉƚŝŶŐ ƚŚĞoffer from pharmacy staff. These three patients gave 
pragmatic reasons for declining the invitation for an MUR when approached in the pharmacy. 
However, more complex reasons for declining the offer were only revealed in the interview. 
Their initial response hid what might have been construed as less acceptable or more complex 
motives for declining an MUR. In the following section I return to focus on patients perceptions 
of the MUR consultation.  
 
6.4.3 Patient perceptions of MURs  
6.4.3.1 The consultation room  
There were a range of views reported about the consultation room. Most patients considered 
that the consultation room, in both pharmacies, was adequate for undertaking an MUR. No 
patients felt that privacy was a problem:   
 
ZĞƐĞĂƌĐŚĞƌ P Qthat did you think of the consultation area? 
tŝůƐŽŶ P/ƚŚŝŶŬŝƚ ?ƐǀĞƌǇŐŽŽĚ ?ĂůůƉŚĂƌŵĂĐŝĞƐƐŚŽƵůĚŚĂǀĞƚŚĞŵ QŝĨƚŚĞƌĞ ?ƐĂƐŚŽƉĨůŽŽƌ ?
you don't want your views in public and sometimes you want that bit of confidential 
ŝŶĨŽƌŵĂƚŝŽŶ Q/ƚŵŝŐŚƚŽŶůǇďĞƚƌŝǀŝĂů ?ďƵƚĂƚůĞĂƐƚǇŽƵ ?ƌĞŐĞƚƚŝŶŐƐĂƚŝƐĨĂĐƚŝŽŶĂŶĚǇŽƵŐĞƚ
a proper anƐǁĞƌ ?dŚĞƌĞŝƐŶŽďŽĚǇ ?ƐĂǇŝŶŐ ? “ŽŚǁŚĂƚ ?ƐŚĞƚĂŬŝŶŐƚŚĂƚĨŽƌ ?. 
Patient interview 4 - 75yr M. Independent 
 
Researcher: What did you think of the little room? 
ĞƚŚ PYƵŝƚĞŶŝĐĞ ?ǇĞƐŶŝĐĞĂŶĚƉƌŝǀĂƚĞ ?ŶĚǇŽƵŬŶŽǁŶŽďŽĚǇĐĂŶƐĞĞǇŽƵĂŶĚǁŚĂƚ ?Ɛ
ŐŽŝŶŐŽŶŝŶƚŚĞƌĞ ?ŝƚ ?ƐƋƵŝƚĞŶŝĐĞ ?ƉƵƚƐǇŽƵĂƚĞĂƐĞ Q 
Patient interview 3 - 76yr F. Multiple 
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Most patients welcomed discussions being in the consultation room rather than on the shop 
floor, where it was felt that conversations could be overheard. However, several patients 
reported being dissatisfied with the room and voiced strong opinions that it needed to be 
improved. Within the multiple, the lack of a window and the bare walls made a few patients 
ĨĞĞůƚŚĂƚƚŚĞƌŽŽŵǁĂƐ “intimidating ?ĂŶĚ “claustrophobic ? ?dŚĞƐŝǌĞŽĨƚŚĞƌŽŽŵǁĂƐĂůƐŽĂŶ
issue for some: 
 
Megan: The room was appalling, I mean even this is untidy [managers ŽĨĨŝĐĞ ? ?ďƵƚŝƚ ?Ɛ
ďĞƚƚĞƌƚŚĂŶƚŚĂƚƌŽŽŵ ?/ƚ ?ƐƐŽƌƚŽĨůŝŬĞĂƉŽƌƚĂĐĂďŝŶƌĞĂůůǇŝƐŶ ?ƚŝƚ ? 
Patient interview 5 - 73yr F. Multiple 
 
The pokey, bare, cupboard like room promoted a poor image for the place where MURs were 
undertaken. Patients who were dissatisfied suggested that the room could be more welcoming 
by having a window and soft furnishings. A sitting or coffee room environment was suggested 
by one patient which would create a more relaxed atmosphere. Within the independent, one 
patient commented that the room was like a storage area, another mentioned that the area 
was cramped: 
 
Researcher: What did you think of the consultation area? 
Renata: [Laughs] BŝƚĐƌĂŵƉĞĚ QǁĞůů/ŵĞĂŶ ?ŝĨƚŚĂƚǁĂƐŽƵƚŽĨƚŚĞǁĂǇ ?ƌĞĨĞƌƐƚŽĞŵƉƚǇ
water containers] it wouldn't be so bad.  
Patient interview 8 - 81yr F. Independent 
 
IŶZĞŶĂƚĂ ?ƐĐĂƐĞ above, two people were invited for an MUR (mother with daughter) and this 
made the seating arrangement restrictive. Poorly accommodating patients may have affected 
how patients perceived the value of MURs and the status of service.  
 
6.4.3.2 Describing the MUR  
Patients were asked to recall their experience of what happened during their MUR. 
Respondent accounts supported the fieldwork observations made during their MUR. Patients 
provided ambivalent or somewhat confusing accounts of their MUR. Most patients generally 
ĚĞƐĐƌŝďĞĚŚŽǁƚŚĞƉŚĂƌŵĂĐŝƐƚ “went through ?ƚŚĞŝƌŵĞĚŝĐŝŶĞƐĂŶĚ had asked them questions 
to see how and why they took them:  
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Moya: Well all the medication was discussed and hoǁ/ƚŽŽŬŝƚĂŶĚǁŚǇ/ĚŝĚŶ ?ƚƚĂŬĞŝƚ
and whether I was taking it right and the workings of it you see.  So I thought, you 
know, it was quite good. 
Patient interview 10 - 79yr F. Independent 
 
ZĞƐĞĂƌĐŚĞƌ P QtŚĂƚĚŽǇŽƵƌĞŵĞŵďĞƌŽĨƚŚĞƌĞǀŝĞǁ ? 
Molly: I remember ƚŚĞǇŽƵŶŐůĂĚǇ QĂŶĚƐŚĞĂƐŬĞĚŵĞƚŚĞƋƵĞƐƚŝŽŶƐ ?ĂŶĚǇŽƵƐĂƚŝŶ, on 
ĂƐƚŽŽůĂŐĂŝŶƐƚƚŚĞĚŽŽƌ Q 
Researcher: Is there anything in the consultation that stood out?  Or made you think? 
Molly: Not really no. Not that I can think of, everything was just plain sailing. 
Patient interview 6 - 76 yr F. Multiple 
 
Jacques: Um we were discussing the actual uh medicine, medication that I was taking, 
ŝĨƚŚĞƌĞ ?ĚďĞĞŶĂŶǇĐŚĂŶŐĞƐ Q/ǁĂƐŝŶǀŽůǀĞĚŝŶǁŚĞƚŚĞƌŽƌŶŽƚŝƚǁĂƐĂĐĐƵƌĂƚĞ ? 
 Patient interview 9 - 78 yr M. Multiple  
 
Many patients framed the MUR as having an important monitoring or checking function that 
ĞŶƐƵƌĞĚ ƚŚĂƚ ƚŚĞǇ ƚŽŽŬ ƚŚĞ ŵĞĚŝĐŝŶĞ ĐŽƌƌĞĐƚůǇ ĂŶĚ ƚŽ ĞŶƐƵƌĞ ƚŚĞǇ ŚĂĚ ŶŽƚ  “misunderstood ?
any directions on their medication. Patients were asked what they thought the purpose of the 
MUR was. Most acknowledged that the MUR benefited them in some way. One reason was to 
ensure that the medication they took was appropriate and necessary: 
 
Primrose: I thought it was to um, to make sure I have a better understanding of what 
I'm taking and because there are certain things I have to take at certain times and in a 
certain way. Um I thought perhaps it was an opportunity to go over that, to make sure 
ƚŚĂƚ/ ?ǀĞŶŽƚŐŽƚĐŽŶĨƵƐĞĚĂďŽƵƚĂŶǇƚŚŝŶŐ ?
Patient interview 17 - 56yr F. Independent  
 
ZĞƐĞĂƌĐŚĞƌ Q,ŽǁǁŽƵůĚǇŽƵĚĞƐĐƌŝďĞƚŚĞƌĞǀŝĞǁƚŽƐŽŵĞŽŶĞǁŚŽŚĂƐŶ ?ƚŚĂĚŝƚďĞĨŽƌĞ ?
ŽŵĨŽƌƚ P tĞůů / ƚŚŝŶŬ ŝƚ ?Ɛ ǀĞƌǇ ŚĞůƉĨƵů ƚŽ ƚŚĞ ĐƵƐƚŽŵĞƌ ƵŚ ŝĨ ƚŚĞǇ ĚŽ ǁĂŶƚ ƚŽ ĚŝƐĐƵƐƐ
ƚŚŝŶŐƐ ŝŶƉƌŝǀĂƚĞ QŝƚŵĂĚĞŵĞĨĞĞůĂďŝƚŵŽƌĞĐŽŶĨŝĚĞŶƚ ?ƚŚŝŶŬŝŶŐǁĞůů ?Ăŵ /ĚŽŝŶŐƚŚe 
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ƌŝŐŚƚƚŚŝŶŐ ?Ăŵ/ƚĂŬŝŶŐƚŚĞƌŝŐŚƚƚŚŝŶŐ ?Ăŵ/ƚĂŬŝŶŐŝƚŝŶ ƚŚĞƌŝŐŚƚǁĂǇ ?zĞĂŚŝƚ ?ƐŚĞůƉĞĚ
me, it really has. 
 Patient interview 15 - 72yr F. Multiple 
 
Nearly all patients described the MUR in positive terms. Most accounts suggested that the 
pharmacist provided reassurance for them about their medicines. The process of asking about 
ĞĂĐŚŵĞĚŝĐŝŶĞŝŶƚƵƌŶƉƌŽǀŝĚĞĚƉĂƚŝĞŶƚƐǁŝƚŚĐŽŶĨŝĚĞŶĐĞƚŚĂƚƚŚĞǇǁĞƌĞ “doing the right thing ? P 
 
EŝĐŬ P Q/ĨŽƵŶĚŝƚǀĞƌǇŚĞůƉĨƵůƚŚĂƚĨŝƌƐƚŽĨĂůůŝƚǁĂƐƋƵŝƚĞƌĞůĂǆĞĚĂŶĚƐĞĐŽŶĚůǇ QŝƚǁĂƐ
useful to go through each and every piece of medication.  I suppose really 90% of the 
ƚŝŵĞ ĐŽŶĨŝƌŵŝŶŐ ǁŚĂƚ / ĂůƌĞĂĚǇ ŬŶĞǁ ? ďƵƚ ŝƚ ĚŽĞƐŶ ?ƚ ĚŽĂŶǇ ŚĂƌŵ ƚŽ ƌĞĨƌĞƐŚ ǇŽƵƌ
ŵĞŵŽƌǇ ?ĞĐĂƵƐĞŽĐĐĂƐŝŽŶĂůůǇƚŚĞǇĚŽĐŚĂŶŐĞŵĞĚŝĐĂƚŝŽŶ Q 
Patient interview 13 - 80yr M. Multiple  
 
&ŝŽŶĂ P Q/ĚŝĚĨŝŶĚƚŚĂƚǀĞƌǇŚĞůƉĨƵů ?ǇŽƵŬŶŽǁĂůƚŚŽƵŐŚ/ǁĂƐƉƌŽďĂďůǇĚŽŝŶŐƚŚĞƌŝŐŚƚ
ƚŚŝŶŐĂůůĂůŽŶŐ ?ďƵƚŝƚ ?ƐƐƚŝůůŶŝĐĞƚŽŚĂǀĞƐŽŵĞďŽĚǇ ?ĂŶĞǆƉĞƌƚƚŽƚĞůůǇŽƵĂƌĞĚŽŝŶŐƚŚĞ
right thing. And um you never know when there might be something that will crop up 
ƚŚĂƚ/ŵŝŐŚƚǁĂŶƚƚŽĂƐŬǇŽƵĂďŽƵƚ QǁŚĞŶǇŽƵĐŽŵĞƚŽƐĞĞƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐŚĞŚĂĚŝƚ
ĂůůƚŚĞƌĞ QŝƚǁĂƐŶŝĐĞĨŽƌŵĞƚŽƚŚŝŶŬǁĞůůƐŚĞĐĂŶƐĞĞĞǀĞƌǇƚŚŝŶŐƚŚĂƚ/ ?ŵƚĂŬŝŶŐ ? 
Patient interview 2 - 70yr F. Multiple    
 
When patients were asked if the MUR improved their knowledge of their medicines there was 
little evidence from their responses that it did so. Rather, as the extracts illustrate, the 
consultation provided reassurance that they were taking the medicines in the right way. These 
responses are further investigated in section 6.5.5.  
 
Patients were asked whether they felt comfortable or apprehensive during the MUR. All of the 
patients reported feeling comfortable speaking to the pharmacist. Several patients appeared 
to value being invited for an MUR and showed some appreciation to the pharmacy for the 
service that was offered to them. As well as providing reassurance about their medicines, 
patients also expressed gratitude to the pharmacist and commented that they felt special 
because the pharmacist had spent time with them:  
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ZĞŶĂƚĂ P Qzou feel they know more about you and what your needs are and they get to 
ŬŶŽǁǇŽƵ ?/ŶĨĂĐƚ ?ŝŶŚĞƌĞƚŚĞǇĚŽ ?ǀĞƌǇĨƌŝĞŶĚůǇƵŵĂŶĚ/ƚŚŝŶŬǇŽƵĨĞĞůƚŚĞǇ ?ƌĞŵŽƌĞ
interested in you, than actually some doctors are [laughs]. 
ZĞƐĞĂƌĐŚĞƌ P QŽǇŽƵĨĞĞůŝƚ ?ƐŶĞĐĞƐƐĂƌǇ ?DhZ ? ? 
ZĞŶĂƚĂ P Qŝƚ ?ƐƐŽŶĞǁƚŽŵĞ ?/ĚŽŶ ?ƚ ?ǇĞĂŚŝŶĂǁĂǇ ?ǇĞƐ/ĚŽ ?/Ĩŝƚ ?ƐǁŽƌƚŚƚŚĞŝƌƚŝŵĞ ?ŝƚ ?Ɛ
worth mine. 
Patient interview 8 - 81yr F. Independent 
 
DŝĂ P  QŝŶ ĨĂĐƚ / ?ŵ ŐůĂĚ ƚŚĂƚ ƚŚĞǇ ƌĞŵĞŵďĞƌĞĚ ŵĞ ĂƐ ĂŶ ŝŶĚŝǀŝĚƵĂů ?  ‘ĐĂƵƐĞ ŶŽǁĂĚĂǇƐ ?
ŚŽƐƉŝƚĂůƐ ĂŶĚ ƚŚŝŶŐƐ ůŝŬĞ ƚŚĂƚ ? ǇŽƵ ?ƌĞ ůŝŬĞ Ă ĐŽŶǀĞǇŽƌďĞůƚ ĂŶĚ ŶŽďŽĚǇƐĞĞŵƐ ƚŽ ŚĂǀĞ
time to talk to you.    
   Patient interview 17 - 66yr F. Multiple 
 
Despite a lack of perceived personal usefulness to improve their knowledge of their medicines, 
ŵŽƐƚƉĂƚŝĞŶƚƐǀĂůƵĞĚƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĂĚǀŝĐĞĂŶĚŽƉŝŶŝŽŶƐ during an MUR. Others made wider 
comments that the MUR was useful particularly in reducing the workload of the GP: 
 
ZĞƐĞĂƌĐŚĞƌ P Qo you think that your pharmacist should be involved in services like this? 
Robert: Oh yes. I think they can be quite useful really and take a lot of strain from the 
'W ?ƐĂƚƚŝŵĞƐ ?ǇŽƵŬŶŽǁ ?ǁŝƚŚŵŝŶŽƌƚŚŝŶŐƐ QƌĂƚŚĞƌƚŚĂŶƐĞĞŝŶŐƚŚĞĚŽĐƚŽƌĂƚĞǀĞƌǇĞŶĚ
and turn. 
  Patient interview 1 - 79yr M. Multiple 
 
AnŶĂďĞů P Q/ƚ ƐĞĞŵƐ ƚŽ ŵĞ ƚŚĂƚ ƚŚĞ 'ŽǀĞƌŶŵĞŶƚ ŝƐ ƚƌǇŝŶŐ ƚŽ ƉƵůů loads of things away 
from the doctors, ĂƌĞŶ ?ƚ ƚŚĞǇ? Onto other people; nurse practitioners are prescribing 
drugs um and all that kind of thing. I mean you get doctors now that cannot take blood 
ďĞĐĂƵƐĞƚŚĞǇ ?ƌĞũƵƐƚŶŽƚƵƐĞĚƚŽĚŽŝŶŐŝƚ ? 
Patient interview 14 - 61yr F. Independent  
 
Patient responses were shaped by their previous understanding of what the pharmacist did. 
Participants viewed MURs as a means to manage minor concerns that could be resolved by 
speaking to the pharmacist. MURs were therefore perceived to have a role to play in saving 
'WƐ ? ƚŝŵĞ ĂŶĚ ƌĞĚƵĐŝŶŐ ƚŚĞŝƌ ǁŽƌŬůŽĂĚ ?In contrast to these views, a couple of patients 
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recognised the time constraints the pharmacist was already under. One respondent 
considered the potentially adverse impact MUR might have on the pharmacistƐ ? workload.   
  
ĞƚŚ P Q/ĚŽŶ ?ƚ ƚŚŝŶŬ ƚŚĞǇƐŚŽƵůĚďĞƉƵůůĞĚ ĨƌŽŵƚŚĞƌĞ ƚŽĚŽ ƚŚĂƚ ƐŽƌƚŽĨǁŽƌŬ ? ŝŶ ƚŚĂƚ
room, reviews, and then have to go back again. Because ƚŚĂƚ ?ƐƚŚĞir ũŽďŝƐŶ ?ƚŝƚ ?ƚĂďůĞƚƐ
ƉŚĂƌŵĂĐŝƐƚƐ QƐŽŵĞƚŝŵĞƐ ƚŚĂƚ ?ƐŚŽǁŵŝƐƚĂŬĞƐĂƌĞŵĂĚĞ ? ƚŚĞǇ ?ƌĞ ƌƵƐŚĞĚ QWŚĂƌŵĂĐŝƐƚ ?Ɛ
ũŽď ŝƐ ƚĂďůĞƚƐ ? ŵĞĚŝĐŝŶĞƐ ĂŶĚ ƚŚĂƚ ?Ɛ ƚŚĞŝƌ ũŽď ? ĂŶĚ Ă ƌĞǀŝĞǁ ƐŚŽƵůĚ ďĞǁŝƚŚ Ă ĂŶŽƚŚĞƌ
person or with another pharmacist that knows what they ?ƌĞĚŽŝŶŐ ?EŽƚĚŽŝŶŐƚǁŽũŽďƐ
at once. 
Patient interview 3 - 76yr F. Multiple 
 
As the extract illustrates Beth had concerns over the perceived additional task the pharmacist 
was required to undertake. The following section explores misunderstandings surrounding the 
MUR service.  
  
6.4.3.3 Misunderstanding the purpose of MUR 
It emerged from the interviews that not all patients had been fully informed about what the 
purpose of the MUR service were. There were a range of misunderstandings. Some patients 
perceived that by agreeing to the invitation by the pharmacy staff that they were helping the 
pharmacy or pharmacist in some way: 
 
ZĞƐĞĂƌĐŚĞƌ P^ŽŽŶ^ĂƚƵƌĚĂǇǇŽƵĐĂŵĞŝŶ ?ƉƌĞƐƵŵĂďůǇǇŽƵǁĞƌ Ŷ ?ƚĞǆƉĞĐƚŝŶŐĂƌĞǀŝĞǁĂƚ
all? 
Terrie: No absolutely not [laughs], I was ŝŶĂŚƵƌƌǇĂĐƚƵĂůůǇ Q/ĚŝĚŶ ?ƚŵĞŶƚŝŽŶŝƚ ?ďĞĐĂƵƐĞ
/ƚŚŽƵŐŚƚŝĨ/ĐĂŶďĞŚĞůƉĨƵůǁŝƚŚƚŚŝƐ Qŝƚ ?ƐŽďǀŝŽƵƐůǇŵŽƌĞŝŵƉŽƌƚĂŶƚƚŚĂŶ ǁŚĂƚ/ ?ǀĞŐŽƚ
ƉůĂŶŶĞĚ Q 
Patient interview 3 - 54yr F. Independent 
 
ZĞƐĞĂƌĐŚĞƌ P Qo you feel that the review is therefore necessary for people like 
ǇŽƵƌƐĞůĨ Q ? 
WƌŝŵƌŽƐĞ PtĞůů /ĚŝĚŶ ?ƚƚŚŝŶŬƚŚĂƚƚŚĞƌĞǀŝĞǁǁĂƐƵŚspecifically to help me anyway. I 
felt that the review was to also have the pharmacist put in the picture and kind of 
involved with my on-going treatment. So to me although I'm up to speed and informed 
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ǁŝƚŚǁŚĂƚ ?ƐŚĂƉƉĞŶŝŶŐǁŝƚŚŵǇƐĞůĨ ?/ĨĞůƚƚŚĂƚ/ǁĂƐŚĂƉƉǇƚŽĚŽƚŚĞŝŶƚĞƌǀŝĞǁĨŽƌƚŚĞ
benefit of the pharmacist. 
Patient interview 17 - 56yr F. Independent  
  
The deference felt for the pharmacist and the sense that they had been asked to undertake an 
MUR was a strong motivator for patients to take part in the review. Some patients perceived 
that undertaking the MUR would enable the pharmacist to be better informed about their 
medicines. This in turn would be useful if a subsequent problem about their medicines arose in 
the future. Pharmacists ? lack of tailored explanation as to the purpose of MURs meant that 
patients who were less able to understand remained confused after the consultation. Despite 
having had now two MURs, one patient enquired during the interview what the purpose of the 
DhZǁĂƐĂŶĚǁŚǇŝƚǁĂƐďĞŝŶŐĚŽŶĞ ?,ĞĂůƐŽƋƵĞƌŝĞĚŝĨŝƚǁĂƐĂŶ “annual thing ?: 
 
Morris: I'm just wondering what ?Ɛ ƚŚĞ ƉƵƌƉŽƐĞ ŽĨ ŝƚ ? ǁŚǇ ŝƚ ?Ɛ ďĞŝŶŐ ĚŽŶĞ ? ĞĐĂƵƐĞ /
suppose the GP knows all about it, ŝƚ ?ƐĚŽŶĞǁŝƚŚƚŚĞŝƌƐƵƉƉŽƌƚ Q 
Patient interview 11 - 79yr M. Independent 
 
 ĨƵƌƚŚĞƌ ƉĂƚŝĞŶƚ ĚĞƐĐƌŝďĞĚ ŚŝƐ DhZ ĂƐ ĂŶ  “interview on a research programme ? ƐƵŐŐĞƐƚŝŶŐ
that the recruitment process used for this study appeared to have shaped to how he perceived 
the purpose of his MUR. The following section will further explore how patients contextualised 
their MUR in relation to other health services they received.    
 
6.4.4 ŽŶƚĞǆƚƵĂůŝƐŝŶŐƚŚĞDhZǁŝƚŚŝŶƚŚĞƉĂƚŝĞŶƚ ?Ɛwider health care  
Patient interviews aimed to better understand how patients contextualised the MUR within 
their existing framework of care. The following three sections will explore this in more depth. 
Patients were asked about other health professionals that were involved in their health care. 
As mentioned, all patients perceived their GP to be the main authority over their medications 
and considered that problems with their medications would be best resolved by talking to 
them rather than with the pharmacist during an MUR: 
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ZĞƐĞĂƌĐŚĞƌ P Q ?ǁŚĂƚ ?ŝĨǇŽƵ had a side effect with your medication? 
ĚĂŵ P/ ?ĚŐŽĂŶĚƐĞĞƚŚĞĚŽĐƚŽƌ Q/ǁŽƵůĚŶ ?ƚĂƐŬƚŚĞƐĞ QŽŶůǇďĞĐĂƵƐĞŝŶƌĂŶŬŝŶŐ QƚŚĂƚ ?Ɛ
ǁŚĂƚŚĞ ?Ɛ ?ĚŽĐƚŽƌ ?ƚŚĞƌĞĨŽƌ Q 
Patient interview 6 - 79yr M. Independent   
 
:ŝůů P Q/ĨŝƚŝƐĂƌĞĂůĐŽŶĐĞƌŶƚŚĞŶ/ǁŽƵůĚŐŽďĂĐŬƚŽ the GP. I mean I do go back to the 
'WĞǀĞƌǇ ƐŽŽĨƚĞŶ ĨŽƌĂƌĞǀŝĞǁŽĨŵǇƚĂďůĞƚƐ ? /ĚŽĚŽ ƚŚĂƚ ? / ?ǀĞŐŽƚĂŶŽƚŚĞƌŽŶĞŶĞǆƚ
ǁĞĞŬ Q 
   Patient interview 8 - 76 yr F. Multiple 
 
Patients viewed the pharmacist as subordinate to the GP. This meant that when a patient 
considered a problem to be more than a minor practical issue, it was reserved for discussion 
with their GP who had originally prescribed the medicine. Most patients saw their GP 
periodically and revealed they took the opportunity to resolve any medication issues then. 
Patients were asked to discuss other medication review activity they had elsewhere. The 
doctor review was most commonly cited. In contrast to the MUR that focused solely on 
medicines, the review with the doctor included measuring the patieŶƚ ?ƐďůŽŽĚƉƌĞƐƐƵƌĞ ?ďůŽŽĚ
ƚĞƐƚƐ ĂŶĚ ǁĞŝŐŚƚ ? DŽƐƚ ƉĂƚŝĞŶƚƐ ? ĂĐĐŽƵŶƚƐwere not specific about how the doctor actually 
reviewed their medicines. Doctors were reported to enquire about how they were getting on 
with medications, if they had any problems and informed patients about whether medications 
were ƐƚŝůůŶĞĞĚĞĚŽƌǁŚĞƚŚĞƌƚŚĞǇĐŽƵůĚďĞ  “dropped off ? ?dŚĞĚŽĐƚŽƌǁĂƐƚŚĞƌĞĨŽƌĞƐĞĞŶĂƐ
someone who understood which medicines were needed and which were not. In comparison, 
MURs were seen by patients to be specific only to medicines: 
 
ZĞƐĞĂƌĐŚĞƌ P  QŚŽǁ ?ƐƚŚĞƌĞǀŝĞǁƚŚĂƚǇŽƵŚĂĚŽŶdŚƵƌƐĚĂǇĚŝĨĨĞƌĞŶƚĨƌŽŵƚŚĞŽŶĞƚŚĂƚ
you have from your doctor? 
ŶŶĂďĞů P tĞůů / ŵĞĂŶ ŚĞ  ?'W ? ĚŽĞƐŶ ?ƚ ƵƐƵĂůůǇ ŐŽ ƚŚƌŽƵŐŚ ĞĂĐŚ ŵĞĚŝĐĂƚŝŽŶ
ŝŶĚŝǀŝĚƵĂůůǇ QŝƚƚĞŶĚƐƚŽďĞ ŝĨ /ƐĂǇ  ‘ǁŚĂƚĚŽǇŽƵ ƚŚŝŶŬĂďŽƵƚƐƵĐŚĂŶĚƐƵĐŚ ?ƚŚĞŶŚĞ ?ůů
look at it. But otherwise I think on the whole doctors probably are a bit busy and tend 
ƚŽŶŽƚƌŽĐŬƚŚĞďŽĂƚĚŽƚŚĞǇ QŝĨŝƚ ?ƐŶŽƚďƌŽŬĞŶǇŽƵĚŽŶ ?ƚŵĞŶĚŝƚŬŝŶĚŽĨƚŚŝŶŐ QŚĂǀŝŶŐ
ƐĂŝĚƚŚĂƚ/ ?ǀĞŐŽƚĂŐŽŽĚĚŽĐƚŽƌǁŚŽǁŝůůĚŝƐĐƵƐƐĂŶǇƚŚŝŶŐǁŝƚŚŵĞ Q 
Patient interview 14 - 61yr F. Independent 
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/ƌŝƐ P  QƚŚĞǇ ?ůů  ?'W ? ůŽŽŬĂƚ ŝƚĂŶĚ ŝĨ  Q/ĚŽŶ ?ƚƵƐĞ ŝƚĂŶǇ ŵŽƌĞŽƌĚŽŶ ?ƚŶĞĞĚŝƚĂŶǇŵŽƌĞ
ƚŚĞǇ ?ůůƚĂŬĞŝƚŽĨĨ ?^ŽƚŚĞǇ ?ůůůŽŽŬĂƚǇŽƵƌƌĞƉĞĂƚƉƌĞƐĐƌŝƉƚŝŽŶĂŶĚůŽŽŬŝĨǇŽƵĚŽĂĐƚƵĂůůǇ
neeĚƚŚĞƚŚŝŶŐƐƚŚĂƚǇŽƵ ?ƌĞƚĂŬŝŶŐ Q 
ZĞƐĞĂƌĐŚĞƌ P QƚŚĞƌĞǀŝĞǁƚŚĂƚǇŽƵŚĂĚǁŝƚŚƚŚĞƉŚĂƌŵĂĐŝƐƚŝƚǁĂƐƐůŝŐŚƚůǇĚŝĨĨĞƌĞŶƚ ? 
Iris: Yes, in as much as how you were taking it and when you were taking it. Any 
ƋƵĞƐƚŝŽŶƐ ĂŶĚ ƐŚĞ ǁŽƵůĚ QƌĞĨĞƌ ǇŽƵ ďĂĐŬ ƚŽ ǇŽƵƌ 'W ŽƌƐŽŵĞthing if she thought 
necessary.  
Patient interview 7- 65yr F. Multiple    
 
With GP medication reviews the onus was usually on patients to report any problems. This was 
not seen as an issue as most felt that they were adequately informed about the medication 
which had been prescribed long-term. Patients were accustomed to seeking help with 
prescribed medicines from their GP. When asked if the MUR had been useful, patients tended 
ƚŽ ƵƐĞ ƚŚĞ ƚĞƌŵƐ  “satisfying ? Žƌ  “interesting ?.  Some patients described how talking to the 
pharmacist allowed them to articulate their medicine issues. They therefore felt better 
prepared to discuss matters with their GP: 
 
ZĞƐĞĂƌĐŚĞƌ P Q,ow useful did you feel the review was? 
Nick: Well, a review like that is always useful you might tŚŝŶŬŝŶŝƚŝĂůůǇ ‘ǁĞůůƚŚĂƚǁĂƐĂ
ǁĂƐƚĞ ŽĨ ƚŝŵĞ ? ? Ƶƚ / ĚŽŶ ?ƚ ƚŚŝŶŬ ŝƚ ŝƐ ? ďĞĐĂƵƐĞ ŝƚ ũƵƐƚƌĞĨƌĞƐŚĞƐ ǇŽƵƌ ŵŝŶĚ QĞĐĂƵƐĞ
ƚŚĞǇ ?ƌĞ ?'WƐ ?ĂůǁĂǇƐďƵƐǇǁĂƚĐŚŝŶŐƚŚĞĐůŽĐŬ QƐŽ/ĚŽŶ ?ƚůŝŬĞƚĂŬŝŶŐŵƵĐŚƚŝŵĞƵƉƚŚĞƌĞ ?
I ask what I believe are vital questions. I mean the cholesterol, dry mouth, tired legs, 
the things that really hit me hard and beyond that I try not to take any time up. So 
coming down here, sitting down as I'm doing with you now is useful, very useful. 
Patient interview 13 - 80yr M. Multiple   
 
Researcheƌ P Q/ ?ŵŶŽƚĞŶƚŝƌĞůǇƐƵƌĞǁŚĞƚŚĞƌŝƚŝƐƉŽƐƐŝďůĞǁŝƚŚŝŶƚŚĞƐŚŽƌƚƉĞƌŝŽĚŽĨƚŝŵĞ
 ?DhZ ? QƚŽƌĞƐŽůǀĞƚŚĞĐŽŵƉůĞǆŝƐƐƵĞƐ ? 
WŽůůǇ PWƌŽďĂďůǇŶŽƚďƵƚŝƚ ?ƐŐŽŝŶŐƚŽŵĂŬĞǇŽƵƚŚŝŶŬĂďŽƵƚŝƚ ?^ŽǁŚĞŶǇŽƵƚŽƐĞĞƚŚĞ'W
ǇŽƵ ?ƌĞŶŽƚƐƚĂƌƚŝŶŐĂŐĂŝŶƌĞĂůůǇĨƌŽŵƐĐƌĂƚĐŚ ?zŽƵ ?ǀĞďĞĞŶŵĂĚĞƚŽƐŽƌƚŽĨƚŚŝŶŬĂďŽƵƚŝƚ
ŝŶƚŚĞĨŝƌƐƚƉůĂĐĞ ?^ŽǇŽƵŬŶŽǁŝƚ ?ƐƉƌŽďĂďůǇĂŐŽŽĚŝ ĞĂ ? 
Patient interview 15 - 58yr F. Independent  
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As was discussed in section 6.3.3 the pharmacist was seen as a knowledgeable expert on 
medicines and able to provide patients with support and reassurance about their minor 
medication or health related problems. However, a few patients did not consider the MUR had 
been useful:  
 
ZĞƐĞĂƌĐŚĞƌ P Qid you find any part of it, you know, quite useful or not? 
Robert: Well, /ƚŚŝŶŬŝƚǁĂƐŝŶƚĞƌĞƐƚŝŶŐƌĂƚŚĞƌƚŚĂŶƵƐĞĨƵůĂŶĚŚĂǀŝŶŐƐĂŝĚ/ĚŝĚŶ ?ƚĨŝŶĚŝƚ
ƵƐĞĨƵůĨŽƌŵǇƐĞůĨƵŵ/ ?ŵƋƵŝƚĞƐƵƌĞƚŚĂƚŝƚǁŽƵůĚďĞƵƐĞĨƵůĨŽƌŽƚŚĞƌƉĂƚŝĞŶƚƐ ?zŽƵŬŶŽǁ ?
without the same sort of background [retired nurse].   
  Patient interview 1 - 79yr M. Multiple 
 
Summer: I think the questions are very elementary and sort of might be geared 
ƚŽǁĂƌĚƐƐŽŵĞŽŶĞŽůĚĞƌƚŚĂŶŵĞ Q/ĨĞůƚůŝŬĞƐĂǇŝŶŐ ‘ŽĨĐŽƵƌƐĞ/ĐĂŶƐǁĂůůŽǁƚŚŝŶŐƐ ? ?ǇŽƵ
know, hello! 
Patient interview 12- 62yr F. Multiple 
 
As these extracts illustrate, some patients felt that the MUR was not necessary for them 
personally as they believed they could effectively manage their medicines and felt that they 
could access help should they need it. However, they recognised that the MUR could be useful 
for others. Older patients, those who were confused and those who would not ask for advice 
were seen to be those who would benefit from the service. Nearly all patients said that they 
would wait to be asked for their next MUR rather than ask for an MUR themselves as the 
pharmacist would know when they needed the next review. A few patients did comment that 
they would ask should they feel the need: 
 
Researcher: Would you ask for an MUR or would you wait until you were asked? 
Molly: No, I would wait until I was approached,  
Researcher: Why is that? 
Molly: Well unless there is any other specific reason, you know why I should want one 
ƐŽŽŶĞƌĂŶĚĂƚƚŚĞŵŽŵĞŶƚ ?/ĐŽƵůĚŶ ?ƚƐĞĞƚŚĂƚ ?^ŽǇĞĂŚ, I would wait to be approached, 
I would willingly come, yeah. 
Patient interview 6 - 76 yr F. Multiple    
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Eve: Well, I would ǁĂŝƚƚŽďĞĂƐŬĞĚďĞĐĂƵƐĞƚŚĞǇ ?ůůŬŶŽǁǁŚĞŶŝƚ ?ƐƐƵŝƚĂďůĞǁŽŶ ?ƚƚŚĞǇ ?
but I would ask if I needed to, yes. 
Patient interview 5 - 75yr F. Independent   
 
Patients contextualised the MUR as a pharmacist-initiated activity that was interesting and 
provided reassurance that they were doing the right thing. Although this consultation was 
more focused on the medicines than the reviews received from the GP, they were only seen to 
potentially resolve minor practical issues of medicine taking. Only the GP prescriber was seen 
as having the mandate to add, delete or make necessary changes to prescribed medicines. In 
the following section I further explore patient views on professional boundaries.         
 
6.4.5 Professional boundaries  
Several patients expressed concerns that the MUR could potentially cause tension between 
the pharmacist and the GP and were wary of the potential conflict that could arise between 
them:  
 
ĚĂŵ PtĞůů/ĂůǁĂǇƐƚŚŝŶŬƚŚĞƌĞ ?ƐĂĐĞƌƚĂŝŶĂŵŽƵŶƚŽĨĐŽŵƉĞƚŝƚŝŽŶŝƐŶ ?ƚƚŚĞƌĞ ?ĞĐĂƵƐĞ
ǁŚĞƚŚĞƌ ǇŽƵ ůŝŬĞ ŝƚ Žƌ ŶŽƚ ǇŽƵ ?ƌĞ Ă ƉŚĂƌŵĂĐŝƐƚ ĂŶĚ ŚĞ ?Ɛ ƚŚĞ ĚŽĐƚŽƌ ƐŽ ĞǀĞƌǇďŽĚǇ ?Ɛ
ůŽŽŬŝŶŐ ĂĨƚĞƌ ƚŚĞŝƌ ŽǁŶ ůŝƚƚůĞ ƵŚ ĚŽŵĂŝŶ QǇŽƵ ?ƌĞ Ă ďŝƚ ŽĨ Ă ƚŚƌĞĂƚ ƚŽ Ă ĚŽĐƚŽƌ ĂƌĞŶ ?ƚ
ǇŽƵ ? Q 
Patient interview 6 - 79yr M. Independent  
 
ƐŚůĞǇ P / ĚŽŶ ?ƚ ƚŚink they [GPs] like it, outside interference...being from a novice, a 
ƉŚĂƌŵĂĐŝƐƚŽƌĂŶǇďŽĚǇĞůƐĞ Q 
Researcher: They actually communicate with the GP, if there were any actions. 
Ashley: So he will know that I went in last Wednesday and talked to Jane 
[pharmaĐŝƐƚ ? Q ? 
ZĞƐĞĂƌĐŚĞƌ P Q/ĚŽŶ ?ƚŬŶŽǁŝĨ:ĂŶĞŝƐŐŽŝŶŐƚŽƐĞŶĚŝƚŽĨĨ ?DhZĨŽƌŵ ? QďƵƚŽƚŚĞƌǁŝƐĞǇĞƐ
they usually send it off if there are actions. 
ƐŚůĞǇ PZŝŐŚƚ ?ůĂƵŐŚƐ ?/ ?ůůŐĞƚĂĨƵĐŬŝŶ ?ďŽůůŽĐŬŝŶ ?ŽĨĨŚŝŵŶĞǆƚƚŝŵĞƚŚĞŶ ? 
Patient interview 14 - 67yr M. Multiple    
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Ashley was sceptical about how influential any pharmacist suggestions to his GP may have 
been. When probed further, he was also surprised to hear that the GP may have been 
informed about the MUR, having not been told ƚŚĂƚƚŚŝƐŵĂǇŽĐĐƵƌ ?ƐŚůĞǇ ?ƐƌĞsponse was one 
of concern ƚŚĂƚ ŚĞ ǁŽƵůĚ ŐĞƚ  ‘ƚŽůĚ ŽĨĨ ? ďǇ ŚŝƐ 'W ? ůƚŚŽƵŐŚ ƐŚůĞǇ ǁĂƐ ƚŚĞ ŵŽƐƚ explicit, 
several patients indicated that they had concerns over professional boundaries and wanted to 
ensure that the relationship between their GP was not jeopardised by the MUR. In the 
following section, I explore whether patient views of the pharmacist changed as a result of 
having had an MUR.  
 
6.4.6 Opinions of the pharmacist   
Most patients felt the MUR did not significantly affect their opinion of what the pharmacist did 
or encourage them to use the pharmacist more. They were already aware that they could 
access the pharmacist if they had any concerns about their medicines. Furthermore, fieldwork 
observations revealed that the patients who were invited for an MUR already tended to have 
good relationships with the pharmacy staff. A couple of patients commented that the MUR 
allowed the pharmacist, themselves, ƚŽ ůĞĂƌŶ ŵŽƌĞ ĂďŽƵƚ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞƐ ĂŶĚ ƚŚĞŝƌ
medical conditions. Their preconceived notions of the pharmacist being accessible, 
knowledgeable and available to treat minor ailments were unchanged: 
 
ZĞƐĞĂƌĐŚĞƌ P Q,as it [MURs] affected your opinion of what the pharmacist does?  
ůŝƐŽŶ PEŽƚƌĞĂůůǇ ?ĞĐĂƵƐĞ/ĂůǁĂǇƐƚŚŽƵŐŚƚƚŚĞǇ ?ƌĞƌĞĂůůǇǁĞůůƚƌĂŝŶĞĚĂŶĚŬnew what 
they were doing. 
Patient interview 7 - 46yr F. Independent  
 
ZĞƐĞĂƌĐŚĞƌ P  Qthen you had the review did it encourage you to use the pharmacist 
more or did it make you more aware of the things that you can ask them?  
Primrose: I knew that anyway. Like with my sonƐ ?ŝĨƚŚĞǇ ?ǀĞŐŽƚƐŽŵĞƚŚŝŶŐǁƌŽŶŐĂŶĚ/
ĚŝĚŶ ?ƚƚŚŝŶŬŝƚǁĂƐĂĚŽĐƚŽƌƚŚŝŶŐ ?ƚŚĞŶ/ ?ĚƐĂǇ ‘ǁĞ ?ůůŐŽƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚĂŶĚĐŚĂƚǁŝƚŚ
ƚŚĞŵĂŶĚƐĞĞǁŚĂƚƚŚĞǇƚŚŝŶŬ ? ? 
Patient interview 17 - 56yr F. Independent   
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However, one patient felt that the MUR was a routine and basic activity that could be 
performed by less well qualified staff: 
 
ZĞƐĞĂƌĐŚĞƌ P Q,ŽǁƐƵŝƚĞĚĂƌĞƚŚĞǇ ?ƉŚĂƌŵĂĐŝƐƚƐ ?ĂƚƉĞƌĨŽƌŵŝŶŐƚŚĞƐĞƌǀŝĐĞ Q ? 
ŽůŝŶ P Q/ƚ ?ƐĂĐƚƵĂůůǇĂǁĂƐƚĞŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚ ?Ɛ time. Any member of staff could have 
dŽŶĞƚŚĂƚ ?DhZ ? Q/ƚ ?ƐďĂƐŝĐĂůůǇƋƵĞƐƚŝŽŶƐĂŶĚĂŶƐǁĞƌƐ ?/ĨƚŚĞƌĞǁĂƐĂŶǇƚŚŝŶŐƚĞĐŚŶŝĐĂů
required the person doing the review could always go back and ask the 
ƉŚĂƌŵĂĐŝƐƚ QƚŚĞƉŚĂƌŵĂĐŝƐƚƐŐŽƚo uni, for how many years is it? They learn something 
and then basicalůǇ ŝƚ ?ƐĂƉĂƉĞƌƉƵƐŚĞƌ ?Ɛ ũŽď QǇĞĂŚƐŽ ŝƚ ?ƐƋƵŝƚĞĂǁĂƐƚĞĂŶĚ/ƚŚŝŶŬ ŝƚ ?Ɛ
quite an insult to them [laugh].     
Patient interview 12 - 50yr M. Independent   
 
ŽůŝŶ ?Ɛ ĂĐĐŽƵŶƚ ŽĨ ƚŚĞ DhZ ǁĂƐ ƋƵŝƚĞ Ă ƚĞůůŝŶŐ ŝŶĚŝĐĂƚŝŽŶ ŽĨ ƚŚĞ ǀĞƌǇ ĨƵŶĐƚŝŽŶĂů ĂŶĚ
perfunctory nature of the MUR activity.  
 
dŚĞ ƉƌĞǀŝŽƵƐ ƐĞĐƚŝŽŶƐ ŚĂǀĞ ĚĞƐĐƌŝďĞĚ ƚŚĞ DhZ ĨƌŽŵ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƉĞƌƐƉĞĐƚŝǀĞ ? /ƚ ĞŵĞƌŐĞĚ
from the early patient interviews that in describing their MUR, there appeared to be a 
mismatch between what was being reportedly being achieved and the policy aims of the 
service. In the following section, I report on the findings concerning the extent to which 
patient accounts of their MUR match the intended policy aims of the service. 
 
6.5 The MUR and its aims 
Below, I compare what patients reported in their interviews with the four underlying policy 
aims for the service and then with the ŽǀĞƌĂůůĂŝŵŽĨƚŚĞDhZƚŽŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞ
and use of medicines. The common features between the stated aims do mean that in this 
analysis there is some overlap of the illustrative examples given. The following sections are 
examples from patient reports and are not an assessment of their behaviour. It is also 
important to note that this was a cross sectional study and patients were not followed-up to 
see if the pharmacists ?ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐŚĂĚďĞĞŶaccepted or rejected in the long-term or if 
ƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƵƐĞhad changed. Similarly, it is ŶŽƚŬŶŽǁŶǁŚĂƚĂĐƚŝŽŶƐ ƚŚĞƉĂƚŝĞŶƚ ?Ɛ'W
had made as a result of receiving notification that the patient had an MUR or if the MUR form 
had influenced their care in any way.  
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6.5.1 ƐƚĂďůŝƐŚŝŶŐ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ĂĐƚƵĂů ƵƐĞ ? ƵŶĚĞƌƐƚĂŶĚŝŶŐ ĂŶĚ
experience of taking their medicines   
Most patients, when asked, reported that they felt the pharmacist did manage to establish 
how they took their medicines: 
  
Researcher: Did you feel that the pharmacist really got down to how you actually use 
your medicines? 
Esther: Yes, I mean she was making sure I used them properly; she wanted to know 
why I needed to use them and how I used them. Yes, I thought she was very thorough. 
Patient interview 13 - 61yr F. Independent 
 
However, while discussing their experiences of the MUR, several patients mentioned 
medicines that they were using which had not been discussed during the MUR. The pharmacist 
therefore had not been able to establish a full list of all of ƚŚĞƉĂƚŝĞŶƚ ?ƐĐƵƌƌĞŶƚŵĞĚŝĐŝŶĞƐ. The 
reasons patients reported for this was either because they had not been given the opportunity 
to reveal all the medicines they were taking or they had forgotten to mention to the 
pharmacist at the time of the MUR:     
  
ŽŵĨŽƌƚ P  QdŚĞ ŝďƵƉƌŽĨĞŶŐĞů ĂŶĚ ƚŚĞ ŝďƵƉƌŽĨĞŶ ƚĂďůĞƚƐ ?/ ŵ / ŶŽƚ ƐƵƉƉŽƐĞĚ ƵƐĞ ƚŚĞŵ
together?...  
ZĞƐĞĂƌĐŚĞƌ PĞĐĂƵƐĞ/ĚŽŶ ?ƚƚŚŝŶŬǇŽƵŵĞŶƚŝŽŶĞĚƚŚĞŵƚŽ:ĂŶĞůĂƐƚǁĞĞŬ ? 
ŽŵĨŽƌƚ P /ĚŝĚŶ ?ƚ Q/ĚŝĚŶ ?ƚŵĞŶƚŝŽŶƚŚĂƚĂƚĂůů Qŝƚ ũƵƐƚƐůŝƉƉĞĚŵǇŵŝŶĚĂĐƚƵĂůůǇ Q I was 
ĐŽŶĐĞŶƚƌĂƚŝŶŐŽŶƐŽƌƚŽĨƚŚĞŽƚŚĞƌŽŶĞƐ ?ƋƵĞƐƚŝŽŶƐ ?ƌĂƚŚĞƌƚŚĂŶƚŚĂƚ Q 
   Patient interview 15 - 72yr F. Multiple   
 
Summer: Well I saw her two weeks ago and she gave me a [homeopathic] remedy at 
the time and well I'm always on a remedy really.  
ZĞƐĞĂƌĐŚĞƌ P&ŝŶĞ ?ďĞĐĂƵƐĞǇŽƵĚŝĚŶ ?ƚŵĞŶƚŝŽŶŝƚƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚ ? 
^ƵŵŵĞƌ P^ŚĞĚŝĚŶ ?ƚĂƐŬ ? 
Patient interview 12- 62yr F. Multiple 
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The MUR should involve a discussion of both prescribed and OTC medicines. As the above 
extract from Comfort ?Ɛ ŝŶƚĞƌǀŝĞǁillustrates, the failure of the pharmacist to determine a full 
list of prescribed and OTC medicines meant that the opportunity to resolve confusion over a 
medicine issue, in this case over taking two forms of the medicine ibuprofen, was lost. When 
patients were questioned further, a few revealed that the pharmacist had not, in fact, fully 
established their actual use of medicines. ŶŶĂďĞů ?Ɛ ŝŶƚĞƌǀŝĞǁ ƌĞǀĞĂůĞĚ ƚŚĂƚ ƐŚĞ ǁĂƐ ? Ăƚ ƚŚĞ
time, taking one of her medications differently to that mentioned to the pharmacist during the 
MUR. Her reluctance to mention this in the MUR stemmed from her concern that she may not 
ƉƌŽǀŝĚĞƚŚĞ ‘ĐŽƌƌĞĐƚĂŶƐǁĞƌ ?ƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚ ? 
 
ZĞƐĞĂƌĐŚĞƌ P  Q / ĐĂŶ ?ƚ ƌĞŵĞŵďĞƌ ǁŚĞƚŚĞƌ ǇŽƵ ĚŝĚ ƐĂǇ ǇŽƵreduced the dose [of the 
Colazide capsules]. 
ŶŶĂďĞů P / ƉƌŽďĂďůǇ ĚŝĚŶ ?ƚ ƐĂǇ ĂŶǇƚŚŝŶŐ ďĞĐĂƵƐĞ / ?ŵ ŶŽƚƐƵƌĞ ǁŚĂƚ ŝƚ ƐĂǇƐ ŽŶ ƚŚĞ
prescription [laughs]. This is ǁŚǇƉĞŽƉůĞƐŚŽƵůĚĐŽŵĞŝƐŶ ?ƚŝƚ ?[Laughs ? ?'ĞƚŝƚƐŽƌƚĞĚ Q 
ZĞƐĞĂƌĐŚĞƌ P Qtas there any reason for that? 
ŶŶĂďĞů P Qƚo be honest, /ŚŽŶĞƐƚůǇĚŝĚŶ ?ƚŬŶŽǁǁŚĂƚĚŽƐĞ/ ?ĚŐŽƚŽŶƚŚĞƉƌĞƐĐƌŝƉƚŝŽŶ ? 
         Patient interview 14 - 61yr F. Independent   
 
Other patients reported confusion or uncertainty when questioned about medicines that had 
been discussed during the MUR. These instances indicated that the MUR did not serve its 
purpose to establish and then address issues about the patients understanding of their 
medicines: 
 
Researcher: The ramipril was for your... 
WŽůůǇ P /ƚ ?ƐƐŽŵĞƚŚŝŶŐƚŽĚŽǁŝƚŚŵǇŬŝĚŶĞǇƐ Q/ĚŽŶ ?ƚŬŶŽǁƋƵŝƚĞǁŚĂƚ ŝƚ ŝƐ Q/ƐƵƉƉŽƐĞ/
ŽƵŐŚƚƚŽƐŽƌƚŽĨĨŝŶĚŽƵƚĂďŝƚŵŽƌĞǁŚĂƚŝƚ ?ƐĂďŽƵƚ Q/ŵĞĂŶŝƚŵŝŐŚƚŚĂǀĞďĞĞŶŶŝĐĞůĂƐƚ
ǁĞĞŬǁŚĞŶ/ƐŽƌƚŽĨƐĂŝĚ ?/ĚŽŶ ?ƚƋƵŝƚĞŬŶŽǁ QĂŶĚƐŚĞ ĂĚďĞĞŶĂďůĞƚŽƐĂǇ ‘ƚŚŝƐŝƐǁŚǇ ? ?
At the end of the day... they don ?ƚŚĂǀĞĂƐŵƵĐŚƚƌĂŝŶŝŶŐĂƐƚŚĞĚŽĐƚŽƌƐĚŽƚŚĞǇ Q/ĐĂŶ ?ƚ
ƌĞĂůůǇƌĞĂůŝƐƚŝĐĂůůǇĞǆƉĞĐƚƚŚĞŵƚŽŬŶŽǁĞǀĞƌǇƐŝŶŐůĞŵĞĚŝĐŝŶĞƚŚĂƚ ?ƐĚŝƐƉĞŶƐĞĚ Q 
Patient interview 15 - 58yr F. Independent 
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ZĞƐĞĂƌĐŚĞƌ P Qan you remember what was discussed at all? 
Iris: Well um, I suƉƉŽƐĞƐŚĞĂƐŬĞĚŵĞ ?ǁĞůů/ĚŽŶ ?ƚƌĞĂůůǇŬŶŽǁ ?tĞǁĞŶƚƚŚƌŽƵŐŚĞĂĐŚ
medicine and I sort of told her when I was taking these tablets and um she said that 
was right for the thyroxine. Because otherwise if you took them after food, did she said 
it would block calcium or something? 
Patient interview 7- 65yr F. Multiple 
 
The above extracts show that there remained significant confusion with some patients about 
certain medicines after the MUR. The pharmacist therefore did not identify and resolved these 
particular concerns that patients had with their medicines during the MUR. This is further 
explored in the following section. 
 
6.5.2 Identifying, discussing and resolving poor or ineffective use of 
their medicines 
There was little evidence to suggest that MURs had improved patientƐ ? adherence to their 
medicines. This was because there were few examples where the pharmacist identified a 
problem concerning ƉĂƚŝĞŶƚƐ ?ineffective use of medicines. In a few instances not all of the 
patients ? concerns about their medicines had been identified during the MUR:    
 
DŽƌƌŝƐ P  Q / Ăŵ Ă ůŝƚƚůĞ ďŝƚ ĐŽŶĐĞƌŶĞĚ ŝĨ / ĚŽŶ ?ƚ ŐĞƚ ŵǇ ƐƵůƉŚĂƐĂůĂǌŝŶĞ Q / ĚŽŶ ?ƚ ŬŶŽǁ
ǁŚĂƚ ƚŚĞ ƌĂŶŐĞ ŝƐ QǁŚŝůƐƚ / ǁĂƐ ŽŶ ŚŽůŝĚĂǇ ? ǁĞ ǁĞƌĞ ŽŶ ĨƵŶŶǇ ĚŝĞƚĂƌǇ ĐŚĂŶŐĞƐ ? /ƚ ?Ɛ
alright in the morning after breakfast, go back up to your room and take your tablets 
ďƵƚ QŝŶ ƚŚĞĞǀĞŶŝŶŐ /ŵŝŐŚƚŐŽŽƵƚĂŶĚŚĂǀĞĂŵĞĂů QĂŶĚ ƚŚĞ ƚŝŵĞǇŽƵŐĞƚďĂĐŬ ŝƚ ?s 
bedtime, ŝƚ ?ƐƚŽŽůĂƚĞ ? 
ZĞƐĞĂƌĐŚĞƌ P  QŽ ǇŽƵ ƚŚŝŶŬ ƚŚĂƚ ǁŽƵůĚ ďĞ ƚŚĞ ƐŽƌƚ ŽĨ ƚŚŝŶŐƐƚŚĂƚ ǇŽƵ ?Ě ůŝŬĞ ƚŽ ŚĂǀĞ
discussed with the pharmacist at all or would you mention it to the doctor? 
DŽƌƌŝƐ P tĞůů / ŚĂǀĞŶ ?ƚ ƌĞĂůůǇ Ƶŵ ƚŚŽƵŐŚƚ ĂďŽƵƚ ŝƚ ďĞĐĂƵƐĞ ŵǇ ǁŝĨĞ ƵƐƵĂůůǇ ƐĂǇƐ  “oh 
ǇŽƵ ?ĚďĞĂůƌŝŐŚƚ ?so I say  “OK ? [laughter]. 
Patient interview 11 - 79yr M. Independent   
 
With the pharmacist focusing solely on current use of medicines, wider patient concerns as 
described by Morris above, were not identified and so were not resolved. As indicated in 
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Chapter Five, the format and structured manner in which the MUR was performed restricted 
the scope to identify and address wider patient medication issues. When patients did reveal 
instances where they were non-adherent to their medicine, the pharmacist typically handled 
this by referring the patient back to the GP or other health professional: 
 
DŽǇĂ P QzŽƵƐĞĞŵǇĨƌƵƐĞŵŝĚĞ Q/ƚŚŽƵŐŚƚǁĞůů/ĚŽŶ ?ƚŐĞƚĂŶǇƐǁĞůůŝŶŐŽĨŵǇĂŶŬůĞƐƐŽ
do I need it ĞǀĞƌǇĚĂǇ ?^Ž ?/ŐĞƚĂďŝƚŶĂƵŐŚƚǇĂŶĚ/ĚŽŶ ?ƚƚĂŬĞƚŚĞŵĞǀĞƌǇĚĂǇ ?ŶĚƐŽ
ŽĨĐŽƵƌƐĞƚŚĞƉŚĂƌŵĂĐŝƐƚŐŽƚŽŶƚŽŵĞĂŶĚƐŽ/ ?ǀĞŐŽƚƚŽƚĞůůƚŚĞĚŽĐƚŽƌ QǁŚĞƚŚĞƌŝƚŝƐ
something I should ďĞƚĂŬŝŶŐĞǀĞƌǇĚĂǇ Q 
Researcher: Ok, would you have discussed it with the doctor if the ƉŚĂƌŵĂĐŝƐƚŚĂĚŶ ?ƚ
mentioned it? 
DŽǇĂ PEŽ ?ŶŽ/ ?ĚƉƌŽďĂďůǇǁŽƵůĚŶ ?ƚ Q/ŵŝŐŚƚŚĂǀĞƚŚŽƵŐŚƚĂďŽƵƚŝƚĂŶĚƚŚŽƵŐŚƚǁĞůů
better not say anything else because I might not be ĚŽŝŶŐƚŚĞƌŝŐŚƚƚŚŝŶŐ ?ůĂƵŐŚƐ ? QďƵƚ
/ǁŝůůŵĞŶƚŝŽŶŝƚ ?/ ?ůůŚĂǀĞƚŽďĞĐĂƵƐĞƚŚĂƚĨŽƌŵƐŐŽŶĞƚŽŚŝŵ ?ůĂƵŐŚƚĞƌ ? ? 
Patient interview 10 - 79yr F. Independent   
 
Having revealed to the pharmacist that she was taking her furosemide tablets infrequently, 
Moya described a conventional ƌĞƐƉŽŶƐĞĨƌŽŵƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƚŚĞƉŚĂƌŵĂĐŝƐƚŚĂĚ  “got onto 
ŵĞ ĂŶĚ ƐŽ / ?ǀĞ ŐŽƚ ƚŽ ƚĞůů ƚŚĞ ĚŽĐƚŽƌ ? ? DhZs have been described as a concordance-based 
review (Clyne et al 2008; PSNC 2009) ? ,ŽǁĞǀĞƌ ? ĂƐ DŽǇĂ ?Ɛextract illustrates, the approach 
taken by pharmacists when patients deviated from their prescribed regimens was one 
motivated by professional desires to ensure patients adhered to thĞƉƌĞƐĐƌŝďĞƌƐ ?ŝŶƐƚƌƵĐƚŝŽŶƐ ? 
The following section explores how well the MUR identified and resolved side effects and 
interactions with medicines.      
 
6.5.3 Identifying side effects and drug interactions that may affect 
patient compliance 
Patients were asked about side effects from the medication during the MUR. Most patients 
indicated that they had no side effects from their medicines. A couple of patients did report in 
their interview that their concerns about side effects had not been addressed. One patient 
described a significant side effect from a previously prescribed medicine which was not 
discussed during the MUR: 
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ůŝƐŽŶ P  QŝĨ / ŚĂĚ ƉƌŝŽƌ ǁĂƌŶŝŶŐ  ?ŽĨ ƚŚĞ DhZ ? Q/ ŵŝŐŚƚ ŚĂǀĞ ƐƉŽŬĞŶ ƚŽ ŚĞƌ ĂďŽƵƚ ƚŚĞ
prednisolone and the side effects of that and if she had any ideas about what I could 
ĚŽ Q/ ũƵƐƚ ŐĞƚ Ă ďƵǌǌ ŝŶ ŵǇ ŚĞĂĚ ƌĞĂůůǇ ĂŶĚ / ďĞĐŽŵĞ ĂƐ ŝĨ / ?ŵ ŚǇƉĞƌĂĐƚive.  I cannot 
ƐůĞĞƉŵƵĐŚĂƚŶŝŐŚƚ Q 
ZĞƐĞĂƌĐŚĞƌ P QtĞĚŝĚŶ ?ƚƚŽƵĐŚŽŶƚŚĂƚ ? 
ůŝƐŽŶ PEŽǁĞĚŝĚŶ ?ƚ ?ďĞĐĂƵƐĞ/ ?ŵŶŽƚŽŶŝƚĂƚƚŚĞŵŽŵĞŶƚǇŽƵƐĞĞ ?ƐŽ/ĚŝĚŶ ?ƚ ? 
Patient interview 7 - 46yr F. Independent   
 
Sometimes pharmacists were not able to provide effective reassurance to patients even when 
side effects had been identified: 
 
ZĞƐĞĂƌĐŚĞƌ P  Q/ ĚŽŶ ?ƚ ŬŶŽǁ ŝĨ ǇŽƵ ǁĂŶƚĞĚ ƚŽ ƐƉĞĂŬ ƚŽ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ĂďŽƵƚ ƚŚĂƚ
[reported side effect from citalopram]? 
<ŽŶŶŝĞ P Q/ ƉƌŽďĂďůǇ ǁŽƵůĚŶ ?ƚ ŚĂǀĞ ďƌŽƵŐŚƚ ƚŚĂƚ ƵƉ ŝĨ / ĚŝĚŶ ?ƚ ǁĂŶƚ Ɛome kind of 
ƌĞĂƐƐƵƌĂŶĐĞ Q/ŬŶŽǁƚŚŝŶŐƐŚĂǀĞƐŝĚĞĞĨĨĞĐƚƐĂŶĚŝƚ ?ƐŽŶůǇǁŚĞŶ/ŐĞƚƌĞĂůůǇƚŝƌĞĚ QďƵƚ
ǁŝƚŚƚŚŝƐŽŶĞŝĨ/ŐĞƚƌĞĂůůǇƚŝƌĞĚ/ĐĂŶ ?ƚĞǀĞŶŚŽůĚĂĐƵƉŽĨĐŽĨĨĞĞ Q/ǁĂƐũƵƐƚůŽŽŬŝŶŐĨŽƌ
a bit of reassurance, you know after a couple weeks that will go ?ƵŵǁŚŝĐŚ/ĚŝĚŶ ?ƚŐĞƚ ?
/ŵĞĂŶƚŚƌŽƵŐŚŶŽĨĂƵůƚŽĨŚĞƌŽǁŶƐŚĞŵŝŐŚƚŶŽƚŚĂǀĞŬŶŽǁŶƚŚĂƚ ?ƐǁŚĂƚ/ǁĂŶƚĞĚƚŽ
ŬŶŽǁ ?ƵƚǇĞĂŚ/ƚŚŝŶŬŝƚ ?ƐĂŐŽŽĚŽƉƉŽƌƚƵŶŝƚǇƚŽĚŝƐĐƵƐƐǇŽƵƌŵĞĚŝĐĂƚŝŽŶ ? 
Patient interview 11 - 40yr F. Multiple 
 
Konnie had reported a side effect from taking her antidepressant tablet. The pharmacist (Jane) 
responded during the MUR ďǇƐĂǇŝŶŐ P “/ƚƵƐƵĂůůǇƚĂŬĞƐĂĐŽƵƉůĞŽĨǁĞĞŬƐƚŽƐĞƚƚůĞ ?ƚŚĂƚ ?ƐƋƵŝƚĞ
interesting for me to hear that. Do you have any other problems? ?Konnie responded by saying 
that she wanted to give up smoking. As the extract above ŝůůƵƐƚƌĂƚĞƐ ? :ĂŶĞ ?Ɛ ƐǁŝĨƚ ƌĞƐƉŽŶƐĞ
during the MUR failed to fully explore and provide Konnie with a resolution on this concern.  
 
In another MUR, oŶĞŽĨƚŚĞƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐwas causing her to experience a dry mouth. 
dŚŝƐƉƌŽďůĞŵŚĂĚďĞĞŶĐŽŵŵƵŶŝĐĂƚĞĚƚŽƚŚĞƉĂƚŝĞŶƚ ?Ɛ'WƚŚƌŽƵŐŚƚŚĞDhZƉĂƉĞƌǁŽƌŬ on a 
previous MUR. The patient subsequently reported receiving an oral spray to alleviate her dry 
mouth:  
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ZĞƐĞĂƌĐŚĞƌ P Qid you bring up the situation with the dry mouth or did they [GP] have 
the report [MUR form]? 
:ŝůů PEŽ ?ƚŚĞǇŚĂĚƚŚĞƌĞƉŽƌƚ QƚŚĞŶ/ŐŽƚƚŚĞƐƉƌĂǇǇĞĂŚ ? ? ?/ĨǇŽƵŐĞƚŝƚ ŝŶƚŚĞƌŝŐŚƚƉůĂĐĞ
ǇŽƵ ?ƌĞĂůƌŝŐŚƚ ?ĂŶĚŝĨǇŽƵĚŽŶ ?ƚŝƚĚŽĞƐŶ ?ƚǁŽƌŬ ? 
    Patient interview 8 - 76 yr F. Multiple  
 
The issue with the dry mouth was raised again during her most recent MUR. The pharmacist 
accepted the patient ?Ɛ response that this was not troublesome and did not probe further or 
suggest a course of action. The pharmacist failed to enquire about the spray that had been 
prescribed as a result of the previous MUR as this was not on the patient ?Ɛ current list of 
medications. The opportunity to review or provide additional advice on the sprays use was 
therefore lost. During the interview the patient had said the issue of the dry mouth was not a 
problem for her but when questioned further, it emerged that she was managing this by 
drinking water. The lack of referral to the previous MUR records and the pharmacist ?Ɛ 
intention to move on meant that the discussion was not extended or the point followed up.   
  
6.5.4 Improving the clinical and cost effectiveness of prescribed 
medicines and reducing medicine wastage 
There were several instances where the pharmacist advised the patient to change the way 
they used a medicine. PatientƐ ? acceptance of such advice depended on their understanding of 
the direct advantage of such advice or as a route to avoid future harm: 
 
ĞƚŚ P  Q:ĂŶĞ ƐĂŝĚ ŶŽƚ ƚŽ ŬĞĞƉ ŝƚ ƚŽŽ ůŽŶŐ  ?dƌŝŵŽǀĂƚĞ ĐƌĞĂŵ ?ďĞĐĂƵƐĞ Qŝƚ ĐĂŶ ĐĂƵƐĞ Ă
ĨƵŶŐƵƐŽƌƐŽŵĞƚŚŝŶŐĚŝĚŶ ?ƚƐŚĞ ? ? ? ?
ResearĐŚĞƌ P QŝĨŝƚŽĐĐƵƌƌĞĚĂŐĂŝŶ ?ǁŽƵůĚǇŽƵŚĂǀĞƵƐĞĚƚŚĞĐƌĞĂŵ ? Q 
ĞƚŚ P/ǁŽƵůĚŚĂǀĞĚŽŶĞ Q/ƚŚŝŶŬƐŚĞƐĂŝĚƚŚĞĐƌĞĂŵĐĂŶĐĂƵƐĞƵŚĚŝĚƐŚĞƐĂǇĂĨƵŶŐƵƐ
ŽĨ ƐŽŵĞ ŬŝŶĚ Q/ ŵŝŐŚƚ ďĞ ƚŚŝŶŬŝŶŐ ƚŚĂƚ ?Ɛ ƚŚĞ ƐĂŵĞ ƚŚŝŶŐ ĂŶĚ ƉĞƌŚĂƉƐ ĐŽƵůĚ ďĞ
ƐŽŵĞƚŚŝŶŐĞůƐĞ QŝƚĐŽƵůĚĐĂƵƐĞŵŽƌe harm than good.   
Patient interview 3 - 76yr F. Multiple 
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<ŽŶŶŝĞ PĞĐĂƵƐĞƚŚĞǇƚĂŬĞƐƵĐŚĂůŽŶŐƚŝŵĞƚŽĚŝƐƐŽůǀĞ ?ĂƐƉŝƌŝŶ ? QƚŚĞǇĚŝĚƐĂǇƚŽŵĞĂƚ
the hospital that if I started getting any indigestion or problems with my stomach I had 
to go back because tŚĂƚǁĂƐĂƐǇŵƉƚŽŵ Q 
ZĞƐĞĂƌĐŚĞƌ P  QǇŽƵ ĨŽƵŶĚ ƚŚĂƚ ƵƐĞĨƵů? Q[Pharmacist informed patient to take aspirin 
with water]. 
Konnie: Yeah, I mean at the end of the day you know that you should be doing that, but 
I think sometimes you just need someone to say you should be really taking it that way 
and yes that was helpful. 
Patient interview 11 - 40yr F. Multiple 
 
,ŽǁĞǀĞƌ ? ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ĂĚǀŝĐĞ ǁĂƐ ŝŐŶŽƌĞĚ ǁŚĞŶ ƚŚĞpharmacist had not successfully 
communicated the advice or when the perceived benefits of using the medicine outweighed 
the risk:  
 
ƐƚŚĞƌ P QŝĨ/ĐĂŶ ?ƚŐĞƚƚŽƐůĞĞƉ ?/ ?ůůƚĂŬĞƚŚƌĞĞƉĂƌĂĐĞƚĂŵŽůƐĂŶĚƚŚĂƚŬŶŽĐŬƐŵĞŽƵƚĂŶĚ
ŝƚŬĞĞƉƐƚŚĞƉĂŝŶƵŶĚĞƌĐŽŶƚƌŽů Q 
ZĞƐĞĂƌĐŚĞƌ P QZĞďĞĐĐĂĂĚǀŝƐĞĚǇŽƵƚŚĂƚǇŽƵƐŚŽƵůĚďĞƚĂŬŝŶŐƚǁŽ QǁŝůůǇŽƵĐŽŶƚŝŶƵĞƚŽ
be taking three, if you need it? 
ƐƚŚĞƌ PKŚ/ĚŽŶ ?ƚĨŝŶĚŝƚĚŽĞƐĂŶǇŚĂƌŵ Q/ĨŝŶĚŝĨ/ƚĂŬĞƚǁŽƐŽŵĞƚŝŵĞƐŝƚĚŽĞƐŶ ?ƚƐŽƌƚŽĨ
kill the pain, ok whereas if I take three, it sort of keeps it under control. 
Patient interview 13 - 61yr F. Independent  
 
ZĞƐĞĂƌĐŚĞƌ P Qfter the review, did it affect the way that you take your medicines at all? 
Nick: No, not one iota. 
ZĞƐĞĂƌĐŚĞƌ P  Q:ĂŶĞ ŵĞŶƚŝŽŶĞĚ ĂďŽƵƚ ƚŚĞ ŶŝĐŽƌĂŶĚŝů4 ƚĂďůĞƚƐ QǇŽƵ ŵĞŶƚŝŽŶĞĚ ƚŚĂƚ ǇŽƵ
had a blister open in the morning and one in the evening? 
Nick: For the simple reason that ƐŚĞƐĂŝĚƚŚĂƚŽŶĐĞǇŽƵŽƉĞŶĞĚĂƉĂĐŬĞƚǇŽƵ ?ǀĞ got to 
ĨŝŶŝƐŚŝƚŽĨĨ Q/ŬŶŽǁĨƵůůǁĞůůďĞĐĂƵƐĞ/ƚĂŬĞŽŶĞ ?/ ?ŵǁĞůůǁŝƚŚŝŶƚŚĞƵŚĐŽŵĨŽƌƚǌŽŶĞ Q 
Patient interview 13 - 80yr M. Multiple    
 
                                                          
4
 Nicoradil tablets are available in blister strips of 10 tablets. Each blister is manufactured with its own 
desiccant. Strips have a 30 day shelf life once opened. Patients are advised to start and complete one 
blister at a time. 
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From their accounts, patients presented logical arguments to justify why they had rejected the 
ƉŚĂƌŵĂĐŝƐƚ ?ƐƐƵŐŐĞƐƚŝŽŶƐ ?dŚĞƌĞǁĂƐŶŽexplicit agreement or indication during the MUR that 
the patient would accept the recommendations the pharmacist made. In these cases, 
pharmacists chose to adhere to pharmacological knowledge and provided information that did 
ŶŽƚ ƌĞƐŽŶĂƚĞ ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ĐŝƌĐƵŵƐƚĂŶĐĞƐ ? WŚĂƌŵĂĐŝƐƚs rarely explored how the patient 
intended to respond to the suggestions made and so opportunities to discover how accepting 
and receptive patients were to this advice was lost. With little to no follow-up by the 
pharmacist after the MUR, there was no means of checking whether their recommendations 
had been successfully adopted. When patients were asked about medicine waste, there was 
very little evidence in their accounts that this was perceived to be an issue. In this population, 
ƉĂƚŝĞŶƚƐ ?ĂĐĐŽƵŶƚƐƐƵŐŐĞƐƚĞĚƚŚĂƚƚŚĞDhZŚĂĚůŝƚƚůĞŝŵƉĂĐƚŽŶǁĂƐƚĞĨƌŽŵƵŶƵƐĞĚŵĞĚŝĐŝŶĞƐ ? 
6.5.5 MURs as a means to improve patient knowledge and use of 
medicines 
Most patients reported that the MUR did not improve knowledge of their medicines. The most 
common reasons cited were that their doctor had already explained the necessary information 
to them or they already felt they had adequate knowledge about their medicines most of 
which were prescribed for long-term conditions: 
 
ZĞƐĞĂƌĐŚĞƌ P Qs a result of the review how much more knowledgeable were you about 
your medicines? 
:ŝůů P ?^ŝŐŚƐ ?tĞůů/ĚŽŶ ?ƚƚŚŝŶŬ/ ?ǀĞŐŽƚŶŽŵŽƌĞŬŶŽǁůĞĚŐĞ ?/ƚŚŝŶŬŝƚ ?ƐũƵƐƚƚŚĂƚ/ ?ǀĞďĞĞŶ
on these for so long, and once yŽƵ ?ǀĞďĞĞŶŽŶƚŚĞŵĨŽƌƐŽůŽŶŐ ?ƚŚĞĚŽĐƚŽƌĚŽĞƐŵĂŬĞƐ
ƐƵƌĞƚŚĂƚǇŽƵ ?ƌĞĂůƌŝŐŚƚǁŝƚŚƚŚĞŵ ? 
Patient interview 8 - 76 yr F. Multiple 
 
ZĞƐĞĂƌĐŚĞƌ P Qid it [MUR] make you any more knowledgeable about your medicines at 
all? 
ůŝƐŽŶ P/ĚŽŶ ?ƚĂĐƚƵĂůůǇƚŚŝŶŬŝƚĚŝĚbecause I do ask a lot of questions at the doctors and 
I have a space in my diary where I write it down [in the diary] or they tell me. 
Patient interview 7 - 46yr F. Independent 
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Two patients were retired nurses and felt they had sufficient knowledge about their medicines. 
A few patients expressed no desire to improve upon their knowledge of their medicines. One 
patient commented that she did not want to become any more informed as that could 
potentially increase her anxiety about her medicines:  
 
Researcheƌ P Qid the review make you any more knowledgeable about your medicines 
at all? 
YƵĞĞŶŝĞ PEŽƚƌĞĂůůǇ ?ŶŽ ?ĐŽƐ/ĚŝĚŶ ?ƚŐŽŝŶƚŽĚĞƚĂŝů ?ƐĨĂƌĂƐ/ ?ŵĐŽŶĐĞƌŶĞĚƚŚĞǇ ?ƌĞƚŽĚŽ
ǁŝƚŚ ďůŽŽĚ ƉƌĞƐƐƵƌĞ ? ƚŚĂƚ ?Ɛ Ăůů / ǁŽƌƌǇ ĂďŽƵƚ ? ǁĞůů / ĚŽŶ ?ƚ ĞǀĞŶ ǁŽƌƌǇ ĂďŽƵƚ ƚŚĂƚ
[laughs]. 
ZĞƐĞĂƌĐŚĞƌ P Qtould you have liked more information? 
YƵĞĞŶŝĞ P EŽ ŶŽƚ ƌĞĂůůǇ ? ǁŚĂƚ ǇŽƵ ĚŽŶ ?ƚ ŬŶŽǁ ? ǇŽƵ ĚŽŶ ?ƚǁŽƌƌǇ ĂďŽƵƚ QƚŚĞ ŵŽƌĞ
knowledge you ?ǀĞ got, the more you probably worry. So the less you know the better, 
ƚŚĂƚ ?ƐƚŚĞŽůĚƐĂǇŝŶŐ ? 
Patient interview 10 - 81yr F. Multiple    
 
Despite most patients reporting that the MUR did not improve their knowledge of their 
medicines a few patients reported that their knowledge had improved and remembered 
specific advice that had been given by the pharmacist. Often this resulted from an issue that 
the patient raised during the MUR or was something that interested the patient: 
 
Eve: The only thing I was more knowledgeable about was when she told me it was 
ĂůƌŝŐŚƚƚŽƚĂŬĞƚŚĞŵůŝŬĞƚŚĂƚ ?ƚŽƚĂŬĞƚĂďůĞƚƐƚŽŐĞƚŚĞƌ ? Qŝƚ ƉƵƚŵǇŵŝŶĚĂƚƌĞƐƚ Q/ŬĞƉƚ
ƚŚŝŶŬŝŶŐĞǀĞƌǇĚĂǇƌĞĂůůǇ QŚĞ ?ŚƵƐďĂŶĚ ?ƐĂŝĚǇŽƵƐŚŽƵůĚŶ ?ƚďĞĚŽŝŶŐƚŚĂƚ Q 
Researcher: QtĂƐƚŚĞƌĞĂŶǇƌĞĂƐŽŶǁŚǇǇŽƵĚŝĚŶ ?ƚĂƐŬƚŚĂƚƋƵĞƐƚŝŽŶďĞĨŽƌĞŚĂŶĚ ? 
Eve: Yes, /ŬĞƉƚŵĞĂŶŝŶŐƚŽĂƐŬďƵƚ/ƚŚŽƵŐŚƚƚŚĞǇ ?ƌĞŐŽŶŶĂƚĞůůŵĞŽĨĨŝĨ/do [laugh] 
Researcher: [Laugh] What you mean the pharmacy? 
Eve: [Laugh] No, that was just in my silly mind.  
Patient interview 5 - 75yr F. Independent  
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ƐŚůĞǇ P QƐŚĞǁĂƐƐĂǇŝŶŐƌĞĚfoods are good for you, you know. I thought oh I love tin 
ƚŽŵĂƚŽĞƐ QƐŽ ǁĞ ďƌŽƵŐŚƚ ƚŝŶŶĞĚ ƚŽŵĂƚŽĞƐ ďĂĐŬ ŝŶƚŽ ŽƵƌ ĚŝĞƚ QƚŚĞŽƚŚĞƌ ƚŚŝŶŐ ƐŚĞ
mentioned was the fact that although it says on the box that uh my cholesterol tablets 
ƐŚŽƵůĚďĞƚĂŬĞŶĂƚŶŝŐŚƚ ?ŝƚ ?ƐŶŽƚƐƚƌŝĐƚůǇŶĞĐĞƐƐĂƌǇ ?^ŽŝĨ ŝƚĚŽĞƐŶ ?ƚĨŝƚ ŝŶŵǇĚĂǇ ?/ĐĂŶ
take it when iƚǁŝůůĨŝƚŝŶǁŝƚŚŵǇĚĂǇ ?ďĞĐĂƵƐĞŝƚĚŽĞƐŶ ?ƚŚĂǀĞƚŽďĞũƵƐƚĂƚŶŝŐŚƚ ? 
Patient interview 14 - 67yr M. Multiple   
  
ZĞƐĞĂƌĐŚĞƌ P QŝĚǇŽƵƉŝĐŬƵƉĂŶǇƚŚŝŶŐƚŚĂƚǇŽƵĚŝĚŶ ?ƚĂůƌĞĂĚǇŬŶŽǁ ? 
DŝĂ P QKŶůǇƚŚĂƚƵŚ/ŶĞĞĚĞĚƚŽŐŽďĂĐŬ ? ‘ĐĂƵƐĞƚŚĞsĞŶƚŽůŝ ?/ũƵƐƚƚhought it was me 
ŐĞƚƚŝŶŐǁŽƌƐĞ Q / ƚŚŽƵŐŚƚ /ǁĂƐŽŶƚŚĞŵŽƐƚ /ĐŽƵůĚŐŽŽŶ ?ǇŽƵŬŶŽǁĂŶĚ / ?ĚŚĂǀĞƚŽ
tolerate it but with her saying that, she said that they can help you more.  
   Patient interview 17 - 66yr F. Multiple 
 
When patients were asked whether the MUR had improved or affected the way they used 
their medicines most reported that it had not. Patients continued to use their medicines as 
they previously had done because they perceived that there was no need to change. Several 
patients remarked that the MUR confirmed what they were doing was correct:  
 
ZĞƐĞĂƌĐŚĞƌ P  QzŽƵƚĂůŬĞĚĂďŽƵƚǇŽƵƌ^ƉĞĐƚƌĂďĂŶ  ?ƐƵŶ ůŽƚŝŽŶ ?ĂŶĚƚŚĂƚǇŽƵǁĞƌĞŵŽƌĞ
comfortable using it. But was there anything else that you changed as a result of 
talking to the pharmacist? 
Fiona: No no,  ?ĐĂƵƐĞƐŚĞƐŽƌƚŽĨĐŽŶĨŝƌŵĞĚƚŚĂƚǁŚĂƚ/ǁĂƐĚŽŝŶŐǁĂƐK<ƐŽ/ ?ǀĞĐĂƌƌŝĞĚ
on doing that really. 
Patient interview 2 - 70yr F. Multiple    
 
ZĞƐĞĂƌĐŚĞƌ P Qid it affect or change the way that you use your medicines?    
Esther: No. 
ZĞƐĞĂƌĐŚĞƌ PK<ƚŚĂƚ ?ƐĨŝŶĞ, because you ?ƌĞ continuing as you were? 
Esther: Yes. 
Patient interview 13 - 61yr F. Independent   
 
The preceding five sections have explored what patients accounts reveal about whether the 
aims of the MUR service are being realised in practice. Most participants did not report having 
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concerns with their medicines. Patients who did reveal concerns typically had issues with a 
specific medicine or health matter. The ƉŚĂƌŵĂĐŝƐƚƐ ? formulaic approach, as illustrated in the 
preceding chapter, failed to identify or enable patients to easily express these concerns. 
WŚĂƌŵĂĐŝƐƚƐ ? lack of curiosity, the limited remit and scope provided through the MUR meant 
that they closed off or failed to fully identify and address issues that did arise during the MUR. 
They imparted responsibility to the patient, advising them to follow up issues directly with the 
GP rather than contacting the GP themselves. In the last section of this chapter, I report 
suggestions made by patients on how, if any, improvements to the MUR service could be made.  
 
6.6 Improvements 
ĂƌůŝĞƌ ƐĞĐƚŝŽŶƐ ĚĞƐĐƌŝďĞĚ ƉĂƚŝĞŶƚƐ ? ƐƵŐŐĞƐƚŝŽŶƐfor improving the consultation room and to 
provide prior notice of the MUR to allow reflection of issues they may want to discuss. When 
asked whether the MUR could be better tailored to their particular needs, many commented 
that they were satisfied and that the format of the MUR was acceptable: 
 
ZĞƐĞĂƌĐŚĞƌ P Qould it be improved? 
Fiona: Well obviously she ?Ɛ ŐŽƚ Ă ůŝƐƚ ŽĨǁŚĂƚ ŵĞĚŝĐĂƚŝŽŶ / ?ŵ ŽŶ ŚĂĚŶ ?ƚ ƐŚĞ? Q/ ĚŽŶ ?ƚ
know how that could ďĞŝŵƉƌŽǀĞĚƌĞĂůůǇ ?:ƵƐƚŐŽŝŶŐƚŚƌŽƵŐŚƚŚĞůŝƐƚŽĨǁŚĂƚǇŽƵ ?ƌĞŽŶ
ĂŶĚŚŽǁǇŽƵƚĂŬĞŝƚ Q/ĚŽŶ ?ƚƚŚŝŶŬǇŽƵĐŽƵůĚĚŽŵƵĐŚŵŽƌĞƚŚĂŶƚŚĂƚƌĞĂůůǇ ? 
Patient interview 2 - 70yr F. Multiple    
 
ƐƚŚĞƌ P Q/ŵĞĂŶƚŽŵĞ/ƚŚŝŶŬǁĞǁĞŶƚŽǀĞƌĞǀĞƌǇƚŚŝŶŐĂŶĚǁĞĚŝƐĐƵƐƐĞĚƚhings what 
ǁĂƐŝŵƉŽƌƚĂŶƚ ?/ĚŽŶ ?ƚƚŚŝŶŬƚŚĞƌĞŝƐĂŶǇƚŚŝŶŐ/ĨĞůƚƚŚĂƚǁĂƐůĞĨƚŽƵƚ ? 
 Patient interview 13 - 61yr F. Independent 
 
ĨĞǁƉĂƚŝĞŶƚƐƐƵŐŐĞƐƚĞĚƚŚĂƚƚŚĞƉŚĂƌŵĂĐŝƐƚƐŚŽƵůĚƵƐĞĂŵŽƌĞŽƉĞŶ ‘ĐŽƵŶƐĞůůŝŶŐ ?ŵĞƚŚŽĚƚŽ
ĂůůŽǁƉĂƚŝĞŶƚƐƚŽ ‘ŽƉĞŶƵƉ ? ?KŶĞƉĂtient suggested that the pharmacist asked at the beginning 
of the MUR whether the patient had any concerns so that these could be focused upon and 
addressed. Another patient commented that there should be a follow-up to allow the patient 
to feel that care was on-going: 
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ZĞƐĞĂƌĐŚĞƌ P Q,ow could it be better tailored to what you needed? 
Megan:  QƉĞƌŚĂƉƐůŝƐƚĞŶ ĂďŝƚŵŽƌĞ ?/ĚŽŶ ?ƚƚŚŝŶŬ/ŐŽƚ ? ? ?A?ŽĨŚĞƌůŝƐƚĞŶŝŶŐ QǇŽƵŚĂǀĞ
to dig that little bit deeper, get to know that person sitting in front of you, press the 
right buttons to get the person to open up to you. 
Patient interview 5 - 73yr F. Multiple 
 
dĞƌƌŝĞ P  QŝĨ ŝƚ ǁĂƐ ? ůŝŬĞ ? ĂŶ ŽŶ-going thing for patients. When you came in the 
ƉŚĂƌŵĂĐŝƐƚǁŽƵůĚĂĐƚƵĂůůǇŬŶŽǁǁŚĂƚƐƚĂŐĞǇŽƵǁĞƌĞĂƚ Q/ĚŽŶ ?ƚƚŚŝŶŬƚŚĞǇĐŽƵůĚƚĂŝůŽƌ
ŝƚ ĂĨƚĞƌ ƚŚĞ ĨŝƌƐƚ ŝŶƚĞƌǀŝĞǁ Qŝƚ ǁŽƵůĚ ƐŚŽǁ ǇŽƵ ǁĞƌĞ ŝŶƚĞƌĞƐƚĞĚ ŝŶ ƚŚĞŵ ĂŶĚ ŚĂƐ ƚŚĞŝƌ
ŵĞĚŝĐĂƚŝŽŶĐŚĂŶŐĞĚĂŶĚƌĞĨĞƌďĂĐŬƚŽǁŚĂƚƚŚĞǇ ?ĚĂůƌĞĂĚǇƐĂŝĚ Q 
Patient interview 3 - 54yr F. Independent 
 
A few respondents commented that the MUR had lasted longer than they had expected. The 
estimated time provided by the pharmacy staff did not always match to how long the MUR 
took.  
 
6.7 Summary 
In this chapter, / ŚĂǀĞ ĞǆƉůŽƌĞĚ ƉĂƚŝĞŶƚƐ ? ǀŝĞǁƐ ŽĨ ƚŚĞ DhZ ƐĞƌǀŝĐĞ ? / ŚĂǀĞ ďƵŝůƚ ƵƉŽŶ ƚŚĞ
findings presented in the previous two observation chapters to provide a deeper and 
contextual understanding of how MURs had been received by the participants. WĂƚŝĞŶƚƐ ?
expectation of pharmacy services included the filling of prescriptions and seeking advice on 
managing minor ailments. No patients reported that they saw the pharmacist ?Ɛ role as 
providing an extended consultation about their medicines. The lack of clear promotion of the 
service meant participants constructed their experience of the MUR through what had 
happened and their existing perceptions of the pharmacist. With one exception, patients were 
not observed asking for an MUR. Several respondents questioned the necessity of the MUR or 
its personal relevance. An investigation into why patients declined the invitation for an MUR 
uncovered more complex motives than the reasons reported in the pharmacies.  
 
Most patients reported that they did not expect an MUR when they visited the pharmacy and 
reacted to their invitation with indifference or surprise. Their response did not seem to be 
strongly motivated by self interest or the prospect of personal benefit. This was reflected in 
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most of the respondents ? accounts in which they reported feeling obliged to take part or that 
they were helping the pharmacist in some way by agreeing to an MUR. The few patients who 
viewed the MUR as a chance to improve their knowledge of medicines did not perceive this 
activity to be part of the routine care provided from the pharmacy. Likewise, all those who had 
previously completed an MUR did not anticipate clear, personal benefits from having another. 
With MURs being performed ŝŶĨƌĞƋƵĞŶƚůǇ ĂŶĚ ƉĂƚŝĞŶƚƐ ?awareness of accessing the 
ƉŚĂƌŵĂĐŝƐƚ ?ƐƐŬŝůůƐǁŚen they feel the need, the MUR service did not resonate as a service that 
patients felt was necessary.  
 
Patients gave ambivalent accounts of the purpose and what happened during the MUR.  Most 
did not mind the ad hoc invitation but this left some feeling unprepared and guarded during 
the consultation. This ƌĞĚƵĐĞĚƉĂƚŝĞŶƚƐ ? opportunity to think about what they may want to ask 
or recall existing concerns about their medicines. Participants generally framed the MUR as a 
monitoring activity where the pharmacist was ensuring that the patient did not have problems 
with their medicines. Many patients believed that purpoƐĞŽĨƚŚĞDhZǁĂƐƚŽ ‘ĐŚĞĐŬ ?ŽŶƚŚĞŝƌ
medicines rather than to provide an opportunity for them to discuss their understanding, use, 
beliefs and concerns about their medicines. This impression was reinforced by the discourse 
used by the pharmacists and what they were seen doing during the consultation. Nevertheless, 
most patients valued the time the pharmacist spent with them and appreciated the 
opportunity to speak to them privately. Most patients were receptive to the idea of greater 
pharmacist involvement in services like the MUR. They regarded the pharmacist as a 
knowledgeable expert on medicines, felt comfortable speaking to them and valued the 
reassurance they could provide about their medicines. The MUR itself did not notably change 
this view.   
  
Nearly all the patients interviewed recognised that responsibility for prescribed medicines 
rested with whoever prescribed the medicine, which was their GP or a specialist prescriber. 
These views had important implications for what they perceived could be achieved from the 
MUR. Other than providing simple practical advice, the pharmacist was not considered able to 
ƌĞƐŽůǀĞ ŵŽƌĞ  ‘ƐĞƌŝŽƵƐ ? ƉƌŽďůĞŵƐ ƚŚĂƚ ĂƌŽƐĞ ĚƵƌŝŶŐ ƚŚĞ DhZ ? WĂƚŝĞŶƚƐ ? ƉĞƌĐĞƉƚŝŽŶ ŽĨ ƚŚĞ
subordinate status of the pharmacist compared with the GP meant that some patients were 
aware of the potentially negative impact MURs could have on professional boundaries, 
relationships and responsibilities. The disconnectedness of MURs from other services and 
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professional contacts added to these concerns and reinforced awareness of professional 
ŚŝĞƌĂƌĐŚǇƌĂƚŚĞƌƚŚĂŶĞŶŚĂŶĐŝŶŐƉŚĂƌŵĂĐŝƐƚƐ ?ƉƌŽĨĞƐƐŝŽŶĂůƐƚĂƚƵƐ ? 
 
tŚĞŶ ƉĂƚŝĞŶƚƐ ? ĂĐĐŽƵŶƚƐ ǁĞƌĞ ƐĐƌƵƚŝŶŝƐĞĚ ĨŽƌ ĞǀŝĚĞŶĐĞ ƚŚĂƚDhZƐ ĂĐŚŝĞǀĞĚ ƚŚĞ ĂŝŵƐ ĂŶĚ
intentions of formal policy, there were few clear examples where these had been met. Most 
patients reported that their MUR did not improve their knowledge and rarely affected the use 
of their medicines. There was little evidence to suggest that, in this population, adherence to 
medicine taking had improved or wastage from unused medicines had reduced. Likewise, from 
ƉĂƚŝĞŶƚƐ ? ĂĐĐŽƵŶƚƐ ƚŚĞƌĞ ǁĂƐ ůŝƚƚůĞ ŝŶĚŝĐĂƚŝŽŶ ƚŚĂƚ ƚŚĞ DhZ ŝŵƉƌŽǀĞĚ the clinical or cost-
ĞĨĨĞĐƚŝǀĞŶĞƐƐŽĨƚŚĞƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐ ?tŝƚŚDhZƐŶŽƚďĞŝŶŐĞĨĨĞĐƚŝǀĞůǇƚĂƌŐĞƚĞĚĂƚƚŚĞŵŽƐƚ
needy patients, policy intentions to improve medicine use were not being realised in practice. 
Moreover, patients ? medicine taking habits were shown to be complex and the structured, 
routinised strategy deployed by pharmacists to fill in the MUR form left little scope to tackle 
more inĚĞƚĞƌŵŝŶĂƚĞ Žƌ ǁŝĚĞƌ ŵĂƚƚĞƌƐ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞ ƵƐĞ ? ĚĚĞĚ ƚŽ ƚŚŝƐ ?
ƌĞƐƉŽŶĚĞŶƚƐ ? ĂĐĐŽƵŶƚƐ ŝŶĚŝĐĂƚĞĚ ƚŚĂƚ ƚŚĞǇ ƚĞŶĚĞĚ ƚŽ ĂĐĐĞƉƚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ ƐƵŐŐĞƐƚŝŽŶƐ
when the advice was in line with their own beliefs and preferences. Conversely, they were less 
likely to be receptive to suggestions which conflicted with their personal opinions or were 
difficult or inconvenient to implement.       
 
This chapter has explored patientƐ ? perspectives of the MUR service. The final results chapter 
will report on pharmacy staff views of the service. 
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CHAPTER SEVEN  
The views of pharmacy staff 
 
7.1 Introduction  
In this last results chapter, I present the findings from the pharmacist and support staff 
interviews. This chapter builds upon the three previous results chapters and aims to 
substantiate and extend the observations that were made during the fieldwork. As was 
reported in Chapter Four, pharmacies faced difficulties when implementing the MUR service in 
practice and so I begin by considering the MUR training that pharmacists and their support 
staff had received. I then report the views about how they manage the MUR service and their 
opinions on its integration into the workload of the pharmacy. One primary aim of this study 
was to better understand the MUR consultation. As a result, few observations were made of 
pharmacy activities when the pharmacist was absent during an MUR. Interviews with support 
staff therefore provided valuable insights how they cope when the pharmacist was not present 
during this period.   
 
7.2 Participants  
Interviews were carried out with a total of 17 pharmacy staff (Table 3). These included five of 
the regular pharmacists working at the study pharmacies and 12 of the 14 regular support staff. 
Interviews with pharmacists typically lasted one hour; pharmacy support staff interviews 
lasted between 15 to 90 minutes. All were audio recorded.  
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Table 3: Job roles of staff interviewed (n = 17) 
 
 
Member of staff 
 
 
Independent (n = 9) 
 
Multiple (n = 8) 
Pharmacists: 
Proprietor 
Manager 
Employee 
Locum 
 
1 
1 
0 
1 
 
0 
0 
2 
0 
Non-pharmacist manager1 0 1 
Dispenser 3 2 
Medicines counter assistant (MCA) 1 2 
Pre-registration (Trainee) pharmacist2 0 1 
Saturday staff3 2 0 
 
1 
The manager of the multiple ǁĂƐ ŶŽƚ Ă ƉŚĂƌŵĂĐŝƐƚ ďƵƚǁĂƐ ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ ŵĞĞƚŝŶŐ ƚŚĞ ƉŚĂƌŵĂĐǇ ?Ɛ
targets, including those for MURs. 
2
 A pre-registration pharmacist is required to complete a year of supervised training in employment 
before general registration as a pharmacist. 
3
 Two undergraduate pharmacy students were employed by the independent who tended to work on 
alternate Saturdays in the dispensary.   
 
7.3 The pharmacy staff perspective of MURs 
7.3.1 MUR training  
Pharmacists are required to pass an assessment set by a Higher Education Institute (HEI) in 
order to be accredited to carry out MURs. Pharmacists were asked about their experience of 
the MUR accreditation process. Two pharmacists (Rebecca and Linda) had completed an online 
assessment (provided by the Centre for Pharmacy Postgraduate Education (CPPE)). Three 
pharmacists (Jane, Kate, and Rose) had been accredited from another university. Rebecca and 
Rose had been on a face-to-face MUR training course. Pharmacists were asked how the 
training and accreditation process had prepared them to undertake MURs. Their opinions were 
mixed. One pharmacist could not remember many details of their accreditation as this had 
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been several years ago and the others reported that the accreditation process had, to some 
extent, equipped them to offer the service: 
 
ResearcŚĞƌ P Qo you reckon that [MUR accreditation]  prepared you for your role? 
:ĂŶĞ PDŵ ?EŽƚƌĞĂůůǇ ?/ƚ ?ƐŶŽƚƉƌĂĐƚŝĐĂů ?ŶĚ ?ƚŽďĞŚŽŶĞƐƚ ?/ĐĂŶ ?ƚƚŚŝŶŬŽĨĂŶǇƚŚŝŶŐthat 
I got from it that I benefited ĨƌŽŵ Q^Ž ?/ƚŚŝŶŬǇŽƵ ?ƌĞďĞƚƚĞƌŽĨĨŐĞƚƚŝng more practical 
experience. 
   Employee pharmacist, Multiple  
 
ZĞďĞĐĐĂ QǁĞƐĂƚĚŽǁŶǁŝƚŚƚŚĞŽůĚƐƚǇůĞĨŽƌŵƐ ?ǁĞƐŽƌƚŽĨĚŝĚDhZƐŽŶĞĂĐŚŽƚŚĞƌ ?^Ž
ƚŚĂƚǁĂƐƋƵŝƚĞŐŽŽĚ Q/ǁĂƐƚƌĂŝŶĞĚ ?ƉƌĞƉĂƌĞĚƋƵŝƚĞǁĞůů Q 
   Employee pharmacist, Independent  
 
Undertaking practice sessions were seen by pharmacists as the most practical way to prepare 
them for conducting MURs. Support staff were also asked about how they had been informed 
of the MUR service and about any training they might have received. None reported having 
had any formal training other than the pharmacist informing them that the MUR was a brief 
discussion about the patient ?s medicines, in which they were asked ĂďŽƵƚ  “what they were 
taking ?ĂŶĚ “how they were taking it ? ?ĚŝƐƉĞŶƐĞƌĂŶĚƚŚĞŶŽŶ-pharmacist manager reported 
uncertainty about the purpose of the MUR, whether the pharmacy was legally required to 
engage with the service and reservations over why pharmacists were involved with reviewing 
prescribed mediciŶĞƐĂŶĚŶŽƚƚŚĞƉĂƚŝĞŶƚ ?Ɛ'W:   
  
Researcher P  QǁĞƌĞ ǇŽƵ ŝŶĨŽƌŵĞĚ ďǇ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ĂďŽƵƚ ǁŚĂƚ ƚŚĞ ƉƵƌƉŽƐĞ ŽĨ ƚŚĞ
review is? Are you clear on this? 
>ƵĐǇ PEŽƚƌĞĂůůǇ ?ůĂƵŐŚƐ ?ŶŽ ?KŶůǇƚŚĂƚ ?Ɛŝƚ ?ƐĂĨŝŶĂŶĐŝĂůƚŚŝŶŐŝƐŶ ?ƚŝƚ ?Ƶƚ ?ĂƚƚŚĞĞŶĚŽĨ
ƚŚĞĚĂǇ ?/ĚŽŶ ?ƚŬŶŽǁǁŚĞƚŚĞƌ ?ŚĂǀĞƚŚĞǇŐŽƚƚŽĚŽŝƚ ?/Ɛŝt the law now that this is what 
ƚŚĞǇŚĂǀĞƚŽĚŽƚŽƉƌŽƚĞĐƚƉĞŽƉůĞ ?ĞĐĂƵƐĞ/ĚŽŶ ?ƚŬŶŽǁƌĞĂůůǇ ?ŚŽŶĞƐƚůǇ/ĚŽŶ ?ƚ ? 
Dispenser, Independent  
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DĂƌŐĂƌĞƚ P Q/ŶŝƚŝĂůůǇ ?/ǁĂƐŬŝŶĚŽĨƚŚŝŶŬŝŶŐ ?tŚǇŝƐƚŚĞ ĚŽĐƚŽƌŶŽƚĚŽŝŶŐƚŚĂƚ ?tŚǇŝƐ
that something that falls on ƚŽĂƉŚĂƌŵĂĐŝƐƚ ? Q/ƐƚŝůůŬŝŶĚŽĨĚŽŶ ?ƚƵŶĚĞƌƐƚĂŶĚǁŚǇǁĞ
ĚŽƚŚĞŵĂƐŽƉƉŽƐĞĚƚŽĂĚŽĐƚŽƌ Q      
Manager, Multiple   
 
Furthermore, during their interviews a couple of dispensary support staff appeared to 
misunderstand or expressed confusion about which patients were entitled to an MUR: 
 
^ŽƉŚŝĞ P QƚŚĞƌĞ ǁĂƐŽŶĞůŽĐƵŵ Q ?ŚĞ ?ƐĂŝĚƚŚĂƚ ? “oŚ ?/ǁŽŶ ?ƚĚŽĂŶDhZĨŽƌƚŚĂƚƉĂƚŝĞŶƚ ? 
ƚŚĞǇ ?ƌĞ ũƵƐƚŽŶŽŶĞŵĞĚŝĐĂƚŝŽŶ ? ?Ƶƚ :ĂŶĞ ƚŽůĚ ƚŚĂƚ ůŽĐƵŵ QǇŽƵĐĂŶĚŽ ŝƚ QďƵƚ /ĚŽŶ ?ƚ
really know the answer as well.  Are we able to do the MhZĨŽƌĂƉĂƚŝĞŶƚǁŚŽ ?ƐũƵƐƚŽŶ
one medication? 
 `  Pre-registration pharmacist, Multiple 
 
,ĞůĞŶ P /ĚŽŶ ?ƚ ƚŚŝŶŬ ŝƚ ƐŚŽƵůĚďĞ ũƵƐƚ ĨŽƌŽůĚĞƌƉĞŽƉůĞĞŝƚŚĞƌ ? /ƚ ƐŚŽƵůĚďĞ ĨŽƌĂŶǇĂŐĞ
ƚŚĂƚ ?ƐŽŶĂůŽƚŽĨŵĞĚŝĐĂƚŝŽŶ Q 
  Dispenser, Independent  
 
An experienced MCA also expressed confusion. She explained that her initial training had 
stated that more potent pharmacy medicines were required to be sold under the supervision 
of a pharmacist. Being unaware of the new guidance issued on this matter
5
, she reported 
concerns over selling OTC medicines when the pharmacist was performing the MUR:  
 
>ĞĂŚ P  QǁŚĞŶ / ĨŝƌƐƚĚŝĚŵǇ ƚƌĂŝŶŝŶŐ ? ƚŚĞǇĂůǁĂǇƐƐĂŝĚƚŚĂƚĂƉŚĂƌŵĂĐŝƐƚŚĂĚƚŽďĞ ŝŶ
ǀŝĞǁŽĨ ƐĞůůŝŶŐĂŵĞĚŝĐŝŶĞ ? /Ɛ ƚŚĂƚ ƌŝŐŚƚ Ɛƚŝůů ? ? ? ?ĞĐĂƵƐ  ŝĨ ƚŚĞǇ ?ƌĞŽƵƚŽĨǀŝĞǁ ƚŚĞŶǁĞ
shouldn ?ƚƌĞĂůůǇďĞƐĞůůŝŶŐĂŶǇƚŚŝŶŐĂŶǇǁĂǇ Q/ĚŽŶ ?ƚƌĞĂůůǇŬŶŽǁƚŚĞůĞŐĂůŝƚŝĞƐŽĨƚŚĂƚ ? 
Counter assistant, Multiple  
 
                                                          
5
 The Medicines Act requires that pharmacy and prescription only medicines be sold or supplied by a 
pharmacist, or someone acting under the supervision of a pharmacist. Guidance was issued by the RPS 
(then RPSGB) in 2005 following queries asking if dispensed prescriptions can be supplied and pharmacy-
only medicines sold whilst the pharmacist is undertaking a private consultation with a patient such as an 
MUR. It asserted that pharmacy medicines can be sold and dispensed prescriptions that have been 
 ‘ĐůŝŶŝĐĂůůǇĐŚĞĐŬĞĚ ?ĐĂŶďĞƐƵƉƉůŝĞĚƉƌŽǀŝĚĞĚƚŚĂƚƌŽďƵƐƚƐƚĂŶĚĂƌĚŽƉĞƌĂƚŝŶŐƉƌŽĐĞĚƵƌĞƐĂƌĞŝŶƉůĂĐĞ ? 
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The extracts illustrate some of the confusion over aspects of the MUR activity or support 
ƐƚĂĨĨ ?Ɛpersonal responsibility when the pharmacist was performing an MUR. Consequently, as 
was reported in Chapter Four (section 4.6), when support staff were involved in inviting 
patients for an MUR their approach did not always effectively convey to patients the 
anticipated benefits. In the following section, patient selection and the invitation process will 
be explored.   
 
7.3.2 Selection and invitation  
Pharmacy staff were asked about how they identified and approached patients for an MUR. All 
pharmacists were aware of the minimum selection criteria detailed under the service 
specifications (patients on multiple medicines, using the pharmacy for their dispensed 
medicines for the previous three months and who had not undertaken an MUR in the previous 
12 months). Pharmacists were aware of local guidance issued by tŚĞWdĂďŽƵƚ ‘ƚĂƌŐĞƚ ?ŐƌŽƵƉƐ
including those over the age of 60, those taking four or more medicines and asthma patients. 
Support staff who were involved in inviting patients for an MUR were less aware of target 
groups. However, most were aware of the minimum selection criteria. All participants involved 
in inviting patients for an MUR were asked about what influenced their decision to identify or 
select a patient. Their responses revealed that they tended to perform MURs regardless of the 
target groups, so long as patients were willing to accept the invitation: 
  
ZĞďĞĐĐĂ P  Q ?ǁĞ ƚĞŶĚ ƚŽ ŐŽ ĨŽƌ ƚŚĞ ĞůĚĞƌůǇ ďƵƚ ƌĞĂůůǇ ? ŝƚ ?ƐĂůů ĂďŽƵƚ ũƵƐƚ ĂŶǇďŽĚǇ ǁŚŽ
really wants an MUR, I think, if you offer it to them. 
   Employee pharmacist, Independent  
 
:ĂŶĞ P  Q/ĚŽŶ ?ƚŶĞĐĞssarily pick people out, like, right, I want to know more about this 
ƉĂƌƚŝĐƵůĂƌ ƐŝƚƵĂƚŝŽŶ ? / ũƵƐƚ ƚĞŶĚ ƚŽ ƉŝĐŬ QŽƉƉŽƌƚƵŶŝƚŝĞƐ ĨŽƌ ǁŽƌŬ ? ǇŽƵ ŬŶŽǁ ? ǁŚĞŶ ŝƚ ?Ɛ
quiet-ish and we ?ǀĞ ŶŽƚŝĐĞĚƚŚĞǇ ?ǀĞŶŽƚŚĂĚŽŶĞĚŽŶĞŽƌƚŚĞǇ ?ƌĞĚƵĞĨŽƌŽŶĞ ?ĂŶĚƚŚĞŶ
we mention it. /ĚŽŶ ?ƚƚĂƌŐĞƚĂŶǇƉĂƌƚŝĐƵůĂƌŐƌŽƵƉ ? 
  Employee pharmacist, Multiple 
 
ĞƐƉŝƚĞ ƉŚĂƌŵĂĐŝƐƚƐ ďĞŝŶŐ ĂǁĂƌĞ ŽĨ Wd ŐƵŝĚĂŶĐĞ ĂďŽƵƚ  ‘ƚĂƌŐĞƚ ? ŐƌŽƵƉƐ ? DhZƐ ǁĞƌĞ
performed for patients with any condition so long as they were willing to accept the invitation. 
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Even the minimum selection criteria of patients taking at least two medicines was not always 
reported to be observed by one pharmacist:    
 
ZĞƐĞĂƌĐŚĞƌ P Q,ŽǁǁŽƵůĚǇŽƵŐŽĂďŽƵƚƐĞůĞĐƚŝŶŐĂƉĂƚŝĞŶƚ Q? 
ZŽƐĞ PZĂŶĚŽŵ ?/ůŽŽŬĂƚĂƉĂƚŝĞŶƚƚŽƐĞĞŝĨƚŚĞǇ ?ƌĞŽŶƉŽůǇƉŚĂƌŵacy, even two items, 
ĂŶĚ / ?ůů ƚĂůŬ ƚŽ ƚŚĞŵ ? dŚĞƌĞ ĂƌĞ ƐŽŵĞ ƉĞŽƉůĞǁŚŽ ĂƌĞ ŽŶŽŶĞ ŝƚĞŵ ĂŶĚ ƚŚĞǇ ǁĂŶƚ ƚŽ
ĚŝƐĐƵƐƐŝƚ ?/ ?ǀĞŐŽƚŶŽŝƐƐƵĞƐ Q 
    Pharmacist and proprietor, Independent    
 
Patients were therefore not being selected according to pharmacist identified perceived need 
for further support but rather according to whether they were amenable to the invitation and 
when the pharmacy was less busy. Support staff attitudes similarly did not typically portray an 
intention to identify those patients who would most benefit from an MUR: 
 
Dorothy:  What we do mostly, when we get the PCSs [Prescription Collection Service 
ƉƌĞƐĐƌŝƉƚŝŽŶƐ ?ďĂĐŬ ?ǁĞůŽŽŬ ?ĐŚĞĐŬƚŽƐĞĞŝĨƚŚĞǇ ?ǀĞŚĂĚĂŶDhZǁŝƚŚŝŶƚŚĞůĂƐƚƚǁĞůǀĞ
ŵŽŶƚŚƐ ?/Ĩŝƚ ?ƐůŽŶŐĞƌƚŚĂŶƚǁĞůǀĞŵŽŶƚŚƐǁĞ ?ůůƐƚĂŵƉŝƚƚŽƐĂǇƚŚĞǇ ?ƌĞĂĐĂŶĚŝĚĂƚĞ QĂŶĚ
then when they come in just mention it to them. 
Dispenser, Multiple 
 
Kirsty:  QŝƚũƵƐƚĐŽŵĞƐƵƉŽŶƚŚĞƐǇƐƚĞŵ QŝĨƚŚĞĚŽƐĞŚĂƐĐŚĂŶŐĞd or something you just 
ĂƐŬƚŚĞŵŝĨƚŚĞǇ ?ƌĞŝŶƚĞƌĞƐƚĞĚŝŶĂŶDhZ QŝĨƚŚĞǇ ?ƌĞĨƌĞĞƚŚĞŶǇĞƐ ?/ĨŶŽƚ ?ƚŚĞŶ QŵĂŬĞ
ĂŶ ĂƉƉŽŝŶƚŵĞŶƚ QDŽƐƚ ŽĨ ƚŚĞŵ ĐŽŵĞ ŽŶ Ă ƌĞŐƵůĂƌ ďĂƐŝƐ ĂŶǇǁĂǇ ? >ŝŬĞ ŽƵƌ ƌĞŐƵůĂƌ
ĐůŝĞŶƚƐ QEŽƚĂůůŽĨƚŚĞŵ ?ƚŚŽƵŐŚ ?/ŚĂǀĞƚŽƐĂǇ ?ũƵƐƚ ?ǇŽƵŬŶ ǁ ?ƌĂŶĚŽŵůǇ Q 
Saturday assistant, Independent 
 
Support staff made their decisions based upon the minimum selection criteria. The lack of 
targeting reported by pharmacy staff supported the fieldwork observations. Consequently, this 
may explain patients reports suggesting the MUR was not personally necessary for them 
(Chapter Six section 6.4.4).      
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7.3.3 Recruitment anomalies  
Despite participants reporting that they used the minimum selection criteria for identifying 
patients for an MUR, some expressed in their interviews that they had an aversion to selecting 
particular groups of patients. Older patients, who could potentially become confused with the 
request, were avoided by one MCA: 
 
ĂƚŚ P QŽŶ ?ƚ ŶŽƌŵĂůůǇ ƚĂƌŐĞƚ ? /ŵĞĂŶ ŝƚ ?Ɛ ƉƌŽďĂďůǇ Ăďŝƚbiased, but the really elderly 
because like I said they get confused. So ƐŽŵĞƚŝŵĞƐŝĨǇŽƵĐĂŶƐĞĞƐŽŵĞŽŶĞ ?ƐĂďŝƚ ?ŶŽƚ
say cŽŵƉůĞƚĞůǇƚŚĞƌĞ ? /ĚŽŶ ?ƚ ƚŚŝŶŬ ŝƚ ?Ɛ ĨĂŝƌ ƚŽĂƉƉƌŽĂĐŚďĞĐĂƵƐĞ / ƚŚŝŶŬ ƚŚĞǇŐĞƚĂďŝƚ
ĐŽŶĨƵƐĞĚďƵƚƚŚĞŶĂŐĂŝŶƚŚĞǇ ?ůůƉƌŽďĂďůǇďĞŶĞĨŝƚŵŽƌĞ Q 
Counter assistant, Independent  
 
Cath reported avoiding asking the  “really elderly ? ƉĂƚŝĞŶƚƐfor an MUR. However, she did 
recognise that these patients may potentially benefit most. Likewise, those with many 
prescribed items were also reported to be avoided because there was a perception that these 
MURs would take the pharmacist longer to complete. This was despite the recognition that 
these patients would also probably benefit the most:  
 
ĂǁŶ P QƚŚŝƐ ŝƐǁŚĞŶ ŝƚĚŽĞƐŶ ?ƚǁŽƌŬďĞĐĂƵƐĞǇŽƵƚƌǇ ƚŽĂǀŽŝĚ ƚŚĞŽŶĞƐ ƚŚĂƚŚĂǀĞŐŽƚ
ůŝŬĞ ? ĨŝĨƚĞĞŶ ŝƚĞŵƐ ? ĞĐĂƵƐĞ ƵŶůĞƐƐ ǇŽƵ ?ǀĞ ŐŽƚ ƚǁŽ ƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶ ǁŚŝĐŚ ĐĂƐĞ ŝƚ ?Ɛ ŶŽ
problem whatsoevĞƌ ? ďƵƚ ŝĨ ǇŽƵ ?ǀĞ ŽŶůǇ ŐŽƚ ŽŶĞ ƉŚĂƌŵĂĐŝƐƚ ĂŶĚ ƚŚĞǇ ?ƌĞ ŽŶ ĂďŽƵƚ
ĨŝĨƚĞĞŶ ?ƚǁĞŶƚǇŝƚĞŵƐ ?ǇŽƵũƵƐƚƌĞĂůůǇĐĂŶ ?ƚǁĂƌƌĂŶƚƚŚĂƚƚŝŵĞĨŽƌƉŚĂƌŵĂĐŝƐƚƐŶŽƚƚŽďĞ
checking walk-in prescriptions. 
Dispenser, Multiple  
 
:ĂŶĞ P  QǇŽƵƐĞĞĂŵĂƐƐŝǀĞƐĐƌŝƉƚ ?ǇŽƵƚŚŝŶŬ /ĚŽŶ ?t want to do an MUR on that.  But 
though, probably they would be the best people who would get the most out of it.  You 
ƐĞĞ Ă ƉƌĞƐĐƌŝƉƚŝŽŶ ƚŚĂƚ ?Ɛ ŐŽƚ ŵĂǇďĞ ƚǁŽ ŝƚĞŵƐ ŽŶ ŝƚ ? ĚĞĂĚĞĂƐǇ QƚŚĞ ĞŵƉŚĂƐŝƐ ŝƐ ŽŶ
ƚĂƌŐĞƚƐƐŽŝƚ ?ƐƋƵĂŶƚŝƚǇĂŶĚŶŽƚŶĞĐĞƐƐĂƌŝůǇƋƵĂůŝƚǇ Qo^ I think people are trying to get, 
do the easiest ones possible to get the numbers rather than concentrating on getting 
those that perhaps would benefit from it. 
  Employee pharmacist, Multiple  
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Jane, (pharmacist) had the most overt view and explained that she purposefully chose patients 
on fewer medications being driven by the need to achieve organisational MUR targets. 
WŚĂƌŵĂĐŝƐƚƐ ? views on this organisational pressure are discussed further in section 7.3.7. 
Another group of patients that were reportedly avoided were patients prescribed medication 
for mental illness. Four out of the five pharmacists interviewed reported this aversion: 
 
>ŝŶĚĂ P/ƐƵƉƉŽƐĞ ?ŝĨǇŽƵ ?ĚŐŽƚƉƐǇĐŚŝĂƚƌŝĐƉĂƚŝ- [pause] ǁĞůů ?/ĚŽŶ ?ƚŬŶŽǁǁŚĞƚŚĞƌǇŽƵ ?Ě
pick them out. You know, people that are on a lot of medication, you know, psych- you 
ŬŶŽǁ ? ƚŚĞǇ ĂƌĞ ƉĞƌŚĂƉƐ Ă ďŝƚ ŵŵŵ Qŝƚ ?Ɛ Ă ĨŝĞůĚ ƚŚĂƚ / ?ŵ ŶŽƚ ƌĞĂůůǇ ƚŽŽ ĐŽŶĨŝĚĞŶƚ
ĂďŽƵƚ QŵŽƐƚ ŽĨ ƚŚĞŵ ƚŚĞǇ ?ƌĞ ƵŶĚĞƌa ƉƐǇĐŚŝĂƚƌŝƐƚ ? ƚŚĞǇ ?ƌĞ ƵŶĚĞƌ ƐƉĞĐŝĂůŝƐƚ
ƚƌĞĂƚŵĞŶƚ QĂŶĚ/ ?ĚŚĂǀĞƚŚŽƵŐŚƚ ?ďǇƚŚĞŶ ?ƚŚĞǇ ?ĚŬŶŽǁŚŽǁƚŽƚĂŬĞƚŚĞŝƌŵĞĚŝĐĂƚŝŽŶ Q 
  Locum pharmacist, Independent   
 
<ĂƚĞ P  Q/ ƚĞŶĚ ƚŽ ĨŝŶĚ ƚŚĞ ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ŽŶĞƐ ĂƌĞ ƚŚĞ ŵŽƐƚĞĂƐŝĞƐƚ ďĞĐĂƵƐĞ / ?ǀĞ ŐŽƚ
more of an in-depth knowledge over it.  Whereas I tend to brush over those who are 
anti-psychotics or depression, because, just being a really sensitive topic, and I 
ǁŽƵůĚŶ ?ƚŬŶŽǁŚŽǁƚŽĂƉƉƌŽĂĐŚŝƚ ? 
  Employee pharmacist, Multiple  
 
Pharmacists reported feeling less confident speaking to people who took either 
antidepressants or antipsychotics medicines because they were anxious about prying into their 
personal circumstances. They questioned the value of MURs for these patients and were 
ĂǀĞƌƐĞƚŽĚŝƐĐƵƐƐŝŶŐǁŚĂƚǁĞƌĞĚĞƐĐƌŝďĞĚĂƐ  “sensitive ? ŝƐƐƵĞƐ ?WĂƚŝĞŶƚƐ ƚĂŬŝŶŐŵĞĚŝĐŝŶĞƐ ĨŽƌ
psychiatric problems were assumed to be under the  “specialist ?and so were perceived by two 
pharmacists to be less in need of an MUR. One pharmacist reported that these patients 
probably required more support but thought that it would be too time consuming and they 
 “may not understand it ? ?Although pharmacists reported an aversion to performing MURs with 
patients with mental illness, the observations revealed little evidence that these patients were 
avoided in practice. Indeed 9 of the 54 MUR performed were with patients taking an 
antidepressant or an antipsychotic medication.      
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7.3.4 The invitation 
All pharmacists described difficulty in recruiting patients for an MUR because of a lack of 
ƉĂƚŝĞŶƚĂǁĂƌĞŶĞƐƐŽĨƚŚĞƐĞƌǀŝĐĞ ?WŚĂƌŵĂĐŝƐƚƐĚĞƐĐƌŝďĞĚŝŶƚŚĞŝƌŝŶƚĞƌǀŝĞǁƐƉĂƚŝĞŶƚƐ ?ƌĞƐŝƐƚĂŶĐe 
to their request when they invited them for an MUR:  
 
ZŽƐĞ P QƐŽŵĞƚŝŵĞƐǇŽƵŐĞƚƉĞŽƉůĞǁŚŽĨĞĞůǁŚǇŝƐƚŚŝƐƉŚĂƌŵĂĐŝƐƚƚĂůŬŝŶŐƚŽŵĞ ?>ŝŬĞ ?
ŽŶĞŐƵǇ ?ŚĞďĞŐƌƵĚŐŝŶŐůǇĚŝĚĂŶŝŶƚĞƌǀŝĞǁ ?ŶĚƐŽŵĞƚĂďůĞƚƐŚĞǁĂƐŽŶŚĞĚŝĚŶ ?ƚĞǀĞŶ
ŬŶŽǁǁŚǇŚĞǁĂƐŚĂǀŝŶŐƚŚĞŵ Q 
Pharmacist and proprietor, Independent    
 
<ĂƚĞ P  QƚŚĞƌĞ ?Ɛ ũƵƐƚŶŽƚĞŶŽƵŐŚĂǁĂƌĞŶĞƐƐŽĨ ŝƚ ? ^ŽƚŚĞǇǁŽƵůĚĂƵƚŽŵĂƚŝĐally assume 
ŝƚ ?ƐũƵƐƚĂ ?ŶĂŵĞƐŽŵƉĂŶǇ ?ƚŚŝŶŐ ?ŶĚƚŚĞǇƚŚŝŶŬƚŚĂƚǁĞ ?ƌĞũƵƐƚŚĂƐƐůŝŶŐƚŚĞŵ ? 
  Employee pharmacist, Multiple  
 
Pharmacists reported trying to convince patients of an activity that the patient did not 
perceive as necessary. Pharmacists mandate to undertake an MUR with a patient was not 
perceived to be fully accepted or acknowledged by patients. This is explored further in the next 
section. When pharmacists were asked about external support for promoting the service, such 
as from the GP or PCT, they reported receiving little assistance. The owner of the independent 
pharmacy was particularly scathing and annoyed that the service had been slowly adopted by 
the pharmacy because of poor promotion of the service to patients: 
 
ZĞƐĞĂƌĐŚĞƌ P QǁŚĂƚƐƵƉƉŽƌƚŚĂǀĞǇŽƵŚĂĚĨƌŽŵƚŚĞWd ? 
Rose: EŽŶĞ QtĞ ?ǀĞ ŚĂĚ ĐƌŝƚŝĐŝƐŵ ƚŚĂƚ ǁĞ ?ƌĞ ŶŽƚ ĂĐŚŝĞǀŝŶŐ ƚŚĞ DhZ ƚĂƌŐĞƚƐ QƚŚĞǇ
ŚĂǀĞŶ ?ƚŵĂƌŬĞƚĞĚƚŚĞƐĞƌǀŝĐĞƉƌŽƉĞƌůǇ ?ƚŚĞǇ ?ǀĞďĞĞŶƉĂƚŚĞƚŝĐ ? 
Pharmacist and proprietor, Independent    
 
When support staff were asked about their experiences of how they invited patients for an 
MUR their lack of training became evident. In their accounts, it became evident that there was 
a lack of tailoring of the potential benefits of MURs ƚŽ ŝŶĚŝǀŝĚƵĂůƉĂƚŝĞŶƚƐ ?ĐŝƌĐƵŵƐƚĂŶĐĞĂŶĚ
preference. Their response was akin to that observed in the pharmacy:   
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Researcher:  And how do you approach the patient?  What do you say? Do you think 
they know what the purpose is when you do ask them? 
Dorothy:  Probably not, no.  I ŵĞĂŶ ?ǇŽƵũƵƐƚƐĂǇ ?ǇŽƵŬŶŽǁ ? “ŽŚŝƚ ?ƐƚŽĐŚĞĐŬƚŚĂƚǇŽƵ
understand how you take your medicines and ƐĞĞŝĨǇŽƵ ?ǀĞŐŽƚĂŶǇƉƌŽďůĞŵƐ ?and once 
you get them in there, then, yeaŚ ?ƚŚĞǇ ?ƌĞĂůůƌŝŐŚƚ ? 
Dispenser, Multiple 
 
Lucy P^ŽũƵƐƚĂƋƵĞƐƚŝŽŶŽĨƐĂǇŝŶŐ “ǁĞ ?ƌĞŽĨĨĞƌŝŶŐĂĨƌĞĞƐĞƌǀŝĐĞ ?/ĚŽŶ ?ƚŬŶŽǁǁŚĞƚŚĞƌ
ǇŽƵŬŶŽǁĂďŽƵƚ ŝƚ ? / ƚŚŝŶŬǇŽƵ ?Ě ĨŝŶĚ ŝƚƋƵŝƚĞƵƐĞĨƵů ƚŽǇŽƵƌƐĞůĨ ?ǁĞĐĂŶŵĂŬĞǇŽƵĂŶ
appointment. Come in and speak to the pharmacist at a time that is convenient to 
ǇŽƵƌƐĞůĨ ?ŽŵĞĂŶĚŚĂǀĞĂĐƵƉŽĨƚĞĂǁŝƚŚƵƐ ?ǇŽƵŬŶŽǁĞ ?ůl make you feel sort of at 
ŚŽŵĞ ? and that sort of thing.  
Dispenser, Independent  
 
The lack of clarity of what the MUR involved and could offer the patient was shown to be a 
reason why patients reported declining the invitation for the MUR (Chapter Six, section 
6.4.2.2). The problem of recruiting patients was so problematic that a couple of the dispensers 
had adopted strategies to convince patients to undertake an MUR, rather than relying on 
conveying the benefits of the MUR to patients: 
  
ĂǁŶ QǁŚĂƚ / ƚĞŶĚ ƚŽ ĚŽ ŝƐ ? ǁŚĞŶ ƚŚĞǇ ŚĂŶĚ ƚŚĞ ƉƌĞƐĐƌŝƉƚŝŽŶ ŝŶ / ?ůů ũƵƐƚ ƐĂǇ  “/ ?ůů ũƵƐt 
ĐŚĞĐŬǁĞ ?ǀĞŐŽƚƚŚĞŵŝŶƐƚŽĐŬ ? ?/ ?ŵŶŽƚĂĐƚƵĂůůǇďĞĐĂƵƐĞ/ ?ŵůŽŽŬŝŶŐŽŶƚŚĞƌĞĐŽƌĚƐƚo 
ƐĞĞ ŝĨ ƚŚĞǇĐĂŶŚĂǀĞĂŶDhZ QŶĚƚŚĞŶ ? /ĐĂŶƐĂǇƚŽƚŚĞŵ “KŚ ?ǇĞĂŚ ?ĞǀĞƌǇƚŚŝŶŐ ?Ɛ ŝŶ
ƐƚŽĐŬ ?ǁŚŝůĞ ǇŽƵ ?ƌĞ ǁĂŝƚŝŶŐ ? ŝƚ ?Ɛ ŐŽŝŶŐ ƚŽ ďĞ ĨŝǀĞŵŝŶƵƚĞƐ ? ĚŽ ǇŽƵŵŝŶĚ ŚĂǀing a chat 
ǁŝƚŚƚŚĞƉŚĂƌŵĂĐŝƐƚ ? ? Q 
Dispenser, Multiple  
 
>ƵĐǇ P  Q/ ƚŚŝŶŬ ŝƚ ?Ɛ ũƵƐƚ ƐĂǇŝŶŐ ƚŚŝŶŐƐ ůŝŬĞ  “oh Mr Smith it looks like you might have 
ƐůŝƉƉĞĚƚŚƌŽƵŐŚŽƵƌŶĞƚƐ ?ǁĞ ?ǀĞŶŽƚĂƐŬĞĚǇŽƵĨŽƌĂn DhZ ? ?zŽƵŬŶŽǁ “we really need 
to be speaking to you ?  ‘/ ?ŵƌĞĂůůǇƐŽƌƌǇ ƚŚĂƚǁĞŚĂǀĞŶŽƚĂƐŬed ǇŽƵďĞĨŽƌĞďƵƚǁĞ ?ǀĞ
ŐŽƚƚŚŝƐĨƌĞĞƐĞƌǀŝĐĞĂŶĚǇŽƵŬŶŽǁǁĞ ?d lŝŬĞƚŽŝŶǀŝƚĞǇŽƵƚŽĐŽŵĞŝŶ ? QƐŽŝƚ ?ƐĂůŝƚƚůĞďŝƚ
ŽĨƐƉŝĞůŝƐŶ ?ƚŝƚ ? 
Dispenser, Independent  
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The lack a lack of interest from patients resulted in some support staff having to use creative 
ways to persuade patients to undertake an MUR. The following section will describe staff 
ǀŝĞǁƐŽŶƉĂƚŝĞŶƚƐ ?ƌĞƐƉŽŶƐĞƚŽƚŚĞŝƌŝŶǀŝƚĂƚŝŽŶto have an MUR. 
 
7.3.4.1 VŝĞǁƐŽŶƉĂƚŝĞŶƚƐ ?ƌĞƐƉŽŶƐĞƚŽƚŚĞŝŶǀŝƚĂƚŝŽŶ 
Pharmacy staff described a range of responses when they invited patients for an MUR. A few 
indicated that some patients were keen to accept the invitation. However, as described in 
Chapter Six section 6.4.2, a lack of time appeared to be the main reason given by patients for 
declining the invitation:  
 
ĂƚŚ Q/ ŵĞĂŶ Ă ůŽƚ ŽĨ ƉĞŽƉůĞ ĂƌĞ ƌĞĂůůǇ ƵƉ ĨŽƌ ŝƚ ? /ŵĞĂŶ ƚŽƵĐŚ wood the majority of 
customers thaƚǁĞŚĂǀĞĂƉƉƌŽĂĐŚĞĚŚĂǀĞďĞĞŶ “ŽŚǇĞĂŚƚŚĂƚ ?ƐĨŝŶĞ ? Q 
Counter assistant, Independent  
 
ZĞďĞĐĐĂ P Q/ƚ ?ƐĂƐŚĂŵĞƚŚĂƚƉĂƚŝĞŶƚƐĚŽŶ ?ƚĨĞĞůƚŚĂƚƚŚĞŝƌĂƉƉŽŝŶƚŵĞŶƚƐĂƌĞŝŵƉŽƌƚĂŶƚ
enough to come to, you know, very few of them do Q 
   Employee pharmacist, Independent  
 
Some respondents described how some patients were simply indifferent towards the 
invitation for an MUR. The reasons they mentioned for patients not turning up to 
appointments included the lack of awareness of the service and the low importance attached 
to MUR activity. One dispenser explained that in her experience these attitudes were not 
ĞǆĐůƵƐŝǀĞƚŽDhZƐďƵƚĂůƐŽƚŽƌĞǀŝĞǁƐĂƚƚŚĞĚŽĐƚŽƌ ?ƐƐƵƌŐĞƌǇ P 
 
ŽƌŽƚŚǇ P QĂŶĚǁĞƚƌǇĂŶĚƚĞůůƚŚĞŵƚŚĞƉŽŝŶƚŽĨŝƚďƵƚǇŽƵĐĂŶƐee them thinking,  “No, 
ŶŽ ?/ ?ŵĂůůƌŝŐŚƚ ? QǇŽƵ ?ůůƚĞůůƚŚĞŵƚŚĞǇ ?ƌĞĚƵĞĨŽƌĂƌĞǀŝĞǁĂƚƚŚĞĚŽĐƚŽƌƐ ? “oh no, not 
bothered going there, what have I got to go there for? I ŬŶŽǁǁŚĂƚ/ ?ŵĚŽŝŶŐ ? Q 
Dispenser, Multiple 
 
Patients were seen to decline the invitation for an MUR because they reported to pharmacy 
staff that they ĂůƌĞĂĚǇŚĂĚĂŵĞĚŝĐĂƚŝŽŶƌĞǀŝĞǁĂƚƚŚĞŝƌĚŽĐƚŽƌ ?ƐƐƵƌŐĞƌǇ ?WŚĂƌŵĂĐŝƐƚƐƌĞƉŽƌƚĞĚ
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that patients misunderstood or could not distinguish between the request to undertake an 
MUR in the pharmacy and the medication reviews offered at their GP practice:   
 
<ĂƚĞ P QƚŚĞǇƐĂǇ “ŽŚ ?/ ?ǀĞ Ăůƌ ĂĚǇŚĂĚŝƚǁŝƚŚƚŚĞĚŽĐƚŽƌ ? ĂŶĚŝƚ ?ƐũƵƐƚůŝŬĞĂƚƵŐŽĨǁĂƌ ?
zŽƵ ?ƌĞďĂƚƚůŝŶŐǁŝƚŚƚŚĞŵ ?ǇŽƵŬŶŽǁ ?ŝŶŽƌĚĞƌĨŽƌƚŚĞŵƚŽƐĂǇǇĞƐ ?ĂŶĚƚŚĞŶǇŽƵŐĞƚƚŚĞ
vibe off them, that wĞĚŽŶ ?ƚǁĂŶƚƚŽ QĂŶĚƚŚĞŶǇŽƵũƵƐƚďĂĐŬŽĨĨ Q
  Employee pharmacist, Multiple  
 
:ĂŶĞ P Q^ŽŵĞ ƉĞŽƉůĞ ŵŝƐƵŶĚĞƌƐƚĂŶĚ ? ƚŚĞǇ ƚŚŝŶŬ ƚŚĂƚ ǇŽƵ ŐĞt the review done at the 
doctorƐ ?dŚĞǇĚŽŶ ?ƚƐĞĞƚŚĞƉŽŝŶƚŽĨƚŚŝƐ ?ďƵƚŽŶĐĞǇŽƵŐĞƚƚŚĞŵŝŶƚŚĞƌĞ ?/ƚŚŝŶŬŵŽƐƚŽĨ
the timĞƚŚĞǇƋƵŝƚĞĞŶũŽǇŝƚ Q 
  Employee pharmacist, Multiple  
 
Support staff also described how they struggled to explain the difference between MURs and 
GP medication reviews. A few suggested that the service name should be changed as patients 
frequently confused MURs with medication reviews conducted at the GP surgery. It became 
apparent from support staff interviews that there was a lack of insight into how an MUR 
differed from a medication review:  
 
Researcher:  Why do they decline? 
DorŽƚŚǇ P  QƚŚĞǇ ŶĞĂƌůǇ ĂůǁĂǇƐ ƐĂǇ ?  “ŽŚ ? / ?ǀĞ ũƵƐƚ ŚĂĚ ŽŶĞ ǁŝƚŚ ƚŚĞ ĚŽĐƚŽƌ ? and we 
ĞǆƉůĂŝŶƚŽƚŚĞŵƚŚĂƚƚŚŝƐŝƐ ?ǇŽƵŬŶŽǁ ?ŝƚ ?ƐŶŽƚŝŶƐƚĞĂĚŽĨƚŚĂƚ ?ŝƚ ?ƐƐŽƌƚŽĨ ?ďǇƚŚĞƐŝĚĞŽĨ
that. But, some of them are OK but the otŚĞƌƐ “ŽŚŶŽ ?ŶŽ ?/ĐĂŶ ?ƚďĞďŽƚŚĞƌĞĚ ? Q 
Dispenser, Multiple 
 
Cath:  QŵŽƐƚƉĞŽƉůĞǁŚĞŶǇŽƵĂƐŬƚŚĞŵƚŚĞǇƐĞĞŵƚŽƚŚŝŶŬƚŚĂƚƚŚĞǇŚĂǀĞ them done 
at the doctors, they ?ƌĞůŝŬĞ “ǁĞůů/ ?ǀĞŚĂĚŵǇƌĞǀŝĞǁĂƚƚŚĞĚŽĐƚŽƌƐ ?. SŽŝƚ ?ƐůŝŬĞƚƌǇŝŶŐ ?
ĞǀĞŶƚŚŽƵŐŚŝƚ ?ƐƚŚĞƐĂŵĞƐŽƌƚŽĨƚŚŝŶŐ ?ŝƚ ?ƐŶŽƚƚŚĞƐĂŵĞƚŚŝŶŐ ?ŝƚ ?ƐƐŝŵŝůĂƌ Q 
Counter assistant, Independent  
 
A lack of training for support staff may have been responsible for their poor ability to 
effectively communicate to the patient the difference between an MUR and medication review. 
When staff were asked about how they felt when patients declined the invitation, most did not 
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seem to mind. However, one MCA appeared to be adversely affected. She described how the 
refusal for an MUR had impacted negatively on her confidence to approach subsequent 
patients: 
 
ĂƚŚ P Qŝƚ ?ƐůŝŬĞďĞŝŶŐĂƐĂůĞƐƉĞƌƐŽŶ QůŝŬĞĂĚŽŽƌƚŽĚŽŽƌƐĂůĞƐƉĞƌƐŽŶ ?ŚŽǁŵĂŶǇŬŶŽĐŬ
ďĂĐŬƐĐĂŶǇŽƵƚĂŬĞ ?ŶĚǇŽƵũƵƐƚƚŚŝŶŬŽŚŚ QĂŶĚŝĨƚŚĞǇƐĂǇŶŽ, it sort of puts me off a 
ďŝƚĂƐŬŝŶŐƚŚĞŶĞǆƚƉĞƌƐŽŶďĞĐĂƵƐĞǇŽƵůŽƐĞǇŽƵƌĐŽŶĨŝĚĞŶĐĞĂďŝƚ QŝƚĚŽĞƐŬŶŽĐŬŵĞŝĨ
someone turns you down. /ĚŽŶ ?ƚůŝŬĞƉĞŽƉůĞƐĂǇŝŶŐŶŽ ? 
Counter assistant, Independent  
 
MURs were offered less frequently within the independent pharmacy and in a less busy 
environment compared with the multiple. Being a MCA and therefore in full view of the public, 
as well as being unable to withdraw out of sight into the relative comfort of the dispensary, 
may have impacted upon Cath more than the dispensing staff. Despite reporting difficulties in 
recruitment, all staff broadly welcomed the MUR service. The following section will explore 
ƚŚŝƐĨƵƌƚŚĞƌƐƚĂƌƚŝŶŐǁŝƚŚƉŚĂƌŵĂĐŝƐƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨDhZƐ ? 
 
7.3.5 WŚĂƌŵĂĐŝƐƚƐ ?ǀŝĞǁƐĂŶĚƉĞƌĐĞŝǀĞĚǀĂůƵĞŽĨDhZƐ 
ůůƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĂĐĐŽƵŶƚƐĐŽŶǀĞǇĞĚƚŚĂƚƚŚĞǇĞŶũŽǇĞĚĐĂƌƌǇŝŶŐŽƵƚDhZĐŽŶƐƵůƚĂƚŝŽŶƐĂŶĚ
that they thought most patients did benefit from these. A couple of pharmacists indicated the 
extent to which patients found the MUR useful varied according to their prior knowledge of 
their medicines:  
 
ZĞƐĞĂƌĐŚĞƌ P QĂƚƚŚĞĞŶĚ ?ǇŽƵƌĞĐŬŽŶŝƚĚŽĞƐŝŶĐƌĞĂƐĞƚŚĞƉĂƚŝĞŶƚ ?ƐŬŶŽǁůĞĚŐĞ ?ƵƐĞŽĨ
their medicine? 
:ĂŶĞ P  Q/ ƚŚŝŶŬ ƐŽ ? EŽƚ ? ŶŽƚ Ă ŚƵŶĚƌĞĚ ƉĞƌĐĞŶƚ ŽĨ ƚŚĞ ƚŝŵĞďƵƚ / ǁŽƵůĚ ƐĂǇ Ă ĚĞĐĞŶƚ
percentage, probably seventy percent.  
Employee pharmacist, Multiple 
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ZĞƐĞĂƌĐŚĞƌ P  Ž ǇŽƵ ƚŚŝŶŬ ŝƚ ĂĐƚƵĂůůǇ ŝŵƉƌŽǀĞƐ ƚŚĞ ŬŶŽǁůĞĚŐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
medication and their use? 
ZĞďĞĐĐĂ P/ƚŚŝŶŬƐŽ ?ďĞĐĂƵƐĞƚŚĞĂŵŽƵŶƚŽĨƚŝŵĞƐƉĞŽƉůĞǁŝůůƐĂǇƚŽǇŽƵ ? ‘ƐŝŵǀĂƐƚĂƚŝŶ ?
ƚŚĂƚ ?ƐĨŽƌŵǇďůŽŽĚƉƌĞƐƐƵƌĞ ?ŽƌƐŽŵĞƚŚŝŶŐůŝŬĞƚŚĂƚ ?EŽ ?ĂĐƚƵĂůůǇ ?ƚŚĂƚ ?ƐƚŽůŽǁĞƌǇŽƵƌ
ĐŚŽůĞƐƚĞƌŽů ?ĚĞƌĚĞƌĚĞƌ Q 
ZĞƐĞĂƌĐŚĞƌ P QĂůŽƚŽĨƉĞŽƉůĞĂƌĞŽŶƌĞŐƵůĂƌŵĞĚŝĐŝŶĞƐ Q/ŶƚŚĞƐĞĐŝƌĐƵŵƐƚĂŶĐĞƐ ?ĚŽǇŽƵ
ƚŚŝŶŬŝƚŝŶĐƌĞĂƐĞƐƚŚĞŝƌŬŶŽǁůĞĚŐĞŽƌƚŚĞŝƌƵƐĞĂƚĂůů Q ? 
ZĞďĞĐĐĂ P/ĚŽŶ ?ƚƚŚŝŶŬŝƚ ŝŶĐƌĞĂƐĞƐƚŚĞŝƌŬŶŽǁůĞĚŐĞŽƌƵƐĞďƵƚĂƚůĞĂƐƚĂŐĂŝŶ ?ǇŽƵĐĂŶ
reiterate that look, ŝƚ ?ƐƚŽďĞƚĂŬĞŶĂƚŶŝŐŚƚƚŝŵĞ QƚŚĂƚ ?ƐƚŚŝŶŐƐĚŽĐƚŽƌƐĚŽŶ ?ƚŶŽƌŵĂůůǇ
ĚŝƐĐƵƐƐ ?ƚŝŵŝŶŐƐĂŶĚƐƚƵĨĨ Q 
   Employee pharmacist, Independent  
 
WŚĂƌŵĂĐŝƐƚƐƌĞĐŽŐŶŝƐĞĚƚŚĂƚŶŽƚĂůůƚŚĞDhZƐƚŚĞǇƉĞƌĨŽƌŵĞĚŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞŽƌ
use of their medicines. The MUR provided pharmacists with an opportunity to impart 
information to patients about their medicines and to resolve, what they perceived to be, minor 
issues such as patient queries about when medication could be taken. As well as benefitting 
patients, MUR activity was seen to provide personal benefits to pharmacists. MURs were 
viewed as a means to vary the work activities of the day and seen as a break from the 
pressures of routine dispensing work:  
 
>ŝŶĚĂ P QŝĨ/ǁĞŶƚĂŶĚĚŝĚĂůŽĐƵŵĂŶĚǁĞŶƚŝŶƚŽǁŽƌŬĂŶĚƚŚĞǇƐĂŝĚ ? “Right, we got five 
MURs in this morning ? ? ďƵƚ ƚŚĞƌĞ ?Ɛ ƐŽŵĞ ŽƚŚĞƌ ƉŚĂƌŵĂĐŝƐƚ Q/ ?Ě ďĞ ƋƵŝƚĞ ŚĂƉƉǇ ƚŽĚŽ
ƚŚĂƚ ?ĞĐĂƵƐĞƐŽŵĞƚŝŵĞƐ ?ŝƚĚŽĞƐŐĞƚƚĞĚŝŽƵƐ ?ƚŚĞĚŝƐƉĞŶƐŝŶŐƐŝĚĞŽĨŝƚĚŽĞƐ Q/ƚŚŝŶŬŝƚ
just gives you a break from that, and I do prefer that actually. 
  Locum pharmacist, Independent 
 
Kate P Q/ƚŚŝŶŬƚŚĞƌĞ ?ƐŵŽƌĞƉĂƚŝĞŶƚŝŶƚĞƌĂĐƚŝŽŶĂŶĚ/ůŝŬĞƚŚĂƚ ? I do enjoy it because that 
ǁĂƐŵǇǁŚŽůĞƉƵƌƉŽƐĞŝŶǁĂŶƚŝŶŐƚŽďĞĐŽŵĞĂƉŚĂƌŵĂĐŝƐƚ Q 
  Employee pharmacist, Multiple  
 
Pharmacists reported welcoming the greater patient contact that MURs offered. The process 
of undertaking and preparing for the MUR was also an impetus for them to keep up to date 
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with clinical knowledge. MURs also were seen as an opportunity to learn about the patient 
condition(s):   
 
ZŽƐĞ P  Q/ ǁŽŶ ?ƚ ƐĂǇ ŝƚ ?Ɛ Ăůů ŽŶĞ ǁĂǇ ? ^ŽŵĞ ƉĞŽƉůĞ, you know, you pick up a lot from 
ƚŚĞŵ ?ƉĂƌƚŝĐƵůĂƌůǇƉĞŽƉůĞǁŚŽ ?ǀĞŚĂĚĂůůƐŽƌƚƐŽĨĐĂƌĚŝŽǀĂƐĐƵůĂƌĞƉŝƐŽĚĞƐ Q 
Pharmacist and proprietor, Independent    
 
ZĞďĞĐĐĂ P Q /ƚŚŝŶŬ ?ĂƐĂĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚŝŶĂĚŝƐƉĞŶƐŝŶŐƌŽůĞ ?ǇŽƵĚŽŶ ?ƚƵƐĞƚŚĂƚ
much of your knoǁůĞĚŐĞ ? /ǁŝůůĂĚŵŝƚ ƚŚĂƚ ŝƚŐŽĞƐĂ ůŝƚƚůĞďŝƚĂƐǁĞůů QŶĚ / ƚŚŝŶŬ ƚŚŝƐ
would keep it up to date, as long as you were allowed to do them rather than just  ‘off 
the top DhZƐ ? ?ƚŚĞǇǁŽƵůĚŶĞĞĚƚŽďĞ ? “K< ?ǁŚĂƚ ?ƐǇŽƵƌŵĞĚŝĐĂůŚŝƐƚŽƌǇ ?, go through it, 
do a bit ŽĨƌĞƐĞĂƌĐŚ Q 
   Employee pharmacist, Independent  
 
Pharmacists reported welcoming greater patient involvement and recognised the patient as a 
source of information. However, their responses also revealed reservations about becoming 
 ‘ŽǀĞƌůǇ ?ŝŶǀŽůǀĞĚin more complex medicine-related issues that patients sometimes presented. 
These issues are further explored in section 7.6. Although pharmacists indicated aversion to 
greater involvement with issues relating to medicines, MURs were potentially valued as a way 
to enhance their professional status with the public. However, the impact of this was seen to 
be limited:  
 
ZĞďĞĐĐĂ P QƚŚĞǇ ?ƉĂƚŝĞŶƚƐ ?ŬŶŽǁƚŚĂƚŝƚ ?ƐŶŽƚĂŶĞĐĞƐƐŝƚǇ ?ďĞĐĂƵƐĞůŝŬĞ ?ƚŚĞĚŽĐƚŽƌ ?ǇŽƵ
have to go so that you can get your meds. I guess maybe, if it was like the same in a 
pharmacy, ǁŚĞƌĞ ǇŽƵ ŬŶŽǁ ? ǇŽƵ ĐĂŶ ?ƚ ƵƐĞ ƚŚĞ ƉŚĂƌŵĂĐǇ ƚŝůů ǇŽƵ ?ǀĞŚĂĚ ǇŽƵƌ DhZ ?
[laughter] then maybe it would make a difference. 
   Employee pharmacist, Independent   
 
Jane: I think rather than becoming a glorified dispenser, you become more involved in 
ǁŚĂƚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƵŶĚĞƌƐƚĂŶĚŝŶŐof their ŵĞĚŝĐĂƚŝŽŶ ? ŚŽǁ ƚŚĞǇ ?ƌĞ ŐĞƚƚŝŶŐ ŽŶǁŝƚŚ ŝƚ
and get to know them more as a person. 
  Employee pharmacist, Multiple  
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Pharmacists commented that the MUR service was not being perceived by patients to be an 
essential part of their care. Integrating MURs into their routine workload was also seen to be 
problematic and these issues are discussed in the next section.    
 
7.3.6 Integration of MURs into the existing workload  
All pharmacists reported struggling in some way to perform MURs alongside the existing 
service provision. The unpredictable nature of the workload of the pharmacy meant that 
pharmacists perceived that they had no spare time to perform MURs. When they did occur, 
pharmacists reported that MURs were performed quickly and efficiently in order to return to 
other responsibilities:   
 
ZŽƐĞ P  Q/ ĚŽŶ ?ƚ ƚŚŝŶŬ ƉĞŽƉůĞ ƵŶĚĞƌstand the logistics of pharmacy and the pressure. 
MĂǇďĞƚŚĂƚ ?ƐǁŚǇ ?ǇŽƵŬŶŽǁ ?ƚŚĞƐĞƐŽƌƚƐŽĨƚŚŝŶŐƐƐŚŽƵůĚďĞĚŽĐƵŵĞŶƚĞĚĂďŽƵƚĂůů the 
other things that we do, and how relevant are all of those. Is it important to manage 
walk-ins [prescriptions]?  Is it important to manage everything else? 
Pharmacist and proprietor, Independent    
 
<ĂƚĞ P QŝĨŝƚǁĂƐůŝŬĞĂƚĞŶŝƚĞŵŽŶĞ ?prescription] yŽƵŬŶŽǁǇŽƵ ?ƌĞŐŽŝŶŐƚŽƐƉĞŶĚƐŽŵĞ
time with them. And I hate to be out of the dispensary for about half an hour, 
ĞƐƉĞĐŝĂůůǇŝĨ/ǁĂƐŽŶůǇďǇŵǇƐĞůĨ QǇŽƵŚĂǀĞƚŽĐŽŶƐŝĚĞƌŽƚŚĞƌƚŚŝŶŐƐ ?ďĂƐŝĐĂůůǇ ? 
  Employee pharmacist, Multiple  
 
Pharmacists were conscious of spending too much time away from the dispensary because 
they feared that when they returned they would be greeted with a backlog of prescriptions to 
be checked that had subsequently built up. This affected the way they approached the MUR 
consultation: 
 
:ĂŶĞ P QǁŚĞŶǇŽƵŬŶŽǁƚŚĂƚǇŽƵ ?ƌĞĞǆĐĞƉƚŝŽŶĂůůǇďƵƐǇ ?ŝƚƉƵ ƐǇŽƵƵŶĚĞƌĂƉƌĞƐƐƵƌĞĂŶĚ
you really just want to get through that, those questions as quickly as possible.  
ĞĐĂƵƐĞ ?ǇŽƵŬŶŽǁǇŽƵ ?ƌĞŐŽŝŶŐƚŽŐŽďĂĐŬƚŽďĞĚůĂŵ QzŽƵĐĂŶ ?ƚƐǁŝƚĐŚŽĨĨĨƌŽŵƚŚĂƚ 
becaƵƐĞƚŚĂƚ ?ƐƉĂƌƚŽĨǇŽƵƌƌĞƐƉŽŶƐŝďŝůŝƚǇĂƐǁĞůů ? 
  Employee pharmacist, Multiple  
Chapter Seven: The views of pharmacy staff 
188 
 
 
>ŝŶĚĂ P QǇŽƵĚŽůŝƐƚĞŶƚŽƚŚĞŵ ?ƉĂƚŝĞŶƚƐ ?ďƵƚǇŽƵƚŚŝŶŬ ?ŽŚ / ?ǀĞŐŽƚƚŽŐĞƚďĂĐŬ ?/ ?ǀĞŐŽƚ 
ƚŽŐĞƚďĂĐŬ ?ǇŽƵŬŶŽǁ ?/ĐĂŶ ?ƚ be talking to you too long here. 
  Locum pharmacist, Independent   
 
There was agreement among pharmacists that the whole process, from conducting an MUR 
with a patient through to completing the associated paperwork, was lengthy and its 
integration into the services provided by the pharmacy was ill thought out:  
 
:ĂŶĞ PdŚĞŝĚĞĂůƚŚŝŶŐǁŽƵůĚďĞƚŽĐƵƚďĂĐŬŽŶƚŚĞƉĂƉĞƌǁŽƌŬƐŝĚĞŽĨƚŚŝŶŐƐ QǁĞŚĂǀĞƚŽ
ŶŽƚĞĚŽǁŶŽŶƚŚĞďŽĂƌĚƚŚĂƚǇŽƵ ?ǀĞĚŽŶĞŝƚ ?ǇŽƵŚĂǀĞƚŽƌŝŶŐŝƚŝŶƚŚĞƚŝůů ?ǇŽƵŶĞĞĚƚŽ
ŶŽƚĞŝƚĚŽǁŶĂƚƚŚĞĞŶĚŽĨƚŚĞĚĂǇƚŚĂƚǇŽƵ ?ǀĞĚŽŶĞŝƚ ?ǇŽƵŚĂǀĞƚŽĨŝůĞŝt away at the 
ĞŶĚŽĨƚŚĞŵŽŶƚŚ ?ǇŽƵŚĂǀĞƚŽŶŽƚŝĨǇƚŚĞĚŽĐƚŽƌƚŚĂƚǇŽƵ ?ǀĞĚŽŶĞŝƚ ?ƐŽƚŚĞƌĞ ?ƐĂůůƚŚĞƐĞ
ĂĚĚĞĚƚŚŝŶŐƐ Q 
  Employee pharmacist, Multiple  
 
ZĞďĞĐĐĂ P  Q/ ũƵƐƚĚŽŶ ?ƚƚŚŝŶŬƚŚĞǇ ?ǀĞďĞĞŶŝŵƉůĞŵĞŶƚĞĚ ŝŶƚŽƉŚĂƌŵĂĐǇǁĞůůĞŶŽƵŐŚ ?/ƚ
ũƵƐƚŐĞŶĞƌĂůůǇŚĂƐŶ ?ƚďĞĞŶĚŽŶĞǁŝƚŚƚŚĞĐŽƌƌĞĐƚƚŚŝŶŬŝŶŐ Q 
   Employee pharmacist, Independent  
  
Support manuals to help with implementing the MUR service were available in the multiple, 
although they were not reportedly used by the pharmacists. One pharmacist referred to them 
ĂƐ ďĞŝŶŐ ĂŬŝŶ ƚŽ Ă  “computer manual ? ĂŶĚ ǁĞŶƚ ŽŶ ƚŽ ĞǆƉůĂŝŶ ƚŚĂƚ ŚĂǀŝŶŐ ŽŶĞ ĚŽĞƐ ŶŽƚ
necessarily mean that you necessarily use it. A few of the pharmacists reported that they did 
not like being interrupted by support staff during an MUR consultation but allowed this to 
happen. Pharmacists felt that being interrupted to check a prescription during an MUR was 
intrusive and there were some expressions of concern that accuracy checking a prescription 
during an MUR could contribute to a dispensing error:  
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RĞďĞĐĐĂ P Q/ƚŚŝŶŬŐĞŶĞƌĂůůǇ QDhZƐƐŚŽƵůĚďĞƵŶŝŶƚĞƌƌƵƉƚĞĚĂŶǇǁĂǇ Q/ŚĂǀĞƐĂŝĚ ? “look, 
if I am doing an MUR, /ĚŽŶ ?ƚǁĂŶƚƚŽďĞ ŝŶƚĞƌƌƵƉƚĞĚ ? ?ĞĐĂƵƐĞ ?ĂƐǇŽƵƐĂǇ ?ǇŽƵ ?ƌĞ ŝŶ
thĂƚ DhZŵŽĚĞ QƐŽ ǇŽƵ ?ƌĞ ƚŚŝŶŬŝŶŐ ŽŚ 'ŽĚ ? / ?ŵ ďĞŝŶŐ ŝŶƚĞƌƌƵƉƚĞĚ ? ŝƚŵĂŬĞƐ ǇŽƵ ŶŽƚ
check ǀĞƌǇƚŚŽƌŽƵŐŚůǇ Q 
   Employee pharmacist, Independent  
 
:ĂŶĞ P Q/ ?ǀĞŶĞver really thought about it but yes, I think there is a genuine risk that in 
the rush to get the prescription out you may not concentrate properly on the 
prescription. 
  Employee pharmacist, Multiple   
 
Employee pharmacists were conscious of the added pressure their absence placed on support 
staff. Support staff ?Ɛ ǀŝĞǁƐ ŽŶ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚƐ ? ĂďƐĞŶĐĞ ǁŝůů ďĞ ĚŝƐĐƵƐƐĞĚ ŝŶ ƚŚĞ ĨŽůůŽǁŝŶŐ
section. The expectations of support staff as well as the patients / customers were therefore at 
ƚŚĞďĂĐŬŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐŵŝŶĚǁŚĞŶƉĞƌĨŽƌŵŝŶŐĂŶDhZ P 
 
ZĞďĞĐĐĂ P  Q/ ƚŚŝŶŬ ƚŚĞǇ  ?ƐƵƉƉŽƌƚ ƐƚĂĨĨ ? ĨĞĞů ƵŶĚĞƌ ƉƌĞƐƐƵƌĞ ďĞĐĂƵƐĞ ǁĞ ?ƌe so used to 
ŚĂǀŝŶŐƐƵĐŚĂǀĞƌǇŐŽŽĚƐǇƐƚĞŵĂŶĚƉĞŽƉůĞĚŽŶ ?ƚŚĂǀĞƚŽǁĂŝƚůŽŶŐ QƐŽĨŽƌƚhat period 
of time they do feel under pressure, that oh my God, like, people have got a waiting 
ƚŝŵĞĂŶĚƚŚŝŶŐƐĂƌĞƉŝůŝŶŐƵƉ Q 
   Employee pharmacist, Independent  
 
:ĂŶĞ P  Q/ ƚƌǇ ĂŶĚ be syŵƉĂƚŚĞƚŝĐ ƚŽ ƚŚĞ ƐƚĂĨĨ ĂŶĚ ƐĂǇ  “ůŽŽŬ ? / ?ŵ ƌĞĂůůǇ ƐŽƌƌǇ ? ďƵƚ / ?ǀĞ
reaůůǇŐŽƚ ƚŽĚŽ ƚŚŝƐŽŶĞ ? ?ĞĐĂƵƐĞǇŽƵ ?ǀĞŐŽƚ ƚŚĞƚĂƌŐĞƚ ?ǇŽƵ ?ǀĞŐŽƚ ƚŽĂĐŚŝĞǀĞǇŽƵƌ
ƚĂƌŐĞƚĂŶĚ/ĚĂƌĞŶ ?ƚƐĂǇŶŽƚŽĂŶDhZ Q/ŚŽƉĞŝƚ ?ƐŶŽƚŽďǀŝŽƵƐƚŽƚŚĞƉĞƌƐŽŶŝŶƚŚĞDhZ
ƌŽŽŵ ƚŚĂƚ ǇŽƵ ?ƌĞ ƚƌǇŝŶŐ ƚŽ ƌƵƐŚ ƚŚƌŽƵŐŚ ďĞĐĂƵƐĞ ǇŽƵ ?ƌĞ ĐŽŶƐĐŝŽƵƐ ŽĨ ƚŚĞ ŝŵƉĂĐƚ ŝƚ ?Ɛ
having on the rest of the business. 
  Employee pharmacist, Multiple  
 
Jane was conscious of the effects of her absence on the running of the pharmacy and felt that 
she had to explain to staff the consequences of not attaining organisational targets. Employee 
pharmacists indicated that an additional pharmacist was required in busier pharmacies in 
order for MURs to be delivered effectively. However, they recognised that a pharmacy would 
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only warrant as many pharmacists as were needed to maintain the dispensing function. The 
following section describes the organisational pressure that pharmacists faced to achieve a 
targeted number of MURs.  
7.3.7 Organisational pressure 
Pharmacy staff were asked about any organisational pressure they felt surrounding the MUR 
service. Employee pharmacists in the independent did not report the same views as those 
pharmacists in the multiple. Rebecca, from the independent, mentioned that there was a 
target set by the owner to perform one MUR a day. However, she did not feel there were any 
consequences if this was not achieved. She explained that the owner acknowledged the 
barriers that sole pharmacists working in the pharmacy faced when performing MURs: 
 
ZĞďĞĐĐĂ P  Q/ ŐŝǀĞZŽƐĞ[owner] ĐƌĞĚŝƚ ĂŶĚ /ŵƵƐƚ ĂĚŵŝƚ / ?ŵ ƚŚĞ ŽŶĞǁŚŽ ?Ɛ ŶŽƚ ƉƵůůĞĚ
throƵŐŚďƵƚƐŚĞŚĂƐƐĂŝĚƚŚĂƚ /ƋƵŝƚĞƵŶĚĞƌƐƚĂŶĚǇŽƵĐĂŶ ?ƚĚŽDhZƐǁŚĞŶǇŽƵ ?ƌĞƚŚĞ
ŽŶůǇƉŚĂƌŵĂĐŝƐƚ Q 
   Employee pharmacist, Independent  
 
The owner of the independent was shown to be understanding when MURs were not being 
undertaken and this view was supported through observing the interactions between the 
owner and employee during fieldwork. Likewise, Linda, (the regular locum pharmacist) also 
reported not experiencing any pressure from the owner in the independent pharmacy. These 
views contrasted markedly with the employee pharmacists working in the multiple. 
WŚĂƌŵĂĐŝƐƚƐ ? ŝŶƚĞƌǀŝĞǁ ĂĐĐŽƵŶƚƐ ĐŽŶĨŝƌŵĞĚ ĨŝĞůĚǁŽƌŬ ŽďƐĞƌǀĂƚŝŽŶƐ ĂŶĚ ĐŽnversations which 
suggested that staff did feel pressurised to achieve MUR targets. When asked where the 
pressure was coming from, two pharmacists commented that it was from the area managers 
and from the Company:  
 
ZĞƐĞĂƌĐŚĞƌ P QǇŽƵ ?ǀĞƐƉŽŬĞŶĂďŽƵƚ QƉƌĞƐƐƵƌĞďƵƚǁŚĞƌĞĚŽǇ ƵƚŚŝŶŬŵŽƐƚŽĨŝƚĐŽŵĞƐ
ĨƌŽŵ ?tŚĂƚ ?ƐƚŚĞŵĂŝŶƐŽƵƌĐĞ ?
<ĂƚĞ P Q&ƌŽŵƚŚĞĂƌĞĂŵĂŶĂŐĞƌƐ Q/ŵĞĂŶ ?ǁŚĞŶǇŽƵŚĂǀĞǇŽƵƌĐŽnference call which I 
ƌĞĂůůǇĚŽŶ ?ƚ ?ƌĞĂůůǇĚŽƐŽŵƵĐŚ ?ŵŝŶĚǇŽƵ ?,ŽǁŵĂŶǇŚĂǀĞǇŽƵĚŽŶĞƚŚŝƐǁĞĞŬƚŚĞŶ ?
ůĂŚďůĂŚďůĂŚ Q 
  Employee pharmacist, Multiple  
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Jane: Most pressure, I think, comes from the CŽŵƉĂŶǇ ?ĞĐĂƵƐĞƚŚĞǇ ?ƌĞƐĂǇŝŶŐ ?ŝĨǇŽƵ
ĚŽŶ ?ƚ ĚŽ ƐŽ ŵĂŶǇ ƚĂƌŐĞƚƐ ? ƚŚĞŶ ǇŽƵ ĚŽŶ ?ƚ ŐĞƚ Ă ƉĂǇ ƌŝƐĞ Q^Ž ŝƚ ?Ɛ ŶŽƚ ůŝŬĞ ĚĂŶŐůŝŶŐ Ă
ĐĂƌƌŽƚŝŶĨƌŽŶƚŽĨǇŽƵĂŶĚƐĂǇŝŶŐ ?ǁĞůů ?ŝĨǇŽƵŵĂŶĂŐĞƚŽĂĐŚŝĞǀĞŝƚƚŚĞŶǁĞ ?ůůŐŝǀĞǇŽƵ
ĂŶ ĞǆƚƌĂ ďŽŶƵƐ ? ŝƚ ?Ɛ ŵŽƌĞ ůŝŬĞ ŝĨ ǇŽƵ ĚŽŶ ?ƚ ĂĐŚŝĞǀĞ ŝƚ ?ǇŽƵ ?ůů ŐĞƚ Ă ǁŚĂĐŬ ƵƉ ƚŚĞ
ďĂĐŬƐŝĚĞ Q 
  Employee pharmacist, Multiple  
 
Pharmacists were predominantly motivated to perform MURs to avoid negative consequences 
such as the withholding of staff pay rises. The pressure to achieve MUR targets adversely 
affected service provision; in particular, the way Jane reported selecting patients: 
 
:ĂŶĞ P  tĞůů ? ŝƚ ?Ɛ ŶŽƚ ŝĚĞĂů ďĞĐĂƵƐĞ ǇŽƵ ?ƌĞ ůŽŽŬŝŶŐ ĂƚĨŝŐƵƌĞƐ ƌĂƚŚĞƌ ƚŚĂŶ ƚŚĞ ĂĐƚƵĂů
ƋƵĂůŝƚǇŽĨƚŚĞƐĞƌǀŝĐĞƚŚĂƚǇŽƵ ?ƌĞŐŝǀŝŶŐ Q/ƚŚŝŶŬƚŚĞƉƌĞƐƐƵƌĞ ?ƐŐŽƚƐŽŵƵĐŚƚŚĂƚŝƚ ?ƐũƵƐƚ
ůŝŬĞ ?ŚĞƌĞ ?ƐĂƋƵŝĐŬŽŶĞ ?zŽƵŬŶŽǁ ?ǁĞĐĂŶ ŐĞƚŽŶĞŽƵƚŽĨƚŚĞǁĂǇ Q^ŽǇŽƵ ?ƌĞŶŽƚƉŝĐŬŝŶŐ
the best people for it. 
  Employee pharmacist, Multiple  
 
:ĂŶĞ ĚĞƐĐƌŝďĞĚ ŝŶ ŚĞƌ ŝŶƚĞƌǀŝĞǁ ƚŚĂƚ ƐŚĞ ƐŽŵĞƚŝŵĞƐ ĨĞůƚ ƚŚĂƚ ƐŚĞ ǁĂƐ  “ďƵůůǇŝŶŐ ?patients to 
undertake an MUR. Being the more senior pharmacist, Jane felt the pressure more strongly. 
She personally felt more responsible and was acutely aware that the consequences for not 
achieving the target would not only affect her but also other members of the dispensing team: 
 
:ĂŶĞ P  QdŚĞ ŽŶůǇ ŝŶĐĞŶƚŝǀĞ ƚŚĞǇ ŐŝǀĞ ƵƐ ŝƐ ƚŚĞ ƐƚŝĐŬ ƚŚĂƚǁĞ ǁŽŶ ?ƚ ŐĞƚ Ă ƉĂǇ rise QdŚĞ
ƐƚĂĨĨǁŽŶ ?ƚŐĞƚĂďŽŶƵƐ ?ůůƐƚĂĨĨǁŝůůŶŽƚŐĞƚĂďŽŶƵƐ ?^ŽǇŽƵ ?ǀĞŐŽƚƉĞĞƌƉƌĞƐƐƵƌĞƚŚĞŶ
to do it [MURs]. 
  Employee pharmacist, Multiple  
 
Jane expressed strong views over the perceived pressure to undertake MURs. Despite the 
organisational pressure to achieve the targeted number of MURs, pharmacists reported there 
was little to no additional staffing. When asked to describe any support they had received she 
replied: 
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:ĂŶĞ P  Q/ŵĞĂŶ ? / ?ǀĞŚĂĚƚŚĞdĨŽƌƚǁŽŵŽŶƚŚƐ ?ďƵƚƐŚĞ ?ƐŐŽŶĞ QƚŚĞǇ ?ǀĞƚĂŬĞŶĂǁĂǇ
ŵǇƉŚĂƌŵĂĐŝƐƚ ?ƚŚĞŝĚĞĂďĞŝŶŐƚŚĂƚƚŚĞǇ ?ǀĞŐŝǀĞŶŵĞĂŶdďƵƚƚŚĞŶƚŚĞd ?ƐŐŽŶĞ ?
^Ž/ŚĂǀĞŶŽŽŶĞƚŽĐŽǀĞƌƚŚĞĚŝƐƉĞŶƐĂƌǇǁŚŝůƐƚ/ ?ŵĚŽŝŶŐŝƚ ?DhZƐ ?ĂƚƚŚĞŵŽŵĞŶƚ Q 
  Employee pharmacist, Multiple  
 
<ĂƚĞ P QƚŚĞǇ ũƵƐƚ ƉƌĞƚƚǇ ŵƵĐŚ ƚŚƌŽǁ ǇŽƵ ŝŶ Ăƚ ƚŚĞ ĚĞĞƉ ĞŶĚ QƚŚĞǇ ũƵƐƚ ĚŽŶ ?ƚ ǁĂŶƚ ƚŽ
ŬŶŽǁ ?dŚĞǇũƵƐƚǁĂŶƚƚŽŬŶŽǁŝĨǇŽƵƌŵĞĞƚŝŶŐƚĂƌŐĞƚ Q 
  Employee pharmacist, Multiple  
 
Pharmacists used the lack of staffing as a reason to justify to their superiors why the weekly 
MUR target was not being met:  
 
:ĂŶĞ P Q/ƚ ?ƐƐĞƚŝŶƚŽŵǇĐontract that I need to achieve so manǇDhZƐ Q/ĐĂŶĐŽƵŶƚĞƌďǇ
ƐĂǇŝŶŐ  “ǁĞůůǇŽƵ ?ƌĞƐƵƉƉŽƐĞĚƚŽƉƌŽǀŝĚĞŵĞǁŝƚŚƚŚĞƐƚĂĨĨĂŶĚ/ĐĂŶŶŽƚ achieve these 
ǁŝƚŚŽƵƚƚŚĞƐƚĂĨĨ ? ?^Ž/ ĨĞĞů ůŝŬĞĂďŝƚŽĨƚŚĞƉƌĞƐƐƵƌĞ ?Ɛďeen lifted because I ?ǀĞ got an 
ĂƌŐƵŵĞŶƚĂƐƚŽǁŚǇ/ ?ǀĞŶŽƚĂĐŚŝĞǀĞĚŝƚ ? 
   Employee pharmacist, Multiple  
 
Despite the pressure described by Jane she still recognised that MURs were a useful activity for 
patients:   
 
:ĂŶĞ P QĂƐŵƵĐŚĂƐ/ǁŽƵůĚůŝŬĞƚŽƐĂǇ ? ǇŽƵŬŶŽǁ ?ƚŚĞǇ ?ƌĞĂǁĂƐƚĞŽĨƚŝŵĞ ?ƐŚŽƵůĚŶ ?ƚďĞ
ĚŽŝŶŐ ƚŚĞŵ ? ůĞƚ ?Ɛ ŐĞƚ ƌŝĚ ŽĨ ƚŚĞŵ ĂŶĚ ŝƚ ƚĂŬĞƐ ƚŚĞ ƉƌĞƐƐƵƌĞŽĨĨ ƵƐ ? / ƚŚŝŶŬ ŝƚ ?Ɛ Ă ŐŽŽĚ
ƚŚŝŶŐƚŽŚĂǀĞDhZƐ Q/ ?ǀĞƐĞĞŶƉĞŽƉůĞŐŽŽƵƚĂŶĚƚŚĞǇƐĞĞŵŚĂƉƉǇ ?ŽƌŚĂƉƉŝĞƌ ?ƌĞůŝĞǀĞĚ ?
more relaxed about their medicatiŽŶ Q 
  Employee pharmacist, Multiple  
 
Support staff in the multiple were asked to discuss any pressure they felt. The dispensers did 
not feel personally pressurised or burdened to recruit patients for MURs. However, they were 
very conscious of the effect of such pressure upon the pharmacist:   
 
ĂǁŶ P Q/ ĚŽŶ ?ƚ ĂŐƌĞĞ ǁĞ ƐŚŽƵůĚ ŚĂǀĞ ƚĂƌŐĞƚƐ ĨŽƌ ŝƚ ? /ƚ ƐŚŽƵůĚ ďĞ ĂƐ ĂŶĚ ǁŚĞŶ Ă
ĐƵƐƚŽŵĞƌŶĞĞĚƐĂŵĞĚŝĐĂƚŝŽŶƌĞǀŝĞǁ ?/ƚƐŚŽƵůĚŶ ?ƚďĞĂďŽƵƚ ?ǇŽƵ ?ǀĞŐŽƚƚŽĚŽƚĞŶƚŽĚĂǇ ?
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ĞĐĂƵƐĞŝĨǇŽƵĚŽƚĞŶĂŶĚǇŽƵĚŽŶ ?ƚŐŝǀĞƚŚĞŵƚŚĞ ƋƵĂůŝƚǇŽĨƐĞƌǀŝĐĞ ?ǁŚĂƚ ?ƐƚŚĞƉŽŝŶƚŝŶ
ŝƚ ? ? ? ?WĂƚŝĞŶƚ ĐĂƌĞ ?Ɛ ŝŶǀŽůǀĞĚ ? ƚŚĂƚ ƐŚŽƵůĚ ďĞ ǁŚĂƚ ŝƚ ?ƐĂďŽƵƚ ? ŝƚ ƐŚŽƵůĚŶ ?ƚ ďĞ ĂďŽƵƚ
targets.   
Dispenser, Multiple  
 
ŽƌŽƚŚǇ P  /ĂŵĂǁĂƌĞŽĨǁŚĂƚƚŚĞƚĂƌŐĞƚƐĂƌĞ Q/ŵĞĂŶ ?:ĂŶĞƐĂǇƐƐŚĞ ?ƐƐŽƌƚŽĨĂůŵŽƐƚ
gone into relĂǆĂƚŝŽŶŵŽĚĞ ?ĞĐĂƵƐĞ ƐŚĞ ƐĂǇƐ  “/ ŬŶŽǁ / ?ŵŐŽŝŶŐƚŽ ĨĂŝů ůůŵǇƚĂƌŐĞƚƐ
ĂŶĚŝƚ ?ƐŶŽƚŵǇĨĂƵůƚ Qŝƚ ?ƐŶŽƚĂĐŚŝĞǀĂďůĞ ?ƚŚĞǇĚŽŶ ?ƚŐŝǀĞŵĞƚŚĞďŽĚŝĞƐƚŽĚŽŝƚǁŝƚŚ ?ƐŽ, 
ǁŚĂƚĂƌĞǇŽƵƐƵƉƉŽƐĞĚƚŽĚŽ ? ?  
Dispenser, Multiple 
 
Some support staff had concerns about what effect the pressure to achieve a targeted number 
ŽĨ DhZƐ ŚĂĚ ƵƉŽŶ ƚŚĞ  “quality ? ŽĨ ƚŚĞ ĐŽŶƐƵůƚĂƚŝŽŶ ? dŚĞ ŵĂŶĂŐĞƌ ŽĨ ƚŚĞ ŵƵůƚŝƉůĞ ƌĞƉŽƌƚĞĚ
that she preferred that the MURs did add  “value ? to patients:       
 
DĂƌŐĂƌĞƚ Q/ĚŽŶ ?ƚƐĞĞƚŚĞǀĂůƵĞŝŶŚŝƚƚŝŶŐǇŽƵƌ four hundred target and everyone going 
well done, but those four hundred, a minimal amount of them have had any value....I 
ǁŽƵůĚ ĚĞůŝǀĞƌ ƚŚĞŵ ďĞĐĂƵƐĞ ǁĞ ŚĂǀĞ ƚŽ ĚĞůŝǀĞƌ ƚŚĞŵ ? ĂŶĚ ƚŚĂƚ ?Ɛ ĨŝŶĞ ? / ĚŽŶ ?ƚŚĂǀĞ Ă
problem with it. I would much rather they be four hundred that added value than four 
ŚƵŶĚƌĞĚƚŚĂƚĚŽŶ ?ƚ ? 
Manager, Multiple   
 
As a manager, Margaret also felt the pressure to achieve the targeted number of MURs. It was 
apparent that the manager was conscious of meeting her targets but also expressed concerns 
that the pressure to undertake MURs may be affecting the quality of care the patient received. 
Despite acknowledging the pressure that the pharmacists were under, the manager believed 
that it was her job to deliver the targeted number of MURs. Margaret described how she 
managed to achieve the target of 400 MURs in the previous financial year:  
 
Margaret:  Just talking about it all the time.  Just, every day, how many have we done? 
How many have we done? How many have we done?  And then that did become, Oh 
ŵǇ'ŽĚ ?ƵƚƚŚŝƐǇĞĂƌƚŚĞǇ ?ƌĞŵŽƌĞĨŽĐƵƐƐĞĚŽŶŝƚ Q 
Manager, Multiple   
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There were several unintended consequences of pursuing MUR targets. Not only did 
pharmacists report it influenced selection but the pressure appeared to lead to some perverse 
effects. For example, during fieldwork observations it was found that MURs were offered to 
members of the support staff. Two of the staff members from the multiple pharmacy disclosed 
that they had an MUR in the same pharmacy where they worked. Although they were eligible 
for an MUR, it was apparent that their MURs were not anticipated to benefit them directly but 
rather, were performed in order to meet the quota:     
 
Leah:  Oh, I had one [MUR] last year.  Jane did one on me.  
Researcher:  OK.  How did you feel about that? 
Leah:  Well, it was all right, I sort of, I only did it because to get the figures up.  
ZĞƐĞĂƌĐŚĞƌ P QŝĚǇŽƵŐĞƚĂŶǇƚŚŝŶŐĨƌŽŵŝƚŽƌǁĂƐŝƚůŝƚĞƌĂůůǇ Q ? 
>ĞĂŚ P EŽ Q/ƚǁĂƐ ũƵƐƚ  “you taking it aůů ƌŝŐŚƚ ? ?   “zĞĂŚ ? ? dŚĂƚ ?Ɛ ŝƚ ? / ƐĂŝĚ  “/Ɛ ƚŚĂƚ ŝƚ ? ?
 ?>ĂƵŐŚƐ ? ?:ĂŶĞ ?^ĂŝĚ “zĞĂŚ ?. 
ZĞƐĞĂƌĐŚĞƌ P QzŽƵĚŝĚŶ ?ƚƚŚŝŶŬŝƚǁĂƐŶĞĐĞƐƐĂƌǇ ? 
Leah:  Not really. Not for me, no. 
Counter assistant, Multiple  
 
Although no rules were broken, the circumstances surrounding these MURs did not appear to 
be in the spirit of the service. Pharmacists in the multiple expressed how the target was 
affecting them and their professional decisions. The pressure exerted on employee 
pharmacists appeared to be their prime motivation for engaging with the service. The real 
world pressures of performing MURs have been highlighted in this section. Although support 
staff were not involved in performing MURs, they were, as already discussed, involved with the 
invitation process and also in coping when the pharmacist was absent during an MUR. 
Consideration will be given in the following section to support staff perceptions of the MUR 
service. 
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7.4 The absent pharmacist  
Due to the researcher observing MURs in the consultation room, few observations were made 
of how support staff coped in the absence of the pharmacist during this time. These issues 
were explored in the support staff interviews. To begin with, support staff were asked how 
they felt about the MUR service. Most support staff framed the MUR service in a positive light 
and mentioned it benefited the patient in some way: 
 
,ĞůĞŶ PzĞĂŚŝƚ ?ƐŐŽŽĚĨŽƌƚŚĞƉĂƚŝĞŶƚƐ ‘ĐĂƵƐĞƚŚĞǇ ?ƌĞĞůĚ ƌůǇ ?ƚŚĞǇƉƌŽďĂďůǇĚŽŐĞƚƌĞĂůůǇ
ĐŽŶĨƵƐĞĚ ĂďŽƵƚ ǁŚĂƚ ƚŚĞǇ ?ƌĞ ŽŶ ? ǁŚĂƚ ƚŚĞǇ ?ƌĞ ĨŽƌ ĂŶĚ ĞǀĞƌǇƚŚŝŶŐ QƚŚĞ ĚŽĐƚŽƌƐ ĚŽŶ ?ƚ
always have time to do that. Whereas here they can come in, have a cup of tea if you 
ǁĂŶƚĂŶĚƚŚĞǇĐĂŶƌĞĂůůǇĂƐŬƋƵĞƐƚŝŽŶƐ Q 
  Dispenser, Independent  
 
ĂǁŶ P QƚŚĞŽŶĞƐƚŚĂƚƐĞĞŵƌĞůƵĐƚĂŶƚ ?ĂĐƚƵĂůůǇ ?ŝŶƚŚĞĞŶĚ ?ĐŽŵĞ ƵƚŽĨŝƚƚŚinking  “Žh 
yeah, it was beneficial ? ?zŽƵŐĞƚƚŚĂƚ Q 
Dispenser, Multiple  
 
There were broadly positive views expressed by all support staff regarding the pharmacist 
spending time to talk with patients about their medicines. However, one dispenser expressed 
some concern that the time spent during the MURs could potentially be demanding for some 
patients: 
 
>ƵĐǇ P QƉĞŽƉůĞƐĞĞŵƚŽŐŽĂǁĂǇƋƵŝƚĞŚĂƉƉǇďƵƚ/ƚŚŝŶŬƉĞŽƉůĞƉƌŽďĂďůǇĨŝŶĚŝƚƋƵŝƚĞĂ
tiring experience as well to be sort of cross-ĞǆĂŵŝŶĞĚ QƚŚĂƚ ?ƐŚŽǁ/ƐĞĞ ŝƚ ƐŽŵĞƚŝŵĞƐ ?
ĂůƚŚŽƵŐŚŝƚ ?ƐŐŽŽĚƚŽďĞŝŶĂƌŽŽŵŚĞƌĞ ?/ƚŚŝŶŬƚŚĂƚĐĂŶďĞƋƵŝƚĞ ostracising.   
Dispenser, Independent  
 
When they were asked about how they managed to continue providing services while the 
pharmacist was absent performing an MUR, dispensers and MCAs expressed several concerns. 
As was discussed in the literature review (section 2.3), the pharmacist is legally required to 
ƉĞƌĨŽƌŵĂ  ‘ĐůŝŶŝĐĂů ĐŚĞĐŬ ?on each prescription received in the pharmacy. Most support staff 
recognised that the pharmacist was crucial to the provision of existing services and their 
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absence was seen to create tensions with patients waiting for their prescriptions or wishing to 
speak with the pharmacist. It was left to support staff to explain to patients why the 
pharmacist was not available:     
 
Leah: QǇŽƵƐĞĞ ?ŽŶƚŚĞƚĞůĞǀŝƐŝŽŶ ?ƚŚĞǇŽĨƚĞŶƌƵŶ  ‘ƐŬǇŽƵƌƉŚĂƌŵĂĐŝƐƚ ?ĐĂŵƉĂŝŐŶƐ ?ƐŽ
ƉĞŽƉůĞǁŝůůĐŽŵĞ ŝŶ ƚŽƐƉĞĂŬƐƉĞĐŝĨŝĐĂůůǇ ƚŽ ƚŚĞƉŚĂƌŵĂĐŝƐƚĂŶĚŽĨĐŽƵƌƐĞ ?ƚŚĞǇ ?ƌĞŶŽƚ
available.  
Counter assistant, Multiple  
 
Helen: Everything stops, everything stops [laughs] you know. I mean obviously it is a 
literary stop because we can do all the prescription and everything but ǇŽƵ ?ƌĞŚĂǀŝŶŐƚŽ
ƐĂǇƚŽƉĞŽƉůĞ “oh it wŝůůďĞ ? ?ŵŝŶƵƚĞƐŽƌ ? ?ŵŝŶƵƚĞƐ ?. 
  Dispenser, Independent  
 
As noted above by one MCA, there was a contradiction as television and magazine campaigns 
were promoting greater accessibility to the pharmacist, but when engaged with a patient 
during an MUR, the pharmacist was inaccessible. Dispensing staff described how asking 
patients simply to wait would lead some to go elsewhere to fill their prescription. The 
uncertainty faced over the length of time the pharmacist would perform the review was also a 
concern raised by support staff: 
 
^ŽƉŚŝĞ P QŝĨǇŽƵƚĞůůƚŚĞŵƚŽǁĂŝƚĨŽƌƚĞŶƚŽĨŝĨƚĞĞŶŵŝŶƵƚĞƐ ?ƚŚĞǇǁŽƵůĚũƵƐƚƐĂǇ “why do 
I need to wait for fifteen minutes? ? QƐŽ, some of them will go to another pharmacy. 
dŚĂƚ ?ƐůŝŬĞƚŚĞǁŽƌƐƚŽďũĞĐƚŝŽŶ ? 
Pre-registration pharmacist, Multiple 
 
,ĞůĞŶ P QǇŽƵĐĂŶ ?ƚĞǀĞŶƐĂǇ “well yeah it will be 20 minutes ? or  “it will be 15 minutes ? 
 ‘ĐĂƵƐĞƐŽŵĞďŽĚǇŵŝŐŚƚĐŽŵĞŝŶ [for an MUR] and it wiůůďĞƐŽĚŝĨĨŝĐƵůƚƚŚĂƚǇŽƵ ?ǀĞŐŽƚ
to sit with them maybe for an hour. 
  Dispenser, Independent  
 
A few support staff expressed annoyance due to the combination of the pharmacist being 
absent when performing an MUR and having to explain this to patients and customers:  
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Dorothy:  I mean, when [names locum pharmacist] was here, that just got ridiculous.  
Because he went in with an MUR middle of a Friday morning and it was literally me left 
there on my own, and he was gone for ages.  And that was just beyond ĂũŽŬĞ Q 
Dispenser, Multiple 
 
>ƵĐǇ P/ƚŚŝŶŬŝƚ ?ƐĨƌƵƐƚƌĂƚŝŶŐ ?&ƌƵƐƚƌĂƚŝŶŐĨƌŽŵƚŚĞĨĂĐƚƚŚĂ ǇŽƵŬŶŽǁƉĞŽƉůĞĂƌĞǁĂŝƚŝŶŐ
ĨŽƌƉƌĞƐĐƌŝƉƚŝŽŶƐĂŶĚǇŽƵ ?ƌĞŚĂǀŝŶŐƚŽƐĂǇƚŚĞƉŚĂƌŵĂĐŝƐƚŚĂƐŐŽƚĂƉĂƚŝĞŶƚŝŶǁŝƚŚŚĞƌ
Ăƚ ƚŚĞŵŽŵĞŶƚ ?WĞŽƉůĞ ũƵƐƚǁĂŶƚƚŽŐŽĚŽŶ ?ƚ ƚŚĞǇ? They want their prescription, and 
ƚŚĞǇ ?ƌĞŶŽƚďŽƚŚĞƌĞĚĂďŽƵƚǁŚǇƐŚĞ ?ƐŝŶƚĞƌǀŝĞǁŝŶŐĂŶŽƚŚĞƌƉĂƚŝĞŶƚ Q 
Dispenser, Independent  
 
One dispenser provided further insights. She explained that similar tensions also arose in 
situations other than when the pharmacist was absent during the MUR consultation. For 
example, when there were several prescriptions to be checked and patients were asked to 
wait. However, she perceived that patients became frustrated to a greater extent because the 
pharmacist was not visible to them when they were performing an MUR. All the dispensers 
saw the absence of the pharmacist as problematic except one who mentioned that because 
DhZƐ ǁĞƌĞ  “scattered throughout during the week ? ? ƚŚŝƐ ǁĂƐ ŶŽƚ ĚŝƐƌƵƉƚŝǀĞ for her. One 
reason why she may have reported feeling less concerned was because she was largely 
responsible for assembling prescriptions for nursing and residential homes that did not require 
an immediate clinical and accuracy check by the pharmacist.    
    
In contrast to dispensing staff, MCAs by and large did not perceive the absence of the 
pharmacist to pose a problem. Customers on the whole were seen to be tolerant. The 
pharmacist ?s absence was not usually felt to be an issue as they were usually available again 
after a short while: 
 
^ƚĞĨ P QDŽƐƚŽĨƚŚĞĐƵƐƚŽŵĞƌƐĂƌĞƉĂƚŝĞŶƚĂŶĚƚŚĞǇǁŝůůǁĂŝƚŽƌƚŚĞǇ ?ůůƐŽƌƚŽĨŐŽĂǁĂǇ
ĂŶĚ ĐŽŵĞ ďĂĐŬ ůĂƚĞƌ ? / ?ǀĞ ŶĞǀĞƌ ŚĂĚ ĂŶǇďŽĚǇ ƚŚĂƚ ?Ɛ ďĞĞŶ ?ǇŽƵ ŬŶŽǁ ? ĂŶŶŽǇĞĚ ƚŚĂƚ
ƚŚĞƌĞ ?ƐŶŽƉŚĂƌŵĂĐŝƐƚĂǀĂŝůĂďůĞ ?EŽ ? 
Counter assistant, Multiple 
 
Chapter Seven: The views of pharmacy staff 
198 
 
The contrasting attitude of MCAs compared with dispensers was because the work of 
dispensers was directly dependent upon the pharmacist being present for the final accuracy 
check. MCA could continue their activities as they were less reliant on the pharmacist when 
selling OTC medicines. However, some staff, particularly those who worked in the independent, 
described how sometimes they felt uncomfortable whilst waiting for the pharmacist when 
they were busy performing an MUR. They expressed feelings of being helpless and awkward 
when the pharmacist was unavailable to either talk to a customer about an OTC medicine or 
was waiting for a prescription that needed to be checked:  
 
ĂƚŚ Q/ĚŽĨĞĞůůŝŬĞƐŽŵĞƚŝŵĞƐ ?/ĚŽŶ ?ƚŬŶŽǁ ?ůŝŬĞĂĚƵĐŬĂƚĂĨĂŝƌŐƌŽƵŶĚǇŽƵŬŶŽǁ ?ůŝŬĞ
the hook a duck sŽƌƚŽĨƚŚŝŶŐŽƌƌŝĨůĞƌĂŶŐĞ ? ‘ĂƵƐĞƉĞŽƉůĞĂƌĞƐŝƚƚŝŶŐƚŚĞƌĞǁĂŝƚŝŶŐƚŽ
see the pharmacist or are waiting for the prescription and I'm on the shop floor and 
they ?ƌĞ ůŽŽŬŝŶŐ Ăƚ ŵĞ ĂƐ ŝĨ ƚŽ ƐĂǇ  “ǁŚǇ ĐĂŶ ?ƚ ǇŽƵ ĚŽ ŝƚ ? Q/ ǁĂůŬ ƵƉ ĂŶĚ ĚŽǁŶ ? / ĨĞĞů
ƚŚĞǇ ?ƌĞ ĨŽůůŽǁŝŶŐ ŵĞ ĞǀĞƌǇǁŚĞƌĞ ? tĞůů / ĐĂŶ ?ƚ ĚŽ ĂŶǇƚŚŝŶŐ ? /ƚ ?Ɛ ŶŽƚ ŵĞ ?  /ƚ ?Ɛ ƚŚĞ
pharmacist!   You know, I do feel that like I get daggers pointed at me, ohh. 
Counter assistant, Independent  
 
>ƵĐǇ P QŝĨ ǇŽƵ ĚŽ ŶĞĞĚ ƚŽ ŚĂǀĞ Ă ǁŽƌĚ ǇŽƵ ũƵƐƚ ŚĂǀĞ ƚŽ ƐĂǇ ƚŽ ƚŚĞ ƉĂƚŝĞŶƚ  “I'm really 
ƐŽƌƌǇ ŝƚ ?Ɛ ŽƵƚƐŝĚĞ ŵǇ ƐŽƌƚof capabilities or jurisdiction ? / ĐĂŶ ?ƚ ƐĞůů ǇŽƵ ƚŚŝƐ Ăƚ ƚŚĞ
moment; I ŶĞĞĚƚŽƐƉĞĂŬƚŽƚŚĞƉŚĂƌŵĂĐŝƐƚ ?. 
Researcher: Is that frustrating for the staff? 
>ƵĐǇ P/ƚŚŝŶŬŝƚ ?ƐƵŵŵĂďŝƚŝƌŬƐŽŵĞ Q 
Dispenser, Independent  
 
Support staff on the front-line reported feeling anxious in situations when customers and 
patient were waiting for the pharmacist while they were performing an MUR. To avoid these 
situations they developed coping strategies and these will be reported in the next section.    
 
7.4.1 Support staff strategies during the pharmacist ?Ɛ absence   
It was generally left to support staff to explain to patients why the pharmacist was absent 
when they were performing an MUR. To avoid situations where tensions with customers or 
patients could arise, they deployed a range of coping strategies. Dispensing staff would initially 
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tell those who were waiting for their prescription that the pharmacist was busy with another 
patient. They would then assess how tolerant the patient looked whilst waiting. Dispensers 
were aware that they could interrupt the pharmacist should they need to: 
 
ĂǁŶ P QǁŚĂƚ/ŐĞŶĞƌĂůůǇĚŽŝƐ/ŐĂƵŐĞŝĨƚŚĞǇ ?ƌĞůŽŽŬŝŶŐŝƌƌŝƚĂďůĞ QŝĨŝƚ ?ƐĂĐůĂƐƐŝĐŵǇďƵƐ
ǁŝůůďĞŚĞƌĞŝŶĨŝǀĞŵŝŶƵƚĞƐ ?ĂŶĚƐŚĞƐƚŝůůŚĂƐŶ ?ƚĚŽŶĞŝƚ ?ƚŚĞŶǁŚĂƚ /ƚĞŶĚƚŽĚŽŝƐ/ ?ůůŶŝƉ
ŝŶ Q 
Dispenser, Multiple  
 
>ǇĚŝĂ P QŝĨƚŚĞƉĂƚŝĞŶƚ ?ƐǁĂŝƚŝŶŐ ?/ĚŽƐŽŵĞƚŝŵĞƐŚĂǀĞƚŽŐŽŝŶĂŶĚŬŶŽĐŬĂŶĚƐĂǇ “Rose 
[owner] can you just check? ? ĂŶĚ ƐŚĞ ?ůů ƐŝŐŶ ŝƚ ƌĞĂůůǇ ƋƵŝĐŬ ? ƐŚĞ ĚŽĞƐŶ ?ƚ ŵŝŶĚ ŝĨ /ĚŽ
ƚŚĂƚ Q 
Saturday assistant, Independent 
 
The MUR was seen by all support staff as a private consultation between the patient and 
pharmacist. Support staff were aware that they could interrupt the pharmacist in these 
circumstances and made personal judgements about the need to interrupt a private 
consultation and appeasing waiting patients:  
 
,ĞůĞŶ P  QǇŽƵ ĚŽŶ ?ƚ ůŝŬĞ ĚŽŝŶŐ ƚŚĂƚ ďĞĐĂƵƐĞ ƚŚĂƚ ?Ɛ ƉƌŝǀĂƚĞ, ǇŽƵ ĚŽŶ ?ƚ ůŝŬĞ ŝŶƚĞƌƌƵƉƚŝŶŐ
them but you feel you will because its draŐŐĞĚŽŶƐŽůŽŶŐ QǇŽƵĐĂŶ ?ƚƐĂǇ “ǁĞůůƚŚĞǇ ?ƌĞ
ŶŽƚŽƵƚǇĞƚ ? and then expect them to wait another 10 minutes so you feel obliged to 
ŝŶƚĞƌƌƵƉƚ Q/ŵĞĂŶ ŝĨǇŽƵ ?ƌĞ ŝŶ ƚŚĞĚŽĐƚŽƌ ?ƐƐƵƌŐĞƌǇǇŽƵǁŽƵůĚŶ ?ƚǁĂŶƚƚŚĞƌĞĐĞƉƚŝŽŶŝƐƚ
knocking on the door would you while you were having a consultation. 
  Dispenser, Independent  
 
Although pharmacists were aware of the potential problems the dispensing staff faced, there 
was not Ă ĐůĞĂƌ  ‘ƉƌŽƚŽĐŽů ? ĨŽƌ ĚŝƐƉĞŶƐŝŶŐ ƐƚĂĨĨ ƚŽ ƵƐĞ ŝŶ ŵĂŶĂŐŝŶŐ ƚŚĞƐĞ ƐŝƚƵĂƚŝŽŶƐ ? ^ŽŵĞ
dispensing staff would pre-empt this problem by telling patients their prescriptions will take 
longer:  
^ŽƉŚŝĞ P Q/ŬŶŽǁůŝŬĞƚŚĞƉĂƚƚĞƌŶŽĨƚŚĞƉŚĂƌŵĂĐŝƐƚĚŽŝŶŐ an MUR.  For Kate I will try to 
give more time [laughter]. 
Pre-registration pharmacist, Multiple 
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ĂǁŶ P Q ?/ǁŽƵůĚ ?ĨŝƌƐƚƐĂǇ ? “now the pharmacist is with a patient so it could be about 
ten minutes ? ?ďĞĐĂƵƐĞ ?ƚŽŵĞ ? ŝĨǇŽƵƐĂǇ ŝƚ ?ůůďĞĨŝǀĞĂŶĚƚŚĞŶ ŝƚƚĂŬĞƐƚĞŶ ?ƚŚĞǇ ?ƌĞŶŽƚ
happy.  You might as well say ten and then if they do it quicker, fine. 
Dispenser, Multiple  
 
There was a balance between how support staff dealt with patients waiting for prescriptions 
and the pharmacists wanting time to spend with patients. MURs were seen as an additional 
task that needed to be accommodated. When asked how the service could be improved, there 
was agreement from most support staff that it would be better to have an additional 
pharmacist or an ACT to free up the pharmacist to allow them to perform the MUR. However, 
it was acknowledged by some that it would not be financially viable to have two pharmacists: 
 
<ĂǇ P  Q/ĚŽ ƚŚŝŶŬ ƚŚĂƚ ŝĨ ǇŽƵ ?ƌĞŚĂǀŝŶŐ ƚŚĞƉŚĂƌŵĂĐist whose doing MURs you should 
ŚĂǀĞƐŽŵĞďŽĚǇƚŚĞƌĞƚŽďĂĐŬƵƉ QďĞĐĂƵƐĞŝƚŝƐŝŶĨƵƌŝĂƚŝŶŐǁĂŝƚŝŶŐĨŽƌƚŚŝŶŐƐ. 
Dispenser, Independent  
 
^ƚĞĨ P QĞĐĂƵƐĞƚŚĞǇǁŽŶ ?ƚŐŝǀĞƵƐƚǁŽƉŚĂƌŵĂĐŝƐƚƐĞǀĞƌǇĚĂǇǁŝůůƚŚĞǇ QƐŽůŽŶŐĂƐŽŶĞ
is available.   
ZĞƐĞĂƌĐŚĞƌ P QŚĂǀĞ ǇŽƵ Őot any advice for me about how things would be easier for 
you?... 
^ƚĞĨ PKŚ ?/ƚ ?ƐĂůǁĂǇƐƚŚĞĞǆƚƌĂƐƚĂĨĨ ?ŝƐŶ ?ƚŝƚ ?ƵƚŚĂƚ ?ƐŶŽƚŐŽŝŶŐƚŽŚĂƉƉĞŶ ?/ƚ ?ƐũƵƐƚ
ŶŽƚŐŽŝŶŐƚŽŚĂƉƉĞŶ QĂŶŽƚŚĞƌƉŚĂƌŵĂĐŝƐƚŽƌƐŽŵĞďŽĚǇƚŽ ?ǁĞůů ? ůŝŬĞǁĞŚĂĚƚŚĞd ?
ďƵƚŝƚĚŝĚŶ ?t last long, did it?  [Laughter]. 
Counter assistant, Multiple 
 
This section described the difficulties and frustrations support staff faced when the pharmacist 
was absent during an MUR and the coping strategies used to overcome this. In the following 
section the use of the information collected during the MUR is discussed. 
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7.5 MUR information and ƉĂƚŝĞŶƚƐ ?ǁŝĚĞƌĐĂƌĞ 
During fieldwork, information gathered during the MUR was not observed being referred to 
during the dispensing process or provision of other services from the pharmacy. The issue of 
accessing MUR information was further explored with pharmacists in their interviews. When 
asked, pharmacists reported that any information that was perceived to be important to the 
care of the patient or that was needed during the dispensing process was recorded on the 
WDZ ?dŚŝƐŵĞĂŶƚƚŚĂƚƚŚĞŝŶĨŽƌŵĂƚŝŽŶǁĂƐĂǀĂŝůĂďůĞǁŚĞŶƚŚĞƉĂƚŝĞŶƚƐ ?ƉƌĞƐĐƌŝƉƚŝŽŶǁĂƐ being 
labelled to be dispensed: 
 
Researcher:  How accessible is that [MUR] to  your normal routine dispensing day? 
RebĞĐĐĂ PtĞůů ? /ŐƵĞƐƐ ŝƚ ?ƐĂƚƚŚĞĐůŝĐŬŽĨĂďƵƚƚŽŶďƵƚ /ŐƵĞƐƐ ŝƚĚŽĞƐŶ ?ƚƌĞĂůůǇƐŽƌƚŽĨ
ďƌŝŶŐ ŝƚ ƵƉ ĞǀĞƌǇ ƐŝŶŐůĞ ƚŝŵĞ QĨŽƌ ĞǆĂŵƉůĞ ? / ƚŚŝŶŬ ŽŶĞ ƉĂƚŝĞŶƚ Q ǁĂƐ ĂůůĞƌŐŝĐ ƚŽ Ăůů
ŽƌĂŶŐĞ ĐŽůŽƵƌŝŶŐ ƐŽ ǁĞ ƚŚĞŶ ĨůĂƐŚĞĚ ŝƚ ƵƉ ŽŶ ƚŚĞ ƌĞĐŽƌĚƐ  ?WDZ ?  ‘ĐŚĞĐŬ ŶŽŶĞ ŽĨ ƚŚĞ
tĂďůĞƚƐŚĂǀĞĂŶǇŽƌĂŶŐĞŽƌƌĞĚĐŽůŽƵƌŝŶŐ ?ŝĨƉŽƐƐŝďůĞŐŝǀĞŚĞƌǁŚŝƚĞƚĂďůĞƚƐ ? 
ZĞƐĞĂƌĐŚĞƌ PƵƚƚŚĞŝŶĨŽƌŵĂƚŝŽŶ ?ǇŽƵŚĂǀĞƚŽƉƵƚƚŚĂƚŽŶƚŽƚŚĞWDZƌĞĐŽƌĚ Q 
Rebecca:  We have to put that on the WDZ Q 
Employee pharmacist, Independent  
 
:ĂŶĞ P zŽƵĚŽŶ ?ƚŶĞĐĞƐƐĂƌŝůǇƌĞŵĞŵďĞƌ ŝƚ  ?DhZ ? Q/ŵĞĂŶ ? /ŚĂǀĞƉƵƚƚŚĞŽĚĚƚŚŝŶŐŽŶ
[the WDZ ?ďƵƚŝƚ ?ƐŐŽƚƚŽďĞƌĞĂůůǇŝŵƉŽƌƚĂŶƚĨŽƌŵĞƚŽƐƚŝĐŬŝƚŽŶ ? 
  Employee pharmacist, Multiple  
 
Pharmacists reported that the information recorded onto the MUR form was not accessed 
during roƵƚŝŶĞĚŝƐƉĞŶƐŝŶŐŽĨƉĂƚŝĞŶƚƐ ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŽƌŽƚŚĞƌƐĞƌǀŝĐĞƐƌĞůĂƚŝŶŐƚŽ the patients ? 
care. This supported fieldwork observations that MUR records in the multiple were filed 
alphabetically in folders on the dispensary shelf. The availability of the electronic MUR form in 
the independent was only accessible through a different window and so was not looked at 
during routine provision of services. Better integration of MUR information so that it could be 
accessed was not seen as a priority for pharmacists; indeed one pharmacist responded that 
there was barely enough time to complete the form itself:   
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Kate P QŝƚǁŽƵůĚďĞŶŝĐĞŝĨ ?ŶĂŵĞƐompany] were to give us half an hour in the day just 
ƚŽǁƌŝƚĞƵƉŽƵƌDhZƐ QƐŽŽŶĂƐ / ?ŵďĂĐŬ ŝŶ ƚŚĞĚŝƐƉĞŶƐĂƌǇ ?ŽŚƚŚŝƐŚĂƐ ƚo be checked 
ĂŶĚƐƚƵĨĨůŝŬĞƚŚĂƚ QŝĨǁĞ ?ǀĞŐŽƚƚŚĞƚŝŵĞ ?/ ?ŵŚĂƉƉǇƚŽĚŽƐŽ ?ƉƵƚŝƚŽŶƚŚĞĐŽŵƉƵƚĞƌ Q 
  Employee pharmacist, Multiple  
 
Interviews with pharmacists supported fieldwork observation that the information derived 
from the MUR discussion was poorly integrated with other patient services.  
 
7.6 Indeterminate issues and relationship with GPs  
WŚĂƌŵĂĐŝƐƚƐ ? ĂĐĐŽƵŶƚƐ ƌĞǀĞĂůĞĚ that they all had their individual personal approaches to 
performing MURs. A couple of pharmacists described these, revealing that the process was 
underpinned by their reliance on filling in the MUR form rather than engaging in a process that 
was patient-centred:   
 
ZĞďĞĐĐĂ P Q/ĚŽŶ ?ƚŬŶŽǁŝĨǇŽƵŶŽƚŝĐĞ QŝƚŝƐƚŝĐŬing boxes. But you kind of address a lot of 
ƚŚĞŝƐƐƵĞƐƐƚƌĂŝŐŚƚĂǁĂǇ QǁŚĞŶƚŚe first screen ĐŽŵĞƐƵƉ ?ŝƚ ?ƐůŝŬĞ “K< ?ƚŚŝƐŝƐƚŚĞŵĞĚƐ
ǇŽƵ ?ƌĞŽŶ ? QĂůůƚŚĞǇ ?ƉĂƚŝĞŶƚƐ ?ŶĞĞĚƚŽďĞƐĂǇŝŶŐŝƐ ‘zĞ ?Žƌ ‘EŽ ? Q ?ďƵƚƚŚĞǇƐĂǇ ? “/ƚĂŬĞ
ƚŚĂƚŝŶƚŚĞŵŽƌŶŝŶŐ ? ?ƐŽƚŚĞǇ ?ƌĞĂůƌĞĂĚǇŐŝǀŝŶŐĂůůƚŚĞĚƚĂŝůƐĂŶĚƚŚĞŶǇŽƵŵŽǀĞŽŶ to 
the next page with the  ‘tick-box ? ĂŶĚǇŽƵĐĂŶůŝƚĞƌĂůůǇƚŝĐŬŝƚ Q 
   Employee pharmacist, Independent  
 
:ĂŶĞ P Q/ŐŽƚŚƌŽƵŐŚƚŚĞĨŽƌŵ ?ǇŽƵŬŶŽǁ ? “Ěo you understand it? How are you taking it? 
Are yŽƵ ŚĂǀŝŶŐ ĂŶǇ ƉƌŽďůĞŵƐ ǁŝƚŚ ŝƚ ? ?  Ƶƚ Ăƚ ƚŚĞ ĞŶĚ ? / ƐĂǇ  “have you got any 
questions ĂďŽƵƚ ǇŽƵƌ ŵĞĚŝĐĂƚŝŽŶ ? ? QdŚĂƚ ŝƐ ǁŚĞŶ ƚŚĞǇ ƚĞŶĚ ƚŽ ƉŝƉĞ ƵƉ ĂďŽƵƚ
ƐŽŵĞƚŚŝŶŐƚŚĂƚ ?ƐŐŽŝŶŐŽŶ QtŚĞŶǇŽƵ ?ƌĞŐŽŝŶŐƚŚƌŽƵŐŚƚŚĞĨŽƌŵ ?ƵŶůĞƐƐǇŽƵƌĞĂůůǇŐĞƚ
ŝŶǀŽůǀĞĚŝŶĂƋƵĞƌǇ ?ǇŽƵĚŽŶ ?ƚƚĞŶĚƚŽĚŝƐĐƵƐƐƚŚŝŶŐƐ ?ŝƚ ƐůŝŬĞƚŝĐŬ ?ƚŝĐŬ ?ǇĞƐ ?ǇĞƐ ?ĨŝŶĞ ?ĨŝŶĞ ?
fine, fiŶĞ ?ďĂŶŐ ?ǀĞƌǇƚŚŝŶŐĨŝŶĞ ?ĚŽŶĞ Q 
  Employee pharmacist, Multiple  
 
As the extract illustrates pharmacists focused on filling out the MUR form and did not appear 
to show a desire to understand patients ? concerns or other issues about their medicines. 
Furthermore, when pharmacists were questioned about what they wanted to achieve from the 
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MUR they did not express any wish to be involved with complex or indeterminate issues about 
ƚŚĞƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐŝŶĞƐ P 
 
ZĞƐĞĂƌĐŚĞƌ P QǁŚĂƚdo hope to achieve out of Medicines Use Review?  
:ĂŶĞ P/ĚŽŶ ?ƚƌĞĂůůǇƚĞŶĚƚŽŚĂǀĞĂŶǇŐŽĂůƐĂƉĂƌƚĨƌŽŵůĞƚ ?ƐŐĞƚƚŚŝƐĚŽŶĞĂŶĚŐĞƚŽƵƚĂƐ
quick as possible [laughter]. 
  Employee pharmacist, Multiple  
 
>ŝŶĚĂ QĂůŽƚŽĨƉĞŽƉůĞƚŚŝŶŬŝƚ ?ƐĂĐůŝŶŝĐĂůƌĞǀŝĞǁ ?Ƶƚŝƚ ?ƐŶŽƚ ?ŝƚ ?ƐĂƵƐĂŐĞƌĞǀŝĞǁ ?And 
ǇŽƵ ?ƌĞ ŶŽƚ ƚŚĞƌĞ ƚŽ ƋƵĞƐƚŝŽŶ ƚŚĞ ĂƉƉƌŽƉƌŝĂƚĞŶĞƐƐ ŽĨ ƚŚĞ ŵĞĚŝĐĂƚŝŽŶ ? ǇŽƵ ?ƌĞ ƚŚĞƌĞ ƚŽ
ŵĂŬĞƐƵƌĞƚŚĂƚƚŚĞǇ ?ƌĞƚĂŬŝŶŐŝƚƉƌŽƉĞƌůǇĂŶĚƚŚĞǇƵŶĚĞƌƐƚĂŶĚǁŚĂƚŝƚ ?ƐĨŽƌ ?
  Locum pharmacist, Independent   
 
ZŽƐĞ P / ĚŽŶ ?ƚ ŐŽ ůŽŽŬŝŶŐ ĨŽƌ ƉƌŽďůĞŵƐ ? / ũƵƐƚ ƐĞĞ ƚŚĂƚthe person knows why they're 
ƚĂŬŝŶŐƚŚĞŝƌ ƚĂďůĞƚƐ ? ƚŚĞǇ ?ƌĞ ƚĂŬŝŶŐ ƚŚĞ ƚĂďůĞƚƐĂŶĚ QƚŚĞǇ ?ƌĞĂĐŚŝĞǀŝŶŐ ƚŚĞŽďũĞĐƚŝǀĞŽĨ
ƚĂŬŝŶŐƚŚĞŵ ?ĞĐĂƵƐĞ/ĨĞĞůƚŚĂƚƚŚĂƚ ?ƐĂůů/ ?ŵƌĞĂůůǇǁĂŶƚŝŶŐƚŽĨŝŶĚŽƵƚ ? 
Pharmacist and proprietor, Independent    
 
When asked how ofteŶ ƚŚĞǇ ĐŽŶƚĂĐƚĞĚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ 'W ĨŽůůŽǁŝŶŐ ĂŶMUR, pharmacists 
reported that they rarely did so, instead they relied principally upon the patient to contact 
their GP if they felt this was needed:    
 
:ĂŶĞ Q/ ?ǀĞĂůǁĂǇƐĂĚǀŝƐĞĚƚŚĞƉĂƚŝĞŶƚ ŝĨƚŚĞƌĞ ?ƐĂŶ ŝƐƐƵe that I think they need to sort 
ŽƵƚ ? ĂĚǀŝƐĞ ƚŚĞŵ ƚŽ ŐĞƚ ŝŶ ĐŽŶƚĂĐƚ ǁŝƚŚ ƚŚĞ ƉƌĂĐƚŝĐĞ ŶƵƌƐĞ Žƌ ƚŚĞ ĚŽĐƚŽƌ Q/ ?ǀĞ ŶĞǀĞƌ
come across anything that I felt that I needed to get on the blower. Personally, I think 
ŝƚ ?Ɛ ďĞƚƚĞƌ ŶŽƚ to have a third party involved becĂƵƐĞ ƚŚĂƚ ĐĂŶ ĐŽŵƉůŝĐĂƚĞ ŵĂƚƚĞƌƐ Q/
ƚŚŝŶŬŝƚ ?ƐďĞƚƚĞƌƚŚĂƚƚŚĞƉĂƚŝĞŶƚĂŶĚƚŚĞĚŽĐƚŽƌĚĞĂůǁŝƚŚĞĂĐŚŽƚŚĞƌĚŝƌĞĐƚůǇ ? 
  Employee pharmacist, Multiple  
 
<ĂƚĞ P  Q/ƐĂǇ  ?ƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞĂŬƚŽǇŽƵƌĚŽĐƚŽƌĂďŽƵƚ ŝƚďĞĐĂƵƐĞŽĨĐŽƵƌƐĞ ?ƚŚĞǇ ?ƌĞ
the only ones who can take things further ĂŶĚƚŚĞŶƚŚĞǇ ?ůůŵĞŶƚŝŽŶŝƚƚŽƚŚĞĚŽĐƚŽƌĂŶĚ
ƌĞǀŝĞǁŝƚ Q 
  Employee pharmacist, Multiple  
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Pharmacists generally felt that it was best for the patient to discuss an issue directly with their 
'WƐŚŽƵůĚƚŚĞŶĞĞĚĂƌŝƐĞ ?WŚĂƌŵĂĐŝƐƚƐ ?ƌeluctance to become involved with the patients care 
to a greater degree may stem from their existing relationship with GPs and the very limited 
involvement they had with ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛprescribed medicines. These views were further 
explored when pharmacists were asked if they received any feedback from GPs about the 
MURs. All pharmacists reported they had little to no feedback from GPs or any other health 
professional as a result of their MURs. With little additional communication resulting from the 
MUR service, pharmacists had seen little difference in their relationship with GPs. There were 
some concerns raised ŽǀĞƌ ǁŚĞƚŚĞƌ 'WƐ ǁĞůĐŽŵĞĚ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ ŝŶƚĞƌǀĞŶƚŝŽŶ ? KŶĞ
pharmacist expressed that she did not want to collaborate to any greater degree with GPs:  
 
ZŽƐĞ P/ĚŽŶ ?ƚƌĞĂůůǇĐĂƌĞƚŽƚĂůŬƚŽŽŵƵĐŚƚŽ'WƐƵŶůĞƐƐ/ƌĞĂůůǇŚĂǀĞƚŽ Q/ĨƚŚĞƌĞŝƐĂŶǇ
ƌĞĐŽŵŵĞŶĚĂƚŝŽŶ ? / ?ůůƉƵƚ ŝƚ ŽŶƚŚĞŝƌĨŽƌŵ ?ĂŶĚŝƚ ?ƐƚŚĞŝƌ  ?'WƐ ?ƌĞƐƉŽŶƐŝďŝůŝƚǇ QǁĞ ?ƌĞŶŽƚ
ŐŽŝŶŐƚŽŐŽƌŽƵŶĚĐŚĂƐŝŶŐ'WƐ QŝĨǇŽƵƉƵƚĂǀĂůƵĞŽŶǇŽƵƌƚŝŵĞĂŶĚǇŽƵƐee how much 
each minute of yours is worth, then I want to use it for the benefit of my business, not 
chasing GPs.  
   Pharmacist and proprietor, Independent    
 
Kate:  Q/ĚŽŶ ?ƚƚŚŝŶŬ ƚŚĞǇ ?ƌĞ ?'WƐ ?ŬĞĞŶŽŶƵƐĚŽŝŶŐŝƚ ?ƚŽďĞŚŽŶĞƐƚ ?ƚŽďĞ ƌƵƚŚĨƵů ? 
  Employee pharmacist, Multiple  
 
Pharmacists were largely passive when describing their involvement ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
medicines during MURs. They were content with managing minor issues but were conscious of 
professional boundaries and relied on the patient to discuss more complex or indeterminate 
issues with the GP.  
 
7.7 Summary 
In this chapter, I have reported pharmacist and support staff views of the MUR service and 
confirmed and extended the findings from the previous three chapters. The pharmacists in this 
study reported welcoming MUR activity and perceived that most MUR consultations were 
beneficial to their patients. Pharmacists held professional conceptions of what was to be 
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ĂĐŚŝĞǀĞĚĚƵƌŝŶŐĂŶDhZƌĞůĂƚŝŶŐƚŽŶŽƚŝŽŶƐŽĨĐŚĞĐŬŝŶŐƉĂƚŝĞŶƚƐ ?ĐŽŵƉůŝĂŶĐĞǁŝƚŚŵĞĚŝcines 
and providing information if they felt this was necessary. Personal benefits were also reported 
by pharmacists. These included the MUR as a break from routine activities and as a spur to 
keep up to date with their clinical knowledge. MURs were seen as an opportunity to talk to a 
greater extent with patients and learn about their medical conditions. Despite their positive 
views, pharmacists did not believe all their MURs were of benefit to patients and did not 
perceive their remit to extend to more complicated situations of patients medicine taking. The 
reported lack of feedback from GPs made MURs isolated events. Pharmacists revealed that 
they did not contact the GP directly, but rather, relied upon the patient to follow up any issues 
resulting from the review. Nevertheless, pharmacists did give accounts of where they felt an 
MUR had made a difference and also felt heartened to resolve minor problems that the 
patient had not been mentioned to the GP. In this sense MURs were seen as a 
professionalising and valued activity. 
 
Pharmacists in the study reported they simply had insufficient time to dedicate to MURs. They 
expressed that the MUR policy and its implementation in pharmacies showed little evidence of 
thinking through the implications for the existing workload of the pharmacy. Support staff 
interviews further highlighted this view. During an MUR, dispensers and MCAs reported feeling 
ĨƌƵƐƚƌĂƚĞĚĂƐƚŚĞǇŚĂĚƚŽŵĂŶĂŐĞƉĂƚŝĞŶƚƐ ?ĞǆƉĞĐƚĂƚŝŽŶƐǁŚĞŶƚŚĞƉŚĂƌŵĂĐŝƐƚǁĂƐĂďƐĞŶƚĨƌŽŵ
view in the consultation room. Dispensers knew they could interrupt pharmacists during an 
MUR; the symbolic significance of this supported the notion that the pharmacist was 
ĞĨĨĞĐƚŝǀĞůǇƐƚŝůů ‘ŽŶĐĂůů ?ĚĞƐƉŝƚĞďĞŝŶŐŝŶĂƉƌŝǀĂƚĞĐŽŶƐƵůƚĂƚŝŽŶǁŝƚŚĂƉĂƚŝĞŶƚ ? 
 
Pharmacists and support staff reported other barriers to the service which reduced their 
motivation to perform MURs. On a practical level recruiting patients was a tedious challenge. 
As was illustrated in the previous chapter, when patients were asked about the reasons why 
they used the pharmacy their response did not include reviews of their medications. It is not 
therefore surprising that pharmacy staff reported low awareness among patients of MURs. In 
their accounts, pharmacy staff showed little sign of identifying or targeting patients who 
potentially may benefit most from an MUR. Support staff interviews confirmed a limited 
understanding of what occurs during an MUR and their difficulties in communicating the 
anticipated benefits to patients. The low value attached to MURs compared with other 
pressing activities coupled with vague ideas of their potential benefits resulted in an unfocused 
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approach to patient recruitment. Pharmacists were not concerned about who they recruited 
as long as they met the minimum eligibility criteria. The information that was gathered during 
the MUR was perceived to be poorly integrated or utilised in other pharmacy services such as 
during the provision of dispensing services.  
 
On an organisational level, pharmacists and support staff in the multiple were acutely aware of 
the corporate strategy to achieve a targeted number of MURs. Pharmacists reported feeling 
pressurised to undertake MUR activity to achieve the maximum quota as this was linked to pay 
rises and bonus payments for themselves and the rest of the team. Pharmacists conceded that 
under these circumstances, patients that were potentially in most need of an MUR were at 
times being excluded. Particularly in the multiple, rather than viewing the MUR as an activity 
to benefit the patient, pharmacists fixated on short-term targets and the avoidance of negative 
consequences of not achieving these. Interview accounts suggested that the pressure to 
achieve targets could lead to perverse behaviours. The targeting of patients on fewer 
medicines which could be undertaken quickly and MURs being reportedly undertaken on 
pharmacy staff were two such examples.  
      
This chapter has presented the views of pharmacy staff and is the fourth and final results 
chapter. The following chapter is a discussion of the findings from this study.   
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8.1 Introduction  
National health policies in the UK are increasingly promoting ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐǇ ?Ɛ 
involvement in medication management services (Clifford et al 2010; DH 2001; DH 2003b; DH 
2005b; DH 2008; NICE 2009). Since 2005, community pharmacies in England and Wales have 
had the opportunity to offer the MUR service to their patients. The Government White Paper, 
 ‘Pharmacy in England: building on strengths - delivering the future ?(DH 2008) cited MURs as a 
key opportunity for community pharmacists to intervene in supporting patients with the safe 
and effective use of their medicines (DH 2008). However, the effectiveness and value to 
patients ŽĨ ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚƐ ?involvement in the delivery of such services remains 
unclear (Holland et al 2005; Lenaghan et al 2007; McDonald et al 2010; Salter et al 2007; The 
Community Pharmacy Medicines Management Project Evaluation Team 2007). Moreover, 
patient outcomes from MURs have not been well researched and studies in this area have 
been small and not representative of how MURs typically occur in practice (Bagole et al 2007; 
Colquhoun 2010a; Colquhoun 2010b; Desborough et al 2008; Greenhill et al 2011; Portlock et 
al 2009; Wilcock and Harding 2008; Youssef et al 2010). Furthermore, there have been studies 
suggesting wide variation in how pharmacists are documenting and completing MUR forms 
(John et al 2009; MacAdam and Sherwood 2011; NPA 2010; Ruda and Wood 2007).  
 
This study was an in-depth investigation of the MUR service and aimed to fill current gaps in 
ƚŚĞ ůŝƚĞƌĂƚƵƌĞ ? dŚĞ ƐƚƵĚǇ ǁĂƐ ĚĞƐŝŐŶĞĚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ  ‘ƌĞĂů ǁŽƌůĚ ? ƉƌĂĐƚŝĐĞ ŽĨ DhZƐ
including reporting on the MUR consultation and ƚŚĞ ƉĂƚŝĞŶƚƐ ? ƉĞƌƐƉĞĐƚŝǀĞ of this. In the 
previous four chapters I have presented the findings from this study. In this chapter, these 
findings are discussed in relation to other studies of MURs and the relevant wider literature. I 
consider the findings from this study in the context of two broad themes. Firstly, I consider the 
MUR as a modern developing service and an extended role for community pharmacists. 
However, I argue that the MUR is an unestablished service and role for community 
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pharmacists and one which is not fully recognised by patients or GPs. Secondly, I consider the 
findings from this study in relation to the MUR policy, professional aims and intentions and 
consider whether these are being translated in to practice. The strengths and limitations of the 
study are discussed as are the implications and avenues for future research. Before discussing 
their significance, a short summary of the key findings is presented below.  
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8.2 Summary of findings  
Observations in the two community pharmacies revealed pharmacists ? heavy commitment to 
the dispensing process and to other services that required them to be accessible on the shop 
floor. MUR activity was therefore undertaken by pharmacists opportunistically and 
pragmatically accommodated into their daily workload without additional resource. There was 
little evidence that suggested that pharmacists targeted MUR activity to patients who may 
have benefited most. Rather this was dependent on whether the patient filled the minimum 
selection criteria for eligibility or if they had a good relationship with the patient. Undertaking 
MURs to achieve targets or for financial reasons was a noticeable driver for MUR activity 
within the pharmacies.   
 
Observations of MUR consultations revealed that all the pharmacists adhered to a format for 
conducting MURs which was largely determined by the structure of the MUR form. Typically 
the pharmacist dominated the consultation through their professional discourse. The 
ƉŚĂƌŵĂĐŝƐƚ ĨƌĂŵĞĚ ƚŚĞ ĂĐƚŝǀŝƚǇ ĂƐ Ă ƋƵŝĐŬ ĐŽŶƐƵůƚĂƚŝŽŶ ŝŶ ŽƌĚĞƌ ƚŽ  “check ? ƚŚĞ ƉĂƚŝĞŶƚƐ
medicines. Their formulaic approach and closed questions meant opportunities to discuss 
more complex issues about medicines and wider health issues were lost. Nevertheless, 
compared with patient-pharmacist interactions when handing out dispensed medicines, the 
MUR offered a more private and comprehensive consultation about the patients use of 
medicines.  
 
Patients provided ambivalent descriptions of their experience of MURs and what they 
perceived the purpose to be. This was perceived as a monitoring activity rather than an 
opportunity for them to discuss their use, beliefs and concerns about their medicines. Patients 
reported that the MUR did little to improve their knowledge of their medicines and rarely 
affected their use. Some patients were aware of the potentially negative impact of MURs on 
inter-ƉƌŽĨĞƐƐŝŽŶĂů ďŽƵŶĚĂƌŝĞƐ ? ƌĞůĂƚŝŽŶƐŚŝƉƐ ĂŶĚ ƌĞƐƉŽŶƐŝďŝůŝƚŝĞƐ ? WĂƚŝĞŶƚƐ ? ĂĐĐŽƵŶƚƐdid not 
provide strong evidence that the MUR service is achieving its formal policy aims and objectives. 
 
WŚĂƌŵĂĐŝƐƚƐ ? professional conception of MURs rested on improving patient adherence to 
medicine taking. Pharmacists, particularly in the multiple pharmacy, reported feeling 
pressurised to achieve a targeted number of MURs. This contributed to unintended 
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consequences including a reluctance to offer MURs to patients with complex medicine 
regimens or health problems. This was despite pharmacists acknowledging that these patients 
could potentially benefit most from the service. Implementing the MUR service was 
challenging with staff reporting a lack of time and resource as well as difficulties with recruiting 
patients. Support staff reported their frustration of having to manage patient expectations 
when the pharmacist was absent from the shop floor and unable to respond to queries. This 
study revealed the strategies they used to cope when the pharmacist was absent during an 
MUR.   
 
8.3 MURs: a modern and developing service  
Within this theme, I initially discuss and contextualise the ƉĂƚŝĞŶƚƐ ? perspective of MURs. I then 
discuss the implementation of the MUR service and how this was challenging for pharmacists 
alongside the existing services provided by the pharmacy. I also discuss how the lack of 
collaboration between pharmacists and GPs impacted on service delivery. I then turn to 
consider how the MUR was communicated to patients and how this affected the perceived 
purpose of the MUR.  As a modern yet developing service, I argue that there is a supplier-
induced demand for MURs rather than being driven by patients. I conclude by considering 
MURs as a means of promoting ƚŚĞ ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ ƌŽůĞand its impact on the 
professional status of pharmacists. 
 
8.3.1 Contextualising the patient perspective 
There have been no studies that have sought to observe the MUR as they typically occur in a 
 ‘real world ? practice of a community pharmacy and to explore patient perspectives of the 
service. This study therefore adds to our understanding of what happens during an MUR and 
what the immediate perception and outcomes for the patient were. Observation of 
pharmacists performing MURs showed that they adhered to a format for conducting MURs 
which was largely determined by the structure of the MUR form. This led to patients being 
ƉĂƐƐŝǀĞƌĞĐŝƉŝĞŶƚƐŽĨƚŚĞƐĞƌǀŝĐĞ ?WŚĂƌŵĂĐŝƐƚƐƚĞŶĚĞĚƚŽƵƐĞĂ ‘ƵŶŝůĂƚĞƌĂů ?ĂƉƉƌŽĂĐŚƚŽƉĂƚŝĞŶƚ
counselling (Pilnick 2003) and often provided information without establishing whether the 
patient was already knowledgeable about an issue. There were resemblances with patient-
pharmacist interactions when handing out dispensed medicines. There was a noticeable 
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absence of curiosity or intent to enable patients to reveal their perspectives on their medicines. 
These findings support previous studies of patient-pharmacist communication indicating that 
ƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ĐŽŶǀĞƌƐĂƚŝŽŶĂůƚƵƌŶĂŝŵƐƚŽƉƌŽŵŽƚĞƚŚĞŝƌŽǁŶ agenda rather than altering in 
response to what patients say (Ramalho de Oliveira and Shoemaker 2006; Salter et al 2007; 
Salter 2010). Like in other studies of patient-pharmacist interactions, in most instances the 
pharmacist remained focused on the medicine rather than responding to the patient and 
discussing the issue in relation to the ƉĂƚŝĞŶƚ ?ƐŝůůŶĞƐƐ ?ǇĐŬĞƚĂů ? ? ? ? ?ĞƐĐŚĂŵƉƐĞƚĂů ? ? ? ? ?
Greenhill et al 2011).  
    
Most patients described the MUR in positive terms. This view was concurrent with other 
studies suggesting that MURs are generally well received by patients (Bagole et al 2007; 
Kumwenda and James 2008; NPA 2010; Patel and Lefteri 2009; Portlock et al 2009; RPSGB 
2010; Youssef 2009; Youssef et al 2010). WĂƚŝĞŶƚƐ ?ƉŽƐŝƚŝǀĞǀŝĞǁƐŽĨDhZƐŵĂǇbe indicative of 
a wider satisfaction trend of community pharmacy services in general (Anderson et al 2004; 
Bissell et al 2008; Eades 2011). However, the manner in which MURs were performed by 
pharmacists led to patients framing the MUR as a monitoring or Ă ‘ďŝŐ-ďƌŽƚŚĞƌ ?ĂĐƚŝǀŝƚǇ ?/ŶƚŚĞŝƌ
accounts, patients did not construct their experience of MURs as an opportunity for them to 
discuss their medicine use, beliefs and concerns. Indeed, several patients reported that the 
consultation left them with the impression that this was an activity that the pharmacist was 
required to do rather than being for their benefit. Despite these views, most patients reported 
feeling comfortable during the consultation and were appreciative of the time spent with the 
pharmacist. Pharmacists were perceived as knowledgeable experts on medicines and most 
patients found that the pharmacist was more approachable and had more time than their GP. 
^ŽŵĞƉĂƚŝĞŶƚƐŚĂĚ ƚŚĞĐŚĂŶĐĞ ƚŽĚŝƐĐƵƐƐǁŚĂƚ ƚŚĞǇĐŽŶƐŝĚĞƌĞĚ ƚŽďĞ  ‘ŵŝŶŽƌ ? ŝƐƐƵĞƐ ? ƐƵĐŚĂƐ 
which medicines could be co-administered. These issues were not perceived important enough 
to discuss with their GP but were still considered a concern for the patient. Patient information 
needs have been shown to vary over time (Barber 2001; Britten 2008) and patients may use 
ƚŚĞƉŚĂƌŵĂĐŝƐƚ ?ƐŽƉŝŶŝŽŶĂƐĂƐĂŶĐƚŝŽŶƚŽĂĐĐĞƐƐƚŚĞ'W ?,ĂƐƐĞůůĞƚĂů ? ? ? ? ) ? This may account 
for the MUR process helping reassure patients about their medicines and that they were 
 “doing the right thing ? ? 
 
When the MUR was contextualised within the patient ?Ɛ existing framework of care, it was 
found that most of them took prescribed medicines long-term and were comfortable with 
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their existing level of information about medicines. Patients perceived that the pharmacist 
could resolve few problems as part of an MUR as they perceived, as others have highlighted, 
pharmacists as a 'drug experts' rather than experts on health and illness (Anderson et al 2004). 
Moreover, despite the notion that the pharmacist ĐŽƵůĚƉŽƚĞŶƚŝĂůůǇďĞĂ ‘ďƌŝĚŐĞ ?Žƌ ‘ƚƌĂŶƐůĂƚŽƌ ?
between lay and professional care (Blaxter and Britten 1996), most patients had regular 
contact with their GP and perceived them to be the main authority over their medicines. They 
ĐŽŶƐŝĚĞƌĞĚƚŚĂƚ ‘ƐŝŐŶŝĨŝĐĂŶƚ ?ƉƌŽďůĞŵƐwith their medicines would be best resolved by talking 
to the GP rather than with the pharmacist during the MUR. This supports previous studies that 
have found that patients believe their GP to be the only health professional with the legitimate 
expertise to diagnose and treat disease (Britten 2008; Makoul 1995; Livingstone et al 1993; 
Livingstone 1995). Research into patient perceptions of prescribed medicines suggests that 
they perceive the GP to be best placed to provide information about their medicines and that 
they feel the routine giving of information on repeat medication is unnecessary (Britten 2008; 
Hirsch et al 2009; Makoul 1995; Puspitasari et al 2010). Indeed the distinction between doctors 
ĂƐ  ‘ĂƵƚŽŶŽŵŽƵƐ ? ƉƌĞƐĐƌŝďĞƌƐ ĂŶĚ ƉŚĂƌŵĂĐŝƐƚƐ ĂƐ  ‘ŵĞƌĞ ? ĚŝƐƉĞŶ ĞƌƐ  ?ƌŝƚƚĞŶ ?2001) was one 
which was seen to hold true in the present study.  
 
Patients perceived pharmacists to hold a subordinate position to GPs and to have little 
authority to advise or change their prescribed medicines. MURs were seen by some to 
challenge this autŚŽƌŝƚǇ ?^ŽŵĞŽĨƚŚĞƌĞƐƉŽŶĚĞŶƚƐ ?ĂƐŝŶŝƐƐĞůůĞƚĂů ?ƐƐƚƵĚǇ ?ŝƐƐĞůůĞƚĂů ? ? ? ? ) ?
also expressed anxieties about the pharmacist ?Ɛ role in making recommendations about their 
ƚƌĞĂƚŵĞŶƚ ?ƐƚĞŵŵŝŶŐĨƌŽŵĞǆƉĞĐƚĂƚŝŽŶƐĂďŽƵƚ ‘ǁŚŽĚŝĚǁŚĂƚ ?ǁŝƚŚŝŶƚŚĞŚĞĂůƚŚĐĂƌĞdivision 
of labour. Such findings are congruent with another UK based study which showed that 
patients, who received medication reviews by pharmacists, rebutted their attempts to give 
advice about treatment by calling on the higher authority of the doctor (Salter et al 2007). A 
ƌĞĐĞŶƚƐƚƵĚǇĞǆƉůŽƌŝŶŐƉĂƚŝĞŶƚƐ ?ǀŝĞǁƐŽĨƵƐƚƌĂůŝĂŶ,DZƐŚĂƐĂůƐŽĨŽƵŶĚƐŝŵŝůĂƌĐŽŶĐĞƌŶƐĂŶĚ
that the pharmacists may be compromising patient trust in the doctor (Lee et al 2011). The 
significance of a lack of collaboration between pharmacists and GPs is discussed further in 
section 8.3.3.1. 
8.3.2 Communicating the purpose of MURs  
Previous studies have questioned whether the difficulty in recruiting patients for an MUR was 
due to a lack of patient interest Žƌ ƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ? ŝŶĂďŝůŝƚǇ ƚŽ communicate the MUR as a 
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useful and relevant service to patients (Bassi and Wood 2009; Hall and Smith 2006). The 
findings from this study indicated that both were the case. When inviting a patient for an MUR, 
pharmacy staff struggled to effectively explain how the MUR might be beneficial to them or 
how this differed from a medication review provided by the GP. Support staff in particular 
received little training about how MURs could be useful to patients and what the service 
entailed. Vague phrases were typically used to convey the MUR purpose to patients such as 
 “to go through your medicines ? ? 
 
The difficulties in communicating the purpose of an MUR could be viewed as part of a wider 
problem of the public not being aware of the pharmacists ? engagement in newer roles or their 
existing skills and attributes (Hassell et al 1999; Hassell et al 2000; Roberts et al 2006; Rutter et 
al 2000). Tensions may exist between the well established traditional, technically-oriented 
paradigm that patients are familiar and the less well developed role of the pharmacist as 
patient advocate (Morgall and Almarsdo´ttir 1999). Fieldwork observations and interviews with 
participants supported the widespread consumer notion that pharmacies are used mostly for 
prescription supplies and the purchase of OTC medicines (Anderson et al 2004; Eades et al 
2011; Hassell et al 1999). Patients recognised the pharmacy as a retail environment and 
prioritised a quick and efficient dispensing service above other services. Nevertheless, the 
pharmacist was seen as an accessible adviser, views which were similar to those shown in 
other studies (Guirguis and Chewning 2005; Hassell et al 1997; Ried et al 1999).  
 
Most patients in this study were invited for an MUR in an ad hoc way, a method of recruitment 
commonly used by pharmacy staff (Hall and Smith 2006; Latif and Boardman 2008; Moss 2007; 
Urban et al 2007; Wang 2007). This method of recruiting surprised some patients and made 
others feel guarded which further detracted from opportunities to explore tŚĞ ƉĂƚŝĞŶƚ ?Ɛ
agenda within the MUR. Analysis of patient information leaflets about MURs found that these 
largely communicated a formal assessment message to patients (Donyai and Van den Berg 
2006; Van den Berg and Donyai 2010). Although patient empowerment was implied in these 
leaflets, this was within the boundaries of the biomedical model with the pharmacist as the 
educator for medicines information. The issue of mixed messages being communicated to 
patients via patient information leaflets more generally, has been highlighted by others. Dixon-
Woods (2001) suggested that two discourses could be distinguished. The prominent discourse 
ǁĂƐ ŽŶĞ ƚŚĂƚ ƐĞƌǀĞĚ ƚŚĞ ƉƌŽĨĞƐƐŝŽŶĂů ĂŐĞŶĚĂ ƚŽ ĞŶƐƵƌĞ ŵĞĚŝĐŝŶĞƐ ǁĞƌĞ ƚĂŬĞŶ  ‘ƉƌŽƉĞƌůǇ ? ?
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Patients here are characterised as passive and open to manipulation. The second, more recent 
discourse, contrasted with the first to draw on the political agenda of patient empowerment 
and choice for the patient. This study suggests that clarity of what MURs should aim to achieve 
for patients is needed to develop a rigorous, theoretically grounded approach to MUR patient 
information leaflets and other promotional campaigns. 
  
8.3.3 Challenges of implementing a new service  
One research objective of this study was to observe and report how the MUR service is being 
managed alongside the existing service provision. ZĞƐĞĂƌĐŚ ŝŶƚŽ ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚƐ ?
involvement in patient-oriented services has identified several facilitators to their 
implementation. These include more training and support for pharmacists, reduction of 
administrative work, increase in patient awareness and demand for such services, 
improvements in pharmacist-GP relationships and clearer messages from the pharmacy 
profession about the future of professional practice (Gastelurrutia et al 2009; Roberts et al 
2006). However, findings from this study supported those from several other studies 
suggesting MUR implementation is problematic for pharmacists due to a perceived lack of time, 
increased workload and poor resourcing (Blenkinsopp et al 2007a; Bradley et al 2008a; 
Foulsham et al 2006; Gidman 2011; Hall and Smith 2006; Latif and Boardman 2008; 
Rosenbloom and Graham 2008; Urban et al 2008; Wang 2007; Wilcock and Harding 2008).  
 
Pharmacists pragmatically accommodated MURs when convenient to them and to the 
workload of the pharmacy and felt pressure to return to their  ‘ƚƌĂĚŝƚŝŽŶĂů ?shop floor duties. 
Pharmacists were acutely aware of the negative consequences of their absence on the 
pharmacy support staff while they were occupied in completing an MUR. They indicated that 
this influenced how they conducted the MUR. Perceptions of being busy have been shown to 
reduce the extent to which pharmacists provide information to patients and ability to assess 
their understanding (Svarstad et al 2004). In response to their commitment to their shop floor 
duties, pharmacists allowed MURs to be interrupted to maintain work flow. This study 
provides insights into the range of strategies that were employed by support staff to cope 
while the pharmacist was absent during an MUR. This finding highlights the importance for 
policy makers and professional bodies to consider pharmacists existing responsibilities and 
how new roles affect existing service provision. The implementation of MURs appeared to 
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suffer from the well documented problems of managing extended roles alongside existing 
ones (Amsler et al 2001; Bradley et al 2008b; Eades et al 2011; Krska and Veitch 2001; Lee et al 
2008; Lounsbery et al 2009; Niquille et al 2010; Rutter et al 2000). The MUR service has been 
implemented without due consideration for the practicalities of the modern day pharmacy 
akin to the analysis by Dingwall and Watson (2002). Commenting on the social and economic 
position of the solo practitioner, they stated that there was a clear cultural gap between the 
thinking of NHS policy makers and the pharmacist as an entrepreneurial professional.  
 
The MUR remuneration structure led to a target driven culture and as a result this was the 
main facilitator for MUR activity. Corporate pressure applied to pharmacists was most evident 
in the multiple pharmacy and this has been well reported in the literature (Bassi and Wood 
2009; Blenkinsopp et al 2007a; Bradley et al 2008a; Murphy 2007; McDonald et al 2010a; 
McDonald et al 2010b; Wilcock and Harding 2008; Harding and Wilcock 2010; Urban et al 
2008). Consequently, particularly in the multiple, the motivation for undertaking MURs was 
not strongly driven by personal, professional or altruistic reasons but rather to avoid the 
negative consequences from not achieving a targeted number of MURs. This contributed to 
several unintended consequences which are discussed further in section 8.4.2.   
 
Reasons reported by pharmacists for becoming involved in extended role activities include 
enhanced job satisfaction, a break from the routine task of dispensing and the potential to 
improve their public image to patients and GPs (Edmund and Calnan 2001; Grindrod et al 
2010; Mottram 1995; Roberts et al 2006; Tully et al 2000). Although in principle pharmacists 
did view MURs to be beneficial to patients, when undertaking MURs in practice they proved 
burdensome. The challenges of recruiting patients and a lack of perceived support from GPs 
contribute to this. However, further insights were made by the way the pharmacies 
incentivised their employees to perform MURs. Pharmacists felt pressurised and, particularly 
in the multiple, somewhat coerced to achieve a weekly target number of MURs. This reduced 
their intrinsic motivation to engage in MUR activity (Pink 2009). Being constrained by the 
 ‘ƚĞĐŚŶŽůŽŐǇ ?ŽĨƚŚĞDhZĨŽƌŵ, pharmacists lacked a sense of autonomy in deciding how best 
to help the patient. This resulted in a formulaic approach to MURs which is discussed in section 
8.4.2.2. Implementation of MURs was problematic for pharmacists and due consideration to 
the logistics of the pharmacists existing workload failed to encourage them to take the 
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opportunities to effectively engage with the service. Furthermore, a lack of collaboration with 
the GP was seen to limit the potential of what could be achieved by the service.  
8.3.3.1 Lack of collaboration with GPs 
The literature reports positive results on patient health outcomes arising from effective 
pharmacist-GP collaboration (Chen and De Neto Almeido 2007; Krska et al 2001; Nathan et al 
1999; Sorensen et al 2004; Sturgess et al 2003; Zermansky et al 2001). Although MURs involve 
pharmacists undertaking a consultation with a patient, GPs can become involved by referring 
patients to the pharmacist and considering pharmacist recommendations made as a result of 
an MUR. The findings from this study suggest that the MUR service is not fostering 
collaborative work between pharmacists and GPs. Pharmacists did not report that the GP had 
referred patients to them for an MUR and they also reported receiving no feedback from them 
about the MURs conducted. Pharmacists have reported similar views in other studies 
indicating that they did not perceive MURs to be welcomed or valued by GPs (Blenkinsopp et 
al 2007a; Bradley et al 2008a; Celino et al 2007; McDonald et al 2010; Urban et al 2008; 
Wilcock and Harding 2007).  
 
dŚĞƌĞ ǁĂƐ ůŝƚƚůĞ ĞǀŝĚĞŶĐĞ ĨƌŽŵ ƉŚĂƌŵĂĐŝƐƚƐ ? ĂĐĐŽƵŶƚƐthat MURs contributed to increasing 
collaboration with GPs. Pharmacists chose to shift responsibility of communicating any 
outcomes from MURs to patients. This finding supported other research indicating that MURs 
have not significantly contributed to improving pharmacist-GP relationships (Blenkinsopp et al 
2007a; Bradley et al 2008a; Elvey et al 2006; James et al 2007; Harding and Wilcock 2010; 
Urban et al 2008; Wilcock and Harding 2008). Cultural barriers, a lack of clear shared 
expectations and routine face-to-face interactions between GPs and community pharmacists 
have been cited as obstacles ƚŽĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?ŵĞĚŝĐĂƚŝon review activity (Chen and 
De Neto Almeido 2007). Resistance from the medical profession to the extension of the 
pharmacistƐ ? role has also been highlighted (Edmunds and Calnan 2001; Hughes and McCann 
2003). Other inhibiting factors include the geographical separateness or isolation of 
community pharmacy from general practice, the image of the community pharmacy as a 
commercial outlet rather than a health care provider (Hughes and McCann 2003; Jesson and 
Wilson 2003) and pharmacists not being considered aƐĂ “permanent member of the primary 
health care team ? ?ZŽǇĂůŽůůĞŐĞ of General Practitioners 2007:9). Britten (2008) has suggested 
that health professionals, other than prescribers, could be used to support patients who adjust 
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their medicine regimen to their own preference. However, pharmacists did not take the 
opportunity to adopt this role. The lack of perceived mandate over prescribed medicines and 
ƚŚĞǁŝĚĞƌ ŝƐƐƵĞŽĨƉŚĂƌŵĂĐŝƐƚƐ ?lack of collaboration and access to GPs (Hughes and McCann 
2003) may have been reasons for this.  
 
Poor collaboration between pharmacists and GPs draws attention to the wider issue of 
specialisation in professions. Waddock and Spangler (2000), in their analogy, described a 
 ‘Humpty Dumpty problem ?, where all of the kings horses and men resembled the various 
ƐƉĞĐŝĂůŝƐĂƚŝŽŶƐ ŝŶ ƚŽĚĂǇ ?Ɛ ƉƌŽĨĞƐƐŝŽŶƐ, Ăůů ƚƌǇŝŶŐ ƚŽ ƌĞƐŽůǀĞ ƚŚĞ ƉƌŽďůĞŵ ŽĨ ,ƵŵƉƚǇ ?Ɛ ďƌŽŬĞŶ
body. Each profession, only having some of the knowledge to resolve the problem, is expected 
to help by putting their part ŽĨ,ƵŵƉƚǇ ?s broken body, and only their part, back together again. 
They accomplish this without knowledge of what the other professions are doing or indeed 
what Humpty looked like in the first place. The authors argue that professionals that do not 
have a common, shared care plan for the patient cannot be successful and that professions 
must be able to integrate multiple perspectives for the overall benefit of the patient. This 
study found that collaboration between pharmacists and GPs was typically episodic and any 
problems were resolved via telephone conversations. Only sƉĞĐŝĨŝĐƉƌŽďůĞŵƐǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?Ɛ
prescription were discussed when identified during the dispensing process. There was minimal 
continuum of care involving the patient. Others have suggested that for collaborative 
programmes to be successful, the expectations and practice of collaboration must be pre-
existing (Chen et al 1999a; Chen et al 1999b; Chen et al 2001). Expectations that effective 
pharmacist-GP collaboration would occur as a result of MURs, without understanding the 
limitations of their pre-existing relationship, is idealistic. Nevertheless, better working 
relationships between pharmacists and GPs have been suggested to involve a piecemeal 
process; one that is slowly built over time and with reliance on the essence of goodwill 
relationships (Bradley et al 2008b). MUR activity could facilitate this process. However, in 
order for deep and sustained change to occur, reforms to the MUR policy are needed to 
encourage GPs to become more involved along with a concerted effort to build relationships 
so that pharmacists and GPs are in regular contact for the benefit of the patient.     
8.3.4 Supplier-induced demand   
The community pharmacist ?s social position and role has been argued as being indistinct and 
overshadowed by perceptions of being oriented towards business (Edmund and Calnan 2001; 
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Hibbert et al 2002; Hughes and McCann 2003; Mays 1994). Others have suggested that the 
public infrequently seeks pharmacy care as an alternative to the GP (Hassell et al 1999; Hassell 
et al 2000; Hamilton 1998). The lack of self or GP referral in this study indicated that patients 
did not feel that the community pharmacist had a role in reviewing their prescribed medicines 
as a means to improve their knowledge and use of medicines. Nor did they perceive MURs to 
be an activity that would resolve any serious issues that they had with their prescribed 
medicines. This was reflected in how patients described the MUR ĂƐ ďĞŝŶŐ  “satisfying ? Žƌ
 “interesting ? ƌĂƚŚĞƌ ƚŚĂŶ  “necessary ? or  “personally useful ?. Pharmacists reported patient 
apathy and failure to turn up for booked appointments, a finding supported by other studies 
(Blenkinsopp et al 2007a; Moss 2007; McDonald et al 2010; Urban et al 2008). As other 
researchers have suggested, patients may be resistant to change and prefer to stick with their 
current level of care from the pharmacist (Tinelli et al 2009). Some may even prefer to be in a 
ƐƚĂƚĞŽĨ ‘ďůŝƐƐĨƵůŝŐŶŽƌĂŶĐĞ ?ƌĞŐĂƌĚŝŶŐƚŚĞŝƌown treatment (Lupton et al 1991).  
 
Community pharmacy has faced a long standing problem about who needs advice and when 
and how it should be given (Tully at al 1997). The lack of recognition of the community 
pharmacist ?s role in medication management services is not confined to the UK. Home 
MedŝĐĂƚŝŽŶ ZĞǀŝĞǁƐ  ?,DZƐ ) ƌĞƉƌĞƐĞŶƚ Ă ŬĞǇ ĐŽŵƉŽŶĞŶƚ ŽĨ ƵƐƚƌĂůŝĂ ?Ɛ ŶĂƚŝŽŶĂů ŵĞĚŝĐŝŶĞƐ
policy for achieving  ‘quality use ? of medicines (Commonwealth Department of Health and Aged 
Care 2001). However, a recent study of HMRs also found that patient awareness of the service 
was poor despite its availability since 2001 (Lee et al 2011). In the US, low participation rates in 
medication therapy management services are common and numerous challenges to providing 
such services including reimbursement and stakeholder acceptance of the services have been 
identified (Pellegrino et al 2009). For programmes to be successful, patients must perceive 
value for their time spent engaging with the service (Pellegrino et al 2009). With pharmacists 
ďĞŝŶŐĐŽŶƐƚƌĂŝŶĞĚďǇƚŚĞ ‘ƚŽƉĚŽǁŶ ?DhZƉŽůŝĐǇ ?ƚŚĞDhZdid not resonate with patients as a 
useful service.  
 
WĂƚŝĞŶƚƐ ?ƵƐĞŽĨƚŚĞƉŚĂƌŵĂĐǇŚĂƐďĞĞŶƐƵŐŐĞƐƚĞĚƚŽďĞĂĨĨĞĐƚĞĚďǇƚŚĞŝƌƐƵďũĞĐƚŝǀĞĞǀĂůƵĂƚŝŽŶ
of their need for a service and their actions in managing their illness (Eades et al 2011; Hassell 
et al 2000). Despite the MUR service being available for several years, pharmacy staff reported 
that awareness amongst patients of what the MUR could offer them was poor. With the 
exception of one, all MURs were initiated by the pharmacy staff and so this was largely a 
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service driven by a supplier-induced demand mechanism (Folland et al 2009). In contrast, 
other pharmacy services such as the supply of dispensed medicines and OTC sales of medicines 
are patient or consumer initiated. The infrequency of MUR activity meant that, when viewed 
ĨƌŽŵƚŚĞƉĂƚŝĞŶƚƐ ?ƉĞƌƐƉĞĐƚŝǀĞ ?the consultation was an unexpected and somewhat sporadic 
event and not considered a routine part of the care offered from the pharmacy. Patients who 
had an MUR for the first time reported they had never been offered such a service in the past 
and did not expect this to be offered again in the future. As the demand for MURs is supplier-
induced, this study raises questions as to whether the service is required by patients or 
whether there could be alternate ways of achieving the same goals. Furthermore, as with 
other supplier-induced demand health services, commissioners typically have little way of 
knowing the appropriate quantity of service to be provided resulting in the rationing of service 
payments (Folland et al 2009). Simply placing a cap on the maximum number of MURs that 
each pharmacy can claim has led to a perverse incentive (McDonald et al 2010a; McDonald et 
al 2010b) and the consequences for patients of this are further explored in section 8.4.2.  
 
8.3.5 MURs and professional role extension    
MURs remain largely unrecognised by patients and GPs and have proved to be challenging for 
pharmacists to deliver. It therefore raises questions as to what extent MURs contribute to the 
professional status of community pharmacists. As discussed in Chapter Two, developments in 
technology, automation and organisation of health care has led to growing professional 
ĂƚƚĞŶƚŝŽŶƚŽƌĞĂƉƉƌĂŝƐĞĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐŝƐƚƐ ?ĂĐƚŝǀŝƚŝĞƐĂǁĂǇĨƌŽŵƚŚĞƚĞĐŚŶŝĐĂůaspects of 
dispensing toward clinically-oriented and patient-centred roles (Birembaum 1982; Edmund 
and Calnan 2001; Gilbert 1998; Laine and Davidoff 1996; Nuffield Committee of Inquiry into 
Pharmacy 1986; RPSGB 1997a; RPSGB 1997b). However, far from providing an opportunity to 
ĚĞǀĞůŽƉ ƐŬŝůůƐ ĂŶĚ ƌĂŝƐĞ ƚŚĞŝƌ ƉƌŽĨĞƐƐŝŽŶĂů ƐƚĂƚƵƐ ? ƉŚĂƌŵĂĐŝƐƚƐ ? ƐƵďŽƌĚŝŶĂƚŝŽŶ ƚŽ ƚŚĞ
 ‘ƚĞĐŚŶŽůŽŐǇ ?ŽĨƚŚĞDhZĨŽƌŵƌĞĚƵĐĞĚƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ƐĐŽƉĞĂŶĚŽƉƉŽƌƚƵŶŝƚǇĨŽƌĞǆĞƌĐŝƐŝŶŐ
professional judgement and autonomy during the consultation. Furthermore, evidence 
suggesting ineffective targeting of MURs (Blenkinsopp et al 2007a; Bradley et al 2008a), has 
threatened the extent to which this activity raises the ƉŚĂƌŵĂĐŝƐƚƐ ?professional profile (DH 
2008). 
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Pharmacists hold a licence to undertake MUR activity and in theory, engaging with MURs has 
the potential to ƌĂŝƐĞ ƚŚĞ ĐŽŵŵƵŶŝƚǇ ƉŚĂƌŵĂĐŝƐƚ ?Ɛ status. However, the continued lack of 
ĐŽŶƚƌŽůƚŚĂƚƚŚĞƉŚĂƌŵĂĐŝƐƚƐǁĞƌĞƐĞĞŶƚŽŚĂǀĞŽǀĞƌƉŚĂƌŵĂĐǇ ?s social object, the medicine, 
(Denzin and Metlin 1968) undermined the potential to enhance their professional status. 
Moreover, corporate pressure applied to employee pharmacists, as others have also suggested, 
led to pharmacists focusing on commercial, as opposed to patient interests (McDonald et al 
2010b). A lack of recognition from patients, GPs and organisational constraints signified that 
ƉŚĂƌŵĂĐŝƐƚƐ ? ƐƚƌƵŐŐůĞ to establish a mandate over this activity. Furthermore, it has been 
argued that one facet of professional status involves perceptions of professional time as being 
more valuable than that of the patient (Harding and Taylor 1997). However, where patients 
initiate consultations to see their GP, the MUR was one where the pharmacist was relying on 
the patient to agree to an MUR.  
 
Harding and Taylor (1997) have noted that extended pharmacy roles may ironically have a de-
professionalising effect because many do not have medicines as their focal point and thus has 
traditionally been the pharmacist ?s expertise and claim to professional status (Hepler and 
Strand 1990; Edmund and Calnan 2001) Pharmacists engagement with MURs exposed them to 
ĂŐƌĞĂƚĞƌĚĞŐƌĞĞŽĨŝŶĚĞƚĞƌŵŝŶĂĐǇŝŶƚŚĞŝƌǁŽƌŬƚŚĂŶƚŚĞŝƌ ‘ƚƌĂĚŝƚŝŽŶĂů ?ƐŚŽƉĨůŽŽƌŝŶƚĞƌĂĐƚŝŽŶƐ
 ?:ĂŵŽƵƐ ĂŶĚ WĞůŽŝůůĞ  ? ? ? ? ) ? DƵĐŚ ŽĨ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛshop floor work was routinised and 
when opportunities were presented to intervene on prescribed medicines, this was, as 
indicated by others, largely taken up with bureaucratic or legal issues (Braund 2010). In 
contrast, during the MUR, each medicine was referred to and was asked about and this would 
not have otherwise occurred. The MUR presented pharmacists with more opportunities to 
help patients with their medicines or to respond to a specific query that had been raised by the 
patient. Consequently, pharmacists were exposed to some of the complexity of how patients 
manage their medicines and were challenged to sometimes talk about a sensitive issue that 
would not have been raised by patients on the shop floor. In this way, MURs incrementally 
added to the level of indeterminĂĐǇ ŝŶƉŚĂƌŵĂĐŝƐƚƐ ?ǁŽƌŬ ?This study shows that pharmacists 
have the opportunity to further their professional status through MUR activity. However, they 
are, by and large, not taking full advantage of this at present.  
  
In this section, I have discussed the ƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞŽĨMURs and their implementation in 
light of a modern but still unestablished service. With a supplier-induced demand for MURs, 
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ƋƵĞƐƚŝŽŶƐ ĂƌĞ ƌĂŝƐĞĚ ĂƐ ƚŽ ƚŚĞŝƌ ǀĂůƵĞ ƚŽ ŝŵƉƌŽǀĞ ƉĂƚŝĞŶƚ ?Ɛ ƵƐĞ ŽĨ ŵĞĚŝĐŝŶĞƐ ?I have also 
discussed the topic of MURs as a means for enhancing professional status. In the following 
section, I turn to discuss whether the MUR service is in practice, managing to realise its 
intended policy and professional aims and intentions.   
 
8.4 From policy to practice 
One objective of this study was to investigate whether the aims of the MUR service to improve 
ƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞĂďŽƵƚƚŚĞŝƌŵĞĚŝĐŝŶĞƐĂŶĚ their use are being realised in practice and in 
this section I discuss this objective. Initially consideration is given to the process of 
rationalisation on MUR service provision and the unintended consequences that result from 
this. I then discuss how the MUR policy was being interpreted by pharmacists and its 
manifestation in practice. I conclude by discussing whether the policy and professional 
agendas that have been set out for the service were being met in the  ‘real world ? practice of 
the pharmacy.  
 
8.4.1 MURs and rationalisation 
NHS services have seen an increased focus on operational outcomes which have been brought 
about through a  ‘top-down ? managerial approach and commitment to rational decision making 
(Hogwood and Gunn 1984; North 1997). The MUR policy is no exception and this study 
demonstrated the effect of such rationalisation in practice. As outlined in Chapter Two, one 
way of understanding this process is through ZŝƚǌĞƌ ?ƐĐŽŶĐĞƉƚƵĂůŵŽĚĞůǁŚŝĐŚŝƐďĂƐĞĚŽŶĨŽƵƌ
intertwined dimensions: efficiency, calculability, predictability and control (Ritzer 2008). These 
dimensions were evident and could be applied to the MUR service. For example, the MUR 
consultation centred on the completion of the nationaů ƐƚĂŶĚĂƌĚ DhZ ĨŽƌŵ ? dŚŝƐ  ‘ƚŝĐŬ-ďŽǆ ?
form enabled the efficient questioning of patients about issues that were thought to improve 
ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞƐ ŬŶŽǁůĞĚŐĞ ĂŶĚ ƵƐĞ ? dŚŝƐ  ‘ŽŶe ƐŝǌĞ ĨŝƚƐ Ăůů ? ĂƉƉƌŽĂĐŚ ĞŶĐŽƵƌĂŐĞĚ the 
pharmacist to treat patients who had a diverse range of individual circumstances and issues 
the same. There was evidence suggesting that pharmacists focused on the quantity of MURs 
undertaken over any quality outcome measure. The control element of his model could be 
seen in the way organisations applied pressure on pharmacists to undertake MURs. Ritzer, in 
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his model, warned that systems designed around rationality can lead to irrational and 
unintended consequences and these are discussed next.     
 
8.4.2 Unintended consequences 
In this section, I focus on two areas that contributed to the irrationality that was associated 
with the MUR service. Firstly, the MUR remuneration structure and secondly, the national 
MUR form that is required to be completed as part of the MUR.  
 
8.4.2.1 Irrationality of MUR targets  
The MUR policy remunerates for the volume of MURs undertaken and this has led to 
organisations setting targets for pharmacists. This issue has been well documented in the 
literature (Bassi and Wood 2009; Blenkinsopp et al 2007a; Bradley et al 2008a; Murphy 2007; 
McDonald et al 2010a; McDonald et al 2010b; Wilcock and Harding 2008; Harding and Wilcock 
2010; Urban et al 2008). Within the multiple pharmacy, the threat of withholding staff bonuses 
or pay rises was reflected in the choices that pharmacists made. One pharmacist reported that 
ĂƐĂĐŽŶƐĞƋƵĞŶĐĞŽĨƚŚŝƐƉƌĞƐƐƵƌĞƐŚĞĨĞůƚƐŚĞǁĂƐ “bullying ?ƉĂƚŝĞŶƚƐto undertake an MUR in 
order to achieve the weekly quota. Others have indicated that pharmacies are being 
remunerated for MURs that are not being effectively targeted at those who may benefit the 
most and that the professional status offered through MUR activity is being undermined 
(Bradley et al 2008a; DH 2008; McDonald 2010a; McDonald 2010b). This irrationality was most 
evident when two support staff reported that they themselves had been offered and had 
undertaken an MUR in order to contribute to realising the MUR target.  
 
The lack of optimally selected patients or formal needs assessment prior to the MUR may 
explain the limited improvements in adherence to medicines or reduction of wastage from 
unused medicines reported by patients. Patients on fewer medicines, or those perceived to 
have less complex medical conditions, were targeted for MURs as they coƵůĚďĞ  ‘ƉƌŽĐĞƐƐĞĚ ?
more quickly. This led to some patient groups reportedly being avoided such as patients with 
many medicines, complex conditions such as mental illness and older patients who could 
become confused by the request and participation of an MUR. However, these are precisely 
the patient groups who may have benefited the most from an MUR. Moyo (2010) commenting 
on the perverse effects of quantitative measures as a means to remunerate for MURs, pointed 
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ƚŽ  ‘ĂƌůĞǇ ?Ɛ >Ăǁ ? ƚŽ ƉƌŽǀŝĚĞ ĨƵƌƚŚĞƌ ŝŶƐŝŐŚƚƐ ? dŚŝƐlaw predicts that the more a quantitative 
ŵĞĂƐƵƌĞŝƐƵƐĞĚƚŽĚĞƚĞƌŵŝŶĞĂŶŝŶĚŝǀŝĚƵĂů ?ƐƉĞƌĨŽƌŵĂŶĐĞ ?people will find ingenious ways in 
order to maximise their figures but in the process, lose sight of what the numbers actually 
represent. 
The introduction of different types of incentives to better manage public health services has 
been shown to impact on the professional behaviour of pharmacists and other health care 
professionals in primary care (McDonald et al 2010b). McDonald et al (2010b) showed that 
centrally driven reforms and initiatives do not always change behaviour as intended. For 
example, the use of computerised chronic disease templates, which facilitate GPs achievement 
of Quality and Outcomes Framework (QOF) targets, have led to patient consultations to be 
directed by the GPs agenda to ensure that these target measures are met. The focus on 
recording information that may not be of direct relevance has threatened the balance away 
ĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐŝŵŵĞĚŝate agenda (Campbell et al 2008; Mangin and Toop 2007; McDonald 
et al 2010b). In another example, reforms to the Dental Contract in 2006 led to reports of 
immediate behaviour changes in dental practice. A shift away from complex treatments 
towards less resource intensive procedures was reported by dentists because of the new 
funding structure. This led to dentists switching to treatments which pay more, relative to 
effort expended as opposed to selecting treatments on the basis of clinical factors alone 
(McDonald et al 2010b). 
 
UK studies investigating the effect of pay-for-performance schemes in general practice have 
shown limited effects on processes of care or on clinical outcomes and that providing generous 
financial incentives may not be sufficient to improve the quality of care and outcomes for 
patients (Campbell et al 2009; Serumaga et al 2011). Nevertheless, pay-for-performance 
incentives have been argued to have positive impacts when the policy is designed according to 
the context to which the programme is introduced (Van Herck et al 2010). Van Herck et al 
(2010) suggested, following a systematic review of pay-for-performance programmes in health 
care, that incentives should include targets on the basis of baseline room for improvement. 
Also, they suggested that there should be thorough and direct communication about the 
programs to stakeholders, a focus on quality improvement and a distribution of incentives to 
the individual and / or team level. However few of these suggestions were evident during my 
investigation of the MUR service. 
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Recent national changes to the MUR service have been agreed. These include the introduction 
of national target patient groups including patients taking high risk medicines (e.g. 
anticoagulants, diuretics), patients recently discharged from hospital and those with 
respiratory disease (Livingstone 2010; PSNC 2011e). As part of these reforms, policy makers 
have agreed that 50% of all MURs undertaken by each pharmacy should be with patients 
within the national target groups. It is intended that these measures will improve outcomes 
from MURs and also provide assurance to commissioners that MURs are being effectively 
targeted (PSNC 2011e). Furthermore, outcome measures for each target group have also been 
suggested but details of these outcome measures are yet to be released (PSNC 2011e). 
However, in light of the study findings, simple measures may not be sufficient to address the 
problems associated with the way organisations are motivating pharmacists to achieve their 
allowance of MUR payments. Such measures will also not address the limitations and 
constraints associated with the rational format of the MUR form and how this was being 
deployed by the pharmacist during the MUR consultation and this is discussed next.  
 
8.4.2.2 The MUR format  
One key principle that has been suggested in the current UK national guidelines on medication 
adherence is that health care professionals should adapt their consultation style to the needs 
of individual patients so that they have the opportunity to be involved in decisions about their 
medicines at a level with which they feel comfortable (NICE 2009). Current guidance also 
indicates that central to the MUR process, there should be respect for the patient ?s beliefs 
about medicines and patients should also be able to engage in an open discussion of these 
with the pharmacist (Clyne et al 2008; NICE 2009). However, MUR consultations observed in 
this study, were dominated by the pharmacist ?Ɛ agenda to complete the national standardised 
 ‘ƚŝĐŬ-ďŽǆ ?DhZ form. Closed questions were asked in order for the pharmacist to complete the 
review quickly and efficiently. This pre-empted patient questions or wider discussion of their 
health and medicines. This was akin to the selective attention strategies that have been 
identified where GPs ŵĂŝŶƚĂŝŶĨŽĐƵƐŽŶƚŚĞƉĂƚŝĞŶƚ ?ƐƐǇŵƉƚŽŵƐĂŶĚďǇƉĂƐƐŽƚŚĞƌpatient cues 
and responses (Barry et al 2001; Mishler 1984). Barry et al (2001) suggested that doctors who 
ignored or blocked patient life-world experiences and concerns led to poorer outcomes for 
patients. This may be one of the reasons why several patients reported they did not find the 
MUR personally useful. Furthermore, studies of doctor and pharmacist-patient consultations 
have shown that the computer screen had detracted attention away from the patient (Booth 
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et al 2004; Greenhill et al 2011). In this study the pharmacist was subordinate to the 
 ‘ƚĞĐŚŶŽůŽŐǇ ? ŽĨ ƚŚĞ DhZ ĨŽƌŵ and it was this which detracted attention from exploring the 
ƉĂƚŝĞŶƚ ?ƐĂŐĞŶĚĂŽƌĞǆƉůŽƌŝŶŐŝƐƐƵĞs that they would find useful and relevant. 
 
Studies have indicated that patients who participate more during their consultations through 
asking questions, expressing opinions and raising topics of concern are more likely to 
understand their treatment and follow recommendations than patients who display a passive 
demeanour (Harrington et al 2004; Deschamps et al 2003; Ramalho de Oliveira and Shoemaker 
2006 ) ?ZĞĨŽƌŵƐƚŽ ƚŚĞDhZƉŽůŝĐǇ ƚŽ ƐŝŵƉůŝĨǇ ƚŚĞDhZ ĨŽƌŵƌĞƐƵůƚĞĚ ŝŶ ƚŚĞƋƵĞƐƚŝŽŶ  ‘What 
would the patient like to get out of the review? ?ďĞŝŶŐƌĞŵŽǀĞĚ ?During their interviews, some 
patients, when asked, revealed outstanding concerns or still remained confused about an 
aspect of their treatment. Patients were reluctant to raise health concerns unless they 
perceived these to be directly relevant to the consultation. They reported feeling they did not 
want to interrupt the pharmacist ?ƐĨůŽǁŽĨƋƵĞƐƚŝŽŶƐŽƌƉĞƌĐĞŝǀĞĚƚŚĂƚ the matter could only 
be dealt with by the GP. Barry et al ?Ɛ (2000, 2001) investigation of patients attending GP 
appointments found that often patients had several diverse agendas including concerns about 
their symptoms, illness fears, and emotional and social issues that they wanted to air in the 
consultation. However, patients were found not to ƌĂŝƐĞƚŚĞƐĞ ‘ƵŶǀŽŝĐĞĚĂŐĞŶĚĂƐ ?ǁŚŝĐŚůĞĚƚŽ
poor outcomes including unwanted prescriptions and non-adherence to treatment. The lack of 
a clear invitation for patients to ask questions about their medicines or health concerns at the 
beginning of the MUR consultation may have contributed to them still having unresolved 
concerns. The ad hoc approach to recruitment left some patients feeling surprised and this 
further created a barrier for patients to prepare for or remember to ask questions during the 
MUR.    
  
Pharmacists chose to communicate with the GP via the MUR form or relied on the patient to 
follow up recommendations rather than speaking to the GP directly. Despite the changes made 
to the MUR form to make it ŵŽƌĞ  “user friendly ? for pharmacists, GPs and patients (PSNC 
2007), the patient was still left with the responsibility to follow up any suggestions made by 
the pharmacist resulting from an MUR. Harding and Taylor (1997) described that many 
extended roles for community pharmacy involved ƐŝŵƉůǇ  “asking structured, formulaic 
questions ? ?dŚĞƐƚƌƵĐƚƵƌĞĚDhZĨŽƌŵĂƚand limited scope of the service is at odds with policy 
commitments to develop pharmacy services which are responsive, individually tailored and 
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patient-centred (DH 2000b; DH 2003a; DH 2003b; DH 2005b). The procedural way MURs were 
conducted was not an effective method of improving patient knowledge about their medicines 
or adherence to them. This is further discussed in section 8.4.4.  
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8.4.3 Pharmacists as street-level bureaucrats 
Previous research that has reported benefit from MURs has primarily focused upon certain 
groups of patients (Bagole et al 2007; Desborough et al 2008; Portlock et al 2009; Wilcock and 
Harding 2008). Some studies have shown benefits from MURs that have been tailored to a 
specific medical condition through the addition of supporting material, such as questions to 
assess asthma control (Bagole et al 2007; Colquhoun 2010a; Colquhoun 2010b). Other studies 
have provided additional training before the pharmacist undertook MURs (Portlock et al 2009; 
Cree 2010). However, these studies are limited as they do not reflect how MURs are typically 
being performed in practice. As was introduced in Chapter Two (section 2.10), Lipsky (2010) 
argues that in practice it is the street-level bureaucrats (front-line workers) who determine 
how policies are implemented. They often do so with limited resources and under pressure to 
ŵĞĞƚƚĂƌŐĞƚƐ ?>ŝƉƐŬǇ ?ƐĂƌŐƵŵĞŶƚƐƌĞƐŽŶĂƚĞwith the findings from this study, in particular, how 
pharmacists understood and were implementing the MUR service in practice. The difficulties 
pharmacy staff experienced when recruiting patients meant that target patient groups, who 
may have potentially benefited most, were effectively sidelined. Pharmacists, in response to 
organisational pressures to meet targets, exercised discretion to whom the service was offered 
and how quickly the MUR was performed. In this way the MUR policy was interpreted and at 
times its intentions even subverted to accommodate for the demands of work.  
 
The successful implementation of ƉŽůŝĐǇƚŽŝŵƉƌŽǀĞƉĂƚŝĞŶƚƐ ?ŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨŵĞĚŝĐŝŶĞƐ
through the MUR was not evident from fieldwork observations or patient accounts. The MUR 
was viewed by pharmacists as a means to check that patients were adhering to their medicines 
and to provide further information if they felt that this was necessary. Pharmacists simplified 
or circumvented ĐŽŵƉůĞǆ ƉĂƚŝĞŶƚ ŝƐƐƵĞƐ ƚŚĂƚ ŝŶĞǀŝƚĂďůǇ ĂƌŽƐĞ ǁŚĞŶ ĚŝƐĐƵƐƐŝŶŐ ƉĂƚŝĞŶƚƐ ?
medicines use in order to record the issue on the MUR form and allow the MUR to proceed. 
They made professional judgemenƚƐ ĂďŽƵƚ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞ ƚĂŬŝŶŐ and deemed what 
was acceptable and what was not, according to their own criteria rather than exploring how 
important an issue was for the patient. In instances where the patient reported taking a 
medicine differently or expressed an aversion to their medicine, an inflexible view was taken 
by the pharmacist in order to  ‘correct ? ƚŚĞƉĂƚŝĞŶƚƐ ?ĚĞǀŝĂŶĐĞ ?Pharmacists in these instances 
ĐŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚĂƐ  ‘Ɛƚƌeet-ůĞǀĞůďƵƌĞĂƵĐƌĂƚƐ ?  ?>ŝƉƐŬǇ ? ? ? ? )ĂƐƚŚĞŝƌĂƉƉƌŽĂĐŚƚŽƚŚĞDhZ
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and the decisions they made in practice effectively became the MUR policy and determined 
what the service actually achieved. 
  
Previous studies of pharmacist-patient communication suggest that pharmacists tend to use a 
protocol-driven discourse when advising about prescription medicines as well as medicines 
sold OTC (Greenhill et al 2011; Norris and Rowsell 2003; Rutter et al 2004; Skoglund et al 2003). 
Pharmacists may therefore be ill equipped with the skills to undertake extended and more 
complex consultations such as the MUR. MUR consultations showed similarities to the 
unilateral approach to counseling identified by Pilnick (Pilnick 2003). The message 
communicated in many MUR sequences was that there is only one correct way to take 
medication (as opposed to a choice to be made). Pilnick describes unilateral counselling 
activity as bearing resemblance to conversational sequences of instruction in relation to 
factual or procedural matters. During the MUR, ƉĂƚŝĞŶƚ ?ƐƵƚƚĞƌĂŶĐĞƐŝŶĚŝĐĂƚĞĚƚŽƉŚĂƌŵĂĐŝƐƚƐ
that they had adequate knowledge of their own medicines. However, by merely 
acknowledging this utterance, pharmacists simply confirmed the patient response rather than 
actively seeking to ensure understanding. This may be one reason why patients reported the 
MUR did little to improve their knowledge of their medicines and that they were left feeling 
ƚŚĂƚƚŚĞDhZǁĂƐĂ ‘ĐŚĞĐŬ ? on their medicines.  
 
8.4.4 Translation of MURs policy aims and intentions in practice 
8.4.4.1 The adherence agenda    
There is a long standing public and professional concern about NHS medicines wastage 
(Clifford et al 2010; Horne et al 2005; RPSGB 1997; Trueman et al 2010; WHO 2003) and the 
MUR is part of a strategy to address this (DH 2005a). The underlying and implicit assumption of 
the MUR service rests on an information deficit model (Dunbar et al 1979; Heath 2003). 
Patients in this scenario are viewed as empty vessels into which information can be poured, 
and once enough of the  ‘right information ? has been given this will ƌĞƐƵůƚŝŶƚŚĞ ‘ĐŽƌƌĞĐƚ ? use of 
the medicine. Consequently, this will lead to a reduction in cost from unused medicines and 
the possible prevention of treatment failure. Using the empty vessel metaphor, patients during 
the MUR were checked to see if they were devoid of such knowledge and experience. 
However, simply providing information does not necessarily lead to a change in a patient's 
health behaviour (Lorig 2001). This study showed that in practice patients reported that MURs 
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did little to affect their use of medicines as they felt no need to change their medicine taking 
habits. This was similarly reported by others and what has been attributed to a  ‘ĐĞŝůŝŶŐĞĨĨĞĐƚ ?
where the patients ? treatment is already in line with the agreed guidelines (The Community 
Pharmacy Medicines Management Project Evaluation Team 2007). 
 
There was little evidence from this study that the MUR service in practice was an effective 
means to tackle non-adherence issues. As outlined in Chapter Two, patient non-adherence can 
be classed as intentional or unintentional or both (Horne and Weinman 1999; Horne et al 2005; 
NICE 2009). Pharmacists lacked interest to seek out patients who might be in more need of an 
MUR. This meant that the potential for the pharmacist to address cases where the patient 
unintentionally did not adhere to medicines was limited. Moreover, MURs had limited scope to 
be able to ĂĨĨĞĐƚƉĂƚŝĞŶƚƐ ?ŝŶƚĞŶƚŝŽŶĂůŶŽŶ-adherence to medicines. As others have suggested 
change in the patient's health behaviour is facilitated by an understanding of the patient's 
underlying belief system (Elliott et al 2005; George et al 2008; Haynes et al 2002; Kripalani et al 
2007; Pellegrino et al 2009). WŚĂƌŵĂĐŝƐƚƐ ?  “natural attitude ? to convey pharmacological 
knowledge (Ramalho de Oliveira and Shoemaker 2006) and their lack of intent and curiosity 
about the patient, resulted in the MUR not being an effective mechanism to identify patient 
problems with their medicines. Advice was accepted by patients when the pharmacists ? 
suggestions were in line with their beliefs and preferences. Suggestions that conflicted with 
their opinions or were difficult or inconvenient to implement were less likely to be accepted.       
 
8.4.4.2 MURs as a patient-centred and concordant service  
Developing concordant practice has been a challenging concept to implement in health care 
settings (Heath 2003) and pharmacists may be adapting this practice according to the 
constraints of work and their personal style (Leontowitsch et al 2005). This study suggests that 
the delivery of the MUR service is at odds with policy commitments and strategies to develop a 
responsive service which is individually tailored and patient-centred (Clyne et al 2008; DH 
2000b; DH 2003a; DH 2003b; DH 2005b; Laine and Davidoff 1996; NICE 2009). The 
ĐŽŶƐĞƋƵĞŶĐĞŽĨƉŚĂƌŵĂĐŝƐƚƐ ? ĨŽƌŵƵůĂŝĐ ƐƚǇůĞof conducting MURs meant that they inevitably 
ƐŝĚĞůŝŶĞĚ ƉĂƚŝĞŶƚƐ ? ĐŽŵƉůĞǆ ďĞůŝĞĨƐ ĂŶĚ ĐŽŶĐĞƌŶƐincluding aversion to medicines which was 
expressed by several patients (Britten et al 2004; Donovan and Blake 1992; Conrad 1985; 
Pound et al 2005; Townsend et al 2003). Like others studies have suggested, patients reported 
using medicines in ways that accord with their individual beliefs and preferences and this 
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sometimes deviated from the prescribed recommendations (Adams et al 1997; Conrad, 1985; 
Donovan and Blake 1992; Donovan 1995; Nichter and Vuckovic 1994; Pollock 2001; Pollock 
2005). Constrained by the MUR format, the pharmacist did little to uncover these complex 
views. Furthermore, patients had to wait for a convenient time to ask a question or express 
their views.  
 
The findings from this study share similarities to recent findings exploring pharmacist 
domiciliary medication review encounters (Salter 2010). Salter ?Ɛ findings suggested that a 
 “dominant compliance paradigm ? encourages pharmacist-led encounters with patients failing 
to engage in the medication review process. This led to the author finding little evidence of 
two-way reciprocated discussion or concordant practice (Salter 2010). MURs have been 
criticised for promoting a professional agenda focusing on patient adherence, rather than 
capitalising on an opportunity to explore their beliefs and expectations of medicine and 
approaching the MUR concordantly (Donyai and Van den Berg 2006; Wilcock and Harding 2008; 
Van den Berg and Donyai 2009). Consultation skills such as responding to patient cues, using 
ŽƉĞŶƋƵĞƐƚŝŽŶƐĂŶĚĞůŝĐŝƚŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞŚĂǀĞďĞĞŶŝĚĞŶƚŝĨŝĞĚďǇŽƚŚĞƌƐĂƐĂƌĞĂƐ
where pharmacists need to improve (Greenhill et al 2010).  
 
In contrast to their handling of the MURs, this study indicates that pharmacists can provide 
customised information in responding to patient requests for advice about minor ailments. In 
these circumstances, patients appeared both familiar with and accepted the role of the 
pharmacist as an accessible adviser. The autonomy and willingness of the pharmacists to 
accommodate patient preferences during OTC discussions was in contrast to their constrained 
approach when discussing prescribed medicines during the MUR. A systematic review of two-
way communication between patients and health care professionals, found that patient 
perspectives about their medicines were not discussed in most health care consultations 
(Stevenson et al 2004).  
 
In this discussion, I have argued that although well intentioned, the MUR service in practice is 
not achieving what it should be and substantial changes to the policy, organisational 
arrangement, GP and pharmacy staff perceptions are needed. Professional agendas to 
ƉƌŽŵŽƚĞ ƚŚĞ ƉŚĂƌŵĂĐŝƐƚ ?Ɛextended role also, in practice, fell short of these objectives and 
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stronger professional leadership and changes to cultural practice is required. The implications 
arising from this study are discussed in section 8.6.  
 
8.5 Strengths and limitations 
8.5.1 Strengths  
To my knowledge, this is the only observational study that has explored MUR consultations as 
they occur ŝŶĂ ‘ƌĞĂůůŝĨĞ ?ĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐǇƐĞƚƚŝŶŐ ?/ŶƚŚŝƐƐĞŶƐ ?ƚŚĞƐĞĨŝŶĚŝŶŐƐgo beyond 
what is already known and so make a significant contribution to our understanding of current 
pharmacy practice. The fieldwork observations enabled a personal firsthand account of how 
MURs were being performed and managed alongside the provision of other pharmacy services. 
Adopting this research approach also enabled the identification of patients who declined an 
invitation for an MUR. Whilst this was only a small number of interviewees, this is a hard to 
reach group and this study allowed for the inclusion of their views.     
 
Another important strength was that this study used a combination of two powerful 
qualitative research methodological approaches to enhance the credibility of the findings. The 
fieldwork observations provided access to the same places and events as the participants. The 
interviews with participants allowed them to share their experiences of the MUR in their own 
words which permitted their views to be studied in more depth. The triangulation of direct 
ŽďƐĞƌǀĂƚŝŽŶ  ?ƌĞƐĞĂƌĐŚĞƌ ?Ɛ ĂĐĐŽƵŶƚƐ ) ǁŝƚŚ ĂĐĐŽƵŶƚƐ provided by respondents in interviews 
ƉƌŽǀŝĚĞĚĂƉŽǁĞƌĨƵůŵĞĂŶƐŽĨƵŶĚĞƌƐƚĂŶĚŝŶŐƚŚĞĐŽŵƉůĞǆŝƚǇŽĨƌĞƐƉŽŶĚĞŶƚƐ ?ǀŝĞǁƐ ?ŚŽǁƚŚĞƐĞ
may shift contextually, the situational pressures which underlie them and the resulting 
ĚŝĨĨĞƌĞŶĐĞŝŶǁŚĂƚƉĞŽƉůĞ ‘ƐĂǇ ?ĂŶĚǁŚĂƚƚŚĞǇ ‘ĚŽ ? ?ǇƐƉĞĂŬŝŶŐƚŽƚŚĞƉĂƌƚŝĐŝƉĂŶƚƐ, I was able 
to tailor my questions to clarify, confirm and extend the observational data.  
 
The research design was also found to be a significant strength of this study. Fieldwork 
observations were alternated between pharmacies and spread over a year. Data analysis 
started during the early stages of data collection. This provided an opportunity for the data to 
be collected and analysed iteratively. The longitudinal nature of the study was intended to 
reduce the extent to which participants modify behaviour as a result of a heightened 
awareness of the observer. Therefore the time spent in the pharmacy allowed me to identify 
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recurring patterns of behaviour and also reflect on the observations and interviews with 
patients and to make adjustments in the research focus in light of new findings. The focus of 
the observations and the interview topic guide were revised during the data collection period. 
This inductive approach is considered to be good qualitative practice (Charmaz 2006; Ziebland 
and McPherson 2006).  
 
8.5.2 Limitations  
All research studies, including the present study, have limitations and these should be taken 
into account when interpreting the findings. This study was designed to be undertaken in two 
community pharmacies: a multiple and an independent and involved only 4 different 
pharmacists. There were significant differences between the two pharmacies. Most evident 
was the perceived organisational pressure that was found in the multiple to pursue a targeted 
number of MURs. However, both pharmacies did share some similar characteristics such as 
levels of affluence in the patient catchment area and the volume of prescriptions dispensed. 
Other pharmacy settings, including ones that may have had more supporting staff, different 
patient populations or different relationships with local GP surgeries could have resulted in 
pharmacists implementing and performing MURs in a different way and consequently patients 
perceiving the service differently. The findings of this study therefore need to be viewed in this 
context. Undertaking this study in a wider sample of pharmacies could have been a different 
way of undertaking this study and this may have uncovered different implementation 
strategies and conduct of MURs by pharmacists. As a result, patient reports of the MUR may 
have been different. Nevertheless, the very detailed account in the two contrasting 
pharmacies enabled the incorporation of the perspectives of both patients and pharmacy staff 
and an understanding of complexity and interrelations between participants and how micro-
factors impinge on the delivery of policy in real world settings. Such a detailed study would 
have been less feasible if the number of pharmacies had increased.  
 
Unpacking exactly how transferable the findings are to other settings is challenging. 
dƌĂŶƐĨĞƌĂďŝůŝƚǇ ŚĂƐ ďĞĞŶ ĚĞƐĐƌŝďĞĚ ĂƐ ƌĞƉƌĞƐĞŶƚŝŶŐ ƚŚĞ  “extent to which the findings of a 
particular study may be applied to similar contexts ?  ?DƵƌƉŚǇĞƚĂů  ? ? ? ? P ? ? ?). This study was 
undertaken in two pharmacies. The independent pharmacy recruited for this study was the 
only one that was approached that met the minimum selection criteria of undertaking at least 
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3 MURs per week. The chosen independent pharmacy therefore may have been a more 
atypical setting. Although pharmacies in England and Wales are subject to the same MUR 
policy guidelines and pharmacists are required to fill in the same national standard MUR form 
with patients, the findings of this study cannot be considered typical of all pharmacies and so 
further research is needed and this is further discussed in section 8.7. 
 
Another well known limitation to fieldwork observations is the unknown effect of the 
ƌĞƐĞĂƌĐŚĞƌ ?ƐƉƌĞƐĞŶĐĞŽŶ ƚŚĞƉŚĂƌŵĂĐǇƐƚĂĨĨ ?ƐďĞŚĂǀŝŽƵƌĂŶĚŽŶ ƚŚĞƉŚĂƌŵĂĐŝƐƚĂŶĚƉĂƚŝent 
during the MUR consultation. Pharmacists were occasionally apologetic on days when no 
MURs took place suggesting that they felt obliged to undertake MURs when the researcher 
was present. This was despite reassurances that the study aimed to explore MURs as they 
ŽĐĐƵƌƌĞĚŝŶ ‘ƌĞĂůůŝĨĞ ?ĂŶĚƚŚĂƚƚŚĞǇƐŚŽƵůĚĐĂƌƌǇŽŶand make decisions as they normally would. 
WŚĂƌŵĂĐŝƐƚƐŵĂǇŚĂǀĞĂůƐŽĨĞůƚƉƌĞƐƐƵƌĞƚŽ ‘ƉĞƌĨŽƌŵ ?ƚŽĂŚŝŐŚĞƌƐƚĂŶĚĂƌĚĂƐƚŚĞǇǁĞƌĞĂǁĂƌĞ
of being observed by a fellow pharmacist. The longitudinal nature of the study was intended to 
reduce the extent to which pharmacy staff may modify behaviour as they would become 
accustomed to the presence of the researcher. 
 
There were also some limitations to the data collection and analysis phases of this study. It was 
anticipated at the beginning of the fieldwork observations that an A5 handbook would be used 
to write in the observations. However, this was substituted for a pocket handbook as I felt this 
made participants feel less self-conscious of my presence and being observed. Personal 
tension did arise, particularly at the beginning of the fieldwork, that I would not be able to 
capture all that was happening. Producing a full account of the activities from memory would 
therefore have been subject to what could be remembered and subject to decisions to record 
some things and not others (Murphy and Dingwall 2003b). Audio or video recording the MUR 
consultation would have provided verbatim data. Nevertheless, it was decided, upon 
considering the ethical issues of inviting patients to the study when they were being recruited 
for an MUR in an ad hoc way, that hand written notes would be used by the researcher to 
record the MUR consultation (Latif et al 2010). This would produce a less detailed account of 
the MUR but it was felt that this was a necessary compromise. 
 
My professional background as a pharmacist would have influenced what I perceived as 
important or relevant in the field and consequently what was recorded. My similar training 
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and socialisation compared with the study pharmacists may have affected what I construed as 
ďĞŝŶŐ ‘ŶŽƌŵĂů ?ƉƌĂĐƚŝĐĞ ?/ŶƚŚŝƐǁĂǇ ?ŵǇŽǁŶƉƌŽĨĞƐƐŝŽŶĂůƉƌĞũƵĚŝĐĞƐŵĂǇŚĂǀĞĂůƐŽĂĨĨĞĐƚĞĚŵǇ
interpretation of the phenomena under study. To address this, attempts were made to remain 
neutral during data collection and analysis. Regular discussions with supervisors helped 
consider various viewpoints. Moreover, I have provided a detailed description of my data 
collection and analysis methods. I have also presented adequate fieldwork data to enable the 
reader to make their own judgements of the findings of this research. In the following section, 
the practice implications from this study are discussed. 
 
8.6 Practice Implications  
The results of this study have provided valuable insights that further our understanding of the 
complexities of undertaking MURs in practice and how they are being received by patients. 
The following section draws on the findings of this study and presents the implications for 
patients, health care professionals, organisations and for policy makers. 
 
8.6.1 Practice implications for patients  
This study raises several issues that are of importance to patients. The core purpose of what 
the MUR could potentially offer remained elusive to many patients. This was in part due to the 
confusing and sometimes conflicting messages that were being presented to them. Patients 
should seek to decide for themselves what additional support with their medicines they want 
or may need. During the MUR, patients should be encouraged to take the opportunity to ask 
questions about their medicines and to address any concerns they may have about them. They 
should be aware that the MUR service is funded by the NHS and is available for them to use. 
There should also be a means to elicit and incorporate patient views about the form and 
function of the MUR service. Patient support groups, such as Age Concern, could become 
involved in this process and so provide local feedback to the pharmacy about how patients 
perceive the service. 
 
Many patients felt MURs were largely unnecessary. However, if patients choose to have an 
MUR, the pharmacistƐ ? involvement should be tailored to their agenda. Pharmacists have been 
reported to be more approachable than GPs (Bissell and Traulsen 2005; Turner 1995). They 
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may therefore have an important role in the successful management ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ
medicines. Nevertheless, patients need to feel reassured that pharmacists and GP are working 
collaboratively for their benefit. For MURs to be successful reforms are needed to the MUR 
policy to make MURs more relevant to patients in order to progressively help turn the MUR 
into a consumer-induced demand activity rather than one which is professional-induced. Many 
of the potential benefits of MURs to patients are not currently fully being realised and clearer 
guidance and messaging from policy makers, administrators and those directly involved with 
patient care is required to enable this to happen     
 
8.6.2 Implications for health care professionals  
There are several implications for pharmacists and their staff. One key finding from this study 
is that pharmacists and their support staff did not actively seek to engage the patients who 
potentially could benefit most from an MUR. A cultural shift is required so that the MUR is 
seen as a genuinely patient-centred service. For this to occur, pharmacists need to be clear 
about what they want to achieve for patients during an MUR. They should resist being driven 
by financial incentives or pressures when these are not conducive to delivering effective 
patient care. Additionally, with the service coming under increased scrutiny there is a need for 
increased transparency to demonstrate clear outcomes for patients. A focus on performing 
more Prescription Intervention MURs, which requires the pharmacist to identify a problem 
ǁŝƚŚ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐŝŶĞ ?may better demonstrate the usefulness of the service to 
improving patient care.  
 
Training for all pharmacy staff is needed to better communicate with patients the core 
message of what MURs involve and the potential benefits of the service to patients. Although 
most patients reported that the ad hoc approach used in the pharmacies was acceptable, not 
all patients were comfortable with this method. Pharmacists should therefore routinely assess 
beforehand whether the patient is receptive, willing to take part and be aware of the likely 
benefits of the MUR before commencing the consultation. This would mean reviewing how 
patients are offered an MUR and providing them with information and, if needed, time to 
consider these issues. This may mean that pharmacy staff should uncover initially whether the 
patient would benefit from having prior notice of their MUR in order to avoid patients feeling 
guarded and unable to contribute comfortably during their review. Patients need to be clear 
Chapter Eight: Discussion 
236 
 
that the MUR is for their benefit and be encouraged to think beforehand about any issues they 
would find useful to discuss. This may mean that pharmacists need to implement more 
effective appointment systems or find ways to perform MURs ĂƚƚŚĞƉĂƚŝĞŶƚ ?ƐŚŽŵĞ ? Likewise, 
pharmacists need to explain clearly to patients their purpose for undertaking MURs and that 
this is not a surreptitious activity that should be concealed from their GP.    
 
The findings of this study indicate that there may be a need to introduce specific consultation 
and communication skills training to pharmacists if they are to engage more effectively with 
patients. Pharmacist peer review sessions or shadowing may be useful to facilitate 
improvements in this process. HowĞǀĞƌ ?ŽŶĞŵƵƐƚďĞŵŝŶĚĨƵůŶŽƚƚŽƵŶĚĞƌŵŝŶĞƉŚĂƌŵĂĐŝƐƚƐ ?
professional status (Harding and Wilcock 2008). One aspect that this training should cover is 
how the pharmacist can better elicit the patient ?Ɛ agenda before the start of the consultation 
and effectively explore ƉĂƚŝĞŶƚƐ ? ǀŝĞǁƐ ? ďĞůŝĞĨƐ ĂŶĚ ĐŽŶĐĞƌŶƐ ĂďŽƵƚ ƚŚĞŝƌ ŵĞĚŝĐŝŶĞƐ ?
Pharmacists should also assume greater responsibility for resolving or following up 
indeterminate medicine problems that have been identified as part of the MUR. One way to do 
this is to encourage patients to record their actual use of medicines to determine their own 
optimal drug dose and acceptable balance of symptom control and side effects. Pharmacists 
can then engage and work with the GP to find out ways in which complex issues that have 
been identified can be addressed. The lack of integration of the information obtained from the 
MUR also needs to be reviewed. Pharmacists should be routinely reviewing previous MUR 
records before both dispensing prescriptions and when conducting another MUR. These 
records should be more easily accessible during the provision of other services in order to 
provide patients with a more comprehensive service.    
 
With the DH set to continue to pay for the MUR service for the foreseeable future, GPs should, 
if they choose, refer patients who they think may benefit from extra support from the 
pharmacist. In this study, MURs were shown to provide reassurance to most patients and a 
referral from the GP could legitimise the pharmacist ?s role to provide MURs and so 
consequently remove tensions that some patients reported. The MUR provides an opportunity 
to foster a culture of collaboration between pharmacist and GP. However the pharmacists in 
this study reported receiving no feedback from GPs on the MURs they undertook. The relative 
isolation in which the pharmacist chose to undertake the MUR limited their potential and 
reduced the capacity to resolve issues that did arise. Pharmacists need to take the initiative 
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and proactively speak to GP Practice Managers to develop or improve GP referral systems and 
agree with GPs suitable patients that are most in need of an MUR. This will help improve the 
chances of identifying and resolving problems where the patient is genuinely ineffectively 
using their medicines.              
 
8.6.3 Implications for organisations  
The results of this study highlighted some of the barriers pharmacists faced when conducting 
MURs. One of these was their heavy involvement with the dispensing process. A key 
observation was the variety of tasks the pharmacist was expected to accomplish resulting in 
them feeling they had no spare time to perform MURs. Organisations need to consider 
providing additional staffing to allow pharmacists the requisite time to perform MURs without 
feeling the need to return quickly to their dispensing responsibilities. This may be challenging if 
it is decided that the pharmacist will continue to provide MURs in an ad hoc way. Allocating 
additional pharmacist resource at certain times along with developing an effective 
appointment system may help manage MUR activity better. Furthermore, organisations should 
review the impact of the pharmacist ?Ɛ absence on support staff activities. This may mean 
training for staff on how to better manage the work flow when the pharmacist is absent during 
an MUR.   
 
Pharmacist pursuit of a targeted number of MURs, in response to organisational pressure, had 
serious consequences for how the service was delivered in practice. Organisations need to 
reconsider the way they incentivise or motivate pharmacy staff to offer and undertake MURs. 
The threat of sanctions for not achieving the arbitrary target number of MURs, contributed 
towards some of the irrational and unintended consequences found in this study. 
Organisations may consider encouraging pharmacists to undertaking more Prescription 
Intervention MURs. These arise when the pharmacist identifies an issue or problem with the 
ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐŝŶĞƐ and this could develop ƉŚĂƌŵĂĐŝƐƚƐ ? ŵŽƚŝǀĂƚŝŽŶand curiosity to engage 
more earnestly with the service.  
 
The findings from this study revealed some logistical matters that organisations should 
consider to ensure patients attain maximum benefits from the service. One such matter is to 
develop effective systems that allow information collected from the patient during an MUR to 
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be better integrated and available when the patient uses other services from the pharmacy. 
Another matter is that of the suitability of the consultation room to perform MURs. Although 
both pharmacies had consultation rooms that met the minimum required standards, a poor 
image was promoted to several patients. At a time when it is challenging to convince both 
patients and other health professionals of the value MURs could potentially bring, 
organisations should seek to invest in a better consultation room to promote a more 
professional image of the service.  
 
8.6.4 Implications for policy makers and administrators 
The broad MUR policy aims and objectives made assessment of whether these were being 
achieved in practice difficult. Nevertheless, an important finding arising from this study was 
that the MUR policy intentions were not being effectively interpreted or realised in the two 
study pharmacies. Effective policies depend on purpose. However, the different discourses 
that are being communicated about the service have created confusion over what should be 
achieved for patients who undertake an MUR. Policy makers and professional bodies need to 
consider whether the MUR service should be abandoned, reformed or if there are other more 
effective ways of achieving better use of medicines. Policy makers should acknowledge and 
review how their proposed policies are being interpreted by front-line staff and how their 
intentions are understood and put into practice by those delivering the service. PharmacisƚƐ ?
concerns over a lack of time, resource and the issue of perverse incentives need addressing.     
   
A review of the existing MUR policy is needed. For the foreseeable future pharmacies will 
continue to be remunerated for the number of MURs undertaken. The arbitrary cap placed on 
MURs is being interpreted as a target and this has been well reported (Blenkinsopp et al 2007a; 
Bradley et al 2008a; Urban et al 2008; Wilcock and Harding 2008). Better selection of patients 
who potentially could benefit from an MUR is needed or a GP referral based system could be 
used. Furthermore, if policy makers are intending to support patients ? use of medicine, 
pharmacists should be provided with greater autonomy over the frequency at which MURs 
should be undertaken. MURs should occur at times according to when patients feel this is 
necessary and pharmacist could use their discretion to follow ƉĂƚŝĞŶƚ ?Ɛ ƉƌŽŐƌĞƐƐto provide 
continuing support to those who may need it the most. In Australia, HMRs allow the 
pharmacist to work more closely with the GP, and with full access to the patient ?Ɛ medical 
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records, they have been shown to improve the quality use of medicines (Castelino et al 2011). 
Lessons from more successful programmes should be learnt.    
 
If policy makers choose to focus on reducing cost associated with avoidable medicine waste, 
then better targeting of MUR activity is needed. One study found that targeting patients with 
more expensive medicines for a community pharmacy-based medication review program 
could be an effective way to reduce costs (Krahenbuhl et al 2008). Current proposals to define 
target patient groups and monitor specific outcome measures for each target group 
(Livingstone 2010; PSNC 2011e) may prove fruitless without a deeper understanding of the 
challenges that community pharmacists face when providing the service. The consequence of 
implementing a rationalised policy to improve patient adherence to medicines led to a service 
that was unresponsive to the ƉĂƚŝĞŶƚ ?Ɛindividual circumstance. One example where this was 
ĞǀŝĚĞŶƚ ǁĂƐ ƚŚƌŽƵŐŚ ƚŚĞ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ ƚŚĞ  ‘Version 2 ? MUR form (PSNC 2007). The 
streamlŝŶŝŶŐŽĨƚŚĞĨŽƌŵĂŶĚŝƚƐ ‘ƚŝĐŬ-ďŽǆ ?ĨŽƌŵĂƚ reduced opportunities for patients to express 
their concerns as the question about what the patient wanted from the MUR has been deleted.  
 
PCTs or the newly proposed commissioning groups (Mannion 2011) may also consider how to 
support pharmacies to deliver MURs. One way may be to improve patient awareness of the 
potential benefits of MURs through promotional campaigns. Another way to improve patients ? 
understanding and encourage recognition of the service may be through fostering greater 
collaborative involvement from GPs. In Australia, the HMR service is supported by a facilitator 
program to provide support and resources to GPs, practice staff, pharmacists and others. 
Pharmacists have expressed positive satisfaction with this additional help in explaining the 
review process to patients and in providing opportunities to discuss HMR issues and concerns 
(Scwartzkoff 2005). A similar support mechanism has been shown to be welcomed for MURs 
(Portlock et al 2009) and this needs to be considered to be offered more widely.  
 
8.7 Future research  
This study has highlighted future research that would benefit from both qualitative and 
quantitative investigation but also research that could help guide or reform the MUR policy. 
Qualitative studies often open up a field of enquiry for subsequent quantitative study. 
Undertaking a detailed investigation in two pharmacies allowed an opportunity to learn about 
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ŚŽǁƉŚĂƌŵĂĐŝƐƚƐŵĂŶĂŐĞDhZĐŽŶƐƵůƚĂƚŝŽŶƐ ?ƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌƐƉĞĐƚŝǀĞŽĨDhZƐĂŶĚŚŽǁƚŚĞ
implementation of the service influenced the delivering the MUR policy in practice. These 
findings could now form the basis for further research within a wider and more diverse range 
of community pharmacy settings. Patient views of the MUR service have been under 
researched. Previous attempts to establish patient views have relied simply on asking simple 
questions such as whether the MUR improved paƚŝĞŶƚƐ ? ŬŶŽǁůĞĚŐĞ ŽĨ ƚŚĞŝƌ ŵĞĚŝĐŝŶĞƐ Žƌ ŝĨ
ƚŚĞǇĨŽƵŶĚƚŚĞDhZ ‘ƵƐĞĨƵů ? ?ĂŐŽůĞĞƚĂů ? ? ? ? ?<ƵŵǁĞŶĚĂĂŶĚ: ŵĞƐ ? ? ? ? ?EW ? ? ? ? ?WĂƚĞů
and Lefteri 2009; Portlock et al 2009; Youssef 2008; Youssef 2009; Youssef et al 2010). Using 
the findings from this study, a more comprehensive and searching questionnaire could be 
developed from the findings arising from this study. Questions such as those below could be 
used to develop an instrument for use in pharmacies to achieve a clearer picture of how the 
MUR policy is being realised in practice: 
 
 ? Who are the patients being targeted for MURs? 
 ? Was the MUR initiated by the patient or was this done by the pharmacy staff? 
 ? What are patient expectations of the MUR service and did they expect an MUR 
when they visited the pharmacy? 
 ? Why did patients accept the invitation for an MUR? 
 ? What is the level of patient awareness and current knowledge of the MUR 
service? 
 ? What is the number and type of medication concern that patients had before 
the MUR and to what extent were these addressed by the pharmacist? 
 ? To what extent did the MUR provide reassurance to the patient and did this 
avoid the patient having to see the GP or another health professional?   
 ? dŽǁŚĂƚĞǆƚĞŶƚĚŝĚƚŚĞDhZĂĨĨĞĐƚƉĂƚŝĞŶƚƐ ?ƐƵďƐĞƋƵĞŶƚŵĞĚŝĐŝŶĞƐƵƐĞ ? 
 
This study also raised questions that would benefit from more qualitative research. Further 
exploratory studies are needed to explore more widely the way pharmacists address 
indeterminate issues arising from an MUR. Pharmacists in this study were found to deal with 
indeterminate issues in a superficial way. The underlying reasons for this should be 
investigated further to ensure that pharmacists can effectively address and are fully prepared 
to deal with matters arising from an MUR. In-depth interviews with a sample of pharmacists 
from different pharmacy settings could be used to investigate their perceived remit for 
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managing more complicated medicine-related issues arising from an MUR. A better 
understanding of the impact of conventional relationships between pharmacists and GPs and 
ƉŚĂƌŵĂĐŝƐƚƐ ? ƌĞůƵĐƚĂŶĐĞ ƚŽ ĞŶŐĂŐĞ ŵŽƌĞ ĂĐƚŝǀĞůǇ ǁŝƚŚ 'WƐ ĂďŽƵƚ ƉĂƚŝĞŶƚƐ ? ŵĞĚŝĐŝŶĞƐ ŝƐ Ă
prerequisite for instigating changes in professional roles and interaction which could help to 
increase the value and efficacy of the MUR service. Additionally, an investigation into the 
ƉŚĂƌŵĂĐŝƐƚƐ ?ĞĚƵĐĂƚŝŽŶĂůƚƌĂŝŶŝŶŐĂŶĚƉƌŽĨĞƐƐŝŽŶĂůƐŽĐŝĂůŝƐĂƚŝŽŶĐŽƵůĚďĞĂǁĂǇƚŽŚĞůƉĐůĂƌŝĨǇ
how these problems arise. A future study could explore how the training of pharmacy students 
prepares them for extended consultations such as the MUR. Observations and comparisons 
could be made between undergraduate medical and pharmacy teaching strategies to reveal 
how managing complexity in the patient care is communicated and taught within the two 
professions. With the profession of pharmacy aiming to adopt further extended roles for 
pharmacists, an understanding of how pharmacists could be better prepared for more 
professionally-oriented and less technically defined roles is essential.     
 
This study also uncovered several complex processes which could help inform a study about 
the MUR policy and its implementation. The value of this qualitative study is that issues were 
raised, such as the underlying reasons why patients decline the invitation for MURs, which had 
not previously been documented in the literature. This study has made these processes more 
explicit which can enable a better assessment of how we monitor the efficiency of MURs or 
how this can be translated to a better informed economic evaluation of the service. 
ƌƵŵŵŽŶĚ Ğƚ Ăů  ? ? ? ? ? ) ĚĞĨŝŶĞƐ ĞĐŽŶŽŵŝĐ ĞǀĂůƵĂƚŝŽŶ ĂƐ  “the comparative analysis of 
alternative courses of action in terms of both their costs and consequences ? ? ,ĞĂůƚŚ ĐĂƌĞ
resources are increasingly becoming limited by the total funds available and health care and 
Government agencies could use an economic evaluation as an adjunct to existing findings to  
implement changes to ensure MURs become more efficient, equitable and, most  importantly, 
useful to patients. A future research study could aim to answer both whether MURs are worth 
doing compared with medication reviews performed by pharmacists in GP surgeries or a 
comparison of MUR outcomes with routine prescription counselling by the pharmacy staff. 
This study was a cross-sectional study. To facilitate an effective economic evaluation, future 
research should seek to collect longitudinal data from the MUR intervention to explore 
whether or not the service improves outcomes for patients and the NHS. The design of such a 
study should incorporate the quantification of the practical impact of MURs in terms of 
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reduced costs of medicines, other health care resources and investigating whether MURs have 
any impact on hospital admissions. 
 
Further policy research is similarly needed into newer advanced phaƌŵĂĐǇƐĞƌǀŝĐĞƐ ?dŚĞ ‘EĞǁ
DĞĚŝĐŝŶĞ^ĞƌǀŝĐĞ ? ?ED^ )ŝƐƚŚĞĨŽƵƌƚŚĚǀĂŶĐĞĚƐĞƌǀŝĐĞĂŶĚǁĂƐŝŵƉůĞŵĞŶƚĞĚŽŶ ?ƐƚKĐƚŽďĞƌ
2011 (PSNC 2011b). This aims to provide support to people newly prescribed a medicine to 
manage a long term condition. The service involves an initial consultation and a follow-up 
intervention by the pharmacist in order to support medication adherence with new medicines. 
This service has been informed by the findings of a study investigating the cost effectiveness of 
a telephone-based pharmacy advisory service (Elliott et al 2008). However, it is yet to be seen 
how pharmacists will adopt this service in practice, how the service will be managed alongside 
existing service provision and whether, in practice, it will be useful for patients. Under the new 
guidelines, an MUR cannot be performed within 6 months of a patient receiving an NMS 
intervention. This clearly will affect how MURs are conducted and it would be important to 
assess what effect this has on MUR activity. As highlighted with MURs, there may well be some 
unintended consequences associated with implementing the NMS service and these will need 
to be explored in order to ensure that the services is beneficial to patients. 
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There is an increasing global trend for countries to invest in medication review programmes. 
Since 2005, reforms to the pharmacy contract have given community pharmacists in the UK 
the opportunity to undertake MURs. The cornerstone of this service is to improve patient 
adherence to medicines, reduce avoidable waste and therefore reduce cost as a result from 
the better use of medicines (DH 2005a). MURs also offers the potential for community 
pharmacists to become more involved in patient advisory services and therefore extend their 
professional role by moving away from their involvement in the technical, routine task of 
dispensing. However, with the exception of one study, Greenhill et al (2011), there has been a 
lack of transparency into what actually happens during an MUR, the value they bring to 
patients and the patients ? perspective of the service. Policy development is a dynamic process 
and for the MUR service to improve, this must be responsive to research in order to develop a 
sustainable model of practice. However, the lack of understanding of what occurs during an 
MUR consultation and patient expectations and experience of these has meant that reforms to 
the MUR service are likely to reflect professional, rather than patient objectives. 
 
In this thesis, I have presented an in-depth investigation of patient and pharmacy staff 
perspectives of the MUR service and its implementation in the  ‘real world ? practice of two 
community pharmacies. This study used qualitative methods in order to provide an in-depth 
investigation of the service. In order to answer the aims and objectives of this study, two 
complementary research methods were used: ethnographically-oriented unstructured 
observations and face-to-face interviews with participants. These methods provided a detailed 
description or  ‘ĨŝƌƐƚŚĂŶĚ ?account of MUR consultations as they happen in everyday practice 
and how patients contextualised this service. To my knowledge, this is the only study that has 
ƐŽƵŐŚƚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ  ‘ůŝǀĞ ƉƌĂĐƚŝĐĞ ? ŽĨMURs consultatiŽŶƐ ĂƐ ƚŚĞǇ ŽĐĐƵƌ  ‘ŶĂƚƵƌĂůůǇ ? ŝŶ Ă
community pharmacy setting. This may reflect the challenges of researching services that are 
performed ad hoc (Latif et al 2010). The strength of this study over others lies in its capacity to 
compare what pharmacists actually do during an MUR as opposed to what they say they do. 
  
Chapter Nine: Concluding remarks 
244 
 
This study adds to our knowledge of the MUR consultation. The reasons why patients accepted 
or declined the invitation for an MUR has provided novel ŝŶƐŝŐŚƚƐ ŝŶƚŽƉĂƚŝĞŶƚƐ ?ĞǆƉĞĐƚĂƚŝŽŶƐ
and their perspective of the service. The pharmacist-led approach and structured format of the 
MUR consultation served professional rather than patient objectives. Pharmacists lacked 
curiosity to search for patient problems and concerns. Overall, the core message that the MUR 
was for the patientƐ ?ďĞŶĞĨŝƚ was not effectively communicated before or during the MUR. This 
study highlights the need for pharmacists to undertake consultation and communication skills 
training to better manage the MUR interaction. During OTC consultations, pharmacists 
involved patients to a greater extent indicating they already have many skills to effectively 
engage patients in decisions about their health care. Policy makers need to better adapt their 
policies to encourage patients to be full participants in the care they receive. More effective 
promotional campaigns are needed to communicate the message that the MUR service is 
available for patients to access and is there to assist them with their medicines. The lack of 
connection between MURs and other professional contacts raised concerns among some 
patients over boundary encroachment. Patients need to be reassured that the pharmacist is 
working collaboratively with the GP for their benefit.    
 
The MUR is a modern and developing service but one which remains unestablished. The idea 
of pharmacists undertaking medication reviews and assuming greater responsibility for the 
ƉĂƚŝĞŶƚ ?ƐŵĞĚŝĐŝŶĞƐŵĂŶĂŐĞŵĞŶƚis not novel. However, the reality of undertaking such roles 
in a community pharmacy setting has challenged the traditional identity of community 
pharmacists and requires patients to participate in a new interaction with the pharmacist. This 
study showed that MURs have yet to be fully recognised and accepted by patients. Patients 
were unaccustomed to the pharmacist offering a service which they had not asked for or felt 
that they needed. The lack of awareness of what MURs could potentially offer and the existing 
limited mandate of pharmacists over the ƉĂƚŝĞŶƚƐ ?ƉƌĞƐĐƌŝďĞĚŵĞĚŝĐŝŶĞƐƌĞĚƵĐĞĚ the potential 
for the MUR to become a useful service for patients. GPs have not taken the opportunity to 
refer patients indicating that they have yet to be convinced of their value.  
 
The findings of this study provide valuable insights into whether the policy and professional 
intentions for the MUR service are being realised in practice. I argue that although the MUR 
service is well intentioned, there is little indication from this study that MURs, as they are 
being practiced, are meeting their intended stated policy and professional aims. There remains 
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a lack of clarity over the purpose of the MUR service and what it should aim to achieve for 
patients. From their accounts, patients suggested that MURs were not an effective means for 
improving their knowledge, understanding and use of medicines. Neither were they reported 
to reduce waste from unused medicines. Policy and professionalising agendas were limited by 
 ‘real world ? pressures of limited resource, perceived lack of time and pressure to achieve MUR 
targets. MURs have ďĞĞŶ ŝŵƉůĞŵĞŶƚĞĚǁŝƚŚŽƵƚĚƵĞĐŽŶƐŝĚĞƌĂƚŝŽŶŽĨ ƚŚĞƉŚĂƌŵĂĐŝƐƚƐ ?ŚĞĂǀǇ
commitment to the dispensing process which means there was poor integration of the MUR 
service into their routine workload. The way organisations implement and incentivise staff to 
perform MURs had a substantial bearing on how pharmacists viewed the service and what was 
subsequently achieved. As a result, pharmacists often failed to take full advantage of the 
opportunities offered by MURs.  
 
Pharmacists, by undertaking MURs, have now a licence that greatly increases their 
responsibility to patients. If pharmacists are to become patient advocates they need to be 
proactive and take the initiative to make the service work for their patients. Pharmacists were 
constrained by situational pressures and the need to accommodate MURs pragmatically 
between other services provided and under the influence of commercial pressures to generate 
income. However, they should resist compromising their professional integrity to ensure that 
MURs are only performed when they and the patient deem it necessary. Strong professional 
leadership and organisational support is needed to support pharmacists in achieving this. 
Furthermore, the New Medicines Service which commences from October 2011, presents 
community pharmacists with an opportunity to further their involvement with patient care. 
Pharmacists need to learn from the challenges of implementing MURs in their pharmacies to 
ensure that this service is effectively managed.          
   
This study investigated how the MUR policy had been translated into practice. It highlighted 
how the rational implementation of MURs led to unintended consequences which subverted 
the potential benefits of MURs to patients. The decision taken to streamline the MUR form has 
been for the professional benefit of pharmacists and GPs rather than improving the service for 
patients. This thesis takes forward the argument of the need to re-evaluate pharmacy services 
that rely on the traditional information deficit model. Each MUR should aim to be purposive 
when viewed from both the patient and pharmacist perspective. Agreed changes to the MUR 
policy to target patient groups may prove unsuccessful in improving outcomes for patients if 
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the format for undertaking MURs and the manner MURs are being conducted in practice are 
not also reviewed. Research will be necessary to investigate these developments and to what 
extent they improve care for patients. Pharmacists should seek to perform a needs assessment 
before considering undertaking an MUR with a patient. This may prove a more effective means 
of identifying patients who could potentially benefit most from an MUR rather than simply 
dictating which group of patients pharmacists should target. This assessment could be 
performed during the routine encounter with the patient when the pharmacist hands out their 
prescribed medicines.   
 
Despite the difficulties faced in implementing MURs in practice and the questionable value to 
improving ƚŚĞƉĂƚŝĞŶƚƐ ?use of medicines or pharmaceutical care, most patients in this study 
reported valuing the time the pharmacist spent with them and the reassurance they received 
about their medicines. Patients did recognise the pharmacist as an approachable and 
knowledgeable health professional who they perceived could resolve issues they considered 
too  ‘minor ? for a GP consultation. Pharmacists are already well recognised by the public for 
their ability to treat minor ailments. There is therefore potential for pharmacists ? greater 
involvement ŝŶƉĂƚŝĞŶƚƐ ?prescribed medicines and wider health care if they can demonstrate 
how the service is beneficial to patients. Pharmacists need to therefore capitalise on the 
opportunities that MURs present for it to become a successful patient-centred service. To do 
this, however, they need access to information about which patients are the neediest who 
could potentially benefit most from an MUR. This requires a bold rethink to develop a platform 
for pharmacists and GPs to exchanging reliable, accurate, and consistent patient information.  
 
This study raises questions about the future of the MUR service. Is the service one that is 
valuable and benefiting patients? In times of austerity measures, pharmacists need to clearly 
demonstrate that MURs are value for money. Policy makers and ƉŚĂƌŵĂĐǇ ?Ɛ ƉƌŽĨĞƐƐŝŽŶĂů
bodies should be forthright and seek to objectively review the evidence of whether MURs are 
achieving their intended aims or whether they should consider more effective ways of 
achieving the same goals. Strong professional leadership is required to decide what the role of 
the community pharmacist, in supporting patients with their medicines, should be and how 
this can be best translated into practice.  
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The findings from this study provide a clearer understanding of how MURs are being 
implemented in practice, what happens during an MUR and the views of patients who have 
taken part in the service. In my opinion, the MUR service in practice, is largely failing to 
achieve its intended policy aims and objectives. Consideration of whether the MUR service 
should continue, at least in its current form, should therefore be reviewed. Policy makers, 
professionals and organisations need to refocus on how community pharmacists can best help 
patients with their medicines. A successful community pharmacy medication review service 
should be one that seeks out the neediest patients who require help with their medicines, fully 
involves them from the onset, anĚŝƐĨůĞǆŝďůĞƚŽƚŚĞŝŶĚŝǀŝĚƵĂů ?s circumstance and preference. 
In order for the MUR policy to be effective, a culture shift is required to allow community 
pharmacists to have dedicated time to be fully involved with patient-centred services and also 
enables them to become more active participants in the wider health care team. Rationalising 
service by dictating their scope and format will largely fail to identify and address real concerns 
that patients have with medicines. Furthermore, this may deskill pharmacists and prevent 
them from effectively using their unique knowledge and skill set to best help patients with 
their medicines.         
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APPENDIX ONE Literature review search strategy 
APPENDIX ONE  
Literature review search strategy 
 
This literature review aimed to draw on the works from previous research, to identify gaps 
within the existing literature and so preventing duplication of earlier works. Additionally, a 
review of the literature has helped identify key issues, the research design and data collection 
techniques. Many of the principles outlined by Hart (2002) were employed in the initial 
preparation for the literature search. This included defining a research topic, developing a 
working title and creating key words. A broad criteria for the research was therefore 
established which incorporated the limits of the topic i.e. what would be included / excluded.   
 
An initial search of the literature was performed in 2007 and repeated at regular intervals, it 
included the following major search terms: Medicines Use Reviews (MUR), community 
pharmacy Advanced service, medication reviews / management services, compliance, 
adherence, concordance, patient perspectives. The data bases and information sources used 
included EMBASE, International Pharmaceutical Abstracts, MEDLINE 1966-present, Web of 
Science, Google ScholarTM ? ĐŽŶĨĞƌĞŶĐĞ ƉƌŽĐĞĞĚŝŶŐƐ ? ŽĨĨŝĐŝĂů ƉƵďůŝĐĂƚŝŽŶƐ ĂŶĚ  ‘ŐƌĂǇ ůŝƚĞƌĂƚƵƌĞ ?
(list of items not published).  The Zetoc alert system was also used with these terms to inform 
of any new publications. Data was assessed for importance using the selection criteria detailed 
ďǇ ,Ăƌƚ  ? ? ? ? ? ) ? dŚŝƐ ŝŶǀŽůǀĞĚ ĐŽŶƐŝĚĞƌĂƚŝŽŶ ŽĨ ƚŚĞ ŵĂƚĞƌŝĂůƐ  ‘ ƵƚŚŽƌŝƚǇ ? ƐƉĞĐŝĨŝĐĂůůǇ ŵĂƚĞƌŝĂůƐ
produced by a reputable publisher, seminal works and works that were within the parameters 
of the aims and objectives of the study. 
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APPENDIX TWO Original MUR form and  ‘sĞƌƐŝŽŶ ? ? MUR form   
APPENDIX TWO  
Original MUR form and  ‘sĞƌƐŝŽŶ ? ? MUR form   
Original MUR form (4 pages): 
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 ‘sĞƌƐŝŽŶ ? ?DhZĨŽƌŵ (2 pages): 
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APPENDIX THREE 
Approval letters for the study 
Ethical approval letter:  
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Research and development approval letter:  
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Indemnity support letter: 
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Confidentiality agreement letter: 
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Protocol amendment letter: 
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APPENDIX FOUR Independent pharmacy recruitment letter 
APPENDIX FOUR     
Independent pharmacy recruitment letter 
Dear Sir or Madam,       
 I am a PhD student at the University of Nottingham and I am currently conducting research into patient perceptions of MURs. As 
you know, MURs are an integral part of the community pharmacy contract; however there has been little research into what 
ƉĂƚŝĞŶƚƐ ?ƚŚŝŶŬŽĨƚŚĞƐĞƌǀŝĐĞ ? 
 
My research involves recruiting two pharmacies (one independent and one multiple) in order to undertake observational work in 
each. I am contacting you as to ask if you would be willing to participate in the study - I have selected your pharmacy from a list of 
pharmacies in the Nottingham area. The study would involve you and your staff being observed in their daily practice and 
investigating how MURs are incorporated into your routines. The study will also involve observing MUR consultations, with 
permission of the patient. Patients whose MUR consultations are observed will be invited to an interview at a later date to talk 
about their experiences of the MUR.     
 
The primary purpose of the study is to look at patient perceptions of the service.  This will not be an evaluation of the service that 
is provided in the pharmacy. Your pharmacy, staff and patients details will be kept confidential in the reports and publications 
arising from this study.  All information will be anonymised to ensure pharmacies and individuals who participate are not 
identifiable.   
 
I have received NHS ethical approval for this study and I am awaiting Research Governance approval so that I can conduct this 
research in the Nottingham PCT area.  I have attached a summary of the planned research for your information as well as a 
pharmacist and pharmacy staff information sheet. In order to be eligible for this study and allow a suitable number of patients to 
be recruited for interviews, the pharmacy will need to be performing on average at least 3 to 4 MURs each week.  I intend to start 
this study during October / November 2008.   
 
I will contact you in a few days time, to ask if you would be willing to participate and, if so, to arrange a meeting to discuss the 
project and what participating would mean for you, your staff and patients. In the meantime please do not hesitate to contact me 
if you have any queries, my contact details are below.  
 
Yours faithfully, 
 
 
Asam Latif MA MRPharmS 
PhD Research Student 
Division of Social Research in Medicines and Health School of Pharmacy University of Nottingham 
NG7 2RD 
Mobile xxxxxxxxxxx; E-mail: xxxxx@nottingham.ac.uk 
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APPENDIX FIVE Pharmacist and support staff information sheets and consent forms  
APPENDIX FIVE 
Pharmacist and support staff information sheets and 
consent forms 
Pharmacy staff information sheet: 
 
 
Project title: Exploring patient and professional views of pharmacy Medicine Use Review (MUR) services 
 
Information for pharmacists and pharmacy staff about the research 
 We would like to invite you to take part in a research study. Before you decide you need to understand why the research is being 
done and what it would involve for you. Please take time to read the following information carefully. Talk to others about the 
study if you wish. This information sheet tells you the purpose of this study and what will happen to you if you take part. Please 
ask us if there is anything that is not clear or if you would like more information and take time to decide whether or not you wish 
to take part. 
 
What is the purpose of the study? 
A Medicine Use Review (MUR) is a NHS service that involves a pharmacist periodically talking to a patient about their medicines 
and aims to improve the paƚŝĞŶƚ ?ƐŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨƚŚĞŝƌĚƌƵŐƐ ?dŚŝƐŝƐŶŽƌŵĂůůǇĐĂƌƌŝĞĚŽƵƚĨĂĐĞƚŽĨĂĐĞǁŝƚŚƚŚĞƉĂƚŝĞŶƚŝŶĂ
private consultation room located within the community pharmacy.  dŚŝƐ ƐƚƵĚǇ ĂŝŵƐ ƚŽ ƵŶĚĞƌƐƚĂŶĚ ƉĞŽƉůĞƐ ? ǀŝĞǁƐ ŽĨ ƚŚĞ
Medicines Use Review (MUR) service that is provided by this community pharmacy.  As a provider of the MUR service this 
pharmacy has been selected to partake in this study.  We will be investigating what patients think about MURs and how MURs are 
incorporated into your daily practices. 
  
Why have I been asked to participate in the study?  
We have chosen two contrasting pharmacies to take part in this study.  As a provider of the MUR service you and other pharmacy 
staff involved with MURs are eligible to take part.  We are interested in observing the pharmacist and the staff that are involved 
with MURs and speaking to them about the experience of providing this new service. 
 
Do I have to take part? 
It is up to you to decide.  You do not have to take part in this study. We will describe the study and go through this information 
sheet, which is yours to keep. We will then ask you to sign a consent form to show you have agreed to take part (you will be given 
a copy to keep). You are free to withdraw at any time, without giving a reason.  
 
What will happen to me if I take part? 
If you agree to take part in this study, the researcher will spend some time observing you (pharmacist and  pharmacy staff) during 
your normal work and may ask you questions about how you feel about the MUR service.  The researcher will ask the pharmacist if 
ŚĞĐĂŶ ?ǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌŵŝƐƐŝŽŶ ) ‘ƐŝƚŝŶ ?ŽŶDhZ ĐŽŶƐƵůƚĂƚŝŽŶƐ ?ĨƚĞƌƚŚĞDhZĐŽŶƐƵůƚĂƚŝŽŶ ?ƚŚĞƌƐĞĂƌĐŚĞƌǁŝůůĂƉƉƌŽĂch the 
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patient and ask if he or she would be willing to take part in an interview to discuss their experiences of the MUR.  The researcher 
may also approach patients who have declined an offer for an MUR to get a more comprehensive view of the service and patients 
perspectives of its usefulness.    
 
The observations within pharmacies will typically take place at a week at a time.  There will be approximately four to five weeks of 
observations which will be spread over a period of about eight to nine months.  At the end of the observations, you may be invited 
to take part in an interview to talk about your experience of providing MURs to your patients.   
 
If you decide that you would like to talk about your experience of MURs, you will have the opportunity to choose the venue, time 
and date that you want the interview to take place.  You will be sent a letter confirming the details of your interview.  If you are 
ƵŶĂďůĞƚŽŵĂŬĞǇŽƵƌ ŝŶƚĞƌǀŝĞǁĂƉƉŽŝŶƚŵĞŶƚĨŽƌǁŚĂƚĞǀĞƌ ƌĞĂƐŽŶ ?ĚŽŶ ?ƚǁŽƌƌǇ ? WůĞĂƐĞ ůĞƚƵƐŬŶŽǁĂŶĚǁĞǁŝůůĂƌƌĂŶŐĞĂŵŽƌĞ
suitable time. Interviews are expected to last approximately one hour, and with your permission, will be audio-recorded. Also with 
your permission we may use direct quotes from the interview material in any publication of the results but you will not be 
identified.    
 
Can I change my mind once I have signed the consent form? 
If you have agreed to take part in the study, and for whatever reason you are unable to or change your mind and want to 
withdraw, that is absolutely fine. If you initially decided not to take part, and would now like to be involved that is OK too. All you 
need to do is contact us and let us know.     
 
Will I be paid for taking part in the study? 
No, you will not receive any money for taking part in this study.  If you incur any expenses as a result of this study (i.e. for any 
travel associated with the study), you will be fully reimbursed.      
 
What are the possible benefits of taking part? 
 
We cannot promise the study will benefit you directly, but the information we get from this study may help improve the service 
that is provided by pharmacies in the future. 
 
What are the risks of taking part in this study? 
This study involves a researcher observing you at work, asking you how you put the MUR service into practice and what you think 
patients feel about the service. If you decide to, you may be invited for an interview to talk to a researcher further about the MUR 
service.  We believe that the risks of taking part in this project are minimal.  
 
What happens if something goes wrong? 
If you have any concerns or complaints concerning any aspect of this study please speak to the researcher who will do his best to 
answer your questions (contact Asam Latif on xxxx xxxx or email xxxx xxxx).    
 
If you would prefer to share your complaint with someone else or remain unhappy about a decision you may contact the academic 
supervisors of this project Dr Helen Boardman on xxxx xxxx or email xxxx xxxx or Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx. 
 
Will the information provided be kept confidential? 
All information which is collected about you during the course of this research will be kept confidential, and any information about 
you will have the name, address and any other identifying features removed so that you cannot be recognised. 
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Will you be contacting GPs? 
Individual MURs that are performed within this pharmacy will not be discussed with GPs.  After the observations within this 
pharmacy are over, local GPs and practice staff will be invited to partake in an interview or focus group discussion to discuss their 
general views of the MUR service.  
 
Will the information be handled and stored safely? 
The overall responsibility for handling any information you provide during the course of this study lies with Asam Latif.  The 
information you provide us with will be held on secure password protected computers and / or in a locked and secure drawer / 
filling cabinet. 
 
Who will have access to the data collected during the study? 
Only the research team involved will have access to the collected data.  The data collected will be stored at the University of 
Nottingham for 7 years following completion of the study. 
 
What will happen to the results of the study? 
We will send you a short communication of the findings of this study.  We will also present results at conferences and write journal 
articles so that other people can learn form our study.  No findings will have any of your personal information.     
 
Who is organising and funding this research? 
This research is being organised by the University of Nottingham for completion of an educational qualification (PhD) for Asam 
Latif.  This study is conducted under the supervision of Dr Helen Boardman and Dr Kristian Pollock and is funded jointly by the 
Economic and Social Research Council and the Medical Research Council. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity.  This study has been reviewed and given favorable opinion by (insert name) Research Ethics 
Committee.  This project is supported by (insert name of clinical services manager of organisation or pharmacy owner) who has 
given us permission to do this study in this pharmacy. 
 
Who should I contact for further information? 
If you need further information about this study please feel free to contact us on the details provided below: 
 
Name of researcher: Asam Latif Tel: xxxx xxxx or email xxxx xxxx 
 
Academic supervisors: Dr Helen Boardman tel: xxxx xxxx or email xxxx xxxx  
Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx 
 
 
 
 
Thank you for reading this information sheet. 
WůĞĂƐĞĚŽŶ ?ƚŚĞƐŝƚĂƚĞƚŽĂƐŬŵĞĂŶǇƋƵĞƐƚŝŽŶƐŝĨǇŽƵŶĞĞĚƚŽ ? 
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Pharmacy staff consent form (observations): 
         
STAFF CONSENT FORM 
Protocol number: 1 
Staff identification number for this study: 
Title of the Study: Exploring patient and professional views of pharmacy Medicine Use Review services 
 
Name of the researcher: Asam Latif 
 
Please initial Box 
1. I confirm that I have read and understand the information sheet dated 01/05/2008 (Version 1) for the above study.  I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason.  
3. I understand that relevant data collected during the study, may be looked at by individuals from regulatory authorities 
(i.e. for University auditing purposes) where it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to this data.   
 
4. I give my consent for the researcher to observe my normal daily work as described in the information sheet.   
5. I agree to take part in the above study   
 
Name of staff   Date  Signature 
Name of Person taking consent (if different 
from researcher)  
 Date  Signature 
Researcher  
Asam Latif 
 Date  Signature 
 
When completed, 1 for staff member; 1 for researcher  
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Pharmacy staff consent form (interview): 
      
STAFF CONSENT FORM 
Protocol number: 1 
Staff identification number for this study: 
Title of the Study: Exploring patient and professional views of pharmacy Medicine Use Review services 
 
Name of the researcher: Asam Latif 
Please initial Box 
1. I confirm that I have read and understand the information sheet dated 01/05/2008 (Version 1) for the above study.  I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason.  
3. I understand that relevant data collected during the study, may be looked at by individuals from regulatory authorities 
(i.e. for University auditing purposes) where it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to this data.  
 
4. I give my consent for the researcher to audio-record the interview as described in the information sheet.   
5. I give my consent for anonymised direct quotes to be used in reports and publications.  
6. I agree to take part in the above study   
 
Name of staff  Date  Signature 
Name of Person taking consent (if different 
from researcher)  
 Date  Signature 
Researcher  
Asam Latif 
 Date  Signature 
 
When completed, 1 for staff member; 1 researcher  
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APPENDIX SIX Pharmacy study poster 
APPENDIX SIX 
Pharmacy study poster  
 
What do you think about the Medicines Use Review (MUR) service that 
is provided in this pharmacy? 
We are currently conducting some research at the University of 
EŽƚƚŝŶŐŚĂŵŝŶƚŽǁŚĂƚƉĂƚŝĞŶƚƐ ?ƚŚŝŶŬŽĨƚŚĞDhZƐĞƌǀŝĐĞ ? 
 
You may be asked to have a Medicines Use Review (MUR) with your 
pharmacist.  Whether you agree or decline, you may be invited to take 
part in this study  W ŝƚ ?ƐĞŶƚŝrely optional. 
 
For further details please contact: 
Asam Latif on xxxx xxxxxxx; mobile xxxxxxxxx 
 
Email: xxxxx@nottingham.ac.uk 
Asam Latif 
School of Pharmacy 
University of Nottingham 
University Park 
Nottingham 
NG7 2RD 
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APPENDIX SEVEN Patient information sheet and consent forms 
APPENDIX SEVEN 
Patient information sheet and consent forms 
Patient information sheet: 
 
 
Project title: Exploring patient and professional views of pharmacy Medicine Use Review (MUR) services 
 
Information about the research 
We would like to invite you to take part in a research study. Before you decide you need to understand why the research is being 
done and what it would involve for you. Please take time to read the following information carefully. Talk to others about the 
study if you wish. This information sheet tells you the purpose of this study and what will happen to you if you take part. Please 
ask us if there is anything that is not clear or if you would like more information and take time to decide whether or not you wish 
to take part. 
 
What is the purpose of the study? 
A Medicine Use Review (MUR) is a NHS service that involves a pharmacist periodically talking to a patient about their medicines 
ĂŶĚĂŝŵƐƚŽŝŵƉƌŽǀĞƚŚĞƉĂƚŝĞŶƚ ?ƐŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨƚŚĞŝƌĚƌƵŐƐ ?dŚŝƐŝƐŶŽƌŵĂůůǇĐĂƌƌŝĞĚŽƵƚĨĂĐĞƚŽĨĂĐĞǁŝƚŚƚŚĞƉĂƚŝĞnt in a 
private consultation room located within the community pharmacy.  This study aims ƚŽ ƵŶĚĞƌƐƚĂŶĚ ƉĞŽƉůĞƐ ? ǀŝĞǁƐ ŽĨ ƚŚĞ
Medicines Use Review (MUR) service that is provided by your local community pharmacy.  We are interested in what happens in 
the consultation and how you felt about the service. 
 
Why have I been asked to participate in the study?  
As a user of this community pharmacy you are eligible for a review of your medication. You will have been invited for a Medicines 
Use Review with your pharmacist.  We are interested in speaking to approximately 30-40 people who have either had an MUR or 
chose not to do so.           
 
Do I have to take part? 
It is up to you to decide.  You do not have to take part in this study, it is entirely voluntary.  We will describe the study and go 
through this information sheet, which we will then give to you. We will then ask you to sign a consent form to show you have 
agreed to take part (you will be given a copy to keep).  You are free to withdraw at any time, without giving a reason.  
 
Will my decision affect the care I receive? 
You may decide not to take part, please be assured that this would not affect the standard of care you receive.  This is whether 
you take part in this study or not. 
 
What will happen to me if I take part? 
If you agree to take part in this study the MUR consultation will be observed by the researcher.  This will mean that the researcher 
ǁŝůů  ‘Ɛŝƚ ŝŶ ?ŽŶƚŚĞĐŽŶƐƵůƚĂƚŝŽŶ ? ĨƚĞƌƚŚĞDhZĐŽŶƐƵůƚĂƚŝŽŶ ?ƚŚĞƌĞƐĞĂƌĐŚĞƌǁŝůůĂƉƉƌŽĂĐŚǇŽƵĂŶĚŝŶǀŝƚĞǇŽƵƚŽƚĂŬĞƉĂƌƚ in an 
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interview to talk about your experience of having the MUR.  You do not have to decide at this stage whether you would like to 
take part in an interview.   
 
If you decide to participate in an interview, you will be contacted by the researcher at a later date to arrange an interview.  If you 
do not want to be interviewed simply let me know or return the slip below to me in the pre-paid envelope.  If you decide that you 
would like to talk about your experience of having an MUR, you will have the opportunity to choose the venue, time and date that 
you want the interview to take place.  
 
You will be sent a letter confirming the details of your interview.  We will also ask you about how you felt about being chosen for a 
review by your pharmacist and more generally about your experiences of your community pharmacy.  You will not have to answer 
any questions about issues you do not want to discuss.  If you are unable to make your interview appointment for whatever 
ƌĞĂƐŽŶ ?ĚŽŶ ?ƚǁŽƌƌǇ ?WůĞĂƐĞůĞƚƵƐŬŶŽǁĂŶĚǁĞǁŝůůĂƌƌĂŶŐĞĂŵŽƌĞƐƵŝƚĂďůĞƚŝŵĞ ? 
 
Interviews will last approximately one hour.  With your permission we may use direct quotes from the MUR observations or from 
the interview material in any publication of the results but you will not be identified.  Also with your permission we would like to 
audio record the interview. 
 
Will my decision affect the care I receive? 
Please be assured that the standard of care you receive will not be affected in any way. This is whether you take part in this study 
or not. 
 
Can I change my mind once I have signed the consent form? 
If you have agreed to take part in the study, and for whatever reason you are unable to or change your mind and want to 
withdraw that is absolutely fine; please let us know if you would like us to erase the data collected from the MUR consultation.  If 
you initially decided not to take part, and would now like to be involved that is OK too. All you need to do is contact us and let us 
know.     
 
Will I be paid for taking part in the study? 
No, you will not receive any money for taking part in this study.  If you incur any expenses as a result of this study (i.e. travel / 
parking costs) please retain your receipt and we will fully reimburse you.  
 
What are the possible benefits of taking part? 
It is unlikely that the study will benefit you directly, but the information we collect may help improve the service that is provided 
by pharmacies in the future. 
 
What are the risks of taking part in this study? 
This study involves a researcher observing your MUR consultation with the pharmacist, and if you decide to, talking to a 
researcher about the Medicines Use Review service. We believe that the risks of taking part in this project are minimal.  
 
What happens if something goes wrong? 
If you have any concerns or complaints concerning any aspect of this study please speak to the researcher who will do his best to 
answer your questions (contact Asam Latif on xxxx xxxx, mobile xxx xxxxxxxx or email xxxx xxxx).    
 
If you would prefer to share your complaint with someone else or remain unhappy about a decision you may contact the academic 
supervisors of this study, Dr Helen Boardman on xxxx xxxx or email xxxx xxxx or Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx. 
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If you remain unhappy you may complain formally to Patient Advice and Liaison Service (PALS) who provide confidential advice 
and support to patients, families and carers.  They can be contacted on 0115 912 3320. 
 
Will the information provided be kept confidential? 
All information which is collected about you during the course of this research will remain confidential.  All identifying information 
about you will be removed from reports and publications resulting from this study so that you will not be recognised as a 
participant.   
 
Will you be contacting my GP? 
We will not disclose any information to your GP.  If any issues arise about your medication that may warrant further attention 
during the interview, we will refer you either back to the pharmacist or to your GP.  What you tell us is confidential and will not be 
reported back to your GP or the pharmacist.  If you want, please feel free to speak to your GP or pharmacist about any aspect of 
this study. 
 
Will the information be handled and stored safely? 
The overall responsibility for handling any information you provide during the course of this study lies with Asam Latif.  The 
information you provide us with will be held on secure password protected computers and / or in a locked and secure drawer / 
filing cabinet. 
 
Who will have access to the data collected during the study? 
Only the research team involved will have access to the collected data.  The data collected will be stored at the University of 
Nottingham for 7 years following completion of the study. 
 
What will happen to the results of the study? 
We will send you a short communication of the findings of this study.  We will also present results at conferences and write journal 
articles so that other people can learn form our study.  No findings will include any of your personal information.   
 
Who is organising and funding this research? 
This research is being organised by the University of Nottingham for completion of an educational qualification (PhD) for Asam 
Latif.  This study is conducted under the supervision of Dr Helen Boardman and Dr Kristian Pollock and is funded jointly by the 
Economic and Social Research Council and the Medical Research Council. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity.  This study has been reviewed and given favorable opinion by Nottingham Research Ethics 
Committee.  [Insert name of pharmacy] has provided permission and supports this study.    
 
Who should I contact for further information? 
If you need further information about this study please feel free to contact us on the details provided below: 
 
Name of researcher: Asam Latif Tel: xxxx xxxx, mobile xxx xxxxxxxx or email xxxx xxxx 
 
Academic supervisors: Dr Helen Boardman tel: xxxx xxxx or email xxxx xxxx  
Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx 
    
Thank you for reading this information sheet. 
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WůĞĂƐĞĚŽŶ ?ƚŚĞƐŝƚĂƚĞƚŽĂƐŬŵĞĂŶǇƋƵĞƐƚŝŽŶƐŝĨǇŽƵŶĞĞĚƚŽ ? 
 
Following on from our discussion in the pharmacy, I will as agreed, contact you in the next few days, however, should you wish not 
to be contacted, please indicate this by completing the reply slip below.   
 
Please tear along this line and return in the self addressed envelope whether or not you would be willing to participate in an 
interview as described in this information sheet: 
 Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
Please tick one option  W  
 
I do not wish to further take part in this study.   
 
Yes, I would be interested in continuing in this study by talking to you about my experiences of my MUR.    
      
 
 
EĂŵĞ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
 
ŽŶƚĂĐƚĚĞƚĂŝůƐ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? 
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Patient consent form (observation of MUR): 
       
PATIENT CONSENT FORM 
Protocol number: 1 
Patient identification number for this study:   
Title of the Study: Exploring patient and professional views of pharmacy Medicine Use Review services 
 
Name of the researcher: Asam Latif 
Please initial Box 
1. I confirm that I have read and understand the information sheet dated 01/05/2008 (Version 1) for the above study.  I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, 
without my care or legal rights being affected.  
 
3. I understand that relevant data collected during the study, may be looked at by individuals from regulatory authorities 
(i.e. for University auditing purposes) where it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to this data.   
 
4. I give my consent for the researcher to observe my MUR with the pharmacist as described in the information sheet.   
5. I give my consent for any notes taken during the consultation to be used in reports and publications.  
6. I agree to take part in the above study   
 
Name of Patient   Date  Signature 
Name of Person taking consent (if different 
from researcher)  
 Date  Signature 
Researcher  
Asam Latif 
 Date  Signature 
 
When completed, 1 for patient; 1 for researcher  
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Patient consent form (interview): 
       
PATIENT CONSENT FORM 
Protocol number: 1 
Patient identification number for this study: 
Title of the Study: Exploring patient and professional views of pharmacy Medicine Use Review services 
 
Name of the researcher: Asam Latif 
 
Please initial Box 
1. I confirm that I have read and understand the information sheet dated 01/05/2008 (Version 1) for the above study.  I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw from the interview at any time, without 
giving any reason, without my care or legal rights being affected.  
 
3. I understand that relevant data collected during the study, may be looked at by individuals from regulatory authorities 
(i.e. for University auditing purposes) where it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to this data.   
 
4. I give my consent for the interview to be audio-recorded as described in the information sheet.   
5. I give my consent for anonymised direct quotes to be used in reports and publications.  
6. I agree to take part in the above study   
 
Name of Patient   Date  Signature 
Name of Person taking consent (if different 
from researcher)  
 Date  Signature 
Researcher  
Asam Latif 
 Date  Signature 
 
When completed, 1 for patient; 1 for researcher  
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Patient information sheet (declined MUR): 
  
Project title: Exploring patient and professional views of pharmacy Medicine Use Review (MUR) services 
 
Information about the research 
We would like to invite you to take part in a research study. Before you decide you need to understand why the research is being 
done and what it would involve for you. Please take time to read the following information carefully. Talk to others about the 
study if you wish. This information sheet tells you the purpose of this study and what will happen to you if you take part. Please 
ask us if there is anything that is not clear or if you would like more information and take time to decide whether or not you wish 
to take part. 
 
What is the purpose of the study? 
A Medicine Use Review (MUR) is a NHS service that involves a pharmacist periodically talking to a patient about their medicines 
ĂŶĚĂŝŵƐƚŽŝŵƉƌŽǀĞƚŚĞƉĂƚŝĞŶƚ ?ƐŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨƚŚĞŝƌĚƌƵŐƐ ?dŚŝƐŝƐŶŽƌŵĂůůǇĐĂƌƌŝĞĚŽƵƚĨĂĐĞƚŽĨĂĐĞǁŝƚŚƚŚĞƉĂƚŝĞnt in a 
private consultation room located within the community pharmacy.  dŚŝƐ ƐƚƵĚǇ ĂŝŵƐ ƚŽ ƵŶĚĞƌƐƚĂŶĚ ƉĞŽƉůĞƐ ? ǀŝĞǁƐ ŽĨ ƚŚĞ
DĞĚŝĐŝŶĞƐhƐĞZĞǀŝĞǁ ?DhZ )ƐĞƌǀŝĐĞƚŚĂƚŝƐƉƌŽǀŝĚĞĚďǇǇŽƵƌůŽĐĂůĐŽŵŵƵŶŝƚǇƉŚĂƌŵĂĐǇ ?dŚŝƐƌĞƐĞĂƌĐŚĂŝŵƐƚŽĞǆƉůŽƌĞƉĞŽƉůĞƐ ? 
attitudes towards the MUR service. 
 
Why have I been asked to participate in the study?  
As a user of this community pharmacy you are eligible for a review of your medication. You will have been invited for a Medicines 
Use Review with your pharmacist.  As part of our research we are interested in the reasons why people decline the offer to have 
an MUR.  We are interested in speaking to approximately 30-40 people who have either had an MUR or chose not to do so.      
 
Do I have to take part? 
It is up to you to decide.  You do not have to take part in this study. We will describe the study and go through this information 
sheet, which we will then give to you. If you agree to take part, we will ask you to sign a consent form to show you have agreed to 
take part (you will be given a copy to keep).  You are free to withdraw at any time, without giving a reason.  
 
Will my decision affect the care I receive? 
 Please be assured that this will not affect the standard of care you receive.   
 
What will happen to me if I take part? 
If you agree to take part in this study, you will be contacted by the researcher at a later date to arrange an interview.  If you do not 
want to be interviewed simply return the slip below to me in the pre-paid envelope.  If you decide that you would like to talk 
about your experiences, you will have the opportunity to choose the venue, time and date that you want the interview to take 
place. You will be sent a letter confirming the details of your interview.  We will ask you about how you felt about being chosen for 
a review by your pharmacist or pharmacy staff, the reasons why you chose to decline the offer on this occasion and more 
generally about your experiences of your community pharmacy.  You will not have to answer any questions about issues you do 
not want to discuss.   
 
If you are unable ƚŽŵĂŬĞǇŽƵƌŝŶƚĞƌǀŝĞǁĂƉƉŽŝŶƚŵĞŶƚĨŽƌǁŚĂƚĞǀĞƌƌĞĂƐŽŶ ?ĚŽŶ ?ƚǁŽƌƌǇ ?WůĞĂƐĞůĞƚƵƐŬŶŽǁĂŶĚǁĞǁŝůůĂƌƌĂŶŐĞĂ
more suitable time. Interviews will last approximately half an hour.  If you decide that you do not want a face-to-face interview, 
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you may choose to have a telephone interview instead.  If you choose this option you will be contacted by us to arrange a 
convenient date and time for the interview to take place.  With your permission we would like to audio record the interview and 
also with your permission we may use direct quotes from the interview material in any publication of the results but you will not 
be identified and all identifiable information will be removed. 
 
Can I change my mind once I have signed the consent form? 
If you have agreed to take part in the study, and for whatever reason you are unable to or change your mind and want to 
withdraw, that is absolutely fine. If you initially decided not to take part, and would now like to be involved that is OK too. All you 
need to do is contact us and let us know.     
 
Will I be paid for taking part in the study? 
No, you will not receive any money for taking part in this study.  If you incur any expenses as a result of this study (i.e. travel / 
parking costs) please retain your receipt and we will fully reimburse you.  
 
What are the possible benefits of taking part? 
It is unlikely that the study will benefit you directly, but the information we collect may help improve the service that is provided 
by pharmacies in the future. 
 
What are the risks of taking part in this study? 
This study involves you talking to us about your reasons for declining an MUR.  We believe that the risks of taking part in this 
project are minimal.  
 
What happens if something goes wrong? 
If you have any concerns or complaints concerning any aspect of this study please speak to the researcher who will do his best to 
answer your questions (contact Asam Latif on xxxx xxxx, mobile xxx xxxxxxxx or email xxxx xxxx).    
 
If you would prefer to share your complaint with someone else or remain unhappy about a decision you may contact the academic 
supervisors of this project Dr Helen Boardman on xxxx xxxx or email xxxx xxxx or Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx. 
 
If you remain unhappy you may complain formally to Patient Advice and Liaison Service (PALS) who provide confidential advice 
and support to patients, families and carers.  They can be contacted on 0115 912 3320. 
 
Will the information provided be kept confidential? 
All information which is collected about you during the course of this research will remain confidential.  All identifying information 
about you will be removed from reports and publications resulting from this study so that you will not be recognised as a 
participant.   
 
Will you be contacting my GP? 
We will not disclose any information to your GP.  If any issues arise about your medication that may warrant further attention 
during the interview, we will refer you either back to the pharmacist or to your GP.  What you tell us is confidential and will not be 
repeated back to your GP or the pharmacist.  If you want, please feel free to speak to your GP about any aspect of this study. 
 
Will the information be handled and stored safely? 
The overall responsibility for handling any information you provide during the course of this study lies with Asam Latif.  The 
information you provide us with will be held on secure password protected computers and / or in a locked and secure drawer / 
filing cabinet. 
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Who will have access to the data collected during the study? 
Only the research team involved will have access to the collected data.  The data collected will be stored at the University of 
Nottingham for 7 years following completion of the study. 
 
What will happen to the results of the study? 
We will send you a short communication of the findings of this study.  We will also present results at conferences and write journal 
articles so that other people can learn form our study.  No findings will include any of your personal information.   
 
Who is organising and funding this research? 
This research is being organised by the University of Nottingham for completion of an educational qualification (PhD) for Asam 
Latif.  This study is conducted under the supervision of Dr Helen Boardman and Dr Kristian Pollock and is funded jointly by the 
Economic and Social Research Council and the Medical Research Council. 
 
Who has reviewed this study? 
All research in the NHS is looked at by an independent group of people called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity.  This study has been reviewed and given favorable opinion by Nottingham Research Ethics 
Committee.  [insert name] has provided permission and supports this study.    
 
Who should I contact for further information? 
If you need further information about this study please feel free to contact us on the details provided below: 
 
Name of researcher: Asam Latif Tel: xxxx xxxx, mobile xxx xxxxxxxx or email xxxx xxxx 
 
Academic supervisors: Dr Helen Boardman tel: xxxx xxxx or email xxxx xxxx  
Dr Kristian Pollock on xxxx xxxx or email xxxx xxxx 
 
Thank you for reading this information sheet. 
WůĞĂƐĞĚŽŶ ?ƚŚĞƐŝƚĂƚĞƚŽĂƐŬŵĞĂŶǇƋƵĞƐƚŝŽŶƐŝĨǇŽƵŶĞĞĚƚŽ ? 
 
Following on from our discussion in the pharmacy, I will as agreed, contact you in the next few days, however, should you wish not 
to be contacted, please indicate this by completing the reply slip below: 
 
Please tear along this line and return in the self addressed envelope whether or not you would be willing to participate in an 
interview as described in this information sheet: 
 Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
Please tick one option  W  
I do not wish to take part in this study      
Yes, I would be interested in talking to you about my experiences of pharmacy services:     
      
EĂŵĞ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
 
ŽŶƚĂĐƚĚĞƚĂŝůƐ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q ? 
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Patient consent form (declined MUR): 
       
PATIENT CONSENT FORM 
Protocol number: 1 
Patient identification number for this study:  
Title of the Study: Exploring patient and professional views of pharmacy Medicine Use Review services 
 
Name of the researcher: Asam Latif 
Please initial Box 
1. I confirm that I have read and understand the information sheet dated 01/05/2008 (Version 1) for the above study.  I 
have had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw from this interview at any time, without 
giving any reason, without my care or legal rights being affected.  
 
3. I understand that relevant data collected during the study, may be looked at by individuals from regulatory authorities 
(i.e. for University auditing purposes) where it is relevant to my taking part in this research.  I give permission for these 
individuals to have access to this data.   
 
4. I give my consent for the researcher to audio-record the interview.   
5. I give my consent for anonymised direct quotes to be used in reports and publications.  
6. I agree to take part in the above study   
 
Name of Patient   Date  Signature 
Name of Person taking consent (if different 
from researcher)  
 Date  Signature 
Researcher  
Asam Latif 
 Date  Signature 
When completed, 1 for patient; 1 for researcher  
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APPENDIX EIGHT Topic guides  
APPENDIX EIGHT 
Topic guides  
Patient interview topic guide: 
 
Demographic details. 
 
Opening question: could you tell me from beginning to the end your experience of the MUR in as much detail as possible? 
 
ZĞƐƉŽŶĚĞŶƚ ?ƐĂǁĂƌĞŶĞƐƐŽĨDhZƐĞƌǀŝĐĞand views of being approached. 
 
ZĞƐƉŽŶĚĞŶƚ ?ƐĞǆƉĞĐƚĂƚŝŽŶƐand views of purpose of the MUR. 
 
Exploration of what happened during the MUR (using observation notes). 
 
Views on necessity/usefulness/would respondent like to have discussed anything? 
 
Affect knowledge or use of medicines? 
 
Likes and dislikes about review? 
 
Who in your opinion would most benefit from MUR? 
 
Improving the service/another MUR in future? 
 
Pharmacy use and perceptions around role of the pharmacist. 
 
ZĞƐƉŽŶĚĞŶƚ ?ƐŵĞĚŝĐŝŶĞƐand medical care. 
 
Beliefs, necessity and concerns over medicines. 
 
Perceived authority over medicines. 
 
GP and other health professional role in rĞƐƉŽŶĚĞŶƚ ?ƐĐĂƌĞ ? 
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Pharmacist interview topic guide: 
 
Demographic data and accreditation process. 
 
WŚĂƌŵĂĐŝƐƚ ?ƐĞǆƉĞƌŝĞŶĐĞŽĨDhZƐ P 
 
Patient selection. 
 
Views and use of MUR forms. 
 
Necessity of MURs. 
 
Most common concerns patients have about their medicines? 
 
Organisational pressure and targets. 
 
Professional boundaries. 
 
Objectives of MUR: 
 
What do you hope to achieve? Good outcome/bad outcome. 
 
sŝĞǁŽŶŝŵƉƌŽǀŝŶŐŬŶŽǁůĞĚŐĞĂŶĚƵƐĞŽĨƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐŝŶĞƐ ? 
 
ZĞƐŽůǀŝŶŐƉĂƚŝĞŶƚ ?ƐŝŶĞĨĨĞĐƚŝǀĞƵƐĞŽĨŵĞĚŝĐŝŶĞƐand examples. 
 
How often do you make suggestions/are these accepted? 
 
Views on value for money for NHS. 
 
Support: 
 
Do you welcome MURs/has this added anything to your role? 
 
What support have you had to help you develop the service? (employers, local surgery, Primary Care Trust) 
 
How can MURs be improved? 
 
Appendices  
330 
 
Pharmacy support staff interview topic guide: 
 
Demographic data. 
 
Training received. 
 
Patient selection. 
 
Identifying patients. 
 
Explore patient responses. 
 
Organisational issues: 
 
View on pharmacist performing MURs. 
 
Managing work without pharmacist. 
 
Examples where the pharmacist was needed but was unavailable and patient response. 
 
Organisational pressures and MUR targets. 
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APPENDIX NINE: List of patient medications  
APPENDIX NINE  
List of patient medications  
(Recorded during MUR and patient interviews) 
List of patient medicines - Multiple Pharmacy:  
 
Alias name Medications that have been discussed during MUR or at 
Interview
1 
Number of 
medications 
Anthony Metformin tablets, Ramipril, Simvastatin tablets, Atenolol 
tablets, Aspirin tablets, Xalatan eye drops, Timolol eye drops. 
7 
Ashley Atorvastain tablets, Amlodipine tablets, Lisinopril tablets. 3 
Autumn Amlodipine tablets, Aspirin tablets, Co-codamol tablets, 
Furosemide tablets, Ramipril tablets.   
5 
Beth Paracetamol (soluble) tablets, Tolterodine tablets, 
Levothyroxine tablets, Trimovate cream, Lansoprazole, 
Imodium (OTC).  
6 
Betty Metformin tablets, Simvastatin tablets, Losartan tablets, 
Amlodipine tablets, Aspirin tablets. 
5 
Cady Adcal tablets, Alendronic acid tablets, Amantadine tablets, 
Aspirin (OTC) tablets, Atenolol tablets, Doxazocin tablets, 
Glucosamine and Chrondroitin, Primrose oil (OTC), Ramipril, 
Simvastatin tablets. 
10 
Charlie Ramipril, Levothyroxine tablets. 2 
Comfort Alendronic acid tablets, Calcichew tablets, Multivitamins
 
(OTC), Ibuprofen tablets (OTC), Ibuprofen gel (OTC).   
5 
Dotty Allopurinol tablets, Atorvastatin tablets, Bezefibrate tablets, 
Co-tenidone tablets, Diltiazem, Dosulepin tablets, Doxazocin 
tablets, Ibuprofen tablets, Paracetamol tablets.   
9 
Faith Amitriptyline tablets, Felodipine tablets, Lactulose liquid 
Levothyroxine tablets, Prazocin tablets.  
5 
Fiona Methotrexate tablets, Folic acid tablets, Spectroban liquid, 
Ventolin inhaler, Support stockings.  
5 
Iris Cetirizine tablets, Beconase nasal spray, Feldene gel, Aspirin 
tablets, Rennie (OTC), Levothyroxine 50mg and 25mg tablets. 
7 
Jacques Aspirin tablets, Simvastatin tablets, Metformin tablets, 
Lansoprazole. 
4 
Jessica Benylin (OTC) liquid, Seretide inhaler, Spacer device, Ventolin 
inhaler.   
4 
Jill Aspirin (OTC) tablets, Eprosartan, Phisiotens tablets (One 
further  “blood pressure ? medication not reported in MUR).  
6 
Jimmy Aspirin tablets, Atenolol tablets, Bendroflumethiazide tablets, 
Ramipril. 
4 
Konnie Aspirin (OTC) tablets, Citalopram tablets (two strengths), 
Dovonex cream, Flecainide tablets. 
5 
Megan Prednisolone tablets, Alendronic acid tablets, Paracetamol 
tablets, Ibuprofen tablets, Calcichew tablets, Codeine tablets. 
6 
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Mia Amlodipine tablets, Atrovent inhaler, Dosulepin tablets, 
Paracetamol tablets, Symbicort inhaler, Uniphylline tablets, 
Ventolin inhaler.  
7 
Michael Alfuzocin tablets, Atorvastatin tablets, Felodipine tablets, 
Meptid tablets, Ramipril capsules, Symbicort inhaler, Ventolin 
inhaler. 
7 
Molly Bendroflumethiazide, Clexane injection, Support stockings.  3 
Murial Citalopram tablets, Co-amilofruse tablets, Lansoprazole. 3 
Nick Bezefibrate tablets, Diclofenac tablets, Diprobase cream, 
Ezetamide tablets, Felodipine tablets, Lansoprazole capsules, 
Metformin tablets, Nicorandil tablets.  
8 
Nicola Calcichew D3 forte tablets, Fortipine tablets, Paracetamol 
tablets, Simvastatin tablets, Slow K tablets, Valsartan capsules. 
6 
Noble Atrovent, Iron tablets, Isosorbide Mononitrate, Nitrolingual 
spray, Salbutamol inhaler, Seretide inhaler.  
6 
Noleen Aspirin tablets, Bendroflumethiazide tablets, Dipyridamole 
tablets, Felodipine tablets (two strengths), Simvastatin 
tablets.  
6 
Oprah Bendroflumethiazide tablets, Co-codamol tablets, Codeine 
tablets, Hypromellose eye drops, E45 cream, Losartan tablets. 
6 
Queenie Lisinopril tablets, Nizoral shampoo. 2 
Robert Amlodipine tablets Atenolol tablets, Co-codamol tablets, 
Paracetamol tablets, Ranitidine tablets, Arthrotec tablets, 
Quinine tablets, Aspirin tablets. 
8 
Sue Antibiotics (Short course), Amlodipine tablets, Lansoprazole, 
Alendronic Acid tablets, Paracetamol tablets, Glucosamine and 
Chrondroitin.  
6 
Summer Aspirin tablets, Celluvisc eye drops, Crestor tablets, 
Lansoprazole Levothyroxine tablets, Steriod eye drops. 
6 
Tally Allopurinol tablets, Ventolin inhaler, Glyceryl Trinitrate tablets, 
Co-amilofruse tablets , Aspirin tablets, Pulmicort inhaler, 
Simvastatin tablets, Omeprazole, Cinnarizine tablets, 
Buccastem tablets, Betahistadine tablets. 
11 
Timotha Atenolol tablets, Bendroflumethiazide tablets, Erythromycin 
tablets, Loratadine tablets, Simvastatin tablets.  
5 
 
1
Medications that have been italicised are those which were revealed during the study interview with 
the researcher but not during the MUR with the pharmacist. 
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List of patient medicines - Independent Pharmacy: 
 
Alias Medications that have been discussed during MUR or at 
interview
1 
Number of 
medications 
Adam Bendroflumethiazide tablets, Ramipril.  2 
Alison Alphaderm cream, Antihistamine eye drops, Diprobase cream, 
Flixonase spray, Loratadine tablets, Peak flow metre, Seretide, 
Ventolin, Volumatic spacer. 
9 
Annabel Alendronic acid tablets, Calcichew tablets, Cetirizine tablets, 
Co-enzyme Q10 tablets (OTC), Colazide tablets, Felodipine 
tablets, Gaviscon liquid, Losartan tablets, Omeprazole 
capsules, Paracetamol tablets.   
10 
Cilla Co-codamol tablets, Diclofenac tablets, Ibuprofen (OTC) 
tablets, Paracetamol (OTC) tablets, Sertraline tablets.   
5 
Colin Arthrotec tablets, Cetirizine tablets, Doxazocin tablets, 
Felodipine tablets, Lisinopril tablets, Omeprazole capsules, 
Salbutamol inhaler, Symbicort inhaler. 
8 
Connie Amitriptyline tablets, Arimidex tablets, Brufen tablets, Co-
amoxiclav tablets, Co-danthramer capsules, Cyclizine tablets, 
Emla cream, Fentanyl patches, Flucloxacillin capsules, 
Gabapentin capsules, Lansoprazole capsules, Oxynorm 
capsules, Paracetamol tablets, Tegaderm dressing, Zoladex 
injection, Zometa infusion, Zopiclone tablets. 
17 
Daisy Beconase, Aqueous cream, Sudocrem, Eurax, Co-codamol, 
Movicol, Fybogel, Senna, Dihydrocodeine, 
Bendroflumethiazide, Cetirizine tablets, Gaviscon liquid. 
12 
Esther Bendroflumethiazide tablets, Cetirizine tablets, Co-codamol 
tablets, Dacktacort ointment, Dermovate ointment,  Epaderm 
emollient, Feldene gel, Feldene melts,  Fluconazole capsules, 
Fluoxetine capsules, Omeprazole capsules, Paracetamol 
tablets, Pregabalin capsules, Quinine tablets, Trimovate 
cream. 
15 
Eve Bendroflumethiazide tablets, Ramipril, Diprobase cream, 
Ibuprofen tablets, Felodipine tablets, Atenolol tablets. 
6 
Geri Alendronic acid tablets, Calcichew tablets, Co-amilofruse 
tablets, Co-codamol tablets, Felodipine tablets, 
Simvastatin tablets. 
6 
Harry Amlodipine tablets, Cetirizine tablets, Gaviscon liquid, 
Simvastatin tablets. 
4 
Howard Amitriptyline tablets, Co-dydramol tablets, Diclofenac tablets, 
Etanacept injection,  “Lubricant eye drops ?, Folic acid, 
Methotrexate tablets. 
7 
Morris Clopidogrel tablets, Dutasteride tablets, Lansoprazole 
capsules, Salbutamol inhaler, Simvastatin tablets, 
Sulphasalazine tablets. 
6 
Moya Aspirin tablets, Bisoprolol tablets, Calcium tablets, Furosemide 
tablets, Lansoprazole, Lisinopril tablets, Lotriderm Cream, 
Simvastatin tablets, Solpadeine (OTC).    
9 
Polly Alphosyl liquid, Amitriptyline tablets, Chlorpromazine tablets, 
Dovonex cream, Exorex Lotion, Polytar liquid, Ramipril tablets, 
Temazepam tablets.  
8 
Primrose Alendronic acid tablets, Annadin tablets (OTC), Docusate 12 
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capsules, Exemestane tablets, Fybogel sachets, Lansoprazole 
capsules, Lorazepam tablets, Morphine Liquid, Priadel tablets 
400mg and 200mg, Senna tablets, Venlafaxine tablets.    
Renata  “Antihistamines ? (OTC), Celluvisc eye drops, Co-proxamol 
tablets, Glucosamine tablets, Thyroxine tablets.  
5 
Renita Aloe Vera (OTC), Citalopram, Cod Liver oil (OTC), Co-proxamol 
tablets, Domperidone, Garlic tablets (OTC), Gaviscon tablets, 
Lansoprazole, Levothyroxine, Multivitamins (OTC), 
Pregabalin.    
11 
Syd Aspirin tablets, Cetirizine tablets, Cod liver oil capsules (OTC), 
Glucosamine tablets (OTC), Lansoprazole capsules, Lisinopril 
tablets, Metformin tablets, Multivitamins, Naproxen tablets, 
Simvastatin tablets, Xenical capsules.  
11 
Terrie Gaviscon, Preservative free eye drops, Lacrilube eye drops, 
Indigestion capsules.  
4 
Wilson GTN spray, Imdur tablets, Lansoprazole, Simple Linctus (OTC), 
Simvastatin tablets, Symbicort inhaler, Tildiem tablets, 
Ventolin inhaler, Warfarin tablets.  
9 
 
1 
Medications that have been italicised are those which were revealed during the study interview with 
the researcher but not during the MUR with the pharmacist. 
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APPENDIX TEN Paper arising from the study 
APPENDIX TEN 
Paper arising from the study 
Latif A, Pollock K, Boardman H. (2011) The contribution of the Medicines Use Review (MUR) 
consultation to counseling practice in community pharmacies. Patient Education and 
Counseling, 83, 336-44. 
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